{"title": "PDF", "author": "PDF", "url": "https://seq.es/wp-content/uploads/2019/07/full.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "REVISTA ESPA\u00d1OLA DEREVISTA ESPA\u00d1OLA DEQuimioterapiaQuimioterapia\nISSN: 0214-3429\nVolumen 32\nN\u00famero 4\nAgosto 2019\nP\u00e1ginas: 288-409SPANISH JOURNAL\nOF CHEMOTHERAPY\nImagen portada: Mar\u00eda Teresa CorcueraPublicaci\u00f3n Oficial\nde la Sociedad Espa\u00f1ola\nde QuimioterapiaQuimioterapiaREVISTA ESPA\u00d1OLA DE\nRevista Espa\u00f1ola de \nQuimioterapia tiene un car\u00e1cter multidisciplinar y est\u00e1 dirigida a todos aquellos profesionales involucrados en la epidemiolog\u00eda, diagn\u00f3stico, cl\u00ednica y tratamiento de las enfermedades infecciosas\nFundada en 1988 por la Sociedad \nEspa\u00f1ola de Quimioterapia\nIndexada en\nScience Citation IndexExpanded (SCI),Index Medicus (MEDLINE), Excerpta Medica/EMBASE,\u00cdndice M\u00e9dico Espa\u00f1ol (IME), \u00cdndice Bibliogr\u00e1fico en Ciencias de la Salud (IBECS)\nSecretar\u00eda t\u00e9cnica \nDpto. de Microbiolog\u00edaFacultad de MedicinaAvda. Complutense, s/n28040 Madridrevista@seq.esDisponible en Internet:www.seq.esPublicidad y SuscripcionesSociedad Espa\u00f1ola de QuimioterapiaDpto. de Microbiolog\u00edaFacultad de MedicinaAvda. Complutense, s/n28040 Madrid\nAtenci\u00f3n al cliente\nTel\u00e9fono 91 394 15 12Correo electr\u00f3nicoinfo@seq.es\nConsulte nuestra p\u00e1gina web\nwww.seq.es\n\u00a9 Copyright 2019Sociedad Espa\u00f1ola deQuimioterapia\nReservados todos los derechos.\nQueda rigurosamente prohibida,sin la autorizaci\u00f3n escrita deleditor, la reproducci\u00f3n parcialo total de esta publicaci\u00f3npor cualquier medio oprocedimiento, comprendidos lareprograf\u00eda y el tratamientoinform\u00e1tico, y la distribuci\u00f3n deejemplares mediante alquiler opr\u00e9stamo p\u00fablicos, bajo lassanciones establecidas por la leySociedad Espa\u00f1ola de Quimioterapia\nPublicaci\u00f3n que cumple los requisitos de\nsoporte v\u00e1lido\nISSN\n0214-3429\ne-ISSN\n1988-9518\nDep\u00f3sito Legal\nM-32320-2012\nMaquetaci\u00f3n\nKumisai\nImpresi\u00f3n\nEspa\u00f1a\nEsta publicaci\u00f3n se imprime en papel no \u00e1cido. \nThis publication is printed in acid free paper.\nLOPD\nInformamos a los lectores que, seg\u00fan lo previsto en el Reglamento General de Protecci\u00f3n de Datos (RGPD) 2016/679 del Parlamento Europeo, sus datos personales forman parte de la base de datos de la Sociedad Espa\u00f1ola de Quimioterapia (si es usted socio)\nSi desea realizar cualquier rectificaci\u00f3n o \ncancelaci\u00f3n de los mismos, deber\u00e1 enviar una solicitud por e-mail a la Sociedad Espa\u00f1ola de Quimioterapia (info@seq.es)QuimioterapiaREVISTA ESPA\u00d1OLA DE\nDirector\nJ. Barber\u00e1n L\u00f3pez\nComit\u00e9 Editorial\nF. \u00c1lvarez Lerma (Barcelona)\nF. Baquero Mochales (Madrid)\nE. Bouza Santiago (Madrid)\nJ. A. Garc\u00eda Rodr\u00edguez (Salamanca)\nM. Gobernado Serrano (Valencia)\nConsejo Editorial\nL. Aguilar (Madrid)\nJ. I. Al\u00f3s (Madrid)\nJ. R. Azanza (Pamplona)\nJ. Arag\u00f3n (Las Palmas de Gran Canaria) \nA. Artero (Valencia)V. Asensi (Oviedo)\nG. Barbeito (Santiago de Compostela)\nJ. M. Barbero (Madrid)\nJ. Campos (Madrid)F.J. Candel (Madrid)\nE. Cant\u00f3n (Valencia)\nR. Cant\u00f3n (Madrid)\nJ. A. Capdevila Morell\n(Barcelona)\nM. Casal (C\u00f3rdoba)\nJ. Castillo (Zaragoza) \nF. Cobo (Granada)\nJ. Cobo Reinoso (Madrid)\nN. Cobos (Madrid)\nJ. L. del Pozo (Navarra)R. De la C\u00e1mara (Madrid)\nC. De la Calle (Barcelona)\nM. Dominguez-Gil (Valladolid)\nJ. Eiros (Valladolid)P. Escribano (Madrid)\nA. Estella (C\u00e1diz)\nM. C. Fari\u00f1as \u00c1lvarez (Santander)\nC. Fari\u00f1as (Santander)J. Fort\u00fan (Madrid)J. J. Gamazo (Vizcaya)\nE. Garc\u00eda S\u00e1nchez (Salamanca)\nI. Garc\u00eda Garc\u00eda (Salamanca)\nJ. E. Garc\u00eda S\u00e1nchez (Salamanca)E. Garc\u00eda V\u00e1zquez (Murcia)\nJ. G\u00f3mez G\u00f3mez (Murcia)\nM. L. G\u00f3mez-Lus (Madrid)\nJ. Gonz\u00e1lez del Castillo (Madrid)F. Gonz\u00e1lez Romo (Madrid)\nJ. J. Granizo (Madrid)\nS. Grau (Barcelona)\nJ.M. Guardiola (Barcelona)\nJ. Guinea (Madrid)\nX. Guirao (Barcelona)\nJ. Guti\u00e9rrez (Granada)\nJ. B. Guti\u00e9rrez (C\u00f3rdoba)\nB. Isidoro (Madrid)\nP. Llinares (La Coru\u00f1a)\nJ. E. Losa Garcia (Madrid)J. R. Maestre Vera (Madrid)\nL. Mart\u00ednez Mart\u00ednez (C\u00f3rdoba)\nE. Maseda (Madrid)\nR. Men\u00e9ndez (Valencia)P. Merino (Madrid))\nP. Mu\u00f1oz (Madrid)\nJ. L. Mu\u00f1oz Bellido (Salamanca)\nV. Navarro (Alicante)M. Ortega (Barcelona) \nJ. Oteo (Madrid)\nJ. A. Oteo (Logro\u00f1o)\nE. Palencia Herrej\u00f3n (Madrid) \nA. Pascual Hern\u00e1ndez (Sevilla)\nJ. Pasquau (Sevilla)J. Pem\u00e1n (Valencia)J. L P\u00e9rez-Arellano (Las Palmas)B. P\u00e9rez-Gorricho (Madrid)A. Ramos (Madrid)J. M. Ramos (Alicante)J. Reina (Palma de Mallorca)\nM. A. Ripoll (\u00c1vila)\nI. Rodriguez-Avial (Madrid)M. Ruiz (Alicante)M. Sabri\u00e1 (Barcelona)M. Salavert (Valencia)B. S\u00e1nchez Artola (Madrid)M. Segovia (Murcia)R. Serrano (Madrid)D. Sevillano (Madrid)\nA. Su\u00e1rez (Madrid)\nA. Tenorio (Huelva)A. Torres (Murcia)C. Vallejo (Oviedo)J. Vila (Barcelona)J. Yuste (Madrid)J. Mensa Pueyo (Barcelona)\nJ. J. Picazo de la Garza (Madrid)\nJ. Prieto Prieto (Madrid)\nB. Regueiro Garc\u00eda (Santiago de Compostela)\nA. Torres Mart\u00ed (Barcelona)Secretario de Redacci\u00f3n\nLuis Alou CerveraSumario\nS\u00edndrome de Guillain-Barr\u00e9 y vacuna antigripal: evidencia actual 288\nRosario Sanz Fadrique, Luis Mart\u00edn Arias, Juan Arcadio Molina-Guarneros, Natalia Jimeno Bulnes, \nPilar Garc\u00eda Ortega\nEfectividad de ledipasvir/sofosbuvir durante 12 semanas de tratamiento y factores 296 \npredictivos de fracaso del tratamiento en pacientes con hepatitis C\nJuan Carlos del Rio-Valencia, Roc\u00edo Asensi-Diez, Roc\u00edo Tamayo-Bermejo, Isabel Mu\u00f1oz-Castillo\nBacterias resistentes en las manos de trabajadores sanitarios y en el \u00e1rea de 303 \npaciente: un estudio ambiental en un hospital del sur de Italia\nVincenza La Fauci, Gaetano Bruno Costa, Cristina Genovese, Maria Angela Rita Palamara, Valeria \nAlessi, Raffaele Squeri\nFactores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital  311 \nterciario\nLaura Sante, Mar\u00eda Lecuona, Armando Aguirre Jaime, \u00c1ngeles Arias\nDiagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un 317 \nhospital de tercer nivel\nRoc\u00edo Asensi-Diez, Cristina Fern\u00e1ndez-Cuerva, Juan Jos\u00e9 Alcaraz S\u00e1nchez, Isabel Mu\u00f1oz-Castillo\nPrevalencia de micoplasmas genitales y respuesta al tratamiento de descolonizaci\u00f3n 327 \nen pacientes de reproducci\u00f3n humana asistida\nErnesto Veiga, Mercedes Trevi\u00f1o, Ana Bel\u00e9n Romay, Daniel Navarro, Roc\u00edo Trastoy, Manuel Mac\u00eda\nVacunas para la prevenci\u00f3n de infecciones en adultos: art\u00edculo de opini\u00f3n sobre la  333 \nsituaci\u00f3n en Espa\u00f1a\nEmilio Bouza, Julio Ancochea-Berm\u00fadez, Magda Campins, Jos\u00e9 Mar\u00eda Eir\u00f3s-Bouza, Jes\u00fas Fargas, \nAm\u00f3s Jos\u00e9 Garc\u00eda Rojas, Diego Gracia, Alipio Guti\u00e9rrez S\u00e1nchez, Aurora Limia, Jos\u00e9 Antonio L\u00f3pez, \nMar\u00eda del Carmen Magro, Gloria Mirada, Patricia Mu\u00f1oz, Eduardo Olier, Ra\u00fal Ortiz de Lejarazu, \nLuis Urbiztondo, Esteban Palomo\nComparaci\u00f3n de dos m\u00e9todos que eluden la lisis celular y la extracci\u00f3n de prote\u00ednas 365 \npara la identificaci\u00f3n de bacterias crecidas en hemocultivos mediante espectrometr\u00eda de \nmasas MALDI-TOF  \nIgnacio Torres, Estela Gim\u00e9nez, Dixie Huntley, Mireia Mart\u00ednez, Javier Colomina, David Navarro\nEvaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n de PBP2a en 370 \nStaphylococcus aureus\nRoc\u00edo S\u00e1inz-Rodr\u00edguez, Inmaculada de Toro-Peinado, Miriam Valverde-Troya, M\u00aa Pilar Berm\u00fadez \nRu\u00edz,  Bego\u00f1a Palop-Borr\u00e1s\n\u00bfEs posible extrapolar las tasas de resistencia de Escherichia coli  de bacteriurias  375 \nasintom\u00e1ticas en gestantes a las de E. coli  en ITU no complicada adquirida en la \ncomunidad?\nAlejandra Asenjo, Mart\u00edn C. Grados, Jes\u00fas Oteo-Iglesias, Juan-Ignacio Al\u00f3sRevisi\u00f3n  \nSistem\u00e1tica\nOriginales\nOriginal BreveQuimioterapiaREVISTA ESPA\u00d1OLA DE\nVolumen 32\nN\u00famero 4\nAgosto 2019Sumario\nReactivaci\u00f3n del s\u00edndrome peri\u00f3dico asociado a criopirinas tras la vacunaci\u00f3n 379 \nen una paciente candidata a inmunosupresi\u00f3n\nMar\u00eda Fern\u00e1ndez-Prada, Jessica Rugeles-Ni\u00f1o, Luc\u00eda Su\u00e1rez-P\u00e9rez, Miguel Ruiz-\u00c1lvarez, Jos\u00e9 \nBernardino L\u00f3pez-D\u00edaz, Juan Fern\u00e1ndez-Madera, Carmen Mart\u00ednez-Ortega, Ismael Huerta-\nGonz\u00e1lez\nMeningitis por Nocardia farcinica  en un paciente con enfermedad de Beh\u00e7et:  381 \ncaso y revisi\u00f3n de la literatura\nKiana Shirani, Fatemeh Mohajeri\nDesbridamiento y tratamiento antibi\u00f3tico en un caso de infecci\u00f3n 384 \nprot\u00e9sica de rodillla por Pasteurella multocida\nMaria Pilar Ortega Lafont, Luis Buz\u00f3n Mart\u00edn, Ledicia \u00c1lvarez Paredes, Mar\u00eda Mora Fern\u00e1ndez, \nAntonio Rodr\u00edguez P\u00e9rez, Miguel \u00c1ngel Mor\u00e1n Rodr\u00edguez\nUso de dolutegravir en infecci\u00f3n aguda por VIH-1: primer caso reportado 387\nFranco Garibaldi, Marcia Pozzati, Claudia Rodriguez, Diego Cecchini\nShock s\u00e9ptico secundario a Elizabethkingia  meningoseptica : descripci\u00f3n de un caso 390\nDavid Brandariz N\u00fa\u00f1ez, Paula Rodr\u00edguez Pedreira, Virginia Hern\u00e1ndez Corredoira, Joaquin Puig \nForcada, Francisco J Gurri Hernand, Arturo S Boix Boix\nBacteriemia por Actynomices  oris 393\nJavier Miguel Mart\u00edn Guerra, Miguel Mart\u00edn Asenjo, Claudia Iglesias P\u00e9rez,  \nCarlos Jes\u00fas Due\u00f1as Guti\u00e9rrez\nEndocarditis infecciosa por Candida  glabrata : evidencia del desarrollo in vivo de  395 \nresistencia a equinocandinas\nCaroline Agnelli, Jesus Guinea, Maricela Valerio, Pilar Escribano, Emilio Bouza, Patricia Mu\u00f1oz\nAbsceso periamigdalino producido por Actinomyces  marseillensis  398\nSara G\u00f3mez de Frutos, Marta Soledad Rodr\u00edguez Anzules, Arturo Manuel Fraile Torres, Laura \nCarde\u00f1oso Domingo, Diego Domingo Garc\u00eda\nDocumento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la  400 \nComunidad de Madrid\nEduardo Palencia Herrej\u00f3n, Juan Gonz\u00e1lez del Castillo, Fernando Ramasco Rueda, Francisco \nJavier Candel Gonz\u00e1lez, Beatriz S\u00e1nchez Artola, Andr\u00e9s von Wernitz Teleki, Federico Gordo Vidal, \nPatricia Roces Iglesias, Guillermina Bejarano Redondo, Diego An\u00edbal Rodr\u00edguez Serrano, Francisco \nJavier Cobo Reinoso, Ervigio Corral Torres, Milagros Mart\u00ed de Gracia, Ana Ruiz \u00c1lvarez y el Grupo \nMultidisciplinar C\u00f3digo Sepsis MadridQuimioterapiaREVISTA ESPA\u00d1OLA DE\nVolumen 32\nN\u00famero 4\nAgosto 2019\nCartas al Director\nDocumento  \nde ConsensoContents\nQuimioterapiaREVISTA ESPA\u00d1OLA DE\nVolume 32\nNumber 4\nAugust 2019\nGuillain-Barr\u00e9 syndrome and influenza vaccines: current evidence 288\nRosario Sanz Fadrique, Luis Mart\u00edn Arias, Juan Arcadio Molina-Guarneros, Natalia Jimeno Bulnes, \nPilar Garc\u00eda Ortega\nEffectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in  296 \npatients with hepatitis C\nJuan Carlos del Rio-Valencia, Roc\u00edo Asensi-Diez, Roc\u00edo Tamayo-Bermejo, Isabel Mu\u00f1oz-Castillo\nDrug-resistant bacteria on hands of healthcare workers and in the patient area: 303 \nan environmental survey in Southern Italy\u2019s hospital\nVincenza La Fauci, Gaetano Bruno Costa, Cristina Genovese, Maria Angela Rita Palamara, Valeria \nAlessi, Raffaele Squeri\nRisk factors to secondary nosocomial bacteremia to UTI in a tertiary hospital 311\nLaura Sante, Mar\u00eda Lecuona, Armando Aguirre Jaime, \u00c1ngeles Arias\nHospital admission and mortality causes of HIV patients in a third level hospital 317\nRoc\u00edo Asensi-Diez, Cristina Fern\u00e1ndez-Cuerva, Juan Jos\u00e9 Alcaraz S\u00e1nchez, Isabel Mu\u00f1oz-Castillo\nPrevalence of genital Mycoplasma  and response to eradication treatment in patients  327 \nundergoing assisted reproductive techniques\nErnesto Veiga, Mercedes Trevi\u00f1o, Ana Bel\u00e9n Romay, Daniel Navarro, Roc\u00edo Trastoy, Manuel Mac\u00eda\nThe situation of vaccines for the prevention of infections in adults: An opinion 333 \npaper on the situation in Spain\nEmilio Bouza, Julio Ancochea-Berm\u00fadez, Magda Campins, Jos\u00e9 Mar\u00eda Eir\u00f3s-Bouza, Jes\u00fas Fargas, \nAm\u00f3s Jos\u00e9 Garc\u00eda Rojas, Diego Gracia, Alipio Guti\u00e9rrez S\u00e1nchez, Aurora Limia, Jos\u00e9 Antonio L\u00f3pez, \nMar\u00eda del Carmen Magro, Gloria Mirada, Patricia Mu\u00f1oz, Eduardo Olier, Ra\u00fal Ortiz de Lejarazu, \nLuis Urbiztondo, Esteban Palomo  \nComparison of two methods skipping cell lysis and protein extraction for 365 \nidentification of bacteria from blood cultures by matrix-assisted laser desorption/\nionization time-of-flight mass-spectrometry\nIgnacio Torres, Estela Gim\u00e9nez, Dixie Huntley, Mireia Mart\u00ednez, Javier Colomina, David Navarro\nEvaluation of a rapid assay for detection of PBP2a Staphylococcus  aureus  370\nRoc\u00edo S\u00e1inz-Rodr\u00edguez, Inmaculada de Toro-Peinado, Miriam Valverde-Troya,  \nM\u00aa Pilar Berm\u00fadez Ru\u00edz,  Bego\u00f1a Palop-Borr\u00e1s\nIs it possible to extrapolate the rates of resistance of Escherichia  coli from 375 \nasymptomatic bacteriuria in pregnant women to those of E. coli  in uncomplicated \ncommunity-acquired UTI?\nAlejandra Asenjo, Mart\u00edn C. Grados, Jes\u00fas Oteo-Iglesias, Juan-Ignacio Al\u00f3sSystematic \nReview\nOriginals\nBrief ReportContents\nQuimioterapiaREVISTA ESPA\u00d1OLA DE\nReactivation of the cryopyrin-associated periodic syndrome after vaccination 379 \nin a patient who is a candidate for immunosuppression\nMar\u00eda Fern\u00e1ndez-Prada, Jessica Rugeles-Ni\u00f1o, Luc\u00eda Su\u00e1rez-P\u00e9rez, Miguel Ruiz-\u00c1lvarez, Jos\u00e9 \nBernardino L\u00f3pez-D\u00edaz, Juan Fern\u00e1ndez-Madera, Carmen Mart\u00ednez-Ortega, Ismael Huerta-\nGonz\u00e1lez\nNocardia farcinica  isolated meningitis in a patient with Beh\u00e7et\u2019s disease:  381 \ncase report and literature review\nKiana Shirani, Fatemeh Mohajeri\nAcute zoonotic total knee prosthetic joint infection due to Pasteurella  multocida  384  \ntreated successfully with debridement, irrigation and antibiotics without prosthesis \nremoval\nMaria Pilar Ortega Lafont, Luis Buz\u00f3n Mart\u00edn, Ledicia \u00c1lvarez Paredes, Mar\u00eda Mora Fern\u00e1ndez, \nAntonio Rodr\u00edguez P\u00e9rez, Miguel \u00c1ngel Mor\u00e1n Rodr\u00edguez\nDolutegravir in acute HIV-1 infection: first reported case 387\nFranco Garibaldi, Marcia Pozzati, Claudia Rodriguez, Diego Cecchini\nSeptic shock secondary to Elizabethkingia  meningoseptica : A case report. 390\nDavid Brandariz N\u00fa\u00f1ez, Paula Rodr\u00edguez Pedreira, Virginia Hern\u00e1ndez Corredoira, Joaquin Puig \nForcada, Francisco J Gurri Hernand, Arturo S Boix Boix\nBacteremia by Actynomices  oris 393\nJavier Miguel Mart\u00edn Guerra, Miguel Mart\u00edn Asenjo, Claudia Iglesias P\u00e9rez, Carlos Jes\u00fas Due\u00f1as \nGuti\u00e9rrez\nInfectious endocarditis caused by Candida  glabrata : evidence of in vivo development 395 \nof echinocandin resistance\nCaroline Agnelli, Jesus Guinea, Maricela Valerio, Pilar Escribano, Emilio Bouza, Patricia Mu\u00f1oz\nPeritonsillar abscess  due to Actinomyces  marseillensis  398\nSara G\u00f3mez de Frutos, Marta Soledad Rodr\u00edguez Anzules, Arturo Manuel Fraile Torres, Laura \nCarde\u00f1oso Domingo, Diego Domingo Garc\u00eda\nConsensus document for sepsis code implementation and development in 400 \nthe Community of Madrid \nEduardo Palencia Herrej\u00f3n, Juan Gonz\u00e1lez del Castillo, Fernando Ramasco Rueda, Francisco \nJavier Candel Gonz\u00e1lez, Beatriz S\u00e1nchez Artola, Andr\u00e9s von Wernitz Teleki, Federico Gordo Vidal, \nPatricia Roces Iglesias, Guillermina Bejarano Redondo, Diego An\u00edbal Rodr\u00edguez Serrano, Francisco \nJavier Cobo Reinoso, Ervigio Corral Torres, Milagros Mart\u00ed de Gracia, Ana Ruiz \u00c1lvarez y el Grupo \nMultidisciplinar C\u00f3digo Sepsis MadridVolume 32\nNumber 4\nAugust 2019\nLetters to the \neditor\nConsensus \nDocumentRev Esp Quimioter 2019;32(4): 288-295288\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).S\u00edndrome de Guillain-Barr\u00e9 y vacuna \nantigripal: evidencia actual\nRESUMEN\nIntroducci\u00f3n.  El s\u00edndrome de Guillain-Barr\u00e9 (GBS) despu\u00e9s \nde la administraci\u00f3n de la vacuna frente a la gripe es un tema \nactual que sigue causando preocupaci\u00f3n tanto en el personal \nsanitario como en la poblaci\u00f3n y que permanece sin esclarecer.  \nEl objetivo del presente trabajo es investigar la publicaci\u00f3n de \nnuevos datos desde la realizaci\u00f3n de nuestro metaan\u00e1lisis so -\nbre el GBS y las vacunas frente a la gripe (publicado en 2015).\nM\u00e9todos.  Se ha realizado una revisi\u00f3n sistem\u00e1tica en las \nbases de datos PubMed, Embase y Web of Science (WOS) de \nestudios observacionales que evaluar\u00e1n el riesgo de GBS des -\npu\u00e9s de la administraci\u00f3n de vacunas influenza, desde mayo de \n2014 hasta el 20 de julio de 2017.\nResultados . El resultado de las b\u00fasquedas fue de 107 art\u00ed -\nculos. Finalmente, solo 3 estudios cumpl\u00edan con los criterios de \ninclusi\u00f3n establecidos y refer\u00edan una estimaci\u00f3n del riesgo de \nGBS despu\u00e9s de alguna de las vacunas antigripales. Dos estu -\ndios investigaron el riesgo de GBS con la vacuna pand\u00e9mica A/\nH1N1 y un estudio investig\u00f3 las vacunas estacionales.\nConclusiones.  Esta revisi\u00f3n sistem\u00e1tica parece confirmar \nlos hallazgos obtenidos en nuestro metaan\u00e1lisis. El SGB se po -\ndr\u00eda considerar como un posible efecto adverso poco frecuente \nde las vacuna antigripales, lo cual no deber\u00eda afectar negati -\nvamente en su aceptaci\u00f3n. Desafortunadamente, en nuestra \nrevisi\u00f3n sistem\u00e1tica, hemos encontrado muy pocos estudios \nque cumplieran los criterios de inclusi\u00f3n, este hecho resulta \nllamativo ya que el consenso actual se\u00f1ala la necesidad de una \nmonitorizaci\u00f3n continua sobre la seguridad de las vacunas an -\ntigripales.\nPalabras clave: vacuna A/H1N1, S\u00edndrome de Guillain-Barr\u00e9, gripe.ABSTRACT\nPurpose.  Guillain-Barr\u00e9 Syndrome (GBS) as a consequence \nof influenza vaccination is a relevant topic, yet to be clarified, \nwhich raises concern both amongst health care personnel and \nthe general population. Every study and pharmacovigilance \nsystem point to need of further research and the importance of \ncontinuous monitoring of safety regarding influenza vaccines. \nThe aim of the present study is to investigate the publication \nof new data since the realisation of our meta-analysis of GBS \nand influenza vaccines (published in 2015). \nMethods. A systematic revision of PubMed, Embase, and Web \nof Knowledge (WOS) databases has been carried out. These report \nobservational studies assessing GBS risk after the administration of \ninfluenza vaccines from May 2014 up to July 20th, 2017.\nResults.  The research yielded 107 articles. Only three \nstudies met established inclusion criteria and referred to an \nestimation GBS risk after some influenza vaccine. Two studies \ninvestigated GBS risk by the pandemic A/H1N1 vaccine, while \nonly one looked into season vaccines. \nConclusions.  The present systematic review, conducted \nafter the publication of our previous meta-analysis, seems \nto confirm its previous results. Therefore, GBS should \nbe considered an infrequent adverse effect of influenza \nvaccination, which should not negatively influence its \nacceptance. Unfortunately, very few of the systematically \nsurveyed studies meeting inclusion criteria. This fact sharply \ncontrasts with the current consensus as to the need of \ncontinuously monitoring the safety of influenza vaccines.\nKeywords: A/H1N1 vaccine, Guillain-Barr\u00e9 syndrome, influenza vaccines.Guillain-Barr\u00e9 syndrome and influenza vaccines: \ncurrent evidence\n1Centre for Drug Surveillance (CESME). Valladolid University, Spain.\n2Department of Pharmacology, Faculty of Medicine. National Autonomous University of Mexico.\n3Faculty of Medicine, Valladolid University Spain.Rosario Sanz Fadrique1\nLuis Mart\u00edn Arias1\nJuan Arcadio Molina-\nGuarneros2\nNatalia Jimeno Bulnes3\nPilar Garc\u00eda Ortega3\nCorrespondence:\nJuan A. Molina Guarneros.\nSchool of Medicine\nC/Ram\u00f3n y Cajal, 7 - 45005 Valladolid (Spain)\nPhone: 983 263021 / 983 186456\nFax.: 983 254924\nE-mail: farmacovigilancia.cyl.cesme@uva.esSystematic review\nArticle history\nReceived: 11 March 2019; Revision Requested: 14 April 2019; Revision Received: 1 May 2019; Accepted: 7 May 2019Guillain-Barr\u00e9 syndrome and influenza vaccines: current evidence R. Sanz, et al.\nRev Esp Quimioter 2019;32(4): 288-295289RESULTS\nThe bibliographic review enabled us to identify 107 studies \n(figure 1): PubMed (n=39), EMBASE (n=44), and WoS (n=24). \nFirst, we eliminated the articles lacking an abstract (n=15), \nthose containing lectures and oral comments (n=7), those no -\ntifying isolated cases (n=3), duplicated articles (n=30), and ar -\nticles previously reviewed or included in our earlier meta-anal -\nysis (n=10) [16]. Then, we read the article abstracts and/or the \nwhole texts of the potentially eligible studies. Some of the \nexclusion criteria were the following: a) studies based on the \nresults from surveillance system notifications of serious and \nnon-serious adverse effects supposedly related to any of the \ninfluenza vaccines that did not report any estimates of GBS \nrisk following influenza vaccination [17-22], b) pharmacovigi -\nlance studies on GBS that included any types of paediatric im -\nmunisation [23], c) studies addressing the potential triggering \nagents for GBS [24], c) studies based on risk simulation of GBS \nand other autoimmune diseases associated with either infec -\ntions or influenza vaccination [25, 26], d) studies whose design \nor analysis of data on vaccine safety was considered not to be \nsuitable [27, 28, 29], and e) studies focusing on other influenza \nvaccination adverse effects, such as polyneuropathies, neuro -\nlogical events, Zika virus or surgery\nOnly 3 studies met all the eligibility criteria (table 1), as \nfollows: Kim et al .; 2015 [30], in which an increased risk of \nGBS was observed in South Korea following the administration \nof the adjuvanted and non-adjuvanted pandemic vaccine A/\nH1N1, with the risk expressed as a rate ratio (RR=1.46, 95% \nCI: 1.26-1.68); Ghaderi et al .; 2015 [31], in which the authors \nfound an increased risk of GBS in Norway within 42 days after \nthe administration of the pandemic vaccine A/H1N1 (Pandem -\nrix\u00ae), with the risk expressed as a hazard ratio (HR= 1.1, 95% \nCI: 0.51-2.43); and Sandhu et al.; 2017 [7], which focused on \nthe outcomes for four influenza vaccination campaigns (from \n2010/11 to 2013/14). In this latter study, the authors reported \na statistically non-significant increased risk of GBS (RR=1.25, \n95% CI: 0.96-1.63) for the season 2010/1011 among a Medi -\ncare population (USA); with the risk being much lower than \nthat observed in the season 2009/10 (RR=1,98, 95% CI: 1.42-\n2.76), while an increased risk was not found in the remaining \nthree vaccination campaigns (i. e. from 2011/12 to 2013/14).\nDISCUSSION\nOur systematic review focused on the new data about \ninfluenza vaccination and its potential association with GBS \npublished after the publication of our prior meta-analysis [16]. \nThe review of the published articles enabled us to identify \nonly three epidemiological studies that fulfilled the eligibili -\nty criteria [7, 30, 31]. It is striking the shortage of published \nstudies estimating the magnitude of the GBS risk linked to or \nfollowing the administration of the influenza vaccines when \ntaking into account that the relevant health authorities have \nbeen emphasizing the necessity for continuously monitoring \nthe potential adverse effects of influenza vaccination [21, 28, INTRODUCTION\nGuillain-Barr\u00e9 syndrome (GBS) consists of an acute de -\nmyelinating neuropathy involving the peripheral nervous sys -\ntem. It causes weakness, paralysis, and, in some cases, leads to \ndeath [1-3]. GBS is regarded to be a rare autoimmune disease, \nin which the body is attacked by its own immune system [3-5].\nGBS incidence ranges from 0.8 to 1.9 per 100,000 persons/\nyear, being more frequent among males, and the incidence \nincrease with age [1, 2, 6, 7]. So far, the precise causes that \ntrigger the disease are not well known. It has been reported \nthat GBS is preceded by an infection of the gastrointestinal or \nrespiratory tract in 2/3 of cases. It has been also linked to some \nviral infections, and even to influenza vaccination [5, 8-11].\nThe association of GBS with influenza vaccination was \nfirst reported in 1976, when the seasonal vaccination cam -\npaign was stopped in the United States due to an excess of \nGBS cases (relative risk [RR]: 7-8) [12]. However, few stud -\nies addressing the potential relationship of GBS to influenza \nvaccination were published between 1976 and 2009. Since \nthe pandemic outbreak of influenza A in 2009, the vaccine A/\nH1N1/2009 were rapidly developed, manufactured and com -\nmercialised, and surveillance systems were reinforced, adapted \nor set up with the aim of identifying as early as possible any \nincidence excess of GBS, notably in the United States, wherein \nan increased risk of GBS associated to influenza vaccine was \nfound [13, 14]. \nWhile isolated studies on vaccination campaigns and ac -\ntive and passive notification of GBS cases by surveillance sys -\ntems have been conducted; so far, little research has been de -\nvoted to synthesising the results from epidemiological studies \n[14, 15]. In 2015, we carried out a meta-analysis with the aim \nof studying the possible relationship between GBS and influ -\nenza vaccination. Now, in this article, we present the results of \na systematic review of the literature, whose objective was to \nanalyze the new data that has been appearing since the publi -\ncation of our meta-analysis [16].\nMETHODS\nWe reviewed the databases PubMed, EMBASE, and Web \nof Knowledge (WoS) covering the period 1-May-2014 / 20-Ju -\nly-2017. We used the same search terms and study selection \ncriteria as in our prior meta-analysis [16]. The search was con -\nducted by combining the terms Influenza vaccine* AND Guil -\nlain-Barr\u00e9 syndrome, with no restrictions. Criteria for the in -\nclusion of studies were the following: (a) observational studies \nevaluating the risk of GBS associated with any of the influen -\nza vaccines, and (b) studies reporting risk measures expressed \nas relative risk (RR), odds ratio (OR), relative incidence (RI), or \nincidence rate ratio (IRR); though, in the present review, we \nincluded a new risk measure as well, namely the hazard ratio \n(HR). In all cases, we considered the respective 95% confidence \nintervals (95% CI). Guillain-Barr\u00e9 syndrome and influenza vaccines: current evidence R. Sanz, et al.\nRev Esp Quimioter 2019;32(4): 288-295290ly published meta-analysis (table 2), it should be pointed out \nthat, in one of the studies selected for our review, Kim et al.  \n[30] concluded that the pandemic vaccine (pH1N1) was as -\nsociated with an increased risk of GBS expressed as a relative \nrisk of 1.46; (95% CI, 1.26-1.68). This finding is in keeping with \nthe results from two meta-analyses [15, 16], which reported \na GBS risk estimate expressed as a relative incidence of 2.09 \n(95% CI: 1.28-3.42) and a relative risk of 1.84 (95% CI: 1.36-\n2.50), respectively. The finding by Kim et al. is also in line with \nthe results from other individual studies [36-40]. Another \nmeta-analysis [14] reported a statistically non-significant in -\ncreased risk of GBS for the vaccine H1N1 2009 expressed as \nan incidence rate ratio of 2.35 (95% CI: 1.42-4.01), which con -\ncurs with the results from several other individual studies [33, \n41]. The second study identified by our systematic review was \nthat by Ghaderi et al. [31], who reported that the pandemic \nvaccine (pH1N1) was not associated with an increased risk of \nGBS. This finding is in keeping with the results from some pre -29, 32] .Furthermore, it is well known the importance of hav -\ning post-commercialisation studies on the influenza vaccines \n[17-20, 22, 33], as well as near real-time pharmacovigilance \nstudies aimed at rapidly identifying any risk excess of GBS \nfollowing influenza vaccination [7, 13]. Despite these studies \nhave the disadvantage that it is difficult to quantify any caus -\nal associations; they present the advantage of enabling us to \nrapidly detect the signals for potential adverse events follow -\ning immunization (AEFI). In addition, such studies may consti -\ntute the starting basis for further investigation on potential \ncausal associations. Therefore, it should be emphasised the im -\nportance of conducting and reporting multicentre, collabora -\ntive, epidemiological studies with prolonged follow-up periods \naimed to identifying and quantifying potential unexpected or \nrare adverse effects (e. g. GBS) following influenza vaccination \n[7, 15, 34, 35].\nConcerning the risk reported in the observational studies \nselected for our systematic review (table 1) and our previous -Figure 1  Flow diagram showing identification of studies meeting inclusion \ncriteria.\nGuillain-Barr\u00e9 syndrome and influenza vaccines: current evidence R. Sanz, et al.\nRev Esp Quimioter 2019;32(4): 288-2952918-11, 46-47]. One of the studies selected for our systematic \nreview supported the hypothesis that the influenza infection is \na potential triggering agent among the Norwegian population. \nThese authors found a post-influenza infection risk expressed \nas a hazard ratio (HR) of 4.89 (95% CI: 1.17-20.36), this risk \nmagnitude being much higher than that observed after influ -\nenza vaccination (HR=1.11 95%CI: 0.51-2.43) [31]. Another \nstudy we selected for our review reported that in 82.5% of \nGBS cases there had been a previous respiratory or gastroin -\ntestinal infection [30]. This finding is in agreement with the \nresults from a study reporting a strong association of GBS \nwith either previous respiratory or gastrointestinal infections \nor previous unspecific viral infections (odds ratio=7.73, 95% \nCI: 3.60-16.61) [46]. The results from other studies also sup -\nport the aforementioned hypothesis, since the authors noted \nan important increment in the risk of GBS following a previous \ninfection. Thus, Tam et al. reported an odds ratio (OR) of 18.6, \n(95% CI: 7.5-46.4), whilst Stowe et al.  spoke of a relative risk \n(RR) of 7.35, (95% CI: 4.36-12.38) within the first 60 and 90 \ndays of an influenza-like illness (ILI), respectively [8, 10]. \nAnother potential triggering factor for GBS reported in \nthe studies we have reviewed is surgery. According to the re -\nsults of a study conducted in Finland, the relative risk of devel -\noping GBS within the first 6 weeks after surgery is 13.1-fold \nhigher (95% CI: 5.68-30.3, P \u2264 0.0001) [24]. This finding con -\ncurs with the results of other studies [48, 49]. Also, it has been \nreported an increase in the notified GBS cases related to the \nZiKa virus infection [50].\nWith regard to the type of study, in our systematic review \nwe found that some of the published studies were based on vious studies [34, 42]. Finally, the third study we selected, that \nis, that by Sandhu et al. [7] , focused on the outcomes of four \ninfluenza vaccination campaigns. The authors reported a sta -\ntistically non-significant increased risk expressed as a relative \nrisk (RR=1.25, 95% CI: 0.96-1.63) in the season 2010/11. How -\never, they failed to observe any risk excess in the remaining \nthree seasons. In this latter study, the authors found an in -\ncreased risk of GBS (RR=1.98 95% CI: 1.42-2.76) for the season \n2009/10. In contrast, an investigation based on both simula -\ntion models and previously published risk estimates [26] sup -\nported the hypothesis posed in an earlier study that influenza \nimmunisation was protective against GBS, and, therefore, re -\nsulted in a decreased risk [43] . At any rate, it should be borne \nin mind that the differences in the risk magnitudes reported in \neach study are small and they only approximated to the value \nwith statistical significance by either excess or defect. On the \nother hand, the coverage of influenza vaccination programmes \nis broader every year, and this is not positively correlated with \nthe number of hospitalisations for GBS [44]. In addition, it is \nworth reminding that the financial burden associated with the \ncomplications derived from the infections caused by the in -\nfluenza virus largely exceeds the financial costs of influenza \nvaccination [45]. \nLikewise, other suspected triggering agents of GBS, apart \nfrom influenza vaccination, should be taken into considera -\ntion. The current evidence indicates that previous infections \nare likely to play an important role in the development of \nGBS, notably the infections involving the upper respiratory \ntract or the gastrointestinal tract, those caused by the influ -\nenza virus and the so-called influenza-like infections (ILI) [5, Authors/Year Study location GBS cases Design Influenza vaccine Risk\nGhaderi et al. 2016 Norwey 410 Cohort A(H1N1) 2009 HR=1.11 (95% CI 0.51-2.43)\nKim et al. 2016 Korea 245 Cohort A(H1N1) 2009 RR=1.46 (95% CI: 1.26-1.68)\nSandhu et al. 2017 USA SCRI 2010/11 seasonal RR=1.25 (95% CI: 0.96-1.63)Table 1  Characteristics of selected observational studies.\nSCRI: Self-controlled risk interval (SCRI) design; HR: Hazard ratio; RR=risk relative.\nAuthors/Year Study location Design Influenza vaccine Risk\nSalmon et al. 2013 USA Meta-analysis A (H1N1) 2009 IRR=2.35 (95% CI 1.2-4.01)\nDodd et al. 2013 International* Meta-analysis A (H1N1) 2009 RI= 2.09 (95%CI 1.28-3.42)\nMart\u00edn Arias et al. 2015 International Meta-analysis A(H1N1) 2009\nSeasonalRR= 1.84 (95%CI 1.36-2.50)\nRR= 1.22 (95%CI 1.01-1.48)Table 2  Characteristics of previous published meta-analysis.\n*Australia, Canada, China, Denmark, Finland, The Netherlands, Singapore, Spain, The United Kingdom and The United States \nDatabases.\nIRR: Incidence rate ratio. RI: relative incidence. RR: relative risk.Guillain-Barr\u00e9 syndrome and influenza vaccines: current evidence R. Sanz, et al.\nRev Esp Quimioter 2019;32(4): 288-295292dren. Further investigation is needed to provide information re -\ngarding influenza vaccination during pregnancy. This issue was \naddressed by only three of the studies we found in our initial \nsearch [22, 52, 53]. Thus, in a large cohort of pregnant women \nto whom the vaccine A/H1N1 was given, the authors did not \nfind any cases of GBS within the first 42 days after vaccination \n[52]. Nevertheless, it was notified a case of GBS that occurred \n24 days after the administration of a trivalent influenza vac -\ncine (TIV) to a pregnant woman during the 2013/14 campaign \n[53]. The pharmacovigilance system deployed in Latin America \nand the Caribbean to monitor the potential adverse effects of \nthe vaccine A/H1N1 reported increased adverse effect rates \namong pregnant women as compared to those among health -\ncare personnel and patients with chronic diseases [22], which \nmight be explained by differences in the influenza virus strains \nthat circulate in both hemispheres. \nFew studies initially screened for our systematic review \naddressed the potential relationship between influenza vacci -\nnation and GBS in paediatric populations [47, 54-56]. A pro -\nspective epidemiological study conducted in the UK based on \nthe UK pharmacovigilance system (British Paediatric Surveil -\nlance Unit System) [47] showed that GBS and \u201cMiller Fisher \nsyndrome\u201d associated with the pandemic influenza vaccine \nwere more prevalent among boys compared to girls. In ad -\ndition, this study revealed that most of the affected children \nhad suffered a previous infection, and that the cases associat -\ned with the pandemic vaccine were more frequent than those \nassociated with the seasonal vaccine, though this difference \ndid not reach statistical significance. This finding is in keeping \nwith the results of another study [7], and coincides with those \nof our previous meta-analysis [16]. In a safety study in children \naged 6-12 months conducted in Taiwan, the authors failed to \nfind serious adverse events within the first 7 days after the \nadministration of a killed TIV during the 2010/11 campaign \n[54]. In a USA pharmacovigilance study with the live quad -\nrivalent influenza vaccine (LAIV4), it was found that the most \nfrequently notified non-fatal serious adverse reactions were \nthose involving the nervous and respiratory systems. Neuro -\nlogical adverse reactions were more frequent in children than \namong adults, and GBS was the second most frequently noti -\nfied neurological event [56]. This children\u2019s susceptibility may \nbe related either to genetic heredity or to the type of vaccine, \nsince live vaccines have not been sufficiently investigated in \nchildren aged under 2 years, and the established safety of a \ngiven influenza vaccine cannot be extrapolated to the remain -\nder of vaccines [55]. \nThe advent of inmunogenomics, proteomics, genetic en -\ngineering, biostatistics, and computational studies may help \nto find biomarkers that allow us to identify the differences in \nboth individual and group pathophysiologic mechanisms. In \nturn, these differences might explain why certain individual or \ngroups present a greater susceptibility to autoimmune diseas -\nes following vaccination. Some genetic polymorphisms (e. g. \nHLA-DQB1*) are known to render carriers more susceptible to \ndevelop GBS [57, 58], while computational simulation studies \n(in silico ) have identified some genes involved in 4 types of au -the notifications of supposed adverse reactions related to the \ndifferent influenza vaccines, such as the notifications by the \nVaccine Adverse Reporting System (VAERS). However, it should \nbe kept in mind that, while these notifications are very useful \nfor the quick detection of safety concerns, they are not of val -\nue for establishing potential cause-effect relationships. \nEpidemiological studies with self-controlled design, \nlike self-controlled case series, self-controlled risk-interval, \ncase-centred and case-population studies, represent the most \nsuitable approach in the field of observational studies, since, in \nthis type of investigation, each case acts as its own control. In \naddition, these studies are adjusted for all confounding factors \nthat may vary with time. In our earlier meta-analysis, 24 of the \n39 weighted studies used the self-controlled design [16]. Nev -\nertheless, few studies have reported the risk estimates adjusted \nfor either seasonality or subjects\u2019 previous infections [15, 34]. \nIn the three studies selected for the present systematic review, \nthe authors referred to seasonality as an important factor. In \none of these studies, a larger number of cases was found in \nNovember, January and February [30], whereas another study \nshowed a significant increased risk of GBS during the pandem -\nic period compared to other time intervals [31].\nThe studies selected for our systematic review (i.e. 3/107) \nestimated the risk of GBS following influenza vaccination, \nshowing a very small risk excess magnitude when taking into \naccount the financial and health benefits obtained from im -\nmunisation. Indeed, the risk excess is very small; however, oth -\ner potential explanatory factors should be considered, such as \nthe low incidence rate of GBS, the temporal coincidence with \nthe periods with the largest circulation of the influenza virus, \nthe occurrence of respiratory and gastrointestinal infections, \nor the administration of the vaccine for either seasonal (Oc -\ntober-November) or pandemic influenza. All the above factors \nmay make it difficult to interpret the results from the epidemi -\nological studies on the potential relationship between influen -\nza vaccination and GBS. \nIn relation to the differences in the estimates of the risk as \nreported in the different studies, they can be combined or rec -\nonciled, because post-vaccination GBS is a rare condition [16]. \nAccording to two studies, the risk estimates obtained with the \ncase-population approach (CPA) are consistent with the odds \nratios in the case-control studies, and discrepancies were ob -\nserved only with the vaccine A (H1N1) in Sweden and UK [27, \n28]. In a review of the statistical methods used in vaccine sur -\nveillance studies, the authors indicated that up to 37 different \nmethods can be used depending on the kind of analysis [29].\nThe studies selected for our systematic review reported \nthat GBS was more prevalent among males and elderly peo -\nple, which is in agreement with the results from earlier inves -\ntigation [1-2, 14]. Thus, in 1983 a study was published, whose \nauthors stated that GBS was more frequent in males, the in -\ncidence increased with age, and incidence rates were more \nheightened among white race individuals [51].\nAnother issue of concern for particularly sensitive popula -\ntions is influenza vaccine safety for pregnant women and chil -Guillain-Barr\u00e9 syndrome and influenza vaccines: current evidence R. Sanz, et al.\nRev Esp Quimioter 2019;32(4): 288-295293Mycoplasma infections, and hospital admissions for Guillain-Barre \nsyndrome, England. Emerg Infect Dis. 2006;12(12):1880-7. DOI: \n10.3201/eid1212.051032\n9. Tam CC, O\u2019Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. \nGuillain-Barre syndrome and preceding infection with campy -\nlobacter, influenza and Epstein-Barr virus in the general practice \nresearch database. PLoS One. 2007;2(4):e344. DOI: 10.1371/journal.\npone.0000344\n10. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal \nassociation of Guillain-Barre syndrome with influenza vaccine and \ninfluenzalike illness using the United Kingdom General Practice Re -\nsearch Database. Am J Epidemiol. 2009;169(3):382-8. DOI: 10.1093/\naje/kwn310\n11. Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barre \nsyndrome after exposure to influenza virus. Lancet Infect Dis. \n2010;10(9):643-51. DOI: 10.1016/S1473-3099(10)70140-7\n12. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, \nZiegler DW, Retailliau HF, et al. Guillain-Barre syndrome follow -\ning vaccination in the National Influenza Immunization Program, \nUnited States, 1976--1977. Am J Epidemiol. 1979;110(2):105-23. \nPMID: 463869\n13. Centers for Disease C, Prevention. Preliminary results: surveillance \nfor Guillain-Barre syndrome after receipt of influenza A (H1N1) \n2009 monovalent vaccine - United States, 2009-2010. MMWR \nMorb Mortal Wkly Rep. 2010;59(21):657-61. PMID: 20520590\n14. Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen \nDR, et al. Association between Guillain-Barre syndrome and influ -\nenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: \na meta-analysis. Lancet. 2013;381(9876):1461-8. DOI: 10.1016/\nS0140-6736(12)62189-8\n15. Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom \nM, et al. International collaboration to assess the risk of Guillain \nBarre Syndrome following Influenza A (H1N1) 2009 monovalent \nvaccines. Vaccine. 2013;31(40):4448-58. DOI: 10.1016/j.vac -\ncine.2013.06.032\n16. Martin Arias LH, Sanz R, Sainz M, Treceno C, Carvajal A. Guil -\nlain-Barre syndrome and influenza vaccines: A meta-analysis. Vac -\ncine. 2015;33(31):3773-8. DOI: 10.1016/j.vaccine.2015.05.013\n17. Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, et al. \nPost-licensure surveillance of trivalent live attenuated influenza \nvaccine in adults, United States, Vaccine Adverse Event Reporting \nSystem (VAERS), July 2005-June 2013. Vaccine. 2014;32(48):6499-\n504. DOI: 10.1016/j.vaccine.2014.09.018\n18. Moro PL, Winiecki S, Lewis P, Shimabukuro TT, Cano M. Surveillance \nof adverse events after the first trivalent inactivated influenza vac -\ncine produced in mammalian cell culture (Flucelvax((R))) reported \nto the Vaccine Adverse Event Reporting System (VAERS), United \nStates, 2013-2015. Vaccine. 2015;33(48):6684-8. DOI: 10.1016/j.\nvaccine.2015.10.084\n19. Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT. \nPost-licensure surveillance of quadrivalent live attenuated influen -\nza vaccine United States, Vaccine Adverse Event Reporting System \n(VAERS), July 2013-June 2014. Vaccine. 2015;33(16):1987-92. DOI: toimmune diseases, including GBS, a disease in which as many \nas 73 genes may be implicated [25]. Nonetheless, a meta-anal -\nysis based on Asian and Caucasian populations did not find \nany relationships between alleles and risk of GBS [59]. \nThe present systematic review we conducted after the \npublication of our previous meta-analysis seems to confirm the \nresults of such a meta-analysis. Therefore, GBS should be con -\nsidered an infrequent adverse effect of influenza vaccination, \nwhich should not negatively influence the vaccination accept -\nance. However, unfortunately, very few of the studies meeting \ninclusion criteria that we found in our systematic review pre -\nsented sufficient quality. This fact sharply contrasts with the \ncurrent consensus as to the need of continuously monitoring \nthe safety of influenza vaccines. Therefore, one would expect \nto find a larger number of competent studies that allow us to \ndetect near real-time signals. However, today it is not easy to \nfind such studies in the medical literature. \nFUNDING\nNone to declare\nCONFLICT OF INTEREST\nThe authors declare that they have not conflict of interest.\nREFERENCES\n1. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence \nof Guillain-Barre syndrome: a systematic review and meta-analysis. \nNeuroepidemiology. 2011;36(2):123-33. DOI: 10.1159/000324710\n2. Shui IM, Rett MD, Weintraub E, Marcy M, Amato AA, Sheikh SI, \net al. Guillain-Barre syndrome incidence in a large United States \ncohort (2000-2009). Neuroepidemiology. 2012;39(2):109-15. DOI: \n10.1159/000339248\n3. Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med. \n2012;366(24):2294-304. DOI: 10.1056/NEJMra1114525\n4. Hardy TA, Blum S, McCombe PA, Reddel SW. Guillain-barre syn -\ndrome: modern theories of etiology. Curr Allergy Asthma Rep. \n2011;11(3):197-204. DOI: 10.1007/s11882-011-0190-y\n5. Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, \nand influenza vaccination: the epidemiologic evidence. Clin Infect \nDis. 2014;58(8):1149-55. DOI: 10.1093/cid/ciu005\n6. Benedetti MD, Pugliatti M, D\u2019Alessandro R, Beghi E, Chio A, Logro -\nscino G, et al. A Multicentric Prospective Incidence Study of Guil -\nlain-Barre Syndrome in Italy. The ITANG Study. Neuroepidemiology. \n2015;45(2):90-9. DOI: 10.1159/000438752\n7. Sandhu SK, Hua W, MaCurdy TE, Franks RL, Avagyan A, Kelman J, \net al. Near real-time surveillance for Guillain-Barre syndrome after \ninfluenza vaccination among the Medicare population, 2010/11 \nto 2013/14. Vaccine. 2017;35(22):2986-92. DOI: 10.1016/j.vac -\ncine.2017.03.087\n8. Tam CC, O\u2019Brien SJ, Rodrigues LC. Influenza, Campylobacter and Guillain-Barr\u00e9 syndrome and influenza vaccines: current evidence R. Sanz, et al.\nRev Esp Quimioter 2019;32(4): 288-29529433. Yih WK, Lee GM, Lieu TA, Ball R, Kulldorff M, Rett M, et al. Sur -\nveillance for adverse events following receipt of pandemic 2009 \nH1N1 vaccine in the Post-Licensure Rapid Immunization Safe -\nty Monitoring (PRISM) System, 2009-2010. Am J Epidemiol. \n2012;175(11):1120-8. DOI: 10.1093/aje/kws197\n34. Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturken -\nboom M, et al. Guillain-Barre syndrome and adjuvanted pandemic \ninfluenza A (H1N1) 2009 vaccine: multinational case-control study \nin Europe. BMJ. 2011;343:d3908. DOI: 10.1136/bmj.d3908\n35. Romio S, Weibel D, Dieleman JP, Olberg HK, de Vries CS, Sammon \nC, et al. Guillain-Barre syndrome and adjuvanted pandemic influ -\nenza A (H1N1) 2009 vaccines: a multinational self-controlled case \nseries in Europe. PLoS One. 2014;9(1):e82222. DOI: 10.1371/journal.\npone.0082222\n36. Greene SK, Rett M, Weintraub ES, Li L, Yin R, Amato AA, et al. Risk \nof confirmed Guillain-Barre syndrome following receipt of mon -\novalent inactivated influenza A (H1N1) and seasonal influenza \nvaccines in the Vaccine Safety Datalink Project, 2009-2010. Am J \nEpidemiol. 2012;175(11):1100-9. DOI: 10.1093/aje/kws195\n37. Wise ME, Viray M, Sejvar JJ, Lewis P, Baughman AL, Connor W, et \nal. Guillain-Barre syndrome during the 2009-2010 H1N1 influen -\nza vaccination campaign: population-based surveillance among \n45 million Americans. Am J Epidemiol. 2012;175(11):1110-9. DOI: \n10.1093/aje/kws196\n38. De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, Bouch -\ner RM, et al. Risk of Guillain-Barre syndrome following H1N1 in -\nfluenza vaccination in Quebec. JAMA. 2012;308(2):175-81. DOI: \n10.1001/jama.2012.7342\n39. Crawford NW, Cheng A, Andrews N, Charles PG, Clothier HJ, Day \nB, et al. Guillain-Barre syndrome following pandemic (H1N1) 2009 \ninfluenza A immunisation in Victoria: a self-controlled case series. \nMed J Aust. 2012;197(10):574-8. PMID: 23163689\n40. Prestel J, Volkers P, Mentzer D, Lehmann HC, Hartung HP, \nKeller-Stanislawski B, et al. Risk of Guillain-Barre syndrome fol -\nlowing pandemic influenza A(H1N1) 2009 vaccination in Germa -\nny. Pharmacoepidemiol Drug Saf. 2014;23(11):1192-204. DOI: \n10.1002/pds.3638\n41. Huang WT, Yang HW, Liao TL, Wu WJ, Yang SE, Chih YC, et al. Safe -\nty of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a \nself-controlled case series study. PLoS One. 2013;8(3):e58827. DOI: \n10.1371/journal.pone.0058827\n42. Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain-Barre \nsyndrome and H1N1 (2009) pandemic influenza vaccination using \nan AS03 adjuvanted vaccine in the United Kingdom: self-con -\ntrolled case series. Vaccine. 2011;29(45):7878-82. DOI: 10.1016/j.\nvaccine.2011.08.069\n43. Vellozzi C, Iqbal S, Stewart B, Tokars J, DeStefano F. Cumulative risk \nof Guillain-Barre syndrome among vaccinated and unvaccinated \npopulations during the 2009 H1N1 influenza pandemic. Am J Pub -\nlic Health. 2014;104(4):696-701. DOI: 10.2105/AJPH.2013.301651\n44. Iqbal S, Li R, Gargiullo P, Vellozzi C. Relationship between Guil -\nlain-Barre syndrome, influenza-related hospitalizations, and in -\nfluenza vaccine coverage. Vaccine. 2015;33(17):2045-9. DOI: 10.1016/j.vaccine.2015.01.080\n20. Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licen -\nsure surveillance of quadrivalent inactivated influenza (IIV4) vac -\ncine in the United States, Vaccine Adverse Event Reporting System \n(VAERS), July 1, 2013-May 31, 2015. Vaccine. 2016;34(22):2507-12. \nDOI: 10.1016/j.vaccine.2016.03.048\n21. Mayet A, Duron S, Meynard JB, Koeck JL, Deparis X, Migliani R. \nSurveillance of adverse events following vaccination in the French \narmed forces, 2011-2012. Public Health. 2015;129(6):763-8. DOI: \n10.1016/j.puhe.2015.03.003\n22. Ropero-Alvarez AM, Whittembury A, Bravo-Alcantara P, Kurtis HJ, \nDanovaro-Holliday MC, Velandia-Gonzalez M. Events supposed -\nly attributable to vaccination or immunization during pandemic \ninfluenza A (H1N1) vaccination campaigns in Latin America and \nthe Caribbean. Vaccine. 2015;33(1):187-92. DOI: 10.1016/j.vac -\ncine.2014.10.070\n23. Top KA, Desai S, Moore D, Law BJ, Vaudry W, Halperin SA, et al. \nGuillain-BarrE Syndrome After Immunization in Canadian Chil -\ndren (1996-2012). Pediatr Infect Dis J. 2015;34(12):1411-3. DOI: \n10.1097/INF.0000000000000903\n24. Sipila JO, Soilu-Hanninen M. The incidence and triggers of adult-on -\nset Guillain-Barre syndrome in southwestern Finland 2004-2013. \nEur J Neurol. 2015;22(2):292-8. DOI: 10.1111/ene.12565\n25. McGarvey PB, Suzek BE, Baraniuk JN, Rao S, Conkright B, Lababidi \nS, et al. In silico analysis of autoimmune diseases and genetic rela -\ntionships to vaccination against infectious diseases. BMC Immunol. \n2014;15:61. DOI: 10.1186/s12865-014-0061-0\n26. Hawken S, Kwong JC, Deeks SL, Crowcroft NS, McGeer AJ, Ducharme \nR, et al. Simulation study of the effect of influenza and influenza \nvaccination on risk of acquiring Guillain-Barre syndrome. Emerg \nInfect Dis. 2015;21(2):224-31. DOI: 10.3201/eid2102.131879\n27. Th\u00e9ophile H, Moore N, B\u00e9gaud B, Pariente A. Application of the \ncase-population approach to vaccine safety surveillance. Drug Saf. \n2015;38(10):1014. DOI: 10.1007/s40264-015-0346-0\n28. Th\u00e9ophile H, Pariente A, Moore N, B\u00e9gaud B. Is the case-population \napproach useful for vaccine safety surveillance? Pharmacoepide -\nmiol and Drug Saf. 2015;24(S1):187. DOI: 10.1002/pds.3838\n29. Leite A, Andrews NJ, Thomas SL. Near real-time vaccine safety sur -\nveillance using electronic health records-a systematic review of the \napplication of statistical methods. Pharmacoepidemiol Drug Saf. \n2016;25(3):225-37. DOI: 10.1002/pds.3966\n30. Kim C, Rhie S, Suh M, Kang DR, Choi YJ, Bae GR, et al. Pandemic \ninfluenza A vaccination and incidence of Guillain-Barre syndrome \nin Korea. Vaccine. 2015;33(15):1815-23. DOI: 10.1016/j.vac -\ncine.2015.02.035\n31. Ghaderi S, Gunnes N, Bakken IJ, Magnus P, Trogstad L, Haberg SE. \nRisk of Guillain-Barre syndrome after exposure to pandemic influ -\nenza A(H1N1)pdm09 vaccination or infection: a Norwegian popu -\nlation-based cohort study. Eur J Epidemiol. 2016;31(1):67-72. DOI: \n10.1007/s10654-015-0047-0\n32. Santuccio C, Trotta F, Felicetti P. Ongoing pharmacovigi -\nlance on vaccines. Pharmacol Res. 2015;92:2-5. DOI: 10.1016/j.\nphrs.2014.10.011Guillain-Barr\u00e9 syndrome and influenza vaccines: current evidence R. Sanz, et al.\nRev Esp Quimioter 2019;32(4): 288-29529510.1016/j.vaccine.2015.02.064\n45. Carias C, Reed C, Kim IK, Foppa IM, Biggerstaff M, Meltzer MI, et al. \nNet Costs Due to Seasonal Influenza Vaccination--United States, \n2005-2009. PLoS One. 2015;10(7):e0132922. DOI: 10.1371/journal.\npone.0132922\n46. Greene SK, Rett MD, Vellozzi C, Li L, Kulldorff M, Marcy SM, et al. \nGuillain-Barre Syndrome, Influenza Vaccination, and Anteced -\nent Respiratory and Gastrointestinal Infections: A Case-Centered \nAnalysis in the Vaccine Safety Datalink, 2009-2011. PLoS One. \n2013;8(6):e67185. DOI: 10.1371/journal.pone.0067185\n47. Verity C, Stellitano L, Winstone AM, Stowe J, Andrews N, Miller \nE. Pandemic A/H1N1 2009 influenza vaccination, preceding in -\nfections and clinical findings in UK children with Guillain-Barre \nsyndrome. Arch Dis Child. 2014;99(6):532-8. DOI: 10.1136/archdis -\nchild-2013-304475\n48. Gensicke H, Datta AN, Dill P, Schindler C, Fischer D. Increased in -\ncidence of Guillain-Barre syndrome after surgery. Eur J Neurol. \n2012;19(9):1239-44. DOI: 10.1111/j.1468-1331.2012.03730.x\n49. Yang B, Lian Y, Liu Y, Wu BY, Duan RS. A retrospective analysis \nof possible triggers of Guillain-Barre syndrome. J Neuroimmunol. \n2016;293:17-21. DOI: 10.1016/j.jneuroim.2016.02.003\n50. Saiz JC, Vazquez-Calvo A, Blazquez AB, Merino-Ramos T, Escrib -\nano-Romero E, Martin-Acebes MA. Zika Virus: the Latest Newcom -\ner. Front Microbiol. 2016;7:496. DOI: 10.3389/fmicb.2016.00496\n51. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barre \nsyndrome and the 1978-1979 influenza vaccine. N Engl J Med. \n1981;304(26):1557-61. DOI: 10.1056/NEJM198106253042601\n52. Nordin JD, Kharbanda EO, Vazquez-Benitez G, Lipkind H, Lee GM, \nNaleway AL. Monovalent H1N1 influenza vaccine safety in pregnant \nwomen, risks for acute adverse events. Vaccine. 2014;32(39):4985-\n92. DOI: 10.1016/j.vaccine.2014.07.017\n53. Tomimatsu T, Sugihara M, Nagai T, Sunada Y, Kimura T, Shimoya K. \nGuillain-Barre syndrome after trivalent influenza vaccination dur -\ning pregnancy. Eur J Obstet Gynecol Reprod Biol. 2016;201:225-6. \nDOI: 10.1016/j.ejogrb.2016.03.031\n54. Hwang KP, Hsu YL, Hsieh TH, Lin HC, Yen TY, Wei HM, et al. Im -\nmunogenicity and safety of a trivalent inactivated 2010-2011 \ninfluenza vaccine in Taiwan infants aged 6-12 months. Vaccine. \n2014;32(21):2469-73. DOI: 10.1016/j.vaccine.2014.02.078\n55. Halsey NA, Talaat KR, Greenbaum A, Mensah E, Dudley MZ, Proveaux \nT, et al. The safety of influenza vaccines in children: An Institute for \nVaccine Safety white paper. Vaccine. 2015;33 Suppl 5:F1-F67. DOI: \n10.1016/j.vaccine.2015.10.080\n56. Haber P, Moro PL, Cano M, Vellozzi C, Lewis P, Woo EJ, et al. Post-Li -\ncensure Surveillance of Trivalent Live-Attenuated Influenza Vac -\ncine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting \nSystem, United States, July 2005-June 2012. J Pediatric Infect Dis \nSoc. 2015;4(3):205-13. DOI: 10.1093/jpids/piu034\n57. Blum S, McCombe PA. Genetics of Guillain-Barre syndrome (GBS) \nand chronic inflammatory demyelinating polyradiculoneuropathy \n(CIDP): current knowledge and future directions. J Peripher Nerv \nSyst. 2014;19(2):88-103. DOI: 10.1111/jns5.12074\n58. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, et al. Safety and immunogenicity of AS03B adjuvanted split virion \nversus non-adjuvanted whole virion H1N1 influenza vaccine in UK \nchildren aged 6 months-12 years: open label, randomised, parallel \ngroup, multicentre study. BMJ. 2010;340:c2649. DOI: 10.1136/bmj.\nc2649\n59. Jin PP, Sun LL, Ding BJ, Qin N, Zhou B, Xia F, et al. Human Leukocyte \nAntigen DQB1 (HLA-DQB1) Polymorphisms and the Risk for Guil -\nlain-Barre Syndrome: A Systematic Review and Meta-Analysis. PLoS \nOne. 2015;10(7):e0131374. DOI: 10.1371/journal.pone.0131374Rev Esp Quimioter 2019;32(4): 296-302296\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Efectividad de ledipasvir/sofosbuvir durante 12 \nsemanas de tratamiento y factores predictivos \nde fracaso del tratamiento en pacientes con \nhepatitis C\nRESUMEN\nIntroducci\u00f3n. La eficacia de ledipasvir/sofosbuvir (LDV/\nSOF) se ha demostrado en ensayos cl\u00ednicos, sin embargo, son \nnecesarios m\u00e1s estudios sobre su eficacia en la pr\u00e1ctica cl\u00ednica. \nAdem\u00e1s es importante estudiar los posibles factores predictivos \nde fracaso de tratamiento con LDV/SOF. Los factores predicti -\nvos de respuesta viral sostenida (RVS) a antivirales de acci\u00f3n \ndirecta pueden informar sobre decisiones de tratamiento. Los \nobjetivos de este estudio fueron evaluar la efectividad de LDV/\nSOF, RVS12 como variable principal y RVS24 como secundaria, \ne identificar los factores predictivos de fracaso del tratamiento.\nMaterial y m\u00e9todos. Estudio retrospectivo y observacio -\nnal realizado desde abril de 2015 a enero de 2016. Criterios de \ninclusi\u00f3n: pacientes con infecci\u00f3n por VHC tratados con LDV/\nSOF durante 12 semanas. Se excluyeron los pacientes tratados \ndurante 24 semanas y los tratados con peg-interfer\u00f3n. Apli -\ncamos el m\u00e9todo estad\u00edstico denominado regresi\u00f3n log\u00edstica \nbinaria para predecir qu\u00e9 variable estaba relacionada con el \nfracaso del tratamiento.\nResultados. Se analizaron 122 pacientes logrando el \n91,80% (112/122) RVS12. Los pacientes infectados con genoti -\npo (GT) 1a o GT1b o GT4 lograron RVS12. Solo un paciente, no \ncirr\u00f3tico y previamente tratado, infectado con GT1 no alcanz\u00f3 \nRVS12. Las tasas m\u00e1s bajas de RVS12 se obtuvieron para GT3, \n43.75%, (7/16). Todos los pacientes que obtuvieron RVS12 lo -\ngraron RVS24. Ninguna de las variables analizadas influy\u00f3 sig -\nnificativamente en la RVS12, excepto GT (p=0.001). Casi todas \nlas reca\u00eddas ocurrieron en GT3.\nConclusiones.  La combinaci\u00f3n LDV/SOF ha sido muy efec -\ntiva para tratar a los pacientes infectados con GT1 y GT4, sin SUMMARY\nIntroduction. The efficacy of ledipasvir/sofosbuvir (LDV/SOF) \nhave been demonstrated in randomized controlled trials, howev -\ner, there is an unmet need for real-world effectiveness data. It is \nimportant to gather data regarding potential predictors of treat -\nment failure with (LDV/SOF). Predictors of sustained virologic re -\nsponse (SVR) to all-oral HCV regimens can inform nuanced treat -\nment decisions. The objectives of this study were to evaluate the \neffectiveness of LDV/SOF, SVR12 as main endpoint and SVR24 as \nsecond endpoint, and identify predictors of treatment failure. \nMaterial and methods. Retrospective and observational \nstudy carried out from April 2015 to January 2016. Inclusion \ncriteria: patients with HCV infection treated with LDV/SOF for \n12 weeks during study period. The patients that were treated \nduring 24 weeks were excluded as well as those treated with \npeg-interferon.  Binary logistic regression was used to predict \nwhat variable was associated with treatment failure.\nResults. A total of 122 patients were analyzed achieving \nSVR12 91.80% (112/122) of them. The patients with HCV geno -\ntype (GT) 1a or GT1b or GT4 achieved SVR12. Only one pre-treated \nnon-cirrhotic HCV GT1 patients relapsed to treatment. The lowest \nSVR12 were obtained for GT3, 43.75%, (7/16). Everybody that got \nSVR12 achieved SVR24. None of the variables analyzed significantly \ninfluenced the SVR12, except GT (p=0.001). Almost all the relapses \noccurred in GT3.\nConclusion.  LDV/SOF combination has been very effective \nto treat GT1 and GT4 infected patients, however, has constitut -\ned a suboptimal therapeutic option for those patients infected \nwith GT3, regardless of the rest of the variables analyzed. \nKeywords: Hepatitis C, ledipasvir/sofosbuvir, effectiveness, treatment fai -\nlure, predictors.Effectiveness of 12 week ledipasvir/sofosbuvir and \npredictors of treatment failure in patients with \nhepatitis C\nHospital Regional Universitario de M\u00e1lagaJuan Carlos del Rio-\nValencia\nRoc\u00edo Asensi-Diez\nRoc\u00edo Tamayo-Bermejo\nIsabel Mu\u00f1oz-Castillo\nCorrespondence:\nJuan Carlos del Rio-Valencia. \nHospital Regional Universitario de M\u00e1laga. Avenida de Carlos Haya s/n. CP.29010. M\u00e1laga. \nPhone: 951291435.\nFax: 951291493. \nE-mail: mailto:juancardelrio@telefonica.net.Original\nArticle history\nReceived: 30 November 2018; Revision Requested: 4 February 2019; Revision Received: 14 April 2019; Accepted: 6 June 2019Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al.\nRev Esp Quimioter 2019;32(4): 296-302297ications that reduce the concentrations of LDV or SOF, and hu -\nman immunodeficiency virus (HIV) coinfection [7].\nPredictors of sustained virologic response (SVR) to all-oral \nHCV regimens can inform nuanced treatment decisions [8]. The \nobjectives of this study were to evaluate the effectiveness of \nLDV/SOF treatment in HCV genotype 1, 3 and 4 as measured \nby the rate of SVR12 as main endpoint and SVR24 as second \nendpoint and to identify predictors of treatment failure in the \npatients. \nMATERIAL AND METHODS\nRetrospective and observational  study carried out in a \nthird level hospital. Study period: April 2015-February 2016. \nInclusion criteria: Patients with HCV infection treated with \nLDV/SOF for 12 weeks during study period. \nExclusion Criteria: patients from whom adequate clinical \nand/or analytical information was not available for further \nanalysis. The patients that were treated during 24 weeks were \nexcluded as well as those treated with peg-interferon. \nThe information was obtained from the electronic clinical/\nmedical records and dispensing records from outpatient soft -\nware (Cafydim\u00ae and ATHOS-Prisma\u00ae) Pharmacy Service.\nOutcomes collected: Demographic variables: age and sex. \nClinical data: basal viral load (viral RNA content before starting \ntherapy) (VL), SVR at week 12 (SVR12), defined as HCV RNA ti -\ntres lower than 15 IU/mL 12 weeks after the final of treatment, \nSVR at week 24 (SVR24), defined as HCV RNA titres lower than \n15 IU/mL 24 weeks after the final of treatment. HCV-RNA levels \nwere measured by the COBAS TaqMan HCV Test v2.0 (RCTM) \n(Roche Molecular Diagnostics) with a lower limit quantifi -\ncation (LLOQ) of 15 IU/ml. Respect to fibrosis grade, patients \nwere categorized depending on the fibrosis grade according \nto METAVIR scale (F0-F4). Fibrosis stage was determined by \nnon-invasive device: Fibroscan\u00ae. F4 patients were considered \nas cirrhotic. Other variables picked up were: platelet levels (cel/\n\u00b5l), albumin concentration (g/dl), transaminases hepatic levels \n(IU/L): aspartate transaminase (AST) and alanine transaminase \n(ALT) and bilirubin concentration (mg/dl). \nWe also have assessed whether patients had had liver \ntransplant, HIV co-infection or had been treated previously for \nHCV and adherence.\nThe main endpoint measured was the SVR12 and the sec -\nond endpoint was: SVR24. \nAdherence variable: Adherence was measured according \nto pharmacy dispensing records.\nIn the event that one of the patients was admitted to our \nhospital, the Pharmacy Service provided the DAA agents during \nthe entire hospitalization period. According to this, the adher -\nence calculation also took into account the registration of dis -\npensed medication by unit dose to hospitalized patients.\nStatistical analysis. The variables collected were ex -embargo, ha constituido una opci\u00f3n terap\u00e9utica sub\u00f3ptima \npara los infectados con GT3, independientemente del resto de \nlas variables analizadas.\nPalabras claves: Hepatitis C, ledipasvir/sofosbuvir, efectividad, no respues -\nta tratamiento, factores predictivos \nINTRODUCTION\nChronic hepatitis C (CHC) is a worldwide cause of liver-re -\nlated morbidity and mortality. It affects over 185 million peo -\nple, approximately 2\u20133% of the world\u2019s population. Although \nthis prevalence may be relatively low overall, it varies by age \ngroup and is typically much higher in cohorts between the \nages of 45 and 75. For example, in Central and East Asia, the \nprevalence peaks at 8.8\u20138.9% for those aged 55\u201364 [1].\nOver the last several years, the management of CHC has \nbeen revolutionized by the development of cell-mediated tar -\ngeted therapies [direct-acting antiviral agents (DAAs)] against \nhepatitis C virus (HCV). Indeed, we are at the beginning of a \nnew era of HCV management, which is beneficial to patients \nand clinicians alike. Treatment regimen that have left behind \nwas fraught with side effects, quality of life (QOL) impairment \nand high treatment failure rates. The new regimens are simple, \nsafe, effective regimens of short duration with minimal side \neffects [2].\nSix different genotypes of hepatitis C virus HCV (geno -\ntypes 1, 2, 3, 4, 5, 6) have been identified [3]. Genotype 1, spe -\ncifically 1b, is the most common subtype worldwide affecting \n42% of HCV-infected individuals [3]. This is followed by geno -\ntype 3 (26%), most commonly found in Pakistan and India, and \ngenotype 4 (14%) which is most common in North Africa and \nthe Middle East. In the US, genotype 1a is the most common, \naccounting for 58% of HCV infected individuals; genotype 1b \naccounts for 21%, genotype 2 accounts for 15% and genotype \n3 accounts for 5% [3]. In Spain, different studies [4-6] have re -\nvealed that the most frequent genotype is genotype 1 (69.6%-\n78.4%), predominating the subtype 1b 35.1% and the second \nmost prevalent subtype is 1a, 23.1% [6]; genotype 3 is the \nsecond in frequency (12.03-19.5%) [4, 6]; genotype 4 explains \nbetween 9.1-12.54% [4-6] and finally genotype 2 constitutes \nabout 1.5-2.4% [4-6]. The genotype is clinically relevant given \nthat some of current DAAs do not have pangenotypic efficacy. \nIn addition, each genotype is associated with a different sus -\ntained virologic response (SVR) rate [2].\nAlthough the efficacy of ledipasvir/sofosbuvir (LDV/SOF), \na fixed-dose combination, have been demonstrated in rand -\nomized controlled trials, there is an unmet need for real-world \neffectiveness data and studies that assess the association of \nrates of SVR with specific clinical and demographic factors in \nthe population. It is important to gather data regarding po -\ntential predictors of treatment failure with LDV/SOF. Studies \nhave assessed the association between the rate of SVR12 with \nLDV/SOF in HCV genotype 1 infection and specific clinical and \ndemographic factors, such as sex, history of treatment failure, \npresence of cirrhosis, basal viral load, concomitant use of med -Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al.\nRev Esp Quimioter 2019;32(4): 296-302298(AST), alanine aminotransferase (ALT) and also bilirubin [9]. The \nmedian platelet count was 176,000 (27,000-375,000) cel/\u00b5l, \nthe mean albumin was 4.00 \u00b1 0 .45 g/dL. The median AST, ALT \nand total bilirubin were 50 (18-244) IU/L, 64 (12-346) IU/L and \n0.66 (0.18-3.15) mg/dL, respectively. Baseline demographics, \nanalytical and clinical characteristics of enrolled patients are \nsummarized in table 2. pressed as median (range) or mean and standard deviation. Bi -\nnary logistic regression was used to identify independent clini -\ncal and demographic factors associated with treatment failure. \nAll analyses were performed by using SPSS v.17.  Here p values \n< 0.05 were considered statistically significant.\nRESULTS\nIn the study period, in our hospital, 124 HCV patients were \ntreated with LDV/SOF. Two patients were excluded due to in -\nsufficient clinical or analytical information. The genotypic dis -\ntribution of all patients is summarized in table 1.\nBaseline characteristics.  Of the 122 patients included in \nthe study, 78 (63.93%) were male, with mean age of 56.23 \u00b1 \n9.14 years. Cirrhosis was present in 33.60% (n=41) of the co -\nhort. Also, 15 patients (12.29%) had received liver transplant, \nand 48 patients (39.34%) were pre-treated patients for HCV. \nIn addition, 32 patients (26.23%) were HIV co-infected and 78 \n(63.93%) had VL higher than 800,000 IU/mL. We measured oth -\ner serum biomarkers related to stage of liver fibrosis and liver \nfunction such as platelet, albumin, aspartate aminotransferase Genotypic distribution Number of patients (%)\nGT 1 non-a non-b 12 (9.68%)\nGT 1a 29 (23.38%)\nGT 1b 46 (37.10%)\nGT 3 16 (12.90%)\nGT 4 21 (16.94%)\nTotal 124 (100.00%)Table 1  Genotypic distribution of different \npatients treated from April 2015 to \nFebruary 2016.\nGT1\n(n=10)GT1a\n(n=29)GT1b\n (n=46)GT3\n(n=16)GT4\n(n=21)TOTAL\n(n=122)P \nvalue\nAge (years); mean \u00b1 SD 59.09 \u00b1 9.56 58.43 \u00b1 10.33 58.59 \u00b1 10.18 53.05 \u00b1 9.05 52.00 \u00b1 6.60 56.23 \u00b1 9.14 0.398\nSex\nMale\nFemale5\n525\n421\n2512\n415\n678\n440.09\nStage of fibrosis\nF4\nF3\nF2\nF13\n5\n2\n-10\n8\n8\n314\n15\n16\n17\n6\n2\n17\n7\n4\n341\n41\n32\n80.682\nLiver transplant 2 3 9 1 0 15 0.625\nPreviously treated 3 11 20 4 10 48 0.528\nHIV co-infected 2 12 3 1 14 32 0.243\nBasal VL > 800,000 U/ml 8 24 34 6 6 78 0.338\nPlatelet; median\n(range)147,000 cel/\u00b5l\n(51,000-214,000)192,000 cel/\u00b5l \n(27,000-307,000)176,000 cel/\u00b5l \n(32,000-375,0000)152,000 cel/\u00b5l \n(96,000-326,000)185,000 cel/\u00b5l \n(50,000-243,000)176,000 cel/\u00b5l \n(27,000-375,000)0.226\nAlbumin; mean \u00b1  SD 4.02 \u00b1 0.51 g/dL 4.04 \u00b1 0.50 g/dL 4.05 \u00b1 0.48 g/dL 3.91 \u00b1 0.47 g/dL 4.00 \u00b1 0.29 g/dL 4.00 \u00b1 0.45 g/dL 0.439\nAST; median\n(range)65 IU/L\n(37-127)50 IU/L\n(20-210)48 IU/L\n(18-244)57 IU/L\n(23-170)49 IU/L\n(24-108)50 IU/L\n(18-244)0.324\nALT; median\n(range)65 IU/L\n(31-115)64 IU/L\n(12-253)56 IU/L\n(13-346)70 IU/L\n(26-162)59 IU/L\n(33-217)64 IU/L\n(12-346)0.125\nBilirubin; median \n(range)0.80 mg/dL\n(0.39-3.15)0.65 mg/dL\n(0.18-2.34)0.66 mg/dL\n(0.21-1.63)0.74 mg/dL\n(0.36-2.06)0.54 mg/dL\n(0.28-0.97)0.66 mg/dL\n(0.18-3.15)0.268Table 2  Baseline characteristics of all enrolled patients. Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al.\nRev Esp Quimioter 2019;32(4): 296-302299Finally, we analyzed the treatment adherence and it was of \n100% in all patients. Therefore, this variable was not included \nin the binary logistic regression analysis. \nSustained virologic response (SVR). Of the 122 patients \nincluded in the study, 112 patients (91.80%) achieved SVR12. \nIf we analyze the different genotypes, we observe that 98.82% \n(84/85) of patients with GT1 achieved SVR12, however; only \n43.75% (7/16) of all GT3-infected patients treated with LDV/\nSOF reached SVR12 and 100% (21/21) of the GT4-infected pa -\ntients treated got SVR12 (figure 1).\nA binary logistic regression analysis was carried out to de -\nFigure 1  Percentage of patients who have achieved \nSustained Virologic Response at 12 weeks \n(SVR12) depending on the genotypes. \nGT1= genotype 1, GT3= genotype 3, GT4= \ngenotype 4.\nFigure 3  Percentage of different subgroups of genotype \n3-infected patients (n=16) who have achieved \nSustained Virologic Response at 12 weeks \n(SVR12) with ledipasvir/sofosbuvir.\nFigure 4  Percentage of different subgroups of genotype \n4-infected patients (n=21) who have achieved \nSustained Virologic Response at 12 weeks \n(SVR12) with ledipasvir/sofosbuvir.\nFigure 2  Sustained Virologic Response at 12 weeks \n(SVR12) rates of hepatitis C virus (HCV) \ngenotype 1-infected patients (n=85). \nSVR12 of all patients with chronic \nHCV genotype 1 infection treated with \nledipasvir/sofosbuvir.\ntermine if there were factors associated with treatment failure, \nand it was found that none of the baseline variables analyz -\ned in table 2 had a significant influence on SVR12 (p> 0.05), \nexcept GT (p = 0.001). In fact, almost all relapses occurred in \npatients GT3-infected patients. \na) Genotype 1\nIf we analyze the different subgroups of patients, we observe \nthat all patients achieved SVR12 except one pre-treated non-cir -\nrhotic HCV GT1. Everybody that reached SVR12 achieved SVR24 \n(figure 2).Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al.\nRev Esp Quimioter 2019;32(4): 296-302300ed and seven of the totals were cirrhotic. In ELECTRON-2 study, \nwe do not know if any patients were cirrhotic or not. \nThese results are aligned with the treatment regimens as val -\nuable options for genotype 3 recommended by European Associa -\ntion for the Study of the Liver  (EASL) (guideline 2016), moment in \nwhich the study was carried out. EASL determines that in patients \ninfected with HCV genotype 3, the combination of LDV/SOF is not \nrecommended because LDV is considerably less potent against \ngenotype 3 than velpatasvir (VEL) or daclatasvir (DCV) [15].\nc) Genotype 4\nPatients with HCV GT4 [15] infection are poorly repre -\nsented in pivotal clinical trials of second-generation DAAs \nand in most real world studies. In our cohort, 100% (21/21) \nof all patients with HCV GT4 infection achieved SVR12, that \nis to say, a similar SVR12 rate to other real world studies such \nas Ramos et al. 2017 [5] where 100% (n=11) of the patients \ngot SVR12, respectively. Likewise, the SVR12 rates achieved in \nthis study with the treatment SOF/LDV match the results ob -\ntained in published clinical trials, ION-4 [16] with SVR12=96% \n(n=322/335).\nOn the other hand, we have found that every subject who \nachieved SVR12 subsequently got SVR24, however accord -\ning to other studies between 0.4%-2% of the subjects who \nachieved a SVR12 subsequently relapsed at week 24 (did not \nachieve SVR24) [5, 7, 18]. These studies demonstrated that in \nDAAs regimens, both with or without interferon, SVR12 and \nSVR24 are closely correlated.\nAccording to results obtained and the logistic regression \nanalysis made to identify independent clinical and demograph -\nic factors associated with treatment failure, we can affirm that \nLDV/SOF combination is very effective to treat GT-1 and GT-4 \ninfected patients but not for those with GT-3. These outcomes \nmatch the results achieved by Kouris G et al. [7], in which ana -\nlyzed the effectiveness of LDV/SOF and predictors of treatment \nfailure in patients with HCV GT-1 infection. None of the in -\ncluded variables were found to be associated with statistical -\nly significant differences in odds treatment failure. The same \nresult we got in our cohort, however, we also assessed if the \ngenotype variable could be an important factor of treatment \nfailure observing that GT-3 is a decisive predictor of SVR12 \nfailure. According to the study of Serfaty L. et al. [19] observed \nthat  baseline NS5A resistance-associated substitutions (RASs) \nwere more important than the baseline viral load for predict -\ning the efficacy of elbasvir/grazoprevir in participants with \nHCV GT-1 infection.\nSOF (NS4B) is a pangenotypic nucleotide polymerase inhibi -\ntor with potent activity against all 6 HCV genotypes in both in vit -\nro replicon assays and extensive clinical use. LDV is a potent and \nwell-tolerated NS5A inhibitor with activity against replicons of gen -\notypes 1a,1b, 4, 5 and 6, with 50% effective concentration (EC50) \nvalues ranging from 0.006 nM (genotype 1b) to 1.1 nM (genotype \n6a) [14]. However, LDV is much less active against genotype 3a HCV \nin vitro, with an average EC50 of 168 nM against wild-type virus. b) Genotype 3\nIf we analyze the different subgroups of patients we ob -\nserve that: 50% (N=3) of naive-non cirrhotic patients achieved \nSVR12; 33.33% (N=2) of naive cirrhotic got SVR12; 66.66% \n(N=2) of pre-treated-non cirrhotic patients reached SVR12 \nand nobody of pre-treated cirrhotic patients achieved SVR12. \nEverybody that achieved SVR12 achieved SVR24 (figure 3).\nc) Genotype 4\nAs to GT4, the different subgroups reached SVR12 and like \nGT1 and GT3 everyone, that achieved SVR12, got SVR24 (figure 4).\nDISCUSSION\nIn this study, we have investigated the real-world effec -\ntiveness of the regimen LDV/SOF administered for 12 weeks in \npatients infected with hepatitis C virus (HCV) genotype 1, 3 \nand 4 who met inclusion criteria explained in materials and \nmethods. Also, we have identified factors associated with SVR \nin these patients treated in routine clinical practice.\nOur population was 122 patients, whose genotypic distri -\nbution was similar to that published in other studies in Spain \n[5, 6], regarding to GT1, concretely, the percentage of genotype \n1 of our patients was 70.16% vs. 69.6%-78.4%.) As to genotype \n3 was 12.90% vs. 12.03%-19.5% and genotype 4 was 16.94% \nvs. 9.1-12.54%, genotypic distribution a little bit different and \nit may be explained by the fact that a lot of GT3-4 infected \npatients were treated with other treatment regimens. \na) Genotype 1\nLDV/SOF has showed high rates of SVR12 in our study: \n98.82% (n=84/85). This rate was similar to SVR12 rate (95%) \nderived from the study Ramos et al. (2017). We analyzed \ndifferent subgroups of patients treated with LDV/SOF and \nwe observed that all naive patients achieved SVR12 (100%, \nn=50/50), same result as ION-1 study (99%, 211/213) [10]. \nAs to pre-treated patients, 97.17% (34/35) obtained SVR12, it \nis similar to ION-2 study [11] where SVR12 rate was of 94% \n(202/215). However, it is important to underline that the sam -\nple size in the ION-1 and ION-2 studies was bigger than our \nstudy and basal conditions of the patients could differ.\nb) Genotype 3\nPatients with HCV genotype 3 are at a higher risk of liver \ndisease progression and hepatocellular carcinoma develop -\nment [12, 13]. However, compared with other HCV genotypes, \nDAAs combinations have lower efficacy against genotype 3 in \npatients with liver cirrhosis. In our study, the global SVR12 in \npatients with genotype 3 HCV infection was 43.75% (7/16), \nhowever, in ELECTRON-2 clinical trial [14] was 16/25 (64%). \nThis difference could be explained because in ELECTORN-2 \nstudy, only naive patients were treated with this treatment \nregimen, conversely, in our study, four patients were pre-treat -Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al.\nRev Esp Quimioter 2019;32(4): 296-302301In addition to EC50, another important factor that we should keep \nin mind is the Resistance-Associated Substitution (RAS). Howev -\ner, the genotypic presence of a RAS does not necessarily translate \nto a phenotypic treatment failure. Like advanced cirrhosis or prior \ntreatment experience, the presence of RAS represent an important \nfactor in overall treatment outcomes, and when combined with \nother negative predictors may result in treatment failure. The clin -\nical relevance of resistance testing has been limited to RASs in the \nNS5A gene. Two RASs in particular, Y93H and A30K, have emerged \nas the most clinically relevant polymorphisms in HCV-3 with the \ncurrently approved regimens, and are present at baseline in up to \n8.3 and 6.3% of all HCV-3-infected patients, respectively [14]. To \nput this in perspective, the 1000-fold shift seen with the signature \nY93H resistance-associated substitution in a genotype 1a virus re -\nsults in an EC50 of approximately 6 nM with a clinically significant \nreduction in activity. Hence, one might expect that even at baseline \nthe genotype 3 virus is effectively resistant to LDV [20]. However, \nin the ELECTRON-2 study, 26 patients randomized to receive LDV/\nSOF+RBV and everybody achieved SVR12, including 6 patients with \ncompensated cirrhosis. These results clearly show that RBV is im -\nportant but also suggest that LDV is more active against genotype \n3 HCV than predicted based on the replicon data alone [20]. Cell \nculture assays that can assess all stages of the life cycle are limit -\ned, particularly for genotype 3 HCV; however, recent advances that \nallow replication of serum-derived virus may allow for a deeper in -\nvestigation into the activity of LDV against genotype 3 HCV. It is also \npossible that RBV and/or SOF increase the sensitivity of genotype 3 \nHCV to LDV [20].\nThis study has the usual limitations related to its observa -\ntional and retrospective design, electronic data collection and \nthe small number of patients included in each arm of treat -\nment. In addition, resistance testing was not performed; thus, \nwe were unable to assess the impact of this factor. On the oth -\ner hand, we have not analyzed concomitant drugs, except HIV \ndrugs, therefore, we do not know the influence of this factor \non the effectiveness and it could be analyzed in future studies. \nIn addition, it is important to note that this study was \ncarried out between 2015-2016 and the EASL HCV treatment \nguidelines of those years recommended LDV/SOF to treat \npre-treated patients with GT1a and GT4 [21]. However, the \nEASL HCV treatment guidelines (2018) do not recommend its \nuse for these patients [15]. With respect to genotype 3, both \nguidelines do not recommend LDV/SOF to treat this genotype \ninfection, but this fixed-dose combination was used to treat \nGT3 infection according to the therapeutic strategy estab -\nlished by the Ministry of Health, Consumption and Social Wel -\nfare in Spain in 2015 [22].\nIn conclusion in our patient cohort, LDV/SOF combination is \nvery effective to treat GT-1 and GT-4 infected patients, however, \nconstitutes a suboptimal therapeutic option for those patients in -\nfected with GT-3, regardless of the rest of the variables analyzed. \nFUNDING\nNone to declare.CONFLICT OF INTEREST\nThe authors declare that they have not conflict of interest.\nREFERENCES\n1.  Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Glob -\nal epidemiology of hepatitis C virus infection: new estimates \nof age-specific antibody to HCV seroprevalence. Hepatology. \n2013;57(4):1333\u201342.  DOI: 10.1002/hep.26141\n2.  Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The chang -\ning landscape of hepatitis C virus therapy: focus on interferon-free \ntreatment. Therap Adv Gastroenterol. 2015;8(5):298\u2013312. DOI: \n10.1177/1756283X15587481\n3.  Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus \nOG, et al. Global distribution and prevalence of hepatitis C virus \ngenotypes. Hepatology. 2015;61(1):77\u201387. DOI:10.1002/hep.27259\n4.  Del Rio-Valencia JC, Asensi-Diez R, Villalobos-Torres L, Munoz Cas -\ntillo I. Direct-acting antiviral agents in patients with hepatitis C \ngenotype 1-4 infections in a tertiary hospital. Rev Esp Quimioter. \n2018;31(3):226\u201336. PMID: 29771105\n5.  Ramos H, Linares P, Badia E, Martin I, Gomez J, Almohalla C, et al. \nInterferon-free treatments in patients with hepatitis C genotype \n1-4 infections in a real-world setting. World J Gastrointest Phar -\nmacol Ther. 2017;8(2):137\u201346. DOI: 10.4292/wjgpt.v8.i2.\n6.  Gutierrez-Aroca JB, Ruiz-Martinez P, Rodriguez-Ruiz L, Casal-Ro -\nman M. Distribution of the genotype of the Hepatitis C Virus in \nCordoba-Spain. Rev Esp Quimioter. 2018;31(2):164-165. PMID: \n29616511 \n7.  Kouris G, Hydery T, Greenwood BC, Lavitas P, Price M, Clements \nK, et al. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of \nTreatment Failure in Members with Hepatitis C Genotype 1 In -\nfection: A Retrospective Cohort Study in a Medicaid Population. \nJ Manag care Spec Pharm. 2018;24(7):591\u20137. DOI: 10.18553/jm -\ncp.2018.24.7.591 \n8.  Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Re -\nal-world effectiveness and predictors of sustained virological re -\nsponse with all-oral therapy in 21,242 hepatitis C genotype-1 pa -\ntients. Antivir Ther. 2017;22(6):481\u201393. DOI: 10.3851/IMP3117\n9.  Bang CS, Kang HY, Choi GH, Kim SB, Lee W, Song IH. The Perfor -\nmance of Serum Biomarkers for Predicting Fibrosis in Patients with \nChronic Viral Hepatitis. Korean J Gastroenterol. 2017;69(5):298\u2013\n307.  DOI: 10.4166/kjg.2017.69.5.298\n10.  Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Le -\ndipasvir and sofosbuvir for untreated HCV genotype 1 infection. N \nEngl J Med. 2014;370(20):1889\u201398. DOI: 10.1056/NEJMoa1402454\n11.  Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Na -\nhass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros \nPJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol \nH, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir A KP. \nLedipasvir and sofosbuvir for previously treated HCV genotype 1 \ninfection. N Engl J Med. 2014;370(16):1483\u201393. DOI: 10.1056/NEJ -\nMoa1316366Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C J. C. del Rio-Valencia, et al.\nRev Esp Quimioter 2019;32(4): 296-30230212.  Bochud P-Y, Cai T, Overbeck K, Bochud M, Dufour J-F, Mullhaupt \nB, et al. Genotype 3 is associated with accelerated fibrosis progres -\nsion in chronic hepatitis C. J Hepatol. 2009;51(4):655\u201366.  DOI: \n10.1016/j.jhep.2009.05.016\n13.  Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi \nA, et al. HCV genotype 3 is associated with a higher hepatocel -\nlular carcinoma incidence in patients with ongoing viral C cir -\nrhosis. J Viral Hepat. 2011;18(10):e516-22. DOI: 10.1111/j.1365-\n2893.2011.01441\n14.  Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, et \nal. Efficacy of ledipasvir and sofosbuvir, with or without ribavi -\nrin, for 12 weeks in patients with HCV genotype 3 or 6 infection. \nGastroenterology. 2015;149(6):1454\u20131461.e1. DOI: 10.1053/j.gas -\ntro.2015.07.063\n15.  European Association for the Study of the Liver . EASL Recom -\nmendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; \n69(2):461-511. DOI:10.1016/j.jhep.2018.03.026\n16.  Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, \net al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected \nwith HIV-1. N Engl J Med. 2015;373(8):705\u201313. DOI: 10.1056/NEJ -\nMoa1501315\n17.  Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav \nPR, et al. Earlier sustained virologic response end points for regu -\nlatory approval and dose selection of hepatitis C therapies. Gas -\ntroenterology. 2013;144(7):1450\u20131455.e2. DOI: 10.1053/j.gas -\ntro.2013.02.039\n18.  Yoshida EM, Sulkowski MS, Gane EJ, Herring RWJ, Ratziu V, Ding \nX, et al. Concordance of sustained virological response 4, 12, and \n24 weeks post-treatment with sofosbuvir-containing regimens \nfor hepatitis C virus. Hepatology. 2015;61(1):41\u20135.  DOI: 10.1002/\nhep.27366\n19.  Serfaty L, Jacobson I, Rockstroh J, Altice FL, Hwang P, Barr E, et al. \nThe accuracy of baseline viral load for predicting the efficacy of \nelbasvir/grazoprevir in participants with hepatitis C virus genotype \n1a infection: an integrated analysis. J Viral Hepat. 2019;26(3):329-\n336 . DOI: 10.1111/jvh.13037\n20.  Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, et al. \nLedipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients \nWith Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. \nClin Infect Dis. 2017; 65(1):13-19. DOI: 10.1093/cid/cix289\n21.  European Association for the Study of the Liver . EASL Rec -\nommendations on Treatment of Hepatitis C 2016. J Hepatol. \n2017;66(1):153-94. DOI: 10.1016/j.jhep. 2016 .09.001\n22.  Ministerio de Sanidad, Consumo y Bienestar Social . Estrategia ter -\nap\u00e9utica para la hepatitis cr\u00f3nica causada por el virus de hepatitis \nC en el Sistema Nacional de Salud. Recomendaciones generales \ny pautas actuales de tratamiento [web page]. Madrid 2015. [Ac -\ncessed 2019 February 10]. Available at: http://aeeh.es/wp-content/\nuploads/2015/04/a77478e2a1147600cb9979b5992281cb.pdfRev Esp Quimioter 2019;32(4): 303-310303\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Bacterias resistentes en las manos de trabajadores \nsanitarios y en el \u00e1rea del paciente: un estudio \nambiental en un hospital del sur de Italia \nABSTRACT\nIntroducci\u00f3n.  La OMS reconoce la resistencia a los anti -\nmicrobianos como una creciente amenaza para la salud mun -\ndial con una amplia variabilidad en toda Europa: en Italia estas \ntasas son m\u00e1s altas que en otros pa\u00edses. El objetivo de nuestro \nestudio fue detectar la resistencia a los antimicrobianos en las \nmanos de trabajadores sanitarios  y en las superficies alrededor \ndel paciente as\u00ed como evaluar la variabilidad entre los niveles \nde contaminaci\u00f3n bacteriana en estas superficies y los resulta -\ndos obtenidos hace seis a\u00f1os.\nMaterial y m\u00e9todos. El estudio se realiz\u00f3 entre junio de \n2017 y mayo de 2018 utilizando dispositivos de contacto para \nsuperficies y muestreo activo de aire. Se emple\u00f3  m\u00e9todos bio -\nqu\u00edmicos automatizados para identificar microorganismos y la \nsensibilidad antimicrobiana fue realizada de acuerdo con las \nnormas del EUCAST.\nResultados . Se analizaron 3.760 muestras, de las cuales \nel 16,17% fueron positivas y el 34% de ellas fueron resistentes \na antibi\u00f3ticos. Al analizar los estafilococos, el 39% fueron \nmultirresistentes y el 5% extremadamente resistentes. Un \n30% de las cepas de  Enterococcus faecalis  fueron resistentes \na gentamicina y vancomicina. Se aislaron cepas de Klebsiella  \npneumoniae  resistentes a  ceftrixona, cefoxitina, mecillinam e \nimipenem. Un 7% de las cepas de Acinetobacter baumannii  \ny un 8% de las cepas de Pseudomonas aeruginosa  fueron \nresistentes a gentamicina, imipenem y ceftazidima.\nConclusiones.  Estos hallazgos est\u00e1n en l\u00ednea con los estu -\ndios publicados en otros pa\u00edses, lo que confirma que la resisten -\ncia a los antibi\u00f3ticos tambi\u00e9n est\u00e1 creciendo constantemente en \nItalia con tasas variadas para los diferentes pat\u00f3genos\nPalabras clave: resistencia a antimicrobianos, bacterias, pacientes, superfi -\ncies de hospitales, trabajadores sanitarios.ABSTRACT\nBackground.  The WHO recognized antimicrobial resist -\nance as a growing global health threat with a wide variabili -\nty across Europe: in Italy these rates are higher than in other \ncountries. The aim of our study was to detect antimicrobial \nresistance on the hands of healthcare workers and on surfaces \naround the patient, to assess the variability between levels of \nbacterial contamination on these surfaces and to compare the \nresults with those achieved six years ago.\nMaterial and methods.  The study was conducted from \nJune 2017 to May 2018 using contact slides for surfaces and \nactive sampling for air. We used automated biochemical meth -\nods to identify microorganisms; antibiograms were performed \nin compliance with the EUCAST expert rules.\nResults.  We analyzed 3,760 samples, 16.17% were found \npositive and 34 % of these were antimicrobial-resistant. On \nanalyzing the isolated Staphylococci, 39% were multidrug-\nresistant and 5% extensively drug-resistant. A 30% of the \nEnterococcus  faecalis  isolates were resistant to gentamycin \nand vancomycin. We found Klebsiella pneumoniae  isolates \nresistant to ceftriaxone, cefoxitin, mecillinam and imipenem. A \n7% and 8% of the Acinetobacter baumannii  and Pseudomonas \naeruginosa  isolates, respectively, were resistant to gentamicin, \nimipenem, and ceftazidime\nConclusions.  These findings are in line with the international \nliterature, confirming that antimicrobial resistance is also steadily \ngrowing in Italy with rates varied for the different pathogens.\nKey words: Antimicrobial Drug Resistance, Bacteria, Patients, Hospital sur -\nfaces, Healthcare workersDrug-resistant bacteria on hands of healthcare \nworkers and in the patient area: an environmental \nsurvey in Southern Italy\u2019s hospital\n1Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, A.O.U. Policlinico \n\u201cG. Martino\u201d, Biological tour 1\u00b0 Floor, Messina, Italy\n2Postgraduate Medical School in Hygiene and Preventive Medicine, University of Messina, Messina, ItalyVincenza La Fauci1\nGaetano Bruno Costa1\nCristina Genovese2\nMaria Angela Rita \nPalamara2\nValeria Alessi2 \nRaffaele Squeri1\nCorrespondence:\nVincenza La Fauci\nDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of \nMessina, A.O.U. Policlinico \u201cG. Martino\u201d, Biological tour 1\u00b0 Floor, via Consolare Valeria, 98125 \nMessina, Italy\nTel.: +39 090 2213620 - Fax.:  +39 090 2213351\nE-mail: vlafauci@unime.itOriginal\nArticle history\nReceived: 11 January 2019; Revision Requested: 18 February 2019; Revision Received: 19 March 2019; Accepted: 8 May 2019Drug-resistant bacteria on hands of healthcare workers and in the patient area: an environmental survey in \nSouthern Italy\u2019s hospital V. La Fauci, et al.\nRev Esp Quimioter 2019;32(4): 303-310304of bacterial contamination on different surfaces examined \n(Universitary Hospital of Messina, Gaetano Martino) and to \ncompare the results with those achieved six years ago from a \nprevious study.\nMATERIAL AND METHODS\nSamples were collected from the hands of HCWs and from \nsurfaces considered at risk, namely ones near the patient and \nones touched by HCWs (bed and headboard, sink, floor, med \ntrays). A longitudinal study was conducted from June 2017 to \nMay 2018. Samples were collected from the following wards: \nclinical (Cardiology, Internal Medicine, and Geriatrics), surgical \n(Thoracic Surgery, Orthopaedics and Vascular Surgery) and in -\ntensive care.\nContact slides (Liofilchem) were used to collect samples \nboth for surfaces and hands of healthcare workers with a \ncontact time of 10 seconds for the following types of culture \nmedium used: PCA for bacterial charge, Vogel-Johnson Agar \nfor Staphylococcus  spp, Cetrimide Agar for Pseudomonas  spp, \nRose Bengal-CAF Yeast and Mold Agar, VRBG Agar for Entero -\nbacteriaceae  and Bile-Esculin Agar for Enterococcus  spp.\nAll samples were taken directly to the laboratory and in -\ncubated at 37 \u00b0C for 48-72 hours. \nSamples were classified as positive in accordance with the \nmanufacturer\u2019s instructions for the contact slides (> 14 colo -\nnies on slide corresponding to 117 CFU/100 cm2) [25, 26].\nTest-positive samples were used to grow subcultures in \nselective agar culture media: Mannitol Salt Agar (Oxoid) was \nused for the isolation of Staphylococcus  spp; MacConkey Agar \n(bioM\u00e9rieux) was used for the isolation of Gram-negative bac -\nteria; Enterococcosel Agar (bioM\u00e9rieux) for Enterococcus  spp; \nCetrimide Agar (bioM\u00e9rieux) for Pseudomonas aeruginosa . \nSamples to assess microbial air contamination (expressed \nas CFU/m3) were collected from the center of the room using \na semi-automatic sampler (SAS Super100, Sampler Air System, \nPBI), which aspirated a volume of 180 l/min. The SAS held one \n55 mm diameter plate containing the different selective agar \nculture media (Mannitol Salt Agar, MacConkey Agar, Entero -\ncoccosel Agar and Cetrimide Agar). \nSubsequently, automated biochemical methods (VITEK\u00ae \n2, Bio-M\u00e9rieux, France) were used to identify microorganisms \ngrown in subcultures.\nAntibiograms were performed on the same isolated strains \nusing MIC (minimum inhibitory concentration) and zone diam -\neter breakpoints in compliance with the European Committee \non Antimicrobial Susceptibility Testing (EUCAST) expert rules. \nResults were read after 24 hours by reference to EUCAST Clin -\nical Breakpoint Tables.\nMIC values were determined by spot inoculation of 1-2\u00b5L \nof the inoculums (~0.5 Mc Farland) on Mueller Hinton agar \nplates, containing different concentrations of the antimicro -\nbial and incubated at 37\u00b0C for 18 hours.  Antimicrobial sus -\nceptibility was tested according to the different bacteria: for INTRODUCTION\nNosocomial infections are the leading cause of morbidity \nand mortality worldwide. According to the European Centre \nfor Disease Prevention and Control (ECDC), the impact of six \nhealth care-associated infections (HCAIs) (pneumonia, urinary \ntract infections, surgical site infections, Clostridium difficile  in-\nfections, neonatal sepsis and blood infection) is higher than \nthe combined impact of influenza, HIV/AIDS infections and \ntuberculosis [1]. In Europe, HCAIs account for 37,000 deaths \nannually in 2014 [2]. Their economic impact is also significant \namounting to approximately 9.8 billion US dollars/year for \nthe five main infections [3]. Antimicrobial resistance is one of \nthe main problems associated with HCAIs [4]. The Centers for \nDisease Prevention and Control (CDC) estimates that over two \nmillion people/year acquire antimicrobial-resistant infections, \nand 23,000 die as a result [5]. In Europe, 25,000 people/year \ndie from drug-resistant infections [6]. Several studies have \nbeen published describing links between contaminated patient \nenvironments to an increased risk of HCAIs [7]. Although it is \nwell-[established that pathogens can survive in healthcare en -\nvironments for long periods of time, the exact survival times \nof different pathogens vary depending on certain conditions, \nfor example temperature.  The ECDC point prevalence survey \nof HCAIs and antimicrobial use in acute care hospitals (2011-\n2012) [8] ranked the most frequently isolated microorganisms \nfrom HCAIs as follows: Escherichia coli  (15.9%), Staphylococ -\ncus aureus  (12.3%), Enterococcus  spp. (9.6%), Pseudomonas \naeruginosa  (8.9%) Klebsiella  spp. (8.7%), coagulase-negative \nstaphylococci (7.5%), Candida  spp. (6.1%), Clostridium diffi -\ncile (5.4%), Enterobacter  spp. (4.2%), Proteus spp. (3.8%) and \nAcinetobacter  spp. (3.6%). These pathogens are associated \nwith HCAIs causing increases in mortality and morbidity [9].\nIn Italy, HCAI rates range from 5 to 10%, and infections \ncaused by antimicrobial-resistant microorganisms are becom -\ning more and more common, with a mortality rate of 20-30% \n[10]. Some studies have surveyed the incidence of HCAIs in \nsouthern Italy, including our hospital [11, 12]. The HCAI rate \ndetected for our hospital was 4.3% (each HCAI identified in \naccordance with ECDC criteria) [12, 13]. Many microorganisms \nare involved in these infections, but multidrug resistance or -\nganism (MDROs) play a fundamental role, even in our hospital \nreality [14-16].\nMany studies have reported the isolation of these \nmicroorganisms on hands of healthcare workers (HCWs); for \nexample methicillin-resistant Staphylococcus aureus  (MRSA), \nSerratia marcescens  and other Gram-negative microorganisms \n[17-21]. On hospital surfaces some studies reported isolation \nof MRSA, Escherichia coli  and Klebsiella pneumoniae  with \nextended-spectrum beta-lactamases, and carbapenem-\nresistant Acinetobacter baumannii  [22-23]. In light of these \nfindings, careful monitoring of environmental contamination \nand analysis of the resistance profile of isolated germs is \nessential [24]. The aim of our study was to detect antimicrobial \nresistant bacteria on the hands of HCWs and on surfaces \naround the patient; to assess the variability between levels Drug-resistant bacteria on hands of healthcare workers and in the patient area: an environmental survey in \nSouthern Italy\u2019s hospital V. La Fauci, et al.\nRev Esp Quimioter 2019;32(4): 303-310305the analysed samples were found to be resistant to at least one \nagent in three or more antimicrobial categories (MDR).\nGram-positive bacteria\nStaphylococcus  spp. Isolated staphylococci accounted \nfor 51.97% of the sample (316/608), 81% of these were co -\nagulase-negative staphylococci (CoNS) belonging to the fol -\nlowing species: S. auricularis (3%), S.  capitis (8%), S.  caprae \n(1%), S.  cohnii (4%), S.  epidermidis (6%), S.  haemolyticus (9%), \nS.  hominis (19%), S.  lugdunensis (1%), S.   pasteuri (1%), S.   \nsaprophyticus (4%), S.  simulans (6%), S.   warnerii (5%), S.  xy-\nlosus (14%) .\nThe remaining 19% were coagulase-positive, of which \n10% were S. aureus . Analysis of isolated Staphylococci  showed \n54% to be resistant to at least 1 antimicrobial, 39% MDR and \n5% XDR (75% S. aureus  and 25% S. capitis ) isolated on bed -\nroom patient (25%) and on floor (75%) (table 2).\nOther Gram-positives. Kocuria rosea  was detected in \n0.7% of samples, Kytococcus sedentarius  was also isolated \nin 0.7% of samples and Enterococcus faecalis  was isolated in \n1.3% of samples. For the latter, we analysed antimicrobial re -\nsistance to ampicillin, gentamycin and vancomycin and found \n30% of microorganisms to be antimicrobial-resistant.\nGram-negative bacteria\nEnterobacteriaceae . An 17.77% (108/608) of the ana -\nlysed samples were Enterobacteriaceae  with 67% MDR, and \n22% resistant to all tested antimicrobials isolated on floor \n(66.7%), bedroom patients (16.7%) and  light switch (16.7%); \n41% of Enterobacteriaceae  were resistant to ceftriaxone, 44% \nto cefoxitin and ampicillin, 52% to mecillinam and 33% to im -\nipenem (table 2).Staphylococcus  spp. we used ampicillin, ceftriaxone, cefoxitin, \noxacillin, vancomycin, imipenem, and penicillin, for Enterococ -\ncus spp. we employed ampicillin, gentamicin, and vancomycin, \nfor Enterobacteriaceae  we tested ceftriaxone, cefoxitin, ampi -\ncillin, mecillinam, and imipenem and finally for Pseudomonas  \nspp and Acinetobacter  spp we used imipenem, ceftazidime, \nand gentamicin.  In our study, we used multidrug-resistant \n(MDR) and extensively drug-resistant (XDR) definitions of Ma -\ngiorakos [27].\nStatistical analysis. The sample was determined consid -\nering a percentage of MDR for Staphylococcus  of 15% in our \nhospital estimating a 99% Confidence Interval (CI) and abso -\nlute precision of 5%. For others organisms we did not know \nthe percentage of MDR in our hospital facilities and so we as -\nsumed the percentage of 50%. So, the minim sample size was \n1,058 surfaces examined of which 49.15% (n= 520) hands of \nHCWs and 50.85% (n=538) environmental surfaces. \nWe evaluated whether antimicrobial resistance varied for \nthe different surfaces examined, i.e. in proximity to the patient \nand those touched by healthcare staff. We therefore compared \nantimicrobial susceptibility of Staphylococci , Enterobacteriace -\nae, Pseudomonas  and Acinetobacter  on the hands of HCWs and \non surfaces of the \u2018patient zone\u2019 (as defined by WHO). There -\nfore, 2x2 contingency tables were built and assumptions tested \nby the chi square method, while degrees of freedom were used \nto partition r x k tables. Also we evaluated statistical differenc -\nes between the results recorded between 2012 and 2016 only \nfor Staphylococcus  spp. P-values of <0.05 were considered to \nindicate significance. Software R was used for statistical as -\nsessment [28].\nRESULTS\nWe analysed 3,760 samples, of which 50.85% (n=1,912) \nwere environmental and 49.15% (n=1,848) from hands of \nHCWs, and on total 16.17% (n=608) were positive. The positive \nsamples for environmental surfaces were 26.57% (508/1,912) \nand for hands of HCWS were 5.41% (100/1,848). Table 1 shows \nmicroorganisms recovered from hands of HCWs and environ -\nmental surfaces. The percentage of isolated microorganisms \nwith relative resistance profiles was reported in table 2. \nAntimicrobial-resistant bacteria (at least resistant to one \nantimicrobial) were found in 33.55% (204/608) of the analysed \nenvironmental samples. These originated from the following \nsurfaces: 40% from \u201cfrequent touch\u201d surfaces (bed bar, wash -\nbasin, bedside table and food tray, light switch, door handle); \n38% floor; 10% air; 9% medical devices and 3% HCWs\u2019 hands. \nOf the 608 microorganisms identified, 55.3% were \nGram-positive and 44.7% were Gram-negative, belonging to \nthe following genera: Staphylococcus , Enterobacteria , Pseu-\ndomonas , Acinetobacter , Rhizobium , Sphingomonas , Ochro -\nbactrum , Streptococcus  spp., Aerococci , Burkholderia , Roseo -\nmonas  and Kytococcus . We only analysed the first four genera \nfor antimicrobial susceptibility because others only cause in -\nfections in immunocompromised patients. 32. 2% (196/608) of n TotalaHands of \nHCWsaEnvironmental \nsurfacesa\nStaphylococcus  spp. 316 51.97 5.92% 46.05%\nS. aureus 32 5.27 0.66% 4.61%\nCoNS 284 46.71 5.26% 41.45%\nOther Gram-positive 16 2.63 2.63% 0.00%\nEnterobacteriaceae 108 17.77 3.95% 13.82%\nPseudomonas  spp. 52 8.55 1.97% 6.58%\nAcinetobacter  spp. 44 9.20 1.97% 5.26%\nOther Gram-negative 40 6.58 0.00% 6.58%\nRhizobium  spp. 32 5.26 0.00% 5.26%Table 1  Microorganisms for hands of HCWs and \nenvironmental surfaces \naThe percentage was calculated on the total samples (n=608).  \nHCWs = Healthcare workers. CoNS: coagulase-negative staphylococciDrug-resistant bacteria on hands of healthcare workers and in the patient area: an environmental survey in \nSouthern Italy\u2019s hospital V. La Fauci, et al.\nRev Esp Quimioter 2019;32(4): 303-310306\u2018patient zone\u2019 (as defined by WHO). No statistically significant \ndifferences emerged (table 3).\nWe evaluated whether antimicrobial resistance of the mi -\ncroorganisms investigated had changed compared with results \nobtained six years earlier. We observed increased antimicrobial \nresistance for S. aureus  and for CoNS while a decrease in an -\ntimicrobial resistance was detected for S. epidermidis  (table 4).\nDISCUSSION \nThere are numerous studies demonstrating the presence \nof MDROs in the patient care environment. [29]. These stud -\nies typically focus on MRSA, vancomycin-resistant enterococci \n(VRE), Clostridium difficile , Acinetobacter spp. Other studies \nhave evaluated the presence of other MDROs on environmen -\ntal surfaces. Our research also confirmed the existence of a \nsubstantial percentage of Gram-positive and Gram-negative \nMDROs our hospital [30].\nContaminated inanimate surfaces and health care pro -\nviders can be involved in the transmission of nosocomial in -\nfections and have been often described as the source for such \noutbreaks [31-34].\n In our study, we noticed a high percentage of MDR for S. \naureus and CoNS similar to previous studies [35]. In one study, \nMRSA was cultured from 43% of beds of individuals not known \nto be MRSA positive [29]. In a previous study, we found met -\nicillin-resistant Staphylococcus  strains in 14.7% (20/136) of \nsamples taken from the hands of HCWs and in 35.7% (15/42) \nof those from hospital surfaces [30]. When we compared both \nstudies, we found an increase in the antimicrobial resistance Klebsiella pneumoniae  was isolated in 9.9% of the sam -\nples and resistance rates were as follows: 33% for ceftriaxone, \n44% for cefoxitin, 56% for mecillinam and 25% for imipenem.\nProteus mirabilis  was isolated in 0.7% of the samples and \nfound to be resistant to all tested antimicrobials, with the ex -\nception of imipenem.\nPseudomonas  aeruginosa  and Acinetobacter  bau-\nmannii . P. aeruginosa  was isolated in 8.55% of cases and 21% \nof the isolated microorganisms were resistant to gentamicin \nand 31% to imipenem and ceftazidime. A. baumannii  was iso -\nlated in 9.2% of cases and 36% of the isolated microorganisms \nwere resistant to imipenem, 20% to gentamicin and 22% to \nceftazidime.\nOther Gram-negative bacteria. The Rhizobium radio -\nbacter  species was isolated in 5.26% of cases. We found the \nfollowing other Gram-negative species in 6.58% (40/608) of \ncases: Citrobacter spp. (15%),  Pantoea agglomerans (3%), \nSphingomonas paucimobilis (2%),  Ochrobactrum anthropi \n(2%),  Enterobacter  spp. (1%), Vibrio spp. (1%),  Sphingobacte -\nrium thalpophilum (0.7%),  Achromobacter denitricans (0.7%),  \nRoseomonas gilardii (0.7%)  and Aerococcus viridans  (0.7%). \nThe antimicrobial susceptibility of these microorganisms was \nnot tested because they rarely cause infection and affect \nmainly immunocompromised patients. \nStatistical analysis. We evaluated whether antimicro -\nbial resistance varied for the different surfaces examined, i.e. \nin proximity to the patient and those touched by healthcare \nstaff. We therefore compared antimicrobial susceptibility of \nStaphylococcus spp., Enterobacteriaceae , Pseudomonas  and \nAcinetobacter  on the hands of HCWs and on surfaces of the Resistant to\nIsolated microorganism AMP CTX FOX OX MEL VaN IMP PEN GEN CAZ\nGram-positive \nStaphylococcus  spp. 37% 35% 24% 39% 0% 24% 0%\nS. aureus 50% 63% 50% 25% 0% 0% 38%\nS. epidermidis 40% 40% 0% 0% 0% 0% 20%\nOther CoNS 36% 48% 36% 28% 0% 9% 27%\nEnterococcus faecalis  30% 30% 30%\nGram-negative\nEnterobacteriaceae  41% 44% 52% 33%\nKlebsiella  spp. 33% 44% 56% 25%\nProteus  spp. 0% 100% 100% 0%\nPseudomonas  spp. 31% 21% 31%\nAcinetobacter  spp. 36% 20% 22%Table 2  Percentage of resistance of the isolated microorganisms.\nAMP: ampicillin; CTX: ceftriaxone; FOX: cefoxitin; OX: oxacillin; MEL: mecillinam; VAN: vancomycin; IMP: imipenem; PEN: penicillin; GEN: gentamicin;  \nCAZ: ceftazidime. CoNS: coagulase-negative staphylococci.Drug-resistant bacteria on hands of healthcare workers and in the patient area: an environmental survey in \nSouthern Italy\u2019s hospital V. La Fauci, et al.\nRev Esp Quimioter 2019;32(4): 303-310307tamination rate with MRSA \nor VRE correlates with the \nnumber of culture-positive \nbody sites for patients with \nclinical infections [40]. Thus, \nthe evaluation of microbial \ncontamination on surfaces \nin the patient\u2019s room and \nthe evaluation of clinical an -\ntimicrobial resistance could \nbe important in dealing with \nnosocomial infections.\nAmong the Gram-neg -\native bacteria, the spread \nof carbapenem-resistant \nEnterobacteriaceae  (CRE) strains in patients is frequently as -\nsociated with multiple resistances to different classes of an -\ntimicrobials (pan-resistant strains) due to their high virulence \nand spread capacity among different patients as well as their \nability to transmit by plasmids. Some studies have described \nthat nosocomial surfaces play only a minor role in the trans -\nmission of CRE as it was seldom isolated from environmental \nsurfaces. By contrast, our research indicated that 33% of the \nisolated Klebsiella  were resistant to imipenem (and therefore a \ncarbapenem-resistant Klebsiella pneumoniae  ). This is one of \nthe principal CREs involved in HCAIs (the ECDC data for Eu -\nrope show an increase in the spread of CRE, which is endemic \nin Greek, Italy, Turkey and Malta), suggesting the role of the \nvary surfaces to allow transient contamination of the hands of \nHCWs [31 ,41]. Another important issue reported in the litera -\nture is that patient zone and their furnishing of patient colo -\nnized with CRE is often contaminated by these organisms, with \na reduction in contamination rates as you move away [41]. \nClinically, A. baumannii  and P. aeruginosa , together with \nMRSA, are the most common causes of HCAIs and their pres -\nence is correlated with environmental surface contamination \n[42]. While P. aeruginosa is intrinsically resistant to the ma -\njority of antimicrobial agents, some fluoroquinolones, amino -\nglycosides, some beta-lactams and polymyxins remain active \nin patients. In our study, resistance to imipenem was 36% for \nstrains isolated from the patient environment. This microor -\nganism can survive on several surfaces and it can therefore \nspread easily through a ward from one patient to another. \nAs mentioned above, antimicrobial resistance can also sup -\nport the persistence of such microorganisms, thus becoming \nthe source of dangerous nosocomial outbreaks [43]. Similarly, \ncarbapenem-resistant Acinetobacter spp. is common in Eu -\nrope and in most cases is combined with resistance to fluoro -\nquinolones and aminoglycosides. In our study, 36.4% of strains \nwere found to be resistant to imipenem. It can also cause dan -\ngerous outbreaks and the application of meticulous environ -\nmental hygiene and strict compliance with infection control \npractices are vital to halt transmission. Indeed, some outbreaks \nhave required the complete closure of units [44]. \nWe found no statistical differences between the antimi -\ncrobial resistance of microorganisms isolated from surfaces for S. aureus  and for CoNS while we observed a decrease in the \nantimicrobial resistance for S. epidermidis . This is important \nbecause these microorganisms can spread and cause severe \noutbreaks especially in some high risk wards [36]. \nEnterococci  are intrinsically resistant to a broad range of \nantimicrobial agents, including cephalosporins, sulphonamides \nand aminoglycosides at therapeutic concentrations [37]. We \nfound E. faecium  strains resistant to gentamycin and vanco -\nmycin confirming results in the literature. In fact, many studies \nhave reported varying rates of VRE on hospital surfaces (13-\n16%) [38]. This contamination of rooms is due to not only to \nmicroorganisms spread by previous occupiers, but could also \nbe due to transmission by HCWs, guests, objects as well as air \nflow and this explains the different contamination levels we \ndetected [29, 39]. It is noteworthy that the environmental con -MicroorganismsSurfaces analysed and relative profile of resistance P value\nHands of HCWs (n=100) Patient zone (n=508)\nR S R S\nStaphylococcus aureus 50% 50% 25% 75% 0.375\nCoNS 16.67% 83.33% 25% 75% 0.135\nEnterobacteriaceae 50% 50% 16.67% 83.33% 0.16\nPseudomonas  spp. 33.33% 66.67% 20% 80% 0.17\nAcinetobacter  spp. 33.33% 66.67% 16.67% 83.33% 0.8Table 3  Surfaces analyzed and relative resistance profiles of microorganisms \ndetected\nCoNS: coagulase-negative staphylococci.\n2012 2018 P Value\nS. aureus OX 8% 25% 0.306\nFOX 0% 50% NA\nVAN 0% 0% NA\nMEL 8% 0% NA\nS. epidermidis OX 3% 0% NA\nFOX 1% 0% NA\nVAN 4% 0% NA\nMEL 13% 0% NA\nCoNS OX 0% 28% NA\nFOX 0% 36% NA\nVAN 19% 9% 0.203\nMEL 29% 28% 0.878Table 4  Evaluation of the antimicrobial resistance \nof the isolated bacteria after six years\nCoNS: coagulase-negative staphylococci,  NA = Not applicable\nOX = oxacillin; FOX= cefoxitin; VAN = vancomycin; MEL = mecillinamDrug-resistant bacteria on hands of healthcare workers and in the patient area: an environmental survey in \nSouthern Italy\u2019s hospital V. La Fauci, et al.\nRev Esp Quimioter 2019;32(4): 303-310308In fact, today we are faced with increasingly resistant \ngerms and the weapons at our disposal are increasingly lim -\nited. Consequently, if we do not take urgent steps to remedy \nthis problem, we will find ourselves faced with \u201ckiller germs\u201d \n[49, 50] The prevention of HCAIs is the most widely used meas -\nure to keep them under control and also the most cost-effec -\ntive; the savings from prevention can be as high as 5.5 billion \ndollars [3]. Strengthening infection control strategies such as \nhand washing, environmental sanitizing practices, the contin -\nuous training of physicians and specialists, correct use of an -\ntimicrobials and vaccine are all measures implemented world -\nwide to control HCAIs [47, 51-60].\nREFERENCES\n1. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Ducom -\nble T et al. Burden of Six Healthcare-Associated Infections on Euro -\npean Population Health: Estimating Incidence-Based Disability-Ad -\njusted Life Years through a Population Prevalence-Based Modelling \nStudy. PLoS Med 2016; 13(10): e1002150. \n2. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer \nMA et al. Multistate point-prevalence survey of health care-as -\nsociated infections. N Engl J Med 2014; 370(13): 1198-208. \ndoi:10.1056/NEJMoa1306801.\n3. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK et \nal. Health care-associated infections: a meta-analysis of costs and \nfinancial impact on the US health care system. JAMA Intern Med \n2013; 173(22): 2039-46. doi: 10.1001/jamainternmed.2013.9763.\n4. Glied S, Cohen B, Liu J, Neidell M, Larson E. Trends in mortali -\nty, length of stay, and hospital charges associated with health \ncare-associated infections, 2006-2012. Am J Infect Control 2016; \n44(9): 983-9. doi: 10.1016/j.ajic.2016.03.010. \n5. Centers for Disease Control and Prevention (CDC). Antibiotic/Anti -\nmicrobial Resistance (AR/AMR). Available on: https://www.cdc.gov/\ndrugresistance/index.html  [Last accessed: 2018, 22 Oct].\n6. The European Union summary report on antimicrobial resistance in \nzoonotic and indicator bacteria from humans, animals and food in \n2015. European Food Safety Authority European Centre for Disease \nPrevention and Control. ADOPTED: 26 January 2017. doi: 10.2903/j.\nefsa.2017.4694\n7. Chemaly RF, Simmons S, Dale C Jr, Ghantoji SS, Rodriguez M, Gubb \nJ, et al. The role of the healthcare environment in the spread of \nmultidrug-resistant organisms: update on current best practic -\nes for containment. Ther Adv Infect Dis 2014; 2(3-4): 79-90. doi: \n10.1177/2049936114543287.\n8. European Center for Disease Prevention and Control (ECDC). Stock -\nholm: ECDC, 2013. Point prevalence survey of healthcare-associat -\ned infections and antimicrobial use in acute care hospitals (2011-\n2012). Available on: https://ecdc.europa.eu/sites/portal/files/media/\nen/publications/Publications/healthcare-associated-infections-an -\ntimicrobial-use-PPS.pdf  [Last accessed: 2018, Oct 22].\n9. Harris AD. How Important Is the Environment in the Emergence of \nNosocomial Antimicrobial-Resistant Bacteria? Clin Infect Dis 2008; \n46(5): 686-8. doi: 10.1086/527395.around the patients and those from the hands of HCWs, con -\nfirming literature data that the bacteria on hospital surfaces \nare transferred by the hands of healthcare staff. The role of \nhandwashing is thus vital to prevent the spread of these re -\nsistant microorganisms [45].\nIn literature many studies described that the healthcare \narea may be contaminated by bacteria from different patient \nzones in two ways: direct shedding from patients and via \nHCWs\u2019 hands. High-touch surfaces in the area of patients are \ncontaminated with a higher rate of contamination in infected \npatients than from colonized ones [40]. \n In a cohort study, the authors investigated how frequent -\nly HCWs contaminated gloves and gowns after contact with \npatients [46]. For example, after one of every three interactions \nwith a patient carrying  A. baumannii (present in 80% of rooms \nfrom colonized patients) HCWs contaminated their gloves and \ngowns . In general,  independent risk factors for HCWs contami -\nnation by MDROs were positive environmental cultures, stay in \nroom for more than 5 minutes, performing physical examina -\ntion and contact with the ventilator [46].\nLimitations of our study are that we did not perform a \nmolecular analysis and we did not evaluate the actions carried \nout by HCWs first of sampling.\nIn our study, after finding the positivity of the examined \nsurfaces we made a signal to the health management and to \nthe interested operative unit giving prescriptions on the en -\nvironmental sanitation and on the behaviour of the HCWs. In \nparticular, we have prescribed a more thorough cleaning of \nthe patients zone, cleaning the surfaces with GIOALCOL 70\u00ae \n(hydroalcoholic solution, of 70% ethyl alcohol), and sanitizing \nwith RELY ON VIRKON\u00ae (powdered product based on potassi -\num peroximonosulfate to be diluted according to the indica -\ntions in the technical data sheet (1g/L) alternating with STER-X \n2000\u00ae (sodium hypochlorite 2.5%) or ANIOSPRAY QUICK\u00ae (hy -\ndro-alcoholic solution 55%, quaternary ammonium propion -\nate, perfume).\nFor the behaviour of the operators it was prescribed the \nrespect of the correct technique of washing and disinfection \nof the hands with different methods and products, according \nto the activities that must be carried out, by performing the 5 \nfundamental moments for hand hygiene present on the guide -\nlines issued by the Ministry of Health with the use of hydro-al -\ncoholic gel for the clutch and chlorhexidine for washing.\nAfter prescriptions, we revaluated the contaminations \nboth of HCWs hands that surfaces and we did not found any \npositive sample, confirming the role of monitoring and infec -\ntion control strategies. [47]\nMoreover, it was observed that the awareness of being \nevaluated can improve the adhesion of the HCWs (\u201cHawthorne \neffect\u201d) and of the clean staff, although this effect can still be \nreduced in time [48]. \nWe hope, therefore, to reassess the results obtained over \ntime and evaluate the reduction of MDROs and HCAI in our \nhospital facilities to fight antimicrobial resistance. Drug-resistant bacteria on hands of healthcare workers and in the patient area: an environmental survey in \nSouthern Italy\u2019s hospital V. La Fauci, et al.\nRev Esp Quimioter 2019;32(4): 303-310309role of the hospital environment in the healthcare-associated in -\nfections: a general review of the literature. Eur Rev Med Pharmacol \nSci. 2019;23(3):1266-1278. doi: 10.26355/eurrev_201902_17020.\n24. World Health Organization (WHO). Antimicrobial resistance Glob -\nal Report on Surveillance 2014. Available on: http://www.who.int/\ndrugresistance/documents/surveillancereport/en/   . [Last accessed: \n2018, Oct 22]. \n25. ISO 18593:2004. Microbiology of food and animal feeding stuffs \n-- Horizontal methods for sampling techniques from surfaces using \ncontact plates and swabs\n26. ISO 18593:2018 . Microbiology of the food chain -- Horizontal \nmethods for surface sampling\n27. Magiorakos AP , Srinivasan A , Carey RB , Carmeli Y , Falagas ME , Giske \nCG. Multidrug-resistant, extensively drug-resistant and pan -\ndrug-resistant bacteria: an international expert proposal for in -\nterim standard definitions for acquired resistance. Clin Microbiol \nInfect.  2012;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. \n28. The R Project for Statistical Computing (https://www.r-project.org/)\n29. French GL, Otter JA, Shannon KP, Adams NM, Watling D, Parks \nMJ. Tackling contamination of the hospital environment by me -\nthicillin-resistant Staphylococcus aureus  (MRSA): a comparison \nbetween conventional terminal cleaning and hydrogen peroxide \nvapour decontamination. J Hosp Infect 2004; 57(1): 31-7.\n30. Squeri R, Grillo OC, La Fauci V. Surveillance and evidence of con -\ntamination in hospital environment from meticillin and vancomy -\ncin-resistant microbial agents. J Prev Med Hyg 2012; 53(3): 143-5.\n31. Lemmen SW, H\u00e4fner H, Zolldann D, Stanzel S, L\u00fctticken R. Distribu -\ntion of multi-resistant Gram-negative versus Gram-positive bac -\nteria in the hospital inanimate environment. J Hosp Infect 2004; \n56(3): 191-7.\n32. Weber DJ, Rutala WA, Kanamori H, Gergen MF, Sickbert-Bennett EE. \nCarbapenem-resistant Enterobacteriaceae : frequency of hospital room \ncontamination and survival on various inoculated surfaces. Infect Con -\ntrol Hosp Epidemiol 2015; 36(5): 590-3. doi: 10.1017/ice.2015.17. \n33. La Fauci V, Costa GB, Facciol\u00e0 A, Conti A, Riso, R. Squeri.Humidifiers \nfor oxygen therapy: what risk for reusable and disposable devices? \nJ Prev Med Hyg 2017; 58(2): E161-E165. PMC: 5584085.\n34. Deshpande A, Cadnum JL, Fertelli D, Sitzlar B, Thota P, Mana TS. Are \nhospital floors an underappreciated reservoir for transmission of \nhealth care-associated pathogens? Am J Infect Control 2017; 45(3): \n336-8. doi: 10.1016/j.ajic.2016.11.005.\n35. Koganti S, Alhmidi H, Tomas ME, Cadnum JL, Jencson A, Donskey \nCJ. Evaluation of Hospital Floors as a Potential Source of Pathogen \nDissemination Using a Nonpathogenic Virus as a Surrogate Marker. \nInfect Control Hosp Epidemiol 2016; 37(11): 1374-7. \n36. De Oliveira AC, Damasceno QS. Surfaces of the hospital environ -\nment as possible deposits of resistant bacteria: a review. Rev Esc \nEnferm USP 2010; 44(4): 1118-23.\n37. Miller WR, Munita JM, Arias CA. Mechanisms of antibiotic resistance \nin enterococci. Expert Rev Anti Infect Ther 2014; 12(10): 1221-36.\n38. Trick WE, Temple RS, Chen D, Wright MO, Solomon SL, Peterson LR. \nPatient colonization and environmental contamination by vanco -10.  Messineo A, Marsella LT. Biological hazards and healthcare-associ -\nated infections in Italian healthcare facilities: some considerations \non inspections and accountability. Ann Ig 2015; 27(6): 799-807. \ndoi: 10.7416/ai.2015.2073.\n11. Agodi A, Auxilia F, Barchitta M and SPIN-UTI network of the GISIO \nWorking Group of the Italian Society of Hygiene, Preventive Med -\nicine and Public Health (SItI). Antibiotic consumption and resist -\nance: results of the SPIN-UTI project of the GISIO-SItI. Epidemiol \nPrev 2015; 39(4 Suppl 1): 94-8.\n12. Caselli E, Berloco F, Tognon L and Study Group SAN-ICA. Influ -\nence of Sanitizing Methods on Healthcare-Associated Infections \nOnset: A Multicentre, Randomized, Controlled Pre-Post Interven -\ntional Study. J Clin Trials 2016; 6(5): 1000285. doi:10.4172/2167-\n0870.1000285. \n13. Caselli E, Brusaferro S, Coccagna M, Arnoldo L, Berloco F, Antonioli \nP and the SAN-ICA Study Group. Reducing healthcare-associat -\ned infections incidence by a probiotic-based sanitation system: A \nmulticentre, prospective, intervention study. PLoS One 2018;13(7): \ne0199616. doi: 10.1371/journal.pone.0199616.\n14. La Fauci V, Genovese C, Facciol\u00e0 A, Palamara MAR, Squeri R. Five-\nyear microbiological monitoring of wards and operating theatres in \nSouthern Italy. J Prev Med Hyg 2017; 58(2): 166-72.\n15. La Fauci V, Riso R, Facciol\u00e0 A, Merlina V, Squeri R. Surveillance of \nmicrobiological contamination and correct use of protective lead \ngarments. Ann Ig 2016; 28(5): 360-6. doi: 10.7416/ai.2016.2116.\n16. La Fauci V, Costa GB, Arena A, et al. Trend of MDR-microorganisms \nisolated from the biological samples of patients with HAI and from \nthe surfaces around that patient. New Microbiol 2018;41(1): 42-6.\n17. Creamer E, Dorrian S, Dolan A, Sherlock O, Fitzgerald-Hughes D, \nThomas T. When are the hands of healthcare workers positive \nfor methicillin-resistant Staphylococcus aureus? J Hosp Infect. \n2010;75(2):107-11. doi: 10.1016/j.jhin.2009.12.005. \n18. Cristina ML, Sartini M, Spagnolo AM. Serratia marcescens Infec -\ntions in Neonatal Intensive Care Units (NICUs). Int J Environ Res \nPublic Health. 2019;16(4). pii: E610. doi: 10.3390/ijerph16040610. \n19. Agodi A, Barchitta M, Auxilia F, Brusaferro S, D\u2019Errico MM, Mon -\ntagna MT. Epidemiology of intensive care unit-acquired sepsis in \nItaly: results of the SPIN-UTI network. Ann Ig. 2018;30(5 Supple \n2):15-21. doi: 10.7416/ai.2018.2247.\n20. Spagnolo AM, Sartini M, Battistella A, Casini B, Lo Pinto G, Schinca \nE and Hospital Infection Control Operating Group Galliera Hospital. \nA Clostridium difficile outbreak in an Italian hospital: the efficacy \nof the multi-disciplinary and multifaceted approach.J Prev Med \nHyg. 2018;59(2):E132-E138. \n21. Pasquarella C, Ciorba V, Arnoldo L, Auxilia F, Baldovin T, Barchit -\nta M et al.Hospital hygiene in Italy: the GISIO-SItI survey. Ann Ig. \n2018;30(5 Supple 2):7-14. doi: 10.7416/ai.2018.2246.\n22. Tan TY, Tan JS, Tay H, Chua GH, Ng LS, Syahidah N. Multidrug-re -\nsistant organisms in a routine ward environment: differential \npropensity for environmental dissemination and implications for \ninfection control. J Med Microbiol. 2013;62(Pt 5):766-72. doi: \n10.1099/jmm.0.052860-0.\n23. Facciol\u00e0 A, Pellican\u00f2 GF, Visalli G, Paolucci IA, Venanzi Rullo E. The Drug-resistant bacteria on hands of healthcare workers and in the patient area: an environmental survey in \nSouthern Italy\u2019s hospital V. La Fauci, et al.\nRev Esp Quimioter 2019;32(4): 303-310310mycin-resistant enterococci in a rehabilitation facility. Arch Phys \nMed Rehabil 2002; 83(7): 899-902.\n39. Drees M, Snydman DR, Schmid CH, Barefoot L, Hansjosten K, Vue \nPM et al. Prior environmental contamination increases the risk of \nacquisition of vancomycin-resistant enterococci. Clin Infect Dis \n2008; 46: 678-85.\n40.  Rohr U, Kaminski A, Wilhelm M, Jurzik L, Gatermann S, Muhr G. \nColonization of patients and contamination of the patients\u2019 envi -\nronment by MRSA under conditions of single-room isolation. Int J \nHyg Environ Health 2009; 12(2): 209-15.\n41. Morgan DJ, Rogawski E, Thom KA, Johnson JK, Perencevich EN, \nShardell M et al. Transfer of multidrug-resistant bacteria to \nhealthcare workers\u2019 gloves and gowns after patient contact in -\ncreases with environmental contamination. Critical Care Medicine. \n2012;40(4):1045\u20131051. doi: 10.1097/CCM.0b013e31823bc7c8.\n42. Lerner A, Adler A, Abu-Hanna J, Meitus I, Navon-Venezia S, Carmeli \nY. Environmental contamination by carbapenem-resistant Entero -\nbacteriaceae . J Clin Microbiol 2013; 51(1): 177-81. doi: 10.1128/\nJCM.01992-12. \n43. Sekiguchi J, Teruya K, Horii K, Kuroda E, Konosaki H, Mizuguchi \nY,et al. Molecular epidemiology of outbreaks and containment of \ndrug-resistant Pseudomonas aeruginosa  in a Tokyo hospital. J In -\nfect Chemother 2007; 13(6): 418-22.\n44. Kohlenberg A, Weitzel-Kage D, van der Linden P, Sohr D, V\u00f6geler \nS, Kola A et al. Outbreak of carbapenem-resistant Pseudomonas \naeruginosa  infection in a surgical intensive care unit. J Hosp Infect \n2010; 74(4): 350-7. doi: 10.1016/j.jhin.2009.10.024. \n45. Simor AE, Lee M, Vearncombe M, Jones-Paul L, Barry C, Gomez M \net al. An outbreak due to multiresistant Acinetobacter  baumannii  \nin a burn unit: risk factors for acquisition and management. Infect \nControl Hosp Epidemiol 2002; 23: 261-7. \n46. World Health Organization (WHO). WHO Guidelines on Hand Hy -\ngiene in Health Care: First Global Patient Safety Challenge Clear \nCare is Safer Care. Cap. 7: Transmission of Pathogens by Hands. \nGeneva: WHO, 2009.  Available on: https://www.ncbi.nlm.nih.gov/\nbooks/NBK144014/  [Last accessed: 2018, Oct 22].\n47. Infection control standard precautions in health care. Epidemic and \npandemic alert and response. World Health Organization (2007). \nAvailable on: https://www.who.int/csr/resources/publications/\nEPR_AM2_E7.pdf  \n48. Hagel S, Reischke J, Kesselmeier M, Winning J, Gastmeier P, Brunk -\nhorst FM et al. Quantifying the Hawthorne effect in hand hygiene \ncompliance through comparing direct observation with automat -\ned hand hygiene monitoring. Infect Control Hosp Epidemiol2015; \n36(8): 957-62.\n49. Courvalin P. Why is antibiotic resistance a deadly emerging dis -\nease? Clin Microbiol Infect 2016; 22(5): 405-7. doi: 10.1016/j.\ncmi.2016.01.012. \n50. La Fauci V, Alessi V. Antibiotic resistance: where are we going? Ann \nIg 2018; 30(4 Suppl 1): 52-7. doi: 10.7416/ai.2018.2235. \n51. Squeri R, Genovese C, Palamara MA, Trimarchi G, La Fauci V. \u201cClean \ncare is safer care\u201d: correct handwashing in the prevention of \nhealthcare associated infections. Ann Ig 2016; 28(6): 409-15. doi: 10.7416/ai.2016.2123.\n52. La Fauci V, Riso R, Facciol\u00e0 A, Ceccio C, Lo Giudice D, Calimeri S et al. \nResponse to anti-HBV vaccine and 10-year follow-up of antibody \nlevels in healthcare workers. Public Health. 2016;139:198-202. doi: \n10.1016/j.puhe.2016.08.007.\n53. Genovese C, La Fauci V, Buda A, Nucera S, Alessi V, Carnuccio S et \nal.A potential outbreak of Measles and chickenpox among health -\ncare workers of a university hospital. EMBJ 2019; 14(10): 45-48. \n54. Squeri R, Genovese C, Trimarchi G, Palamara MAR, La Fauci V. An \nevaluation of attitude toward vaccines among healthcare workers \nof a University Hospital in Southern Italy. Ann Ig. 2017;29(6):595-\n606. doi: 10.7416/ai.2017.2188.\n55. Squeri R, Riso R, Facciol\u00e0 A, Genovese C, Palamara MA, Ceccio C et \nal. Management of two influenza vaccination campaign in health \ncare workers of a university hospital in the south Italy. Ann Ig. \n2017;29(3):223-231. doi: 10.7416/ai.2017.2150.\n56. Squeri R, La Fauci V, Picerno IAM, TrimarchiG, Cannav\u00f2 G, Egitto G. \net al. Evaluation of vaccine coverages in the health care workers of \na university hospital in southern Italy. Ann Ig. 2019; 31(2 Supple \n1):13-24. doi: 10.7416/ai.2019.2273.\n57. Genovese C, Picerno IAM, TrimarchiG, Cannav\u00f2 G, Egitto G, Cosen -\nza B. et al. Vaccination coverage in healthcare workers: a multi -\ncenter cross-sectional study in Italy. JMPH. J Prev Med Hyg. 2019; \n60(1):E12-E17. doi: 10.15167/2421-4248/jpmh2019.60.1.1097. \neCollection 2019 Mar.\n58. Lo Giudice D, Capua A, La Fauci V, Squeri R, Grillo OC, Calimeri S. \nCongenital rubella syndrome and immunity status of immigrant \nwomen living in southern Italy: a cross-sectional, seroepidemio -\nlogical investigation.Travel Med Infect Dis. 2014;12(3):253-7. doi: \n10.1016/j.tmaid.2014.01.003. \n59. Genovese C, LA Fauci V, Squeri A, Trimarchi G, Squeri R.HPV vac -\ncine and autoimmune diseases: systematic review and meta-anal -\nysis of the literature. J Prev Med Hyg. 2018;59(3):E194-E199. doi: \n10.15167/2421-4248/jpmh2018.59.3.998. \n60. Squeri R, La Fauci V, Sindoni L, Cannav\u00f2 G, Ventura Spagnolo E. \nStudy on hepatitis B and C serologic status among municipal solid \nwaste workers in Messina (Italy). J Prev Med Hyg. 2006 47(3):110-3.Rev Esp Quimioter 2019;32(4): 311-316311\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).su aparici\u00f3n y mejorar la seguridad de los pacientes hospitali -\nzados. \nPalabras clave: infecci\u00f3n tracto urinario, factores de riesgo, bacteriemia \nnosocomial secundaria, epidemiolog\u00eda\nRisk factors to secondary nosocomial \nbacteremia to UTI in a tertiary hospital\nABSTRACT \nIntroduction.  Nosocomial bacteremia secondary to uri -\nnary tract infections (NBS-UTI) occur in 1-4% of episodes and \nthe associated mortality can increase up to 33%. However, \nvery little is known about the epidemiology of these infections. \nThe determination of modifiable risk factors to develop this ty -\npe of bacteremia could help to control the infection and redu -\nce health costs.\nMaterial and methods.  Cases-control study of NBS-UTI \ndiagnosed at the University Hospital of Canary Islands bet -\nween 2010-2014. The clinical-epidemiological variables and \nthe intrinsic and extrinsic potential risk factors were collected. \nLogistic regression was used to study the variables associated \nwith the development of NBS-UTI.\nResults.  A total of 178 episodes were studied, 85 cases \nand 93 controls. The average stay was significantly greater in \nthe cases; from admission to bacteremia (p <0.003), as well as \nfrom discharge to discharge (p <0.005). Hepatic insufficiency \n(p <0.091), the use of mechanical ventilation (p <0.001), the \ncentral venous catheter (p <0.043) and surgery in the episode \n(p <0.001) behaved as risk factors for the acquisition of NBS-\nITU.\nConclusion. Invasive devices, such as central venous \ncatheter and mechanical ventilation, that had not previously \nbeen studied; as well as the surgery in the episode, which had \nnot been studied either, suppose risk factors. In addition, NBS-\nITU causes a significant increase in hospital stay. Therefore, it is RESUMEN\nIntroducci\u00f3n.  Las bacteriemias nosocomiales secunda -\nrias a infecciones del tracto urinario (BNS-ITU) ocurren en un \n1-4% de los episodios y la mortalidad asociada puede aumen -\ntar hasta el 33%. Sin embargo, se conoce muy poco sobre la \nepidemiolog\u00eda de estas infecciones. La determinaci\u00f3n de los \nfactores de riesgo modificables para desarrollar este tipo de \nbacteriemias podr\u00eda ayudar al control de la infecci\u00f3n y reducir \nel gasto sanitario. \nMaterial y m\u00e9todos.  Estudio de casos y controles de las \nBNS-ITU diagnosticadas en el Hospital Universitario de Cana -\nrias entre 2010-2014. Se recogieron las variables cl\u00ednico-epi -\ndemiol\u00f3gicas y los factores de riesgo potenciales intr\u00ednsecos y \nextr\u00ednsecos. Se utiliz\u00f3 la regresi\u00f3n log\u00edstica para estudiar las \nvariables asociadas al desarrollo de BNS-ITU.\nResultados.  Se estudiaron 178 episodios, 85 casos y 93 \ncontroles. La estancia media fue significativamente mayor en \nlos casos; desde el ingreso hasta la bacteriemia (p< 0,003), co -\nmo desde \u00e9sta hasta el alta (p< 0,005). La insuficiencia hep\u00e1ti -\nca (p< 0,091), el uso de ventilaci\u00f3n mec\u00e1nica (p<0,001), de el \ncat\u00e9ter venoso central (p<0,043) y la cirug\u00eda en el episodio (p< \n0,001) se comportaron como factores de riesgo para la adqui -\nsici\u00f3n de BNS-ITU.\nConclusiones.  Los dispositivos invasivos, como el cat\u00e9ter \nvenoso central y la ventilaci\u00f3n mec\u00e1nica, que no hab\u00eda sido \nestudiada previamente; as\u00ed como la cirug\u00eda en el episodio, que \ntampoco hab\u00eda sido estudiada, suponen factores de riesgo. \nAdem\u00e1s, la BNS-ITU causa un aumento significativo de la es -\ntancia hospitalaria. Por ello, es necesario conocer los factores \nde riesgo para la aparici\u00f3n de estas infecciones, y as\u00ed, prevenir Factores de riesgo en bacteriemias nosocomiales \nsecundarias a ITU en un hospital terciario\n1Servicio de Microbiolog\u00eda y Control de la Infecci\u00f3n, Hospital Universitario de Canarias, Tenerife, Espa\u00f1a\n2Servicio de apoyo a la investigaci\u00f3n. Colegio Oficial de Enfermer\u00eda de Santa Cruz de Tenerife, Espa\u00f1a.\n3Departamento de Medicina Preventiva y Salud P\u00fablica de la Universidad de La Laguna, Tenerife, Espa\u00f1aLaura Sante1\nMar\u00eda Lecuona1 \nArmando Aguirre Jaime2 \n\u00c1ngeles Arias3\nCorrespondencia:\nLaura Sante \nServicio de Microbiolog\u00eda y Control de la Infecci\u00f3n, Hospital Universitario de Canarias\nCtra. Ofra S/N La Cuesta 38320 La Laguna, Tenerife, Espa\u00f1a\nE-mail: laurasante@hotmail.comOriginal\nArticle history\nReceived: 26 February 2019; Revision Requested: 13 April 2019; Revision Received: 23 April 2019; Accepted: 25 April 2019Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital terciario L. Sante, et al.\nRev Esp Quimioter 2019;32(4): 311-316312Los controles se obtuvieron de la base de datos de los uri -\nnocultivos procesados en el Servicio de Microbiolog\u00eda y Con -\ntrol de la Infecci\u00f3n, procedentes de pacientes ingresados en el \nhospital. Se comprob\u00f3 que correspond\u00edan a un episodio de ITU \ndurante ese periodo, pero que no hab\u00edan desarrollado una BNS, \nsiguiendo la definici\u00f3n de los CDC [8] para su diagn\u00f3stico: \n\u00b7  El paciente con o sin sondaje urinario presentaba al menos \nuno de los siguientes signos o s\u00edntomas:\n\u00b7 fiebre (>38\u00ba C)\n\u00b7 dolor en el \u00e1ngulo costovertebral\n\u00b7 frecuencia urinaria*\n\u00b7 disuria*\n\u00b7  y adem\u00e1s, el paciente tuviese un cultivo de orina con no m\u00e1s \nde dos especies de organismos identificados, al menos uno \nde los cuales fuese una bacteria con una recuento \u2265 105 UFC/\nmL.\n*Estos dos s\u00edntomas no pueden considerarse cuando el \npacientes es portador de sondaje urinario.\nLos controles se aparearon a los casos por fecha de \ningreso, sexo, edad, servicio de ingreso y microorganismo \ncausal de la infecci\u00f3n.\nSe revisaron las historias cl\u00ednicas de cada uno de los episo -\ndios de los casos y de los controles. Se recogieron las variables \ncl\u00ednico-epidemiol\u00f3gicas (sexo, edad, servicio, microorganismo, \nd\u00edas de hospitalizaci\u00f3n previos a la bacteriemia, d\u00edas de hospi -\ntalizaci\u00f3n desde la bacteriemia hasta el alta, ingreso previo en \nlos \u00faltimo 6 meses); as\u00ed como los factores de riesgo potencia -\nles intr\u00ednsecos (Neoplasia, Insuficiencia hep\u00e1tica, Insuficiencia \nrenal, \u00dalcera por Presi\u00f3n, Hipertensi\u00f3n Arterial, Diabetes Me -\nllitus, Inmunosupresi\u00f3n, \u00cdndice de comorbilidad de Charlson) \ny los factores de riesgo potenciales extr\u00ednsecos (tratamiento \nantibi\u00f3tico previo a la infecci\u00f3n, Sondaje vesical, Ventilaci\u00f3n \nmec\u00e1nica, Cat\u00e9ter venoso central y Cirug\u00eda durante el ingreso). \nEn cuanto a la prescripci\u00f3n de antibi\u00f3ticos previa a la \nfecha de infecci\u00f3n se consult\u00f3 en las historias cl\u00ednicas de los \npacientes si \u00e9stos hab\u00edan recibido terapia antimicrobiana la se -\nmana anterior a la fecha de infecci\u00f3n y si el microorganismo \naislado era sensible a la misma.\nAn\u00e1lisis estad\u00edstico.  Para dotar al estudio de una poten -\ncia del 80% en pruebas bilaterales de contraste de hip\u00f3tesis \na un nivel de significaci\u00f3n p \u22640.05, se consider\u00f3 que la preva -\nlencia del factor con sospecha de asociaci\u00f3n a la bacteriemia \nsecundaria era de un 30% entre los controles y en un 20% \nmayor, como diferencia sustancial, entre los casos, se estim\u00f3 \nnecesario disponer de 93 sujetos por grupo. Ese tama\u00f1o de \nmuestra permitir\u00eda el empleo de modelos de regresi\u00f3n log\u00eds -\ntica binaria con un m\u00e1ximo de 8 factores con posibilidad de \nasociaci\u00f3n a la bacteriemia secundaria como efecto, seg\u00fan los \nrequisitos de adecuaci\u00f3n de Hosmer-Lemeshov para el empleo \nde un modelo de regresi\u00f3n log\u00edstica. \nLa muestra se describi\u00f3 resumiendo las variables nomi -\nnales con la frecuencia relativa de sus categor\u00edas componen -necessary to know the risk factors for the appearance of these \ninfections, and thus prevent their appearance and improve the \nsafety of hospitalized patients.\nKey words: urinary tract infection, risk factors, secondary nosocomial bac -\nteremia, epidemiology.\nINTRODUCCI\u00d3N\nLas infecciones del tracto urinario (ITU) son una de las \ncausas m\u00e1s frecuentes de infecci\u00f3n nosocomial en Europa \n[1] y en EEUU [2]. Aproximadamente un 80% de los casos, se \nrelacionan con la presencia de cat\u00e9ter urinario [3]. Las bacte -\nriemias nosocomiales secundarias a infecciones del tracto uri -\nnario (BNS-ITU) ocurren en un 1-4% [4] de los episodios y la \nmortalidad asociada a estos procesos puede aumentar hasta el \n33% [2,5]. No obstante, en EEUU se estima que un 17% de las \nde las bacteriemias nosocomiales son secundarias a ITU [6] y en \nEspa\u00f1a, seg\u00fan los datos obtenidos del Estudio de Prevalencia \nde las Infecciones Nosocomiales en Espa\u00f1a (EPINE) suponen un \n37,3% del total de BNS y un 11,8% del total de BN, ocupando \nel primer puesto de las bacteriemias nosocomiales secundarias \n(BNS) [7]. Adem\u00e1s, las consecuencias econ\u00f3micas de este tipo \nde infecciones son tambi\u00e9n importantes y cuantiosas. En un \nestudio realizado por Saint et al. [4] describieron que cada epi -\nsodio relacionado con BNS-ITU supon\u00eda un incremento en el \ncoste sanitario de 3.000 d\u00f3lares. \nA pesar de estas cifras, se conoce muy poco sobre la epi -\ndemiolog\u00eda de las bacteriemias nosocomiales relacionadas con \nlas ITU. La determinaci\u00f3n de los factores de riesgo modificables \npara desarrollar este tipo de bacteriemias podr\u00eda ayudar a de -\nfinir pr\u00e1cticas apropiadas para el control de la infecci\u00f3n y a \nmejorar la seguridad de los pacientes hospitalizados, al mismo \ntiempo que se reducir\u00eda el gasto sanitario. \nEl objetivo del presente estudio es identificar factores de \nriesgo potenciales de padecer una bacteriemia secundaria a in -\nfecci\u00f3n urinaria en los pacientes hospitalizados.\nMATERIAL Y M\u00c9TODOS\nSe realiz\u00f3 un estudio de casos y controles de las BNS-ITU \ndiagnosticadas en el Hospital Universitario de Canarias entre el \n1 de enero de 2010 y el 31 de diciembre de 2014. Se trata de \nun hospital de tercer nivel de 660 camas, que dispone de una \nUnidad de Cuidados Intensivos m\u00e9dico-quir\u00fargica y se reali -\nzan trasplantes renales. Los casos se obtuvieron de las bases \nde datos las bacteriemias nosocomiales (BN) que fueron cla -\nsificadas por la Secci\u00f3n de Control de la Infecci\u00f3n siguiendo \nlos criterios de los CDC [8] en: Bacteriemias Primarias, Bacte -\nriemias Relacionadas con Cat\u00e9ter y Bacteriemias secundarias a \notros procesos infecciosos. Se consider\u00f3 que la bacteriemia era \nsecundaria a una ITU cuando se diagnosticaba una infecci\u00f3n \ncon un hemocultivo positivo para al menos un mismo microor -\nganismo aislado y causante de la infecci\u00f3n de la ITU, y que \nhubiese sido recogido durante el periodo en que se atribu\u00eda la \nbacteriemia secundaria. Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital terciario L. Sante, et al.\nRev Esp Quimioter 2019;32(4): 311-316313Whitney si son ordinales o de escala no-\nnormal. Los factores que alcanzaron en \nestas comparaciones una diferencia a un \nnivel p\u22640,20 fueron introducidas como \nvariables explicativas de la bacteriemia se -\ncundaria a ITU en modelos de regresi\u00f3n lo -\ng\u00edstica binaria multivariable empleando la \nestrategia de modelo lleno por pasos hacia \natr\u00e1s y criterio de Wald. Para la retenci\u00f3n \ndel factor se estableci\u00f3 un valor p \u22640,05. \nTodos los c\u00e1lculos se realizaron con \nayuda del paquete de procesamiento esta -\nd\u00edstico informatizado SPSS\u2122 24.0 de IBM-\nSPSS Inc, Armonk, NY\u00a9.\nRESULTADOS\nSe estudiaron un total de 178 episo -\ndios de infecciones del tracto urinario, de \nlos cuales 85 correspond\u00edan a casos, que \ndesarrollaron bacteriemia nosocomial pos -\nterior y 93 a controles, que no la desarro -\nllaron. \nEn la tabla 1 se observan los poten -\nciales factores de riesgo estudiados, para \nlos casos y para los controles. En los ca -\nsos de BNS-ITU recogidos, observamos un \npredominio de hombres (54,1%) con una \nedad media de 67 a\u00f1os. La mayor\u00eda de es -\ntas BNS se diagnosticaron en los servicios \nm\u00e9dicos (40%), seguidos de los servicios \nquir\u00fargicos (25,8%). El uso de dispositivos \ninvasivos, como la sonda vesical (77,6%), \nla ventilaci\u00f3n mec\u00e1nica (VM) (40%) o el \ncat\u00e9ter venoso central (CVC) (63,5%) fue -\nron utilizados en con frecuencia en estos \npacientes. Adem\u00e1s, un 51,7% de estos pa -\ncientes hab\u00edan sido sometidos a cirug\u00eda en \nel ingreso. Un 18,8% fueron exitus duran -\nte el episodio.\nEntre los casos, los microorganismos \nm\u00e1s frecuentemente aislados fueron los \nbacilos gramnegativos (74,4%), principal -\nmente Enterobacterias (54,9%), seguidos \nde los cocos grampositivos (18,2%), ma -\nyoritariamente Enterococcus  spp. (14,2%) \ny en tercer lugar las levaduras del g\u00e9nero \nCandida (6,5%) (tabla 1 y 2).\nLa estancia media fue significativamente mayor en los \ncasos que en los controles; tanto desde la fecha de ingreso \nhasta el desarrollo de la bacteriemia (p< 0,003), como desde \n\u00e9sta hasta el alta (p< 0,005). Adem\u00e1s, este grupo present\u00f3 con \nmayor frecuencia insuficiencia hep\u00e1tica (p< 0,091). Asimismo, \nel uso de dispositivos invasivos, como la VM o el CVC fue sig -\nnificativamente mayor entre los casos (p<0,001 y p<0,043). El tes, las ordinales y de escala no-normal con mediana(P5\u2212P95) o \nmediana(rango) y las de escala normal con media (DT). La nor -\nmalidad se prob\u00f3 con histogramas y test de Kolmogorov-Smir -\nnov. Los resultados se ofrecen en intervalos de confianza al 95%. \nLa comparaci\u00f3n de los potenciales factores de riesgo en -\ntre casos y controles se efectu\u00f3 con la prueba chi2 de Pearson \ncuando los factores eran variables nominales y U de Mann-POTENCIALES FACTORES DE RIESGO CASOS  \n(n=85)CONTROLES  \n(n=93)Valor-p\nEdad en a\u00f1os, mediana (P 5-P95) 67 (25-85) 70 (25-86) 0,383\nSexo masculino, n (%) 46 (54,1) 48 (51,6) 0,738\nServicios, n (%)\nM\u00e9dicos\nQuir\u00fargicos\nOnco-hematol\u00f3gicos\nIntensivos\nUCI- Pedi\u00e1trica\nPediatr\u00eda34 (40)\n22 (25,8)\n15 (17,6)\n12 (14,1)\n0 (0)\n2 (2,3)30 (32,2)\n35 (37,6)\n12 (12,9)\n12 (12,9)\n2 (2,1)\n2 (2,1)0,392\nMicroorganismos, n(%)\nCocos grampositivos\nBacilos gramnegativos\nLevaduras17 (18,2)\n68 (74,7)\n6 (6,5)13 (13,9)\n72 (77,4)\n8 (8,6)0,668\nEstancia ingreso-infecci\u00f3n, mediana(rango) 18 (2-233) 12 (0-338) 0,003\nEstancia infecci\u00f3n-alta,(mediana (rango) 21 (2-278) 12 (0-175) 0,005\nNeoplasia, n (%) 29 (34,1) 26 (27,9) 0,400\nInsuficiencia, renal n (%) 27 (31,7) 23 (24,7) 0,297\nInsuficiencia hepatica, n (%) 12 (14,1) 6 (6,4) 0,091\n\u00dalcera por Presi\u00f3n, n (%) 12 (14,1) 19 (20,4) 0,267\nHipertensi\u00f3n, n (%) 51 (60) 58 (62,3) 0,746\nDiabetes Mellitus, n (%) 32 (37,6) 40 (43) 0,466\nDislipidemia, n (%) 31 (36,4) 31 (33,3) 0,661\nInmunosupresi\u00f3n, n (%) 27 (31,7) 29 (31,1) 0,933\nSonda vesical, n (%) 66 (77,6) 67 (72) 0,390\nVentilaci\u00f3n mec\u00e1nica, n (%) 34(40) 11(11,8) <0,001\nCat\u00e9ter Venoso Central, n (%) 54 (63,5) 45 (48,3) 0,043\nHospitalizaci\u00f3n previa en 6 meses, n (%) 32 (37,6) 32 (34,4) 0,653\nCirug\u00eda en el ingreso, n (%) 44 (51,7) 26 (27,9) 0,001\n\u00cdndice Charlson, mediana (P 5-P95) 4 (0-7) 4 (0-6) 0,173\nConsumo previo de antibi\u00f3ticos, (n,%) 49 (57,6) 46 (49,4) 0,274\nSensibles, n (%) 11 (22,4) 15 (32,6) 0,243\nExitus, n (%) 16 (18,8) 13 (13,9) 0,382Tabla 1  Resultado de las comparaciones de los potenciales factores de \nriesgo a una bacteriemia secundaria a una infecci\u00f3n del tracto \nurinario entre casos y controles.Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital terciario L. Sante, et al.\nRev Esp Quimioter 2019;32(4): 311-316314calizaci\u00f3n Quir\u00fargica y las Infecciones del Tracto Respiratorio, \nlas BNS m\u00e1s frecuentes y prevalentes en los hospitales [9, 10]. \nEstos 85 casos, supusieron un 24% del total de BNS del pe -\nriodo a estudio, siendo las segundas BNS m\u00e1s prevalentes en \nnuestro hospital, por detr\u00e1s de las bacteriemias nosocomiales \nsecundarias a infecciones de localizaci\u00f3n quir\u00fargica (ILQ) que \nrepresentaron el 28,5% [11]. En Espa\u00f1a, seg\u00fan el estudio EPINE \ndel a\u00f1o 2017, estas bacteriemias fueron un 11,83% del total \nde BN, siendo las m\u00e1s prevalentes [7]. En Europa, seg\u00fan el in -\nforme European Center for Disease and Control (E-CDC) [12] \nlas BNS-ITU supusieron un 8% del total de BN (28,8%), siendo \nlas BNS m\u00e1s prevalentes. En nuestro hospital, el porcentaje de \nprevalencia es menor que en Espa\u00f1a y Europa [11].\nCon estos datos podemos afirmar que las BNS-ITU supo -\nnen un porcentaje no despreciable con respecto a las BN, sin \nembargo, constituyen un grupo de infecciones poco estudiado \ny la bibliograf\u00eda referente a ellas es muy escasa. Por ello, hemos \nrealizado un estudio de casos y controles para determinar los \nfactores predisponentes para que un paciente con infecci\u00f3n \ndel tracto urinario desarrolle una bacteriemia nosocomial. Para \nello, hemos recogido todos los casos de BNS-ITU en el per\u00edo -\ndo de estudio y hemos apareado nuestros controles seg\u00fan el \na\u00f1o de infecci\u00f3n y el servicio, adem\u00e1s de los factores de riesgo \nno modificables como son la edad y el sexo. La edad ha sido \ndescrita como factor de riesgo para la adquisici\u00f3n de BNS-ITU \n[4, 13, 14]. Seg\u00fan un estudio realizado por Griebling et al. [15] \nlas mujeres presentan un mayor riesgo de padecer una ITU, sin \nembargo, a la hora de desarrollar una bacteriemia secundaria \nen nuestro estudio no existieron diferencias de sexos, al igual \nque en el trabajo de Greene et al. [16]. \nEn nuestro estudio, los microorganismos predominantes \nfueron los bacilos gramnegativos, seguidos de los cocos gram -\npositivos (especialmente de los Enterococcus  spp.) y levaduras. \nEste porcentaje es similar al encontrado por otros autores [13, \n14, 17]. En el estudio presentado por de Saint et al. [4] aunque \nlos bacilos gramnegativos fueron globalmente los microorga -\nnismos m\u00e1s frecuentes, si se desglosa por especies, los mayo -\nritarios fueron los Enterococcus spp. tanto en la serie de casos \ncomo en la serie de controles, siendo m\u00e1s frecuentemente ais -\nlados entre los casos (30,2% vs. 22,3%, p= 0,011). Chang et al. \n[2] obtuvieron un predominio de los Enterococcus spp. (29%) \nseguidos de Candida spp., (20%), teniendo los pacientes con \nbacteriemias por Candida  spp. un riesgo 3,4 veces mayor de \nsufrir exitus que los pacientes con bacteriemia por Escherichia \ncoli. \nEn nuestra serie se produjo un 18,8% de exitus, de los \ncuales 10 (62,5%) ten\u00edan infecci\u00f3n causada por bacilos gram -\nnegativos. Diversos autores refieren porcentajes de mortalidad \nasociados a una infecci\u00f3n BNS-ITU que var\u00eda entre el 7,5% [13] \ny el 16,2% [18]. \nSe ha identificado que el uso de dispositivos invasivos, co -\nmo la sonda vesical, como factor de riesgo para el desarrollo de \nbacteriemia [4, 18] y sepsis [19]. En nuestro estudio, en el an\u00e1 -\nlisis univariante obtuvimos que el uso de sonda no se asociaba \na mayor riesgo de desarrollo de bacteriemia; pero sin embargo, 51,7% de los casos hab\u00edan sometido a cirug\u00eda en el ingreso, \nfrente al 27,9% del grupo control (p< 0,001). \nNo se encontraron diferencias significativas en cuanto al \nconsumo previo de antibi\u00f3ticos ni se obtuvieron diferencias en \ncuanto a la sensibilidad de los tratamientos emp\u00edricos aplica -\ndos en ambos grupos de pacientes. \nEn la tabla 3 se muestran los resultados del ajuste del \nmodelo de regresi\u00f3n log\u00edstica en el an\u00e1lisis multivariante. Los \npacientes con ventilaci\u00f3n mec\u00e1nica y los que tuvieron un pro -\nceso quir\u00fargico durante el ingreso presentaron un riesgo supe -\nrior de desarrollar BNS.\nDISCUSI\u00d3N\nLas BNS-ITU son, junto con las BNS a Infecciones de Lo -Microorganismo n (%)\nEscherichia coli 29 (31,8)\nKlebsiella  spp. 18 (19,7)\nPseudomonas  aeruginosa 16 (17,5)\nEnterococcus  spp. 13 (14,2)\nCandida  spp. 6 (6,5)\nStaphylococcus  coagulasa  negativos 3 (3,2)\nStenotrophomonas  maltophilia 2 (2,1)\nStaphylococcus  aureus 1 (1)\nEnterobacter  cloacae 1 (1)\nFusobacterium  nucleatum 1 (1)\nProteus  mirabilis 1 (1)\nSerratia  marcescens 1 (1)Tabla 2  Distribuci\u00f3n de los microorganismos en los \npacientes con BNS-ITU 2010-2014\nEl modelo arranca lleno con los potenciales factores: D\u00edas pre-bacteriemia, Insufi -\nciencia hep\u00e1tica, Ventilaci\u00f3n mec\u00e1nica, Cat\u00e9ter venoso central, Cirug\u00eda al ingreso, \ne \u00cdndice Charlson, como potencialmente explicativos de la bacteriemia secundaria. \nEl modelo converge a los 6 pasos reteniendo s\u00f3lo a la Ventilaci\u00f3n mec\u00e1nica y la \nCirug\u00eda al ingreso.Tabla 3  Resultados del ajuste del modelo de \nregresi\u00f3n log\u00edstica multivariante a los \npotenciales factores de riesgo considerados \nen el estudio para el desarrollo de BSI- \nITU que alcanzan significaci\u00f3n en su \ncomparaci\u00f3n univariante entre casos y \ncontroles\nFactor OR(IC95%) p-Valor\nVentilaci\u00f3n mec\u00e1nica 4,6 (2,1-10,3) <0,001\nCirug\u00eda en el ingreso 2,8 (1,4- 5,5) 0,003Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital terciario L. Sante, et al.\nRev Esp Quimioter 2019;32(4): 311-316315retrospectivo, no pudimos determinar si a todos los pacientes \nque padecieron un episodio de bacteriemia se le solicit\u00f3 cultivo \nmicrobiol\u00f3gico de otras muestras cl\u00ednicas para poder descar -\ntar infecci\u00f3n en otra localizaci\u00f3n, pudiendo tener un exceso \nde clasificaci\u00f3n de bacteriemias primarias quedando as\u00ed las \nBNS-ITU infradiagnosticadas. Otra limitaci\u00f3n, es que el estu -\ndio se realiz\u00f3 en un \u00fanico centro hospitalario, y para conocer \nmejor la epidemiolog\u00eda de las BNS-ITU en los hospitales de ni -\nvel terciario ser\u00eda necesario realizar un estudio multic\u00e9ntrico. \nLa tercera limitaci\u00f3n es el escaso n\u00famero de controles. Esto es \ndebido a que en nuestro planteamiento decidimos aparear los \ncontroles seg\u00fan el tipo de microorganismo, ya que al ser un \nfactor no modificable podr\u00edamos observar si encontr\u00e1bamos \notros factores de riesgo modificables para la prevenci\u00f3n de las \nBNS-ITU.\nEn conclusi\u00f3n, y a pesar de estas limitaciones, creemos \nque nuestro estudio tiene importantes implicaciones cl\u00ednicas. \nObservamos que los dispositivos invasivos, como el cat\u00e9ter \nvenoso central y la ventilaci\u00f3n mec\u00e1nica, que no hab\u00eda sido \nestudiada previamente, se comporta como un factor de riesgo \npara la adquisici\u00f3n de una BNS-ITU. La cirug\u00eda en el episodio, \nque tampoco hab\u00eda sido estudiada previamente, supone tam -\nbi\u00e9n un factor de riesgo. Adem\u00e1s, la bacteriemia asociada a \nITU causa un aumento significativo de la estancia hospitalaria. \nPor ello, consideramos que es necesario conocer los factores \nde riesgo para la aparici\u00f3n de estas infecciones, para poder \nprevenir su aparici\u00f3n y mejorar la seguridad de los pacientes \nhospitalizados. \nFINANCIACI\u00d3N\nLos autores declaran que no han recibido financiaci\u00f3n pa -\nra la realizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener conflicto de intereses.\nBIBLIOGRAF\u00cdA\n1. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Du -\ncomble T et al. Burden of Six Healthcare-Associated Infections on \nEuropean Population Health: Estimating Incidence-Based Disabi -\nlity-Adjusted Life Years through a Population Prevalence-Based \nModelling Study. PLoS Med. 2016;13(10):e1002150. doi: 10.1371/\njournal.pmed.1002150.\n2. Chang R, Greene MT, Chenoweth CE, Kuhn L, Shuman E, Rogers \nMA et al. Epidemiology of hospital-acquired urinary tract-related \nbloodstream infection at a university hospital. Infect Control Hosp \nEpidemiol. 2011;32(11):1127-9. doi: 10.1086/662378. \n3. World Health Organization. 2003. Prevenci\u00f3n de las infecciones \nnosocomiales: gu\u00eda pr\u00e1ctica / revisores : G. Ducel, J. Fabry y L. Ni -\ncolle, 2a ed. Ginebra : Organizaci\u00f3n Mundial de la Salud. [cited 20 \nDecember 2018]. Avaliable from: http://www.who.int/iris/hand -\nle/10665/67877el uso de otros dispositivos invasivos, como la ventilaci\u00f3n me -\nc\u00e1nica y el cat\u00e9ter venoso central si eran factores de riesgo \nsignificativos para el desarrollo de una BNS-ITU, lo que podr\u00eda \nestar relacionado, ya que se trata de pacientes ingresados en \nlas unidades de cuidados intensivos, con la patolog\u00eda de base y \ngravedad de estos pacientes. La insuficiencia hep\u00e1tica, al igual \nque en el trabajo de Greene et al. [16] se comport\u00f3 como un \nfactor de riesgo. \nEncontramos diferencias significativas respecto a la es -\ntancia hospitalaria. Aquellos pacientes que desarrollaron bac -\nteriemia permanecieron m\u00e1s d\u00edas de estancia desde el ingreso \nhasta el desarrollo de la misma y posteriormente desde \u00e9sta \n\u00faltima hasta el alta. En el estudio de Greene et al. [16] la estan -\ncia hospitalaria media tambi\u00e9n fue significativamente superior \nen los casos que en los controles. Esto puede significar un au -\nmento del gasto sanitario, tal y como describieron Riu et al. \n[21] en un estudio sobre el impacto econ\u00f3mico del desarrollo \nde bacteriemia seg\u00fan el foco de infecci\u00f3n y la sensibilidad an -\ntibi\u00f3tica. En dicho estudio, observaron que las BNS-ITU por mi -\ncroorganismo sensibles supon\u00edan un coste adicional de 6.786 \u20ac \ny hasta 13.299 \u20ac en el caso de bacteriemia por microorganis -\nmos multirresistentes.\nNo encontramos diferencias significativas en cuanto al \ntratamiento previo con antimicrobianos a diferencia de otros \nestudios, como el de Saint et al. [4], Greene et al. [16] y Ro-\ngers et al. [22]. en los cuales describieron que el uso de an -\ntibi\u00f3ticos era un factor de riesgo protector para el desarrollo \nde bacteriemia. Por ello, la importancia de aislar e identificar \nel microorganismo productor de la infecci\u00f3n para adecuar el \ntratamiento antibi\u00f3tico y no aumentar el desarrollo de resis -\ntencias bacterianas.\nPadecer diabetes no se comport\u00f3 como un factor de ries -\ngo para desarrollar BNS-ITU, similar a lo descrito por Greene \net al. [16] a diferencia del trabajo de Saint et al. [4], que obser -\nvaron que aquellos pacientes con diabetes ten\u00edan mayor pro -\nbabilidad de desarrollar BNS-ITU. Tampoco encontramos dife -\nrencias en los pacientes con insuficiencia renal, a diferencia de \notro estudio [16], que si encontraron diferencias significativas. \nEn nuestra serie la terapia con inmunosupresores no fue esta -\nd\u00edsticamente significativa, a diferencia de otros autores que la \ndescriben como un factor de riesgo asociado para desarrollar \nBNS-ITU [4,14].\nSeg\u00fan el an\u00e1lisis multivariante, s\u00f3lo dos factores se com -\nportaron como factores independientes asociados a padecer \nun episodio de bacteriemia nosocomial, el haber sido sometido \na un proceso quir\u00fargico en el episodio y llevar un dispositivo \nde ventilaci\u00f3n mec\u00e1nica. En el trabajo publicado por Chang et \nal. [2] la cirug\u00eda en el episodio hab\u00eda sido descrita en el 84% \nde los pacientes con BNS-ITU y Bishara et al. [18] describen \nque un 12% de la poblaci\u00f3n a estudio proced\u00eda de un servicio \nquir\u00fargico; sin embargo no ha sido estudiada como factor de \nriesgo en otros trabajos de casos-control [5, 18]. La ventilaci\u00f3n \nmec\u00e1nica como factor de riesgo no hab\u00eda sido estudiada pre -\nviamente [5, 16 18].\nUna de las limitaciones de nuestro estudio es que, al ser Factores de riesgo en bacteriemias nosocomiales secundarias a ITU en un hospital terciario L. Sante, et al.\nRev Esp Quimioter 2019;32(4): 311-3163164. Saint S, Kaufman SR, Rogers MA, Baker PD, Boyko EJ, Lipsky BA. \nRisk factors for nosocomial urinary tract-related bacteremia: a \ncase-control study. Am J Infect Control . 2006;34(7):401-07. doi: \n10.1016/j.ajic.2006.03.001\n5. Chenoweth CE, Saint S. Urinary tract infection. Infect Dis Clinic N \nAmer. 2011; 25 (1):103\u2013115. doi: 10.1016/j.idc.2010.11.005.\n6.  Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmi- \ngiani G, et al. The clinical significance of positive blood cultures in \nthe 1990s: a prospective comprehensive evaluation of the micro -\nbiology, epidemiology, and outcome of bacteremia and fungemia \nin adults. Clin Infect Dis 1997;24:584-602. PMID: 9145732.\n7.  EPINE Workgroup. EPINE-EPPS 2017 resultados: Informe global de \nEspa\u00f1a. Sociedad Espa\u00f1ola de Medicina Preventiva, Salud P\u00fablica \ne Higiene, 2017. [cited 21 December 2018]. Avaliable from: http://\nhws.vhebron.net/epine/Global/EPINEEPPS%202017%20Infor -\nme%20Global%20de%20Espa\u00f1a%20Resumen.pdf\n8.  Centers for Diseases Control and Prevention. CDC/NHSN Survei -\nllance Definitions for Specific Types of Infections,  2018. [cited 21 \nDecember 2018]. Avaliable from: https://www.cdc.gov/nhsn/pdfs/\npscmanual/17pscnosinfdef_current.pdf\n9. Javaloyas M, Garcia-Somoza D, Gudiol F. Epidemiology and prognosis \nof bacteremia: a 10-y study in a community hospital. Scand J Infect \nDis. 2002;34(6):436-41. PMID: 12160171\n10. Endimiani A, Tambirina A, Luzzaro F, Lombardi G, Toniolo A. A two \nyear analysis of risk factors and outcome in patients with bloods -\ntream infection. Jpn J Infect Dis. 2003; 56: 1-7. PMID: 12711818\n11. Sante L, Aguirre-Jaime A, Miguel MA, Ramos MJ, Pedroso Y, Lecuo -\nna M. Epidemiological study of secondary bloodstream infections: \nThe forgotten issue. J Infect Public Health. 2018;12(1):37-42. doi: \n10.1016/j.jiph.2018.08.011.\n12. European Centre for Disease Prevention and Control. Point preva -\nlence survey of healthcare- associated infections and antimicro -\nbial use in European acute care hospitals. Stockholm: ECDC; 2013. \n[cited 23 December 2018]. Avaliabre from: https://ecdc.europa.eu/\nsites/portal/files/media/en/publications/Publications/healthcare-\nassociated-infections-antimicrobial-use-PPS.pdf\n13. Jerkeman M, Braconier JH. Bacteremic and non-bacteremic febrile \nurinary tract infection--a review of 168 hospital-treated patients. \nInfection. 1992; 20(3):143\u2013145. PMID: 1644489. \n14. Krieger JN, Kaiser DL, Wenzel RP. Urinary tract etiology of bloods -\ntream infections in hospitalized patients. J Infect Dis. 1983; \n148(1):57\u201362. PMID: 6350488. \n15. Griebling TL. Urologic diseases in America project: trends in resource \nuse for urinary tract infections in women. J Urol. 2005;173(4):1281-\n7. PMID: 15758783. \n16. Greene MT, Chang R, Kuhn L, Rogers MA, Chenoweth CE, Shuman E \net al. Predictors of hospital-acquired urinary tract-related bloods -\ntream infection. Infect Control Hosp Epidemiol. 2012;33(10):1001-\n7. doi: 10.1086/667731. \n17. Bouza E, San Juan R, Munoz P, Voss A, Kluytmans J. on behalf of the \nCo-operative Group of the European Study Group on Nosocomial \nInfections (ESGNI). A European perspective on nosocomial urinary \ntract infections I. Report on the microbiology workload, etiolo -gy and antimicrobial susceptibility. Clin Microbiol Infect. 2001; \n7(10):523\u2013531. PMID: 11683792.\n18. Bishara J, Leibovici L, Huminer D, Drucker M, Samra Z, Konisberger \nH, et al. Five-year prospective study of bacteraemic urinary tract in -\nfection in a single institution. Eur J Clin Microbiol Infect Dis. 1997; \n16:563\u2013567. PMID: 9323466.\n19. Conway LJ, Carter EJ, Larson EL. Risk Factors for Nosocomial Bac -\nteremia Secondary to Urinary Catheter-Associated Bacteriuria: A \nSystematic Review. Urologic nursing. 2015;35(4):191-203. PMID: \n26402994\n20. Melzer M, Welch C. Does the presence of a urinary catheter pre -\ndict severe sepsis in a bacteraemic cohort? J Hosp Infect. 2017 \nApr;95(4):376-382. doi: 10.1016/j.jhin.2017.01.003.\n21. Riu M, Chiarello P, Terradas R, Sala M, Garcia-Alzorriz E, Castells \nX et al. Incremental cost of nosocomial bacteremia according to \nthe focus of infection and antibiotic sensitivity of the causati -\nve microorganism in a university hospital. Medicine (Baltimore). \n2017;96(17):e6645. doi: 10.1097/MD.0000000000006645. \n22. Rogers MA, Blumberg N, Heal JM, Kuhn L, Greene MT, Shuman E \net al. Role of transfusion in the development of urinary tract-re -\nlated bloodstream infection. Arch Intern Med. 2011;171(17):1.  doi: \n10.1001/archinternmed.2011.423. Rev Esp Quimioter 2019;32(4): 317-326317\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).en la prescripci\u00f3n del TAR durante el ingreso hospitalario as\u00ed \ncomo solicitar anal\u00edticas de CV y linfocitos CD4 a todos los pa -\ncientes VIH ingresados en el Hospital. \nPalabras Clave: VIH, hospitalizaci\u00f3n, mortalidad. \nHospital admission and mortality causes of \nHIV patients in a third level hospital\nABSTRACT\nIntroduction.  The aim of this study is to describe the HIV \npopulation admitted to a tertiary level hospital and analyze \nhospital admission and mortality causes during hospitalization.\nMaterial and methods.  Observational, retrospective \nstudy carried out in a third level Hospital. Inclusion criteria: \nPatients \u226518 years with a prescription of ART and diagnosis \nof HIV known or discovered during admission. It was accepted \nhospital ward discharge diagnose as hospitalization causes. Cli -\nnical, analytical outcomes as well as causes of mortality were \ncollected.\nResults.  Among 162 hospitalized HIV infected, 128 met \nthe inclusion criteria, 8 of those were diagnosed as naive HIV \npatients. 79.7% were male; Age 50.29 \u00b1 9.81 years. The main \nreasons for hospital admissions (38.3%) were certain infectious \nand parasitic diseases (ICD-10 Classification) and more specifi -\ncally human immunodeficiency virus [HIV] disease represented \n24,1% of whole hospitalizations. Mortality rates of \u226518 years \nHIV patients that were admitted to hospital during 2016-2017 \nwere the 13.52%. The main causes of death were certain infec -\ntious and parasitic diseases followed by malignancies.\nConclusions.  Our results emphasize the need of intensi -\nfying the HIV early diagnosis as well as Pneumocystis jirovecii \nprimary prophylaxis. Insist on ART adherence from infectology \nfollow-up appointment and pharmacy care consultations, edu -\ncate clinics on ART treatment prescription during hospital ad -RESUMEN \nIntroducci\u00f3n. El objetivo del presente trabajo es describir \nel perfil de los pacientes VIH que ingresan en un hospital de \ntercer nivel as\u00ed como analizar las causas de ingreso hospitalario \ny de mortalidad durante el mismo.\nMaterial y m\u00e9todos. Estudio observacional, retrospecti -\nvo llevado a cabo en un Hospital de tercer nivel. Criterios de \ninclusi\u00f3n: Pacientes \u226518 a\u00f1os con prescripci\u00f3n de tratamiento \nantirretroviral (TAR) y diagn\u00f3stico de VIH conocido o descu -\nbierto durante el ingreso. Como motivo de ingreso hospitalario \nse utiliz\u00f3 el diagn\u00f3stico al alta de cada paciente. Se recogieron \nvariables cl\u00ednicas, anal\u00edticas as\u00ed como las causas de exitus. \nResultados. En el periodo de estudio ingresaron un to -\ntal de 162 pacientes VIH. Cumplieron los criterios de inclusi\u00f3n \n128, de los cuales 8 fueron diagnosticados como VIH de novo. \nUn 79,7% fueron varones; edad 50,29\u00b19,81 a\u00f1os. El principal \ndiagn\u00f3stico al alta (38,3%) fueron ciertas enfermedades in -\nfecciosas y parasitarias (Clasificaci\u00f3n CIE-10) y dentro de esta \nclasificaci\u00f3n, las infecciones directamente relacionadas con el \nVIH fueron las mayoritarias (24,1%). Las tasas de mortalidad de \nlos pacientes VIH \u226518 a\u00f1os que ingresaron en el Hospital (a\u00f1os \n2016 y 2017) fue del 13,52%. Las causas de muerte m\u00e1s fre -\ncuentes fueron ciertas enfermedades infecciosas y parasitarias \nseguidas de neoplasias. \nConclusiones. Nuestros resultados enfatizan la necesidad \nde seguir reforzando el diagn\u00f3stico precoz de VIH as\u00ed como la \nprofilaxis primaria de  Pneumocysitis jirovecii en los pacientes \nVIH. Insistir en la adherencia al TAR desde las consultas de se -\nguimiento de especialista en enfermedades infecciosas y en las \nconsultas de atenci\u00f3n farmac\u00e9utica, concienciar a los cl\u00ednicos Diagn\u00f3stico al alta y causas de mortalidad de \npacientes VIH+ ingresados en un hospital de tercer \nnivel\nHospital Regional Universitario de M\u00e1lagaRoc\u00edo Asensi-Diez\nCristina Fern\u00e1ndez-Cuerva \nJuan Jos\u00e9 Alcaraz S\u00e1nchez\nIsabel Mu\u00f1oz-Castillo\nCorrespondencia:\nRoc\u00edo Asensi-Diez\nHospital Regional Universitario de M\u00e1laga. Avenida de Carlos Haya s/n. CP.29010. M\u00e1laga. \nTel\u00e9fono: 951291435. \nFax: 951291493. \nE-mail: rocioasensidiez@hotmail.com.Original\nArticle history\nReceived: 12 March 2019; Accepted: 13 April 2019Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al.\nRev Esp Quimioter 2019;32(4): 317-326318m\u00e1s elevadas en este grupo de pacientes que en la poblaci\u00f3n \ngeneral y parece ser causada por infecciones no relacionadas \ncon el VIH [10].\nEn los pacientes con TAR, las principales causas de morta -\nlidad no son infecciosas, si no enfermedades cardiovasculares \n(CV), enfermedad renal avanzada, enfermedad hep\u00e1tica des -\ncompensada y c\u00e1ncer no relacionado con VIH [11]. Respecto a \nlas enfermedades CV, destacan en incidencia el infarto agudo \nde miocardio y el ictus [12] que son m\u00e1s prevalentes que en \nindividuos no portadores de VIH. Esto se debe a que la infecci\u00f3n \npor VIH produce una inflamaci\u00f3n cr\u00f3nica que incrementa la \nedad biol\u00f3gica y el desarrollo de enfermedades CV [13] y pese a \nque el TAR reduce la inflamaci\u00f3n, los marcadores siguen siendo \nm\u00e1s elevados que en pacientes no infectados [12]. En pacientes \nsin TAR, las principales causas de muerte son las complicacio -\nnes infecciosas debido a la inmunodeficiencia, siendo la tuber -\nculosis la m\u00e1s frecuente. En pa\u00edses de Europa del oeste se est\u00e1 \nproduciendo un incremento de la incidencia de tuberculosis \npor microorganismos multirresistentes [14].\nLa complejidad del paciente VIH con y sin TAR provoca que \nlas causas de ingreso hospitalario sean variadas. Destacan las \ncausas infecciosas, relacionadas con VIH como la tuberculosis \no no relacionadas, como neumon\u00eda y bacteriemia. Tambi\u00e9n se \nproducen ingresos por causas no infecciosas: desnutrici\u00f3n, al -\nteraciones respiratorias, digestivas, cardiovasculares, renales, \npsiqui\u00e1tricas, hep\u00e1ticas, neurol\u00f3gicas y hematol\u00f3gicas [10].\nEl objetivo del presente trabajo es describir el perfil de los \npacientes VIH que ingresan en un hospital de tercer nivel as\u00ed \ncomo analizar las causas de ingreso hospitalario y de mortali -\ndad durante el mismo.\nMATERIAL Y M\u00c9TODOS\nEstudio observacional, retrospectivo llevado a cabo en un \nHospital de tercer nivel. Criterios de inclusi\u00f3n: Pacientes \u226518 \na\u00f1os con prescripci\u00f3n de TAR y diagn\u00f3stico de VIH conocido o \ndescubierto durante el ingreso y que ingresaron en cualquier \nunidad cl\u00ednica del hospital excepto ginecolog\u00eda y obstetricia. \nPeriodo de estudio: Enero 2016 a Diciembre 2017. Criterios de \nexclusi\u00f3n: Aquellos pacientes VIH cuya duraci\u00f3n de ingreso \nfue <24 horas debido a la imposibilidad de recoger suficientes \ndatos cl\u00ednicos y/o anal\u00edticos durante su estancia hospitalaria o \nbien, aquellos fugados antes de aclarar el motivo de su estancia \nhospitalaria. \nLa informaci\u00f3n se recogi\u00f3 de las historias cl\u00ednicas electr\u00f3 -\nnicas y del registro de dispensaci\u00f3n a pacientes externos del \nServicio de Farmacia: ATHOS-Prisma\u00ae \nVariables empleadas: \nPara la recogida de datos se elabor\u00f3 una base de datos en \nExcel que inclu\u00eda: \n1. Variables demogr\u00e1ficas: edad y sexo\n2. Otras variables: \n\u25cf - Variables cl\u00ednicas: n\u00famero de ingresos en el periodo de \nestudio, n\u00famero de ingresos previos al periodo de estudio en mission as well as requesting viral and CD4 lymphocytes loads \nto every HIV admitted patients.\nKeywords: HIV, Mortality, Hospitalization\nINTRODUCCI\u00d3N\nSeg\u00fan los datos de la Organizaci\u00f3n Mundial de la Salud de \n2017, el VIH afectaba a 36,9 millones de personas de todo el \nmundo de los cuales 35,1 millones eran adultos. Actualmente \nnos encontramos en una \u00e9poca en que el acceso generaliza -\ndo a combinaciones efectivas de tratamientos antirretrovirales \n(TAR) ha permitido disminuir la mortalidad asociada al VIH en \nun 59% a nivel mundial. A pesar de esto, desde el inicio de \nla epidemia, 35,4 millones [25,0 millones \u2013 49,9 millones] de \npersonas han muerto a causa de enfermedades relacionadas \ncon el SIDA [1]. \nSeg\u00fan el informe de vigilancia epidemiol\u00f3gica del VIH/\nSIDA en Espa\u00f1a (situaci\u00f3n hasta el 30/06/2018), hasta el 30 \nde junio de 2017 se hab\u00edan recibido, desde las 17 comunida -\ndes aut\u00f3nomas (CCAA), Ceuta y Melilla, la notificaci\u00f3n de 3.381 \nnuevos diagn\u00f3sticos de VIH en el a\u00f1o 2017, lo que representa \nuna tasa de 7,26 por 100.000 habitantes sin ajustar por retraso \nen la notificaci\u00f3n [2].\nEn el periodo 2011-2017, la neumon\u00eda por Pneumocystis \njirovecii  ha sido la enfermedad definitoria de SIDA m\u00e1s fre -\ncuente (28,4%), seguida de la tuberculosis de cualquier locali -\nzaci\u00f3n (20,6%) y de la candidiasis esof\u00e1gica (12,6%) [2]. \nEn el a\u00f1o 2016 se produjeron en Espa\u00f1a un total de \n410.611 fallecimientos, de los cuales 498 (1,2 por 1.000) fueron \npor VIH y SIDA. De \u00e9stos, 385 (77,3 %) se produjeron en hom -\nbres y 113 (22,7%) en mujeres. La tasa de mortalidad global por \nVIH y SIDA fue de 1,1 por 100.000 habitantes [3].\nEl TAR debe iniciarse en todos los pacientes con infecci\u00f3n \npor VIH-1, con o sin sintomatolog\u00eda, y con independencia del \nn\u00famero de linfocitos CD4+ [4]. Los primeros meses del TAR se \nconsideran clave ya que las tasas de mortalidad son m\u00e1s altas \ndurante el primer a\u00f1o de tratamiento [5].\nEn pa\u00edses desarrollados, se calcula que la mitad de pacien -\ntes con VIH tienen \u2265 50 a\u00f1os, por lo que cada vez tienen mayor \nn\u00famero de comorbilidades, entre las que destacan depresi\u00f3n, \nhipertensi\u00f3n arterial, dislipemia, insuficiencia renal, fractura \n\u00f3sea y diabetes mellitus que aparecen hasta diez a\u00f1os antes \nque en personas no infectadas y en mayor n\u00famero [6,7,8].. \nSobre estos pacientes tambi\u00e9n influyen factores del estilo de \nvida, la obesidad, el tabaco y alcohol. En ciertos casos se producen \ncoinfecciones por otros microorganismos, como el caso de virus de \nhepatitis B y hepatitis C. A esto, hay que sumarle que los pacientes \ncon TAR se ven expuestos a la toxicidad a largo plazo de los f\u00e1rma -\ncos utilizados, lo cual puede enmascarar otras comorbilidades. Las \ntoxicidades m\u00e1s frecuentes del TAR son dislipemia, resistencia a la \ninsulina, y diabetes mellitus, y en el caso del tenofovir disoproxilo \nproblemas renales y p\u00e9rdida de masa \u00f3sea [9].\nPese a que la esperanza de vida actual en pacientes VIH \ncon TAR ha aumentado, las cifras de mortalidad siguen siendo Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al.\nRev Esp Quimioter 2019;32(4): 317-326319Se recogi\u00f3 solamente el principal diagn\u00f3stico al alta, ad -\nmiti\u00e9ndose m\u00e1s de uno en los casos en los que el curso de \nla hospitalizaci\u00f3n no se entendiera sin la suma de diferentes \nfactores. No se incluyeron en esta clasificaci\u00f3n aquellos que \nfallecieron durante el ingreso, incluy\u00e9ndose as\u00ed en una clasi -\nficaci\u00f3n a parte, la cual analizaba la principal causa de mor -\ntalidad del episodio de hospitalizaci\u00f3n. Para clasificar la causa \nde mortalidad se utiliz\u00f3 la Estad\u00edstica de Defunciones seg\u00fan la \nCausa de Muerte. Esta estad\u00edstica se realiza siguiendo los crite -\nrios establecidos por la OMS en la CIE-10. Este dato se recogi\u00f3 \ndel informe de defunci\u00f3n registrado en la historia cl\u00ednica de \ncada paciente. A la hora de clasificar la causa de mortalidad \n\u00fanicamente se recogi\u00f3 el motivo principal que llev\u00f3 al mismo, \na diferencia de los diagn\u00f3sticos al alta, en los que se admitieron \nvarios por ingreso hospitalario.\nAn\u00e1lisis estad\u00edstico. El an\u00e1lisis de los datos fue descriptivo. \nLos valores de las variables fueron expresados como medias \u00b1 \ndesviaci\u00f3n est\u00e1ndar (DE), medianas y rangos o porcentajes. Se \nconsider\u00f3 que no exist\u00edan problemas \u00e9ticos en la realizaci\u00f3n del \nestudio, ya que se trat\u00f3 de un trabajo observacional, en el que \nla informaci\u00f3n recopilada se consider\u00f3 confidencial y se utiliz\u00f3 \n\u00fanica y exclusivamente en el \u00e1mbito profesional.\nRESULTADOS\nEn el a\u00f1o 2016 ingresaron 21.755 pacientes \u226518 a\u00f1os en \nnuestro hospital excluyendo ginecolog\u00eda y obstetricia, de los \ncuales 85 pacientes fueron VIH. En 2017 ingresaron 20.832 pa -\ncientes, de los que 77 fueron VIH. Las tasas de ingreso por tanto \nfueron 0,39 y 0,37 respectivamente. \nEn el periodo de estudio ingresaron un total de 162 pa -\ncientes con registro desde admisi\u00f3n como VIH excluyendo gi -\nnecolog\u00eda y obstetricia. Cumplieron los criterios de inclusi\u00f3n \n128, de los cuales 8 fueron diagnosticados como VIH de novo. \nLos 120 restantes ya estaban diagnosticados con anterioridad. \nPor lo que el n\u00famero total de pacientes reales ingresados fue \nde 170. La distribuci\u00f3n de pacientes en funci\u00f3n al tiempo que \nllevaban diagnosticados de VIH viene reflejada en la tabla 1. \nUn 79,7% fueron varones; edad 50,29\u00b19,81 a\u00f1os. Todos \nfueron ingresados al menos una vez por un periodo de tiempo \n\u226524h en el periodo de estudio (a\u00f1os 2016-2017). \nSe analizaron en total 250 ingresos hospitalarios de los \ncuales 11 fueron excluidos. La mediana de la estancia hospita-\nlaria fue de 8 d\u00edas (2-86), presentando una mediana de ingre-\nso por paciente de 1 (1-15) durante los 2 a\u00f1os que abarc\u00f3 el \nestudio.\nLa mediana de ingresos/paciente en nuestro centro ante -\nrior al periodo de estudio fue de 3 (0-32) ingresos. \nDe los 120 ya diagnosticados de VIH, no se dispone de da -\ntos acerca de los a\u00f1os que hab\u00edan pasado desde el diagn\u00f3stico \nen 6 pacientes. La media de a\u00f1os diagnosticados de los 114 \nrestantes fue de 13,85\u00b16,52 a\u00f1os. La tabla 1 muestra la distri -\nbuci\u00f3n de pacientes en funci\u00f3n al tiempo que llevaban diag -\nnosticados de VIH. Se considera \u201cdiagn\u00f3stico en el \u00faltimo a\u00f1o\u201d nuestro centro, unidad cl\u00ednica de ingreso, d\u00edas de hospitali -\nzaci\u00f3n, diagn\u00f3stico previo de VIH y en caso afirmativo, a\u00f1os \ndiagnosticado de VIH, ingreso a la unidad cl\u00ednica del hospital \npor urgencias o programado desde consulta, diagn\u00f3stico al alta \ncomo motivo de ingreso, profilaxis con trimetoprim-sulfame -\ntoxazol prescrita en receta electr\u00f3nica y causa de mortalidad \nen caso de producirse. \n\u25cf - Variables anal\u00edticas: carga viral (copias/ml) aprox. 6 me -\nses antes del ingreso y durante el/los ingreso/s, cifra de lin -\nfocitos CD4 (c\u00e9lulas/\u00b5L) aproximadamente 6 meses antes del \ningreso y durante el/los ingreso/s y coinfecci\u00f3n con virus de la \nhepatitis C (VHC). \n\u25cf En aquellos pacientes que tuvieran m\u00e1s de un ingreso hos -\npitalario durante el periodo de estudio y por tanto pudieran \ntener m\u00e1s de una determinaci\u00f3n de niveles de CV y de linfocitos \nCD4, se consider\u00f3 una \u00fanica medida de CV y CD4. En estos pa -\ncientes se consider\u00f3 la media de sus niveles de CV y de linfoci -\ntos CD4 resultante de todos los ingresos. \n\u25cf - N\u00famero pacientes \u2265 18 a\u00f1os y n\u00famero de pacientes \u2265 \n18 a\u00f1os VIH y n\u00famero de exitus en el hospital en los a\u00f1o 2016 \ny 2017 exceptuando el servicio de ginecolog\u00eda y obstetricia. \nDatos extra\u00eddos de la unidad de documentaci\u00f3n y archivo del \nHospital. \n\u25cf - Variable de adherencia. El c\u00e1lculo se realiz\u00f3 con la si -\nguiente f\u00f3rmula: % adherencia = n\u00famero de unidades de me -\ndicaci\u00f3n ARV total dispensada/N\u00famero de unidades de medi -\ncaci\u00f3n ARV prevista*100.\nSe consideraron unidades previstas las necesarias para \ncumplir el tratamiento en los d\u00edas incluidos desde la primera \ndispensaci\u00f3n hasta la \u00faltima en el periodo de tiempo conside -\nrado para el c\u00e1lculo. \nDefinimos como buena adherencia un % \u226595 en los 6 me -\nses previos al ingreso hospitalario en el periodo de estudio. Una \nadherencia por encima del 95% es necesaria para mantener \nuna supresi\u00f3n virol\u00f3gica \u00f3ptima [15-18]. Los datos se recogie -\nron de los episodios de dispensaci\u00f3n de la consulta de atenci\u00f3n \nfarmac\u00e9utica a pacientes externos de nuestro hospital. En el \ncaso que un paciente tuviera m\u00faltiples ingresos hospitalarios, \nlo cual podr\u00eda traducirse en una infraestimaci\u00f3n del porcentaje \nde adherencia al no acudir a la consulta a recoger su medica -\nci\u00f3n durante el tiempo de hospitalizaci\u00f3n, se determin\u00f3, que en \naquellos pacientes cuyos ingresos hospitalarios distaban menos \nde 6 meses el uno del otro, se aceptar\u00eda como % de adherencia \nel correspondiente al promedio de los 6 meses previos a la pri -\nmera de las estancias hospitalarias.\nComo motivo de ingreso hospitalario se utiliz\u00f3 el diagn\u00f3s -\ntico al alta de cada paciente. Asumimos el diagn\u00f3stico al alta \nde cada ingreso hospitalario como el diagn\u00f3stico primordial de \ntoda la estancia del paciente en la unidad de hospitalizaci\u00f3n, \npues nos proporcionaba mayor informaci\u00f3n que aquel que se \nrecog\u00eda en el primer d\u00eda de ingreso como motivo de ingreso \nhospitalario. El diagn\u00f3stico al alta se identific\u00f3 a trav\u00e9s de un \nc\u00f3digo recogido en Clasificaci\u00f3n internacional de enfermeda -\ndes, CIE-10 dividido a su vez en 20 categor\u00edas [19]. Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al.\nRev Esp Quimioter 2019;32(4): 317-326320aquellos pacientes que llevan diagnosticados menos de un a\u00f1o \nen el momento del ingreso hospitalario. \nLa distribuci\u00f3n de los ingresos en las distintas unidades del \nHospital viene reflejada en la tabla 2.\nEn el 66,5% de los casos los pacientes ingresaron a trav\u00e9s \ndel servicio de urgencias del hospital, mientras que el 33,5% \nrestante lo hizo de forma programada por su consulta de se -\nguimiento de atenci\u00f3n hospitalaria.\nEl diagn\u00f3stico al alta de aquellos pacientes VIH ingresados \ndurante \u2265 24 horas en nuestro hospital, y no fallecidos durante \nel mismo, se recogi\u00f3 en la tabla 3. Recogimos como subclasifi -\ncaci\u00f3n dentro del grupo de ciertas enfermedades infecciosas y \nparasitarias aquellas asociadas a la enfermedad por el virus de \nla inmunodeficiencia humana (tabla 4). \nEl principal diagn\u00f3stico al alta con un 38,3% de los diag -\nn\u00f3sticos fueron ciertas enfermedades infecciosas y parasitarias \ny dentro de esta clasificaci\u00f3n, las infecciones directamente re -\nlacionadas con el VIH fueron las mayoritarias con un 24,1%. De \nlos diagn\u00f3sticos al alta clasificados como enfermedades del sis -\ntema respiratorio, encontramos 22 diagn\u00f3sticos de neumon\u00edas \nde origen infeccioso de un total de 39 que no incluimos dentro \nde la categor\u00eda B20-B24 de enfermedad por el virus del VIH ya \nque no se trataba de neumon\u00edas causadas por Pneumocystis  o \ntuberculosis. \nCuando analizamos la subclasificaci\u00f3n enfermedad por \nvirus de la inmunodeficiencia humana del diagn\u00f3stico al alta, \nencontramos que el 48,4% de los diagn\u00f3sticos fueron por tu -\nmores onco-hematol\u00f3gicos seguido de enfermedad por VIH \nresultante en otras infecciones bacterianas (tabla 4). \nEn total un 47,66% (N=61) de los pacientes incluidos ha -\nb\u00edan padecido o padec\u00edan infecci\u00f3n por el virus de hepatitis C. \nDe ellos, 42 (68,85% estaban a\u00fan infectados durante el periodo \nde estudio) y 19 (31,14%) hab\u00edan sido ya tratados y estaban \ncurados.\nLos datos de CV y linfocitos CD4 en los 6 meses previos al \ningreso y durante el ingreso en el periodo de estudio vienen \nreflejados en la tabla 5. \nCabe destacar que un 6,25% pacientes (N=8/128) fueron \ndiagnosticados de novo. La mediana de CV de los pacientes \ndiagnosticados de novo fue 219.009,48 (697,64 - 1.000.000) \ncopias/ml. Respecto a los niveles de linfocitos CD4 durante el \ningreso, los 8 pacientes diagnosticados de novo ten\u00edan una me -\ndiana de linfocitos CD4 de 45 (22-483) c\u00e9lulas/\u00b5L. \nDe los 98 pacientes de los que ten\u00edamos datos de linfo -\ncitos CD4 en los 6 meses previos al ingreso, 25 pacientes te -\nn\u00edan niveles de CD4 <200 cel/\u00b5L y de estos, solo el 40% (N=10) \nhab\u00edan recibido profilaxis para la infecci\u00f3n por P. jirovecii con \ntrimetoprim-sulfametoxazol. \nEn cuanto a la adherencia al TAR, de los 120 pacientes con \ndiagn\u00f3stico previo de VIH conocido al ingreso, 22,5% (N=27) \nde ellos recog\u00edan fuera de nuestro centro por lo que no dis -\nponemos de datos de su adherencia; el 13,66% (N=16) hab\u00edan \nabandonado el tratamiento en los 6 meses previos al ingreso. \nLa mediana de adherencia de los pacientes restantes: 81,67% A\u00f1os desde el diagn\u00f3stico de VIH N\u00famero de pacientes %\nDiagn\u00f3stico > 1 a\u00f1o y < 20 a\u00f1os 62 48,44\nDiagn\u00f3stico \u2265 20 a\u00f1os 47 36,72\nDiagn\u00f3stico de novo 8 6,25\nSin datos del tiempo desde el diagn\u00f3stico 6 4,69\nDiagn\u00f3stico en el \u00faltimo a\u00f1o 5 3,91\nTOTAL 128 100,00Tabla 1  Distribuci\u00f3n de pacientes en funci\u00f3n al \ntiempo que llevaban diagnosticados de VIH\nUnidad de ingreso N\u00famero ingresos\nN=239 %\nEnfermedades Infecciosas 134 56,07\nHematolog\u00eda y Hemoterapia 28 11,72\nCardiolog\u00eda 12 5,02\nAparato Digestivo 10 4,18\nCirug\u00eda Digestiva 9 3,77\nOncolog\u00eda 7 2,93\nNeurolog\u00eda 6 2,51\nCirug\u00eda Cardiovascular 5 2,09\nTraumatolog\u00eda 4 1,67\nCuidados Paliativos 4 1,67\nCirug\u00eda Pl\u00e1stica 4 1,67\nNeurocirug\u00eda 4 1,67\nNefrolog\u00eda 3 1,26\nMedicina Interna 2 0,84\nCirug\u00eda General 2 0,84\nSalud Mental 2 0,84\nNeumolog\u00eda 2 0,84\nOtorrinolaringolog\u00eda 1 0,42\nTOTAL 239 100Tabla 2  Distribuci\u00f3n de los ingresos en las \ndiferentes unidades del Hospital.\n(N=98) fue del 98% (43-100). De ellos, 42,85% (N=42) pacien -\ntes eran buenos adherentes ( \u226595%).\nLas tasas de mortalidad de los pacientes \u2265 18 a\u00f1os ingresa-\ndos en el hospital excluyendo ginecolog\u00eda y obstetricia, en los \na\u00f1os 2016 y 2017, fueron 5,93% y 6,46%, respectivamente. \nLas tasas de mortalidad de los pacientes VIH \u226518 a\u00f1os que \ningresaron en el Hospital excluyendo ginecolog\u00eda y obstetricia \nen los a\u00f1os 2016 y 2017 fue del 13,52% (23/170). En el a\u00f1o \n2016 la tasa de mortalidad fue de 10,22% y en el a\u00f1o 2017 fue Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al.\nRev Esp Quimioter 2019;32(4): 317-326321Respecto a la adherencia de estos pacientes, 21,74% (N=5) \nhab\u00edan abandonado el TAR previo al ingreso en que fallecen, \n17,39% (N=4) eran pacientes que fueron diagnosticados de \nnovo de VIH durante el ingreso, del 13% (N=3) no tenemos da -\ntos de la adherencia al ser de otros centros. De los 11 restantes, \n26,10% (N=6) eran buenos adherentes ( \u226595%) y 21,74% (N=5) \nten\u00edan una adherencia <95%.\nDISCUSI\u00d3N\nEl acceso global al TAR en la \u00faltima d\u00e9cada ha llevado a \ndisminuciones sustanciales en la morbilidad y mortalidad re -\nlacionadas con el VIH, especialmente en los pa\u00edses de ingresos \nmedios-bajos en los que la prevalencia es mayor. Sin embargo, \nse estima que el VIH fue la sexta causa m\u00e1s com\u00fan de perdida \nde vida a nivel mundial [20].\nLas tasas de ingreso de los a\u00f1os 2016 y 2017 fueron 0,39 \ny 0,37 respectivamente, tasas m\u00e1s bajas que la reportada en \notros estudios como el de \u00c1lvarez Barreneche MF et al (2017) \n[21]. La media de edad de nuestro estudio es m\u00e1s alta, 50,29 \u00b1 \n9,81 a\u00f1os, que la reportada en ese trabajo que fue de 37 a\u00f1os \n(30-49). \nEn nuestro estudio, observamos que la unidad mayoritaria \nde ingreso de los pacientes VIH fue Enfermedades Infecciosas, \nseguida de la unidad de Hematolog\u00eda y Hemoterapia. El moti -\nvo de ingreso mayoritario, clasificado en nuestro estudio como de 17,94%. Un 86,95% eran hombres (N=20) con una media de \nedad \u00b1 desviaci\u00f3n est\u00e1ndar de de 52 a\u00f1os \u00b18,15.\nEstos 23 pacientes supusieron un total de 58 ingresos \n(23,20% de los ingresos totales) durante los dos a\u00f1os que abar -\nc\u00f3 el estudio, con una mediana de ingresos por paciente de 1 \n(1-8). 4 de estos pacientes fallecidos fueron diagnosticados de \nVIH durante el tiempo de estudio, 3 de ellos muriendo durante \nsu primer y \u00fanico ingreso hospitalario y 1 durante su segundo, \ndistanciado 15 d\u00edas del ingreso en el que fue diagnosticado por \nprimera vez. \nLas unidades principales de ingreso fueron: Infecciosos: \n55,17% (N=32), Hematolog\u00eda 27,59% (N=16), Cirug\u00eda Pl\u00e1stica \n5,17% (N=3), Oncolog\u00eda 3,45% (N=2), Cirug\u00eda cardiovascular, \nCirug\u00eda digestiva, Neurolog\u00eda. Cuidados Paliativos y Cirug\u00eda Or -\ntop\u00e9dica y Traumatolog\u00eda cada uno con 1,72% (N=1).\nLas causas principales de mortalidad clasificadas por ca -\np\u00edtulos de la clasificaci\u00f3n CIE-10 se encuentran en la tabla 6.\nLos datos de CV y linfocitos CD4 en los 6 meses previos \nal ingreso y durante el ingreso en el periodo de estudio de los \npacientes que fallecieron est\u00e1n reflejados en la tabla 5. \nUn 17,39% (N=4/23) de los pacientes que fallecieron \ndurante el ingreso fueron diagnosticados de VIH de novo. La \nmediana de CV de estos pacientes durante el ingreso fue de \n81.633,25 copias/ml (39.507 - 1.000.000) y la de linfocitos CD4 \nfue de 68 c\u00e9lulas/\u00b5L (12-130). N\u00ba diagn\u00f3sticos %\nCiertas enfermedades infecciosas y parasitarias 98 38,1\nEnfermedad por virus de la inmunodeficiencia humana 62 24,1\nEnfermedades del sistema respiratorio 39 15,1\nEnfermedades del sistema circulatorio 30 11,7\nEnfermedades del sistema digestivo 22 8,6\nTraumatismos, envenenamientos y algunas otras consecuencias de causas externas 13 5,1\nTumores (neoplasias) 11 4,3\nS\u00edntomas, signos y hallazgos anormales cl\u00ednicos y de laboratorio, no clasificados en otra parte 11 4,3\nEnfermedades del sistema genitourinario 8 3,1\nEnfermedades de la sangre y de los \u00f3rganos hematopoy\u00e9ticos, y ciertos trastornos que afectan el mecanismo de la inmunidad 7 2,7\nEnfermedades de la piel y del tejido subcut\u00e1neo 5 1,8\nEnfermedades del sistema osteo-muscular y del tejido conjuntivo 4 1,6\nFactores que influyen en el estado de salud y contacto con los servicios de salud 3 1,2\nEnfermedades endocrinas, nutricionales y metab\u00f3licas 2 0,8\nTrastornos mentales y del comportamiento 2 0,8\nEnfermedades del o\u00eddo y de la ap\u00f3fisis mastoides 1 0,4\nCausas externas de morbilidad y de mortalidad 1 0,4\nTOTAL 257 100Tabla 3  Diagn\u00f3stico al alta. Clasificaci\u00f3n CIE-10.Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al.\nRev Esp Quimioter 2019;32(4): 317-326322las principales causas de hospitalizaci\u00f3n fueron tuberculosis \npulmonar, candidiasis oral, neumon\u00eda por P. jirovecii y encefa -\nlitis por Toxoplasma. La elevada contribuci\u00f3n de ingresos hos -\npitalarios y mortalidad observada en nuestro centro debidos a \nenfermedades infecciosas y parasitarias pone de manifiesto la \nimportancia de la profilaxis con trimetoprim-sulfametoxazol y \nla vacunaci\u00f3n frente a neumococo y meningococo para pa -\ncientes portadores de VIH. En nuestro estudio resulta llamativo \nque s\u00f3lo el 40% (10/25) de pacientes con niveles de linfocitos \nCD4<200 c\u00e9lulas/\u00b5L tuvieran prescripci\u00f3n de trimetoprim-sul -\nfametoxazol como profilaxis contra la infecci\u00f3n por P. jirovecii \na pesar de que las Gu\u00edas [23] recomiendan profilaxis primaria en \npacientes con linfocitos CD4+ <200 c\u00e9l/\u00b5l (AI). Esto nos lleva a \nconcluir la necesidad de reforzar, desde las consultas cl\u00ednicas \ny de atenci\u00f3n farmac\u00e9utica, la profilaxis primaria contra P. ji-\nrovecii en pacientes con niveles de linfocitos <200 c\u00e9lulas/\u00b5L.\nRespecto a los datos anal\u00edticos de los 120 pacientes conoce -\ndores de su status de portadores antes del ingreso llama la aten -\nci\u00f3n que 69 pacientes ten\u00edan la CV indetectable 6 meses antes de \nla estancia hospitalaria, permaneciendo solo 47 indetectables en \nel periodo de estudio. De los 128 pacientes VIH ingresados no se \ndetermin\u00f3 la CV en el 27,50% de los casos. Respecto a los niveles \nde CD4 en los 6 meses previos al ingreso, la mediana de CD4 de \nlos pacientes de los que se dispon\u00eda de informaci\u00f3n disminuye. \nEstos resultados ponen de relieve la importancia de conocer el \nestatus de ser portador de VIH en admisi\u00f3n y por parte de los \ncl\u00ednicos para pedir determinaciones de CV y linfocitos CD4 sea \ncual sea la unidad cl\u00ednica de ingreso hospitalario. \nSolo 8 pacientes (6,25%) fueron diagnosticados de novo \ndurante el ingreso hospitalario en los dos a\u00f1os que abarc\u00f3 el diagn\u00f3stico al alta, seg\u00fan la clasificaci\u00f3n CIE-10 (a\u00f1o 2016) fue \nciertas enfermedades infecciosas y parasitarias (38,3%) inclu -\ny\u00e9ndose dentro de esta clasificaci\u00f3n la enfermedad por el virus \nde la inmunodeficiencia humana (24,1%) como diagn\u00f3stico al \nalta mayoritario. \nEstos datos coinciden con los reportados del metaan\u00e1lisis \nde Ford N et al (2015) [22] donde se analizaron las causas de \nhospitalizaci\u00f3n y de mortalidad seg\u00fan la clasificaci\u00f3n CIE-10 \n(a\u00f1o 2010) de 313.006 adultos y 6.182 ni\u00f1os correspondientes \na 99 estudios y concluye que las principales causas de hos -\npitalizaci\u00f3n fueron la enfermedad relacionada con VIH e in -\nfecciones bacterianas en todas las regiones geogr\u00e1ficas, siendo \ntambi\u00e9n las causas m\u00e1s frecuentes de mortalidad.\nEste estudio refiere que en Europa, tras las enfermeda -\ndes relacionadas con VIH e infecciones bacterianas, las causas \nm\u00e1s frecuentes de ingreso fueron enfermedades respiratorias \n(14%), desorden psiqui\u00e1trico (13%), enfermedad cardiovascular \n(12%), renal (11%) y hep\u00e1tica (10%), asemej\u00e1ndose en parte a \nnuestros datos, donde el 15,18% de los ingresos fue debido a \nenfermedades del sistema respiratorio, seguido de enfermeda -\ndes del sistema circulatorio (11,67%) y enfermedades del siste -\nma digestivo (8,56%). \nEn nuestro estudio, en lo referente al motivo de ingreso \n(diagn\u00f3stico al alta) en la categor\u00eda de enfermedades relacio -\nnadas con el VIH, destacan los tumores onco-hematol\u00f3gicos \nseguidos por otras infecciones bacterianas, neumon\u00eda por P. ji-\nrovecii,  s\u00edndrome caqu\u00e9ctico, enfermedad por citomegalovirus, \ninfecci\u00f3n por micobacterias y candidiasis. Estos datos coinciden \nen parte con el metaan\u00e1lisis de Ford N et al (2015) [22] donde Tabla 4  Sub-clasificaci\u00f3n del diagn\u00f3stico al alta: enfermedad por virus de la inmunodeficiencia \nhumana.\nSub-clasificaci\u00f3n del diagn\u00f3stico al alta: enfermedad por virus de la inmunodeficiencia humana. N\u00ba ingresos %\nEnfermedad por VIH, resultante en linfoma de Burkitt 12 19,3\nEnfermedad por VIH, resultante en otros tipos de linfoma no Hodgkin 9 14,5\nEnfermedad por VIH, resultante en otros tumores malignos 9 14,5\nEnfermedad por VIH, resultante en otras infecciones bacterianas 6 9,7\nEnfermedad por VIH, resultante en neumon\u00eda por Pneumocystis jirovecii 4 6,5\nEnfermedad por VIH, resultante en otras enfermedades infecciosas o parasitarias 4 6,5\nEnfermedad por VIH, resultante en s\u00edndrome caqu\u00e9ctico 4 6,5\nEnfermedad por VIH, resultante en enfermedad por citomegalovirus 4 6,5\nEnfermedad por VIH, resultante en infecci\u00f3n por micobacterias 3 4,8\nEnfermedad por VIH, resultante en candidiasis 3 4,8\nEnfermedad por VIH, resultante en otras infecciones virales 1 1,6\nEnfermedad por VIH, resultante en encefalopat\u00eda 1 1,6\nEnfermedad por VIH, resultante en sarcoma de Kapossi 1 1,6\nEnfermedad por virus de la inmunodeficiencia humana [VIH], sin otra especificaci\u00f3n 1 1,6\nTotal 62 100Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al.\nRev Esp Quimioter 2019;32(4): 317-326323de 45 (22-483) c\u00e9lulas/\u00b5L y la mediana de CV de 219.009,48 \n(697,64 - 1.000.000) copias/mL. Tal como ocurre con la mor -\ntalidad, se ha reportado que las tasas de ingreso hospitalario \ndescienden con el aumento del recuento de CD4 y que se no -\ntifican mayores tasas de ingreso hospitalario en pacientes con \nrecuento de CD4 <100 c\u00e9lulas/\u00b5L. Los bajos niveles de CD4 ade -\nm\u00e1s predicen el riesgo de reingreso hospitalario, mientras que \nel uso del TAR se ha asociado con mejoras en la supervivencia, \nincrementando los niveles de CD4 y reduciendo el n\u00famero de estudio, dato m\u00e1s bajo que el reportado en el estudio de \u00c1lva -\nrez Barreneche MF et al (2017) [21] con un 22% y en del de Ford \net al (2015) [22] con un 30% de los ingresos hospitalarios. Esto \nes debido probablemente a que nuestro estudio se circunscribe \na un solo hospital regional de tercer nivel dentro de un pa\u00eds \ndesarrollado donde el acceso a las pruebas de determinaci\u00f3n y \nel acceso al TAR son gratuitos. \nDe hecho, de los 8 pacientes de los que no se conoc\u00eda el \nstatus de portador de VIH la mediana de los niveles de CD4 fue Sin datos Diagnosticados con datos (N=100)\n     Indetectable\nCV (mediana, rango)6 meses previos \n(120 pacientes \ndiagnosticados)20 pacientes (16,67%) 69 pacientes (57,50%)31 pacientes (25,83%)\n345 copias/ml\n(37 - 1.183,34)\nSin datos Diagnosticados con datos (N=95)\nDurante ingreso \n(128 pacientes)33 pacientes (25,78%) 47 pacientes (36,71%)40 pacientes (31,25%)\n9.980 copias/ml \n(23 - 239.265)\nCD4 (mediana, rango)Sin datos Diagnosticados con datos (N=98)\n6 meses previos \n(120 pacientes \ndiagnosticados)22 pacientes (18,33%)442,69 cel./\u00b5L \n(1-1.994)\nSin datos Diagnosticados con datos (N=82)\nDurante ingreso \n(128 pacientes)38 pacientes (31,66%)257,50 cel/\u00b5L \n(1-1.687)\nEXITUS (N=23)\nSin datos Diagnosticados con datos (N=15)\n     Indetectable\nCV (mediana, rango)6 meses previos\n(19 pacientes \ndiagnosticados)4 pacientes\n(21,05%)10 pacientes (52,63%)5 pacientes (26,31%) \n626,50 copias/ml \n(161-1.183,34)\nSin datos Diagnosticados con datos (N=20)\nDurante ingreso\n(23 pacientes)3 pacientes\n(13,04%)10 pacientes (43,48%)10 pacientes (43,48%) \n91.324 copias/ml \n(4.481,33-1.697.605)\nCD4 (mediana, rango)Sin datos Diagnosticados con datos (N=15)\n6 meses previos\n(19 pacientes \ndiagnosticados)4 pacientes\n(21,05%)353 cel/\u00b5L \n(27-1.085)\nSin datos Diagnosticados con datos (N=20)\nDurante ingreso\n(23 pacientes)3 pacientes\n(13,04%)130 cel/\u00b5L\n(12-608)Tabla 5  Niveles de CD4 y carga viral de los pacientes y exitus 6 meses antes del ingreso y durante \nel mismo. Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al.\nRev Esp Quimioter 2019;32(4): 317-326324Tabla 6  Causas de mortalidad. \nN\u00ba de pacientes %\nCiertas enfermedades infecciosas y parasitarias 7 30,43\nNeoplasias 5 21,74\nEnfermedades del sistema respiratorio 4 17,39\nS\u00edntomas, signos y hallazgos anormales cl\u00ednicos y de laboratorio, no clasificados en otra parte 3 13,04\nEnfermedades del sistema circulatorio 2 8,70\nEnfermedades del aparato digestivo 2 8,70\nTotal 23 100,00\ningresos hospitalarios por causas debida al VIH [22]. La cifra de \nlinfocitos CD4+ es el indicador fundamental del estado inmu -\nnol\u00f3gico. Sirve para estadificar la infecci\u00f3n por el VIH, evaluar \nel riesgo de comorbilidad, la vulnerabilidad a determinadas in -\nfecciones oportunistas, la necesidad de su profilaxis y su even -\ntual discontinuaci\u00f3n [24].\nRespecto a las tasas de mortalidad observadas en nuestro \nestudio, un 13,52% de los pacientes fallecieron en el hospital \nen el periodo de estudio. Estos % de mortalidad son m\u00e1s altos \nque los observados en otros estudios [21,25] con tasas del 5,4% \no del 2,6%, sin embargo se aproximan a los datos reportados \npor Ford et al (2015) [22] con tasas globales de mortalidad en \nadultos del 20%. Esta \u00faltima tasa de mortalidad procede de un \nmetaan\u00e1lisis que engloba m\u00faltiples estudios realizados a nivel \nmundial, incluyendo pa\u00edses sub-desarrollados como \u00c1frica. \nPodr\u00edamos justificar estas tasas de mortalidad mayores \nque las de otros estudios debido a la situaci\u00f3n geogr\u00e1fica de \nnuestro Hospital, siendo un hospital de referencia de tercer ni -\nvel que recibe pacientes no s\u00f3lo de la provincia y Melilla, si no \nque a la poblaci\u00f3n de derecho se suma tambi\u00e9n la de la pobla -\nci\u00f3n flotante originada por el turismo, que aumenta especial -\nmente en los meses de verano y la de la poblaci\u00f3n inmigrante. \nAdem\u00e1s, 4 de los pacientes que fallecieron, fueron diagn\u00f3sticos \nde novo, 2 pacientes fueron diagn\u00f3sticos recientes (<6 meses) \ny otros 2 fueron pacientes que no estaban en seguimiento en \nnuestro Hospital. De los 15 pacientes restantes, que eran se -\nguidos por la unidad de enfermedades infecciosas de nuestro \nhospital, 4 hab\u00edan abandonado el TAR. \nDe los pacientes que fallecieron, en los seis meses previos \nal ingreso la CV fue indetectable solo en el 43,48%, observando \ncomo la mediana de CV aumenta debido fundamentalmente a \nlos 4 diagn\u00f3sticos de novo que se produjeron durante el ingre -\nso hospitalario. Respecto a los niveles de linfocitos CD4 en los \n6 meses previos al ingreso, la mediana disminuye durante el \ningreso hospitalario por el mismo motivo. Los resultados refle -\njan que los pacientes diagnosticados de novo y que fallecieron, \ningresaron en el hospital con un sistema inmunol\u00f3gico muy \ndeteriorado y con un avanzado estado de la enfermedad. Esto \nnos lleva a reflexionar que en Espa\u00f1a habr\u00eda que reforzar las pol\u00edticas de diagn\u00f3stico precoz ya que el diagn\u00f3stico tard\u00edo y \nla presentaci\u00f3n tard\u00eda dan como resultado una alta morbilidad \ny mortalidad [20].\nLa mayor causa de mortalidad fue la de ciertas enferme -\ndades infecciosas y parasitarias lo cual coincide con las princi -\npales causas de mortalidad encontradas en otros estudios [21, \n22, 25]. \nEn cuanto a la adherencia al TAR, de los pacientes con diag -\nn\u00f3stico previo de VIH conocido al ingreso y que se dispon\u00eda de \ndatos, s\u00f3lo un 42,85% eran buenos adherentes. De los que mu -\nrieron, s\u00f3lo un 26,10% ten\u00edan buena adherencia y un 21,74% \nhab\u00edan abandonado el tratamiento, lo que nos lleva a pensar \nque hay que reforzar desde el diagn\u00f3stico la importancia de la \nadherencia al TAR. De hecho, en las Gu\u00edas GESIDA [24] subrayan \nque la adherencia inadecuada es la primera causa de fracaso \nterap\u00e9utico. Entre los factores asociados con una adherencia \nimperfecta destacan: mala relaci\u00f3n m\u00e9dico-paciente, consumo \nde drogas, enfermedad mental, deterioro neurocognitivo, bajo \nnivel educativo, barrera idiom\u00e1tica, falta de apoyo social, com -\nplejidad terap\u00e9utica y efectos secundarios del tratamiento. Por \nel contrario, el apoyo emocional, la capacidad para incluir la \nmedicaci\u00f3n en las actividades de la vida diaria y la comprensi\u00f3n \nde la importancia del cumplimiento terap\u00e9utico son factores \nque predicen una adherencia correcta. El cumplimiento descri -\nbe la calidad en la ejecuci\u00f3n del tratamiento prescrito; aspectos \nvinculados al TAR, como el acceso y la persistencia en el mismo \nson esenciales para su \u00e9xito. \nNuestro estudio tiene como limitaci\u00f3n el car\u00e1cter retros -\npectivo y limitado a pacientes VIH con prescripci\u00f3n de TAR, de \nhecho, cabe destacar que 34 pacientes VIH no tuvieron pres -\ncripci\u00f3n de TAR en sus ingresos en el Hospital o bien se trat\u00f3 \nde pacientes fugados. Por tanto, no se han podido analizar las \ncausas de ingreso hospitalario de todos los pacientes VIH que \ningresaron en el hospital en el periodo de estudio. \nEn conclusi\u00f3n, nuestros resultados enfatizan la necesidad \nde seguir reforzando el diagn\u00f3stico precoz de VIH, reforzar la \nprofilaxis primaria de  P. jirovecii en los pacientes VIH con nive -\nles de linfocitos CD4<200 cel/\u00b5L tanto en consulta como ingre -\nsados y al alta hospitalaria. Reforzar la adherencia al TAR desde Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al.\nRev Esp Quimioter 2019;32(4): 317-326325las consultas de seguimiento de especialista en enfermedades \ninfecciosas y en las consultas de atenci\u00f3n farmac\u00e9utica. \nHay que concienciar a los m\u00e9dicos para prescribir el TAR \nen los ingresos hospitalarios de los pacientes VIH as\u00ed como so -\nlicitar anal\u00edticas de CV y linfocitos CD4 a todos los pacientes \nVIH ingresados en el Hospital, sea cual sea la unidad cl\u00ednica de \ningreso. \nFINANCIACI\u00d3N\nLos autores declaran que no han recibido financiaci\u00f3n pa -\nra la realizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener conflicto de intereses.\nBIBLIOGRAF\u00cdA\n1. Estad\u00edsticas mundiales sobre el VIH y el SIDA - Hoja informativa \nde 2018. Consulta [Enero 2019]. Disponible en: http://www.unaids.\norg/en/resources/fact-sheet . \n2. Vigilancia epidemiol\u00f3gica de VIH/SIDA en Espa\u00f1a. Situaci\u00f3n a \n30/06/2018. Consulta [Enero 2019]. Disponible en: http://www.\nisciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-\nvigilancias-alertas/fd-enfermedades/fd-sida/sistemas-de-informa -\ncion-poblacionales-sobre-vih.shtml .\n3. Mortalidad por VIH/SIDA en Espa\u00f1a. A\u00f1o 2016. Evoluci\u00f3n 1981-\n2016. Consulta [Enero 2019]. Disponible en: http://www.isciii.es/\nISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilan -\ncias-alertas/fd-enfermedades/fd-sida/informacion-sobre-mortali -\ndad.shtml .\n4. Documento de consenso de Gesida/plan nacional sobre el sida \nrespecto al tratamiento antirretroviral en adultos infectados por \nel virus de la inmunodeficiencia humana (Enero 2018). Consulta \n[Enero 2019]. Disponible en: http://gesida-seimc.org/category/\nguias-clinicas/antirretroviral-vigentes/.\n5. Brennan AT, Maskew M, Sanne I, Fox MP. The interplay between CD \n4 cell count, viral load suppression and duration of antiretroviral \ntherapy on mortality in a resource-limited setting. Trop Med Int \nHealth. 2013. 18(5): 619-631. DOI: 10.1111/tmi.12079. Epub 2013 \nFeb 18\n6.  Maciel RA, Kl\u00fcck HM, Durand M, Sprinz E. Comorbidity is more \ncommon and occurs earlier in persons living with HIV than in HIV-\nuninfected matched controls, aged 50 years and older: A cross-\nsectional study. International Journal of Infectious Diseases, 2018. \n: 30-35. DOI: 10.1016/j.ijid.2018.02.009. Epub 2018 Feb 21. \n7.  Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E et \nal. Premature Age-Related Comorbidities Among HIV-Infected Per -\nsons Compared With the General Population. Clin Infect Dis. 2011. \n53(11):1120-6. DOI: 10.1093/cid/cir627. Epub 2011 Oct 13. \n8.  Cuzin L, Katlama C, Cotte L, Pugliese P, Cheret A, Bernaud C et \nal. Ageing with HIV: do comorbidities and polymedication dri -ve treatment optimization?. HIV Med. 2017; 18(6):395-401. DOI: \n10.1111/hiv.12441. Epub 2016 Oct 7.\n9.  Seyler L, Lacor P, Allard SD. Current challenges in the treatment of \nHIV. Pol Arch Intern Med. 2018; 128(10):609-616. DOI: 10.20452/\npamw.4357. Epub 2018 Oct 31.\n10.  Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E et al. \nPremature age-related comorbidities among HIV-infected persons \ncompared with the general population. Clin Infect Dis. 2011. Dec; \n53(11):1120-6. DOI: 10.1093/cid/cir627. Epub 2011 Oct 13.\n11.  Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek \nK, Justice AC et al. Adjudicated Morbidity and Mortality Outcomes \nby Age among Individuals with HIV Infection on Suppressive Anti -\nretroviral Therapy. PLoS One. 2014; 1; 9(4):e95061. DOI: 10.1371/\njournal.pone.0095061. eCollection 2014. \n12.  Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Com -\nparison of ischemic stroke incidence in HIV-infected and non-HIV-\ninfected patients in a US healthcare system. J Acquir Immune Defic \nSyndr. 2012; 1; 60(4):351-8. DOI: 10.1097/QAI.0b013e31825c7f24.\n13.  Miller CJ, Baker JV, Bormann AM, Erlandson KM, HupplerHullsiek \nK, Justice AC et al. Adjudicated morbidity and mortality outcomes \nby age among individuals with HIV infection on suppressive anti -\nretroviral therapy. PLoS One. 2014; 11; 9(4):e95061. DOI: 10.1371/\njournal.pone.0095061. eCollection 2014.\n14.  Podlekareva DN, Schultze A, Panteleev A, Skrahina AM, Miro JM, \nRakhmanova A et al. One-year mortality of HIV-positive patients \ntreated for rifampicin- and isoniazid-susceptible tuberculosis in \nEastern Europe, Western Europe, and Latin America. AIDS. 2017; \n31(3):375-384. DOI: 10.1097/QAD.0000000000001333.\n15.  Bartlett J. A. Addressing the challenges of adherence. J. Acquir. Im -\nmune. Defic. Syndr. 2002; 29 (Suppl. 1), S2\u2013S10. PMID:11832696\n16.  Miller LG, Hays RD. Adherence to combination antiretroviral thera -\npy: synthesis of the literature and clinical implications, AIDS Read, \n2000; 10(3): 177-85. PMID:10758022\n17.  Turner BJ. Adherence to antiretroviral therapy by human immu -\nnodeficiency virus-infected patients. J Infect Dis. 2002; 185 (Suppl \n2):S143\u201351. DOI: 10.1086/340197.\n18.  Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral \ntherapy for HIV-1 infection and virologic treatment response: A \nmeta-analysis. Journal of Acquired Immune Deficiency Syndromes. \n2005; 38(4):445\u2013448. DOI: 10.1097/01.qai.0000147522.34369.12. \n19.   WHO. International statistical classification of diseases and related \nhealth problems. 10th revision. World Health Organization. versi\u00f3n: \n2016. Consulta [Noviembre 2018]. Disponible en: https://icd.who.\nint/browse10/2016/en. \n20.  GBD 2013 Mortality and Causes of Death Collaborators. Global, re -\ngional, and national age-sex specific all-cause and cause-specific \nmortality for 240 causes of death, 1990\u20132013: a systematic analy -\nsis for the Global Burden of Disease Study 2013. Lancet 2015; 385: \n117\u201371. DOI:10.1016/S0140-6736(14)61682-2\n21.  \u00c1lvarez Barreneche MF, Restrepo Castro CA, Hidr\u00f3n Botero A, Villa Franco \nJP, Trompa Romero IM, Restrepo Carvajal L et al. Hospitalization causes \nand outcomes in HIV patients in the late antiretroviral era in Colombia. \nAIDS Res Ther. 2017 Nov 13; 14(1):60. DOI: 10.1186/s12981-017-0186-3.Diagn\u00f3stico al alta y causas de mortalidad de pacientes VIH+ ingresados en un hospital de tercer nivel R. Asensi-Diez, et al.\nRev Esp Quimioter 2019;32(4): 317-32632622.  Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ et al. \nCauses of hospital admission among people living with HIV world -\nwide: a systematic review and meta-analysis. Lancet HIV. 2015. \n2(10):e438-44. DOI: 10.1016/S2352-3018(15)00137-X. Epub 2015 \nAug 11.\n23.  Ministerio de Sanidad, servicios sociales e Igualdad. Documento de \nprevenci\u00f3n y tratamiento de infecciones oportunistas y otras coin -\nfecciones en pacientes con infecci\u00f3n por VIH. Actualizaci\u00f3n Mayo \n2015. Consulta [Febrero 2019]. Disponible en: http://gesida-seimc.\norg/wp-content/uploads/2017/02/gesida-guiasclinicas-2015-In -\nfeccionesOportunistasyCoinfeccionesVIH.pdf .\n24. Documento de consenso de Gesida/plan nacional sobre el sida res -\npecto al tratamiento antirretroviral en adultos infectados por el \nvirus de la inmunodeficiencia humana (Actualizaci\u00f3n Enero 2019). \nConsulta [Febrero 2019]. Disponible en: http://gesida-seimc.org/\nwp-content/uploads/2019/01/gesida_DC_TAR_2019_v_final.pdf\n25.  Kim JH, Psevdos G Jr, Gonzalez E, Singh S, Kilayko MC, Sharp V. All-\ncause mortality in hospitalized HIV-infected patients at an acute \ntertiary care hospital with a comprehensive outpatient HIV care \nprogram in New York City in the era of highly active antiretrovi -\nral therapy (HAART). Infection. 2013; 41(2):545-51. DOI: 10.1007/\ns15010-012-0386-7. Epub 2012 Dec 21Rev Esp Quimioter 2019;32(4): 327-332327\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Prevalencia de micoplasmas genitales y \nrespuesta al tratamiento de descolonizaci\u00f3n en \npacientes de reproducci\u00f3n humana asistida\nRESUMEN\nIntroducci\u00f3n.  Se han publicado estudios que demues -\ntran mayores tasas de \u00e9xito en las t\u00e9cnicas reproducci\u00f3n \nasistida (TRA) en parejas no infectadas por micoplasmas. El \nobjetivo de este estudio fue determinar la prevalencia de \nlos micoplasmas genitales en muestras de orina del miem -\nbro masculino de las parejas incluidas en el Programa de \nReproducci\u00f3n Asistida en nuestro \u00c1rea Sanitaria realizando \nun tratamiento descolonizador con el fin de incrementar la \ncalidad del semen, mejorar las tasas \u00e9xito de la embriotrans -\nferencia y minimizar los efectos adversos sobre la gestaci\u00f3n.\nMaterial y m\u00e9todos.  Participaron parejas incluidas en \nel Programa de Reproducci\u00f3n Asistida durante 2016. La de -\ntecci\u00f3n de los micoplasmas se realiz\u00f3 por PCR en tiempo \nreal. En los casos positivos, la pareja fue tratada con anti -\nbi\u00f3ticos hasta la erradicaci\u00f3n del microorganismo. Los anti -\nbi\u00f3ticos usados fueron: azitromicina, doxiciclina, levofloxa -\ncino, moxifloxacino y clindamicina.\nResultados.  De los 205 hombres estudiados, 33 fueron \npositivos: Ureaplasma urealyticum 15,1%, Mycoplasma hom -\ninis 3,9%. Azitromicina fracas\u00f3 en el 50% de los casos y \ndoxiciclina en el 10,2%. Con levofloxacino solo en 2 de 5 se \nconsigui\u00f3 la erradicaci\u00f3n de U. urealyticum .\nConclusiones . El cribado de rutina de los micoplas -\nmas genitales puede ser \u00fatil para mejorar la calidad del \nsemen. Esto permitir\u00eda simplificar los procedimientos de \nfertilizaci\u00f3n in vitro  e incrementar las tasas de \u00e9xito en la \nimplantaci\u00f3n de los embriones y en la gestaci\u00f3n, especial -\nmente con la aplicaci\u00f3n de t\u00e9cnicas diagn\u00f3sticas r\u00e1pidas y \nespec\u00edficas como la PCR en tiempo real. \nPalabras clave: Mycoplasma ; Ureaplasma ;; reproducci\u00f3n asistida; doxicicli -\nna; azitromicinaABSTRACT\nIntroduction.  Several studies have reported greater suc -\ncess of fertilisation by ART in couples who were not infected by \nUreaplasma . Increased semen quality and better results have \nalso been observed in couples who were treated with antibiot -\nics to eradicate the infection. The aim of this study was to de -\ntermine the prevalence of genital mycoplasmas in urine sam -\nples from male partners enrolled in the Assisted Reproduction \nProgram (ARP) in our healthcare area so that, positive cases \ncan be treated prior to the use of ART in order to increase the \nquality of semen, improve the embryo implantation rates and \nminimize the risk of adverse effects during pregnancy.\nMaterial and methods.  This study included couples \nenrolled in the ARP during 2016. Mycoplasma detection was \nmade using real-time PCR. In positive cases, both members of \nthe couple were treated with antibiotics until eradication of \nthe microorganism. The antibiotics used were: azithromycin, \ndoxycycline, levofloxacin, moxifloxacin, and clindamycin.\nResults.  Of the 205 men studied, 33 were positive: \nUreaplasma urealyticum  15.1%, Mycoplasma hominis  3.9%. \nEradication treatment with azithromycin failed in 50% com -\npared to 10.2% for doxycycline. Of the 5 cases treated with \nlevofloxacin, only 2 achieved elimination of U. urealyticum .\nConclusions . We consider that genital mycoplasma rou -\ntine screening could be useful in order to increase the quality \nof semen which could simplify the in vitro  fertilisation proce -\ndures and raise the success rate of embryo implantation and \npregnancy, especially when fast, sensitive and specific technics \nas real time PCR are used.\nKeywords: Mycoplasma ; Ureaplasma ; Assisted reproduction; doxycycline; \nazithromycinPrevalence of genital Mycoplasma  and response \nto eradication treatment in patients undergoing \nassisted reproductive techniques\n1Human Assisted Reproduction Unit. University Clinical Hospital of Santiago de Compostela, Spain\n2Clinical Microbiology Unit. University Clinical Hospital of Santiago de Compostela, Spain.Ernesto Veiga1\nMercedes Trevi\u00f1o2\nAna Bel\u00e9n Romay1\nDaniel Navarro2\nRoc\u00edo Trastoy2\nManuel Mac\u00eda1\nCorrespondence:\nMercedes Trevi\u00f1o\nClinical Microbiology Unit. University Clinical Hospital of Santiago de Compostela. c/ Ram\u00f3n \nBaltar s/n. 15702- Santiago de Compostela, Spain\nPhone: (+34)981 951 703\nE-mail: Maria.Mercedes.Trevino.Castellano@sergas.esOriginal\nArticle history\nReceived: 17 March 2019; Revision Requested: 14 April 2019; Revision Received: 19 April 2019; Accepted: 14 May 2019Prevalence of genital Mycoplasma  and response to eradication treatment in patients undergoing assisted \nreproductive techniquesE. Veiga, et al.\nRev Esp Quimioter 2019;32(4): 327-332328Samples.  The first fraction of urine (10-15 mL) was \ncollected from males after at least 2 hours without urinat -\ning. Urine was collected under the same conditions for the \npost-treatment tests in female patients.\nDetermination of M. genitalium , M. hominis , U. ure -\nalyticum , and U. parvum . Genital mycoplasma screening was \nperformed using real-time PCR with LightMix Mycoplasma \ngen/hom Ureaplasma  (Roche, Switzerland) in accordance with \nthe manufacturer\u2019s instructions. Briefly, a 224 or 129 bp frag -\nment of the glyceraldehyde-3-phosphate dehydrogenase (gap) \ngene for M. genitalium  or M. hominis , respectively, was ampli -\nfied with specific primers detected with labelled probes, identi -\nfied by melting curve analysis. In the same way, a 187 bp long \nfragment of 16S RNA gene was applied for U. urealyticum . This \nkit detects also U. urealyticum  Biotype 1 ( U. parvum ) accord -\ning to manufacturer\u00b4s information. The sensitivity of the test is \n10 copies/ mL. \nNucleic acids were extracted previously using the Mag -\nnaPure Compact system (Roche, Switzerland) after concen -\ntrating the sample by centrifuging 2 mL of urine for 20 min -\nutes at 14,000g [14]. After discarding the supernatant, 200 \u00b5L \nof the re-suspended sediment were used to load the extraction \nsystem.\nAntibiotic treatment to eradicate genital colonisation. \nAny positive PCR finding was treated with azithromycin or dox -\nycycline. Quinolones were used when first line treatment failed.\nStatistical analysis. All statistical analyses were carried \nout using SPSS v. 20.0 (IBM Corp., Armonk, NY). Statistical sig -\nnificance was set at p< 0.05.\nRESULTS\nA total of 205 couples were enrolled in the study. The age \nrange was 24 to 54 years in men and 23 to 39 in women, with \na median age of 36 years for men and 35 years for women. \nMost men were Caucasian ( n= 201). Other ethnic groups were \nAmerican ( n= 2) and Gypsy ( n= 2).\nA total of 33 (16.1%) males tested positive by real-time \nPCR for one or more mycoplasmas: U. urealyticum  15.1% ( n= \n31) and M. hominis  3.9% ( n= 8), with 6 (2.9%) cases of coin -\nfection with both microorganisms. No sample proved positive \nfor M. genitalium .\nInitial treatment for Ureaplasma spp . was azithromycin \nin the first 12 couples studied and doxycycline in the remain -INTRODUCTION\nGenital mycoplasmas ( Ureaplasma parvum, Ureaplasma \nurealyticum, Mycoplasma genitalium and Mycoplasma hom -\ninis) are bacteria found in the placenta and/or embryo in preg -\nnant women. They can cause ascending infection after rupture \nof membranes and severe problems such as premature mem -\nbrane rupture, preterm labour, miscarriage, postpartum fever, \nchorioamnionitis, and infection transmission to the newborn \ninfant [1-5]. Several studies have reported greater success \nof fertilisation by assisted reproductive techniques (ART) in \ncouples who were not infected by Ureaplasma spp. [6, 7]. In -\ncreased semen quality and better ART results have also been \nobserved in couples infected by mycoplasmas who were treat -\ned with specific antibiotics to eradicate the infection [8, 9]. \nMoreover, the impact on female reproduction and the health \nof the fetus and newborn that can have genital mycoplasma \nsuggests a role for routine screening and treatment before un -\ndergoing infertility treatment [10-12]. It therefore seems rec -\nommendable to avoid the use of semen contaminated/infected \nwith mycoplasmas in ART procedures. However, currently used \nprocedures for selecting and washing spermatozoa prior to \nfertilisation do not ensure eradication of these bacteria [13].\nWith the advent of highly sensitive and specific nucle -\nic acid amplification technics, more accurate estimate of the \nprevalence of genital mycoplasma as well as the control of the \nefficacy of the antibiotic treatment can be determined.\nThis study presents the results obtained after screening for \ngenital mycoplasmas in urine using amplification by real-time \npolymerase chain reaction (RT-PCR) in patients enrolled in the \nassisted human reproduction program at University Hospi -\ntal Complex of Santiago (CHUS), in Santiago de Compostela, \nSpain.\nMATERIALS AND METHODS\nPatients.  This study included couples enrolled in the as -\nsisted human reproduction program carried out by the Assist -\ned Human Reproduction Unit at CHUS during 2016. Couples \nprovided their informed consent after the study was approved \nby the competent Research Ethics Committee and by the hos -\npital\u2019s management (reference number 2015/493). The screen -\ning for genital mycoplasmas was performed in male urine. In \npositive cases, both members of the couple received specific \nantibiotic therapy and had a post-treatment microbiological \ntest. Couples were asked to use protection (condoms) during \nsexual intercourse for 7-14 days after initiating the treatment. \nBoth members of the couple had a microbiological test 3-4 \nweeks after completing the treatment. Couples failing anti -\nbiotic treatment were prescribed alternative antibiotics un -\ntil both members had negative post-therapy microbiological \ntests. No patient was on antibiotic treatment at least, three \nmonths prior to collection of the sample. As part of the study \nprotocol prior to in vitro  fecundation, all male patients were \nscreened for Chlamydia trachomatis  and Neisseria gonorrhoe -\nae in the same urine sample used for mycoplasma detection.  Men Women Couples\nAzithromycin 1 8 3\nDoxycycline 0 3 1Table 1  Number of therapeutic failures depending \non the antibiotic used for initial treatment \nin patients positive for U. urealyticumPrevalence of genital Mycoplasma  and response to eradication treatment in patients undergoing assisted \nreproductive techniquesE. Veiga, et al.\nRev Esp Quimioter 2019;32(4): 327-332329One of the couples who were successfully treated with \nlevofloxacin initially for U. urealyticum  required further treat -\nment with moxifloxacin 400 mg p.o. for 7 days as M. hominis  \nwas detected in the post-treatment test (couple # 104).\nThe cases of M. hominis  infection (6/7 in coinfection, 86%) \nwere treated with azithromycin (first 2 couples with coinfec -\ntion with Ureaplasma spp .) and doxycycline (the remaining \ncouples). Treatments failed in 3 patients both them (of whom 2 \nwere members of the same couple) (table 3).\nThe statistical analysis showed that the response to treat -\nment was poorer among women ( p< 0.01). In addition, azith -\nromycin in single-dose regime was significantly less efficient \nas compared to doxycycline ( p< 0.01) in both men and women.\nTreatment efficacy was independent of age. However, the \nage range was too small to observe significant differences.\nDISCUSSION\nM. hominis  and Ureaplasma spp. infections are associat -\ned with serious problems during pregnancy (chorioamnionitis, \npremature rupture of membranes, preterm labour, miscarriage \nduring the last trimester of pregnancy) and/or severe infection \nin the newborn (bronchopulmonary dysplasia, chronic lung in -\nfection, intraventricular cerebral haemorrhage) [15, 16]. There \nis evidence that the use of semen infected with Ureaplasma \nspp. for in vitro  fertilisation (IVF) reduces the rate of pregnan -ing 19 couples. Table 1 shows post-treatment test results for \nthe cases positive for U. urealyticum . Treatment failed in 16 \npatients (11 females, 1 male, and 2 couples), including 12 pa -\ntients treated with a single oral dose of azithromycin 1 g and 4 \npatients treated with doxycycline 100 mg/12h p.o. for 7 days. \nOne of the couples (couple # 61) who tested negative for U. \nurealyticum  after initial treatment with doxycycline remained \ncolonised by M. hominis  and was treated with moxifloxacin \n(moxifloxacin 400 mg p.o. for 7 days).\nTable 2 shows the results of subsequent treatments where \nreal-time PCR tested positive for U. urealyticum  following a \nsecond antibiotic cycle administered after failure of the initial \ntreatment. One of the 12 couples who failed treatment with \nazithromycin withdrew from the program. The remaining cou -\nples were treated with doxycycline 100 mg/12h p.o. for 7 days. \nThere was only one case of therapeutic failure, which was \ntreated alternatively with levofloxacin (500 mg/day, 7 days). \nAs the woman remained positive, she was prescribed vaginal \nclindamycin 100 mg/day for 3 days. Her post-treatment test \nwas negative. \nDoxycycline proved ineffective in 4 of the 19 couples \ntreated initially. In these cases, levofloxacin (500 mg/day, 7 \ndays) was used as an alternative. Only one patient remained \nPCR-positive for U. urealyticum.  This patient was then treated \nwith vaginal clindamycin 100 mg/day for 3 days; she required \na second course combined with a vaginal probiotic, but she \nstill tested positive. Table 2  Antibiotics used against Ureaplasma  spp. and post-treatment real-time PCR success test\n1st treatment 2nd treatment Couple Id.RT-PCR  \npost-treatment3rd treatmentRT-PCR  \npost-treatment4th treatmentRT-PCR  \npost-treatment\nAzithromycin No 9\nAzithromycin Doxycyclin10 Positive Levofloxacin Positive Clindamycin Negative\n12 Negative\n25 Negative\n28 Negative\n29 Negative\n31 Negative\n36 Negative\n39 Negative\n43 Negative\n46 Negative\n48 Negative\nDoxycyclin Levofloxacin104 Negative MoxifloxacinaNegative\n106 Negative\n130 Negative\n159 Positive Clindamycin Positive Clindamycin + probiotic Positive\naFor M. hominis  eradication.Prevalence of genital Mycoplasma  and response to eradication treatment in patients undergoing assisted \nreproductive techniquesE. Veiga, et al.\nRev Esp Quimioter 2019;32(4): 327-332330less efficacy at low pH. Interestingly, we have also observed \na higher rate of antibiotic failure against Ureaplasma spp. in \nwomen, as compared to men, and this difference was statisti -\ncally significant ( p< 0.01) for azithromycin. Fluoroquinolones \n(levofloxacin and moxifloxacin) were used as the therapeutic \nalternative where doxycycline did not eradicate colonisation \nby genital mycoplasmas. Levofloxacin was ineffective in one \ncouple colonised by Ureaplasma spp . and in another couple \nwith M. hominis  coinfection. Levofloxacin has been suggested \nas an effective antimicrobial agent against Ureaplasma spp. \nand M. hominis [35], but our results do not support this, as \ntherapeutic failure occurred in 40% of patients treated with \nlevofloxacin. Nevertheless, in view of the small number of cas -\nes, we cannot draw any firm conclusions in this regard. Moxi -\nfloxacin has been reported to be a powerful antibiotic against \nM. hominis [35] and indeed, it was a successful alternative in \nour series for one couple who had failed levofloxacin. \nClindamycin represent a potential well tolerated treatment \nfor unresolved mycoplasma infections after treatment with tet -\nracyclines and macrolides [4, 5]. In fact, this antibiotic is com -\nmonly used to treat bacterial vaginosis involving M. hominis . \nAlthough Ureaplasma spp. are considered intrinsically resistant \nto lincosamides, given the low percentage of sensitive strains \n[35, 36], we decided to use clindamycin as a third-line treatment \nin women showing therapeutic failure with azithromycin, doxy -\ncycline and/or levofloxacin, as it can be administered in vaginal \nsuppositories, resulting in high local drug concentrations. In -\ndeed, eradication of Ureaplasma spp. was achieved in one case. \nMore assays are necessary to know the effect of probiotics on \nthe success of the antibiotic treatments. \nTreatment efficacy was independent of age, even though \nthe age range was too small to observe significant differences.\nUsing mycoplasma-free semen we could replace intracy -\ntoplasmic microinjection by conventional \u201cin vitro\u201d fecunda -\ntion in 7,6% of the cases (from 3% to 10,6%) which means \ncost savings of 7% for each case.\nIn summary, we consider that genital mycoplasma routine \nscreening could be useful in order to increase the quality of se -\nmen which could simplify the in vitro  fertilisation procedures \nand raise the success rate of embryo implantation. When an -\ntibiotic treatment is necessary, real-time PCR significantly re -\nduces time to initiation of treatment and can be used to assess \nits efficacy. Doxycycline was more efficacious than azithromy -\ncin single-dose regime in eliminate genital mycoplasma colo -\nnization. On the other hand, eradication of genital mycoplas -\nmas prior to gestation can avoid possible adverse effects on \npregnancy, fetus or the newborn, so, according to the opinion \nof other authors, as genital mycoplasma colonization of cervix \nis strongly associated with adverse effects as placenta previa, \nbefore a planned pregnancy, eradication of this microorgan -\nisms is necessary to prevent pregnancy negative outcomes. In \naddition, eradication of genital mycoplasma allows, in most \ncases, to use conventional in vitro fecundation technics in -\nstead of intracytoplasmic microinjection which is more labori -\nous, complex and expensive.cies by embryo transfer [6] and increases no-pregnancy [5] \nand miscarriage rates [6, 7, 10, 14, 17]. On the other hand, the \nwashing procedures used for semen preparation prior to IVF \nare not always efficient to eliminate mycoplasmas, as these \nmay remain adhered to the surface of spermatozoa, negatively \naffecting their quality [13, 18, 19]. In this context, mycoplasma \nscreening in urine samples and subsequent eradication with \nantibiotic treatment may provide considerable benefits in the \nART protocol. Molecular techniques such as real-time PCR are \nhighly valuable diagnostic tools as they provide significant time \nreductions compared to conventional cultures, are not affect -\ned by previous antibiotic use and have much higher sensitivity \n[20]. Our study found that 15.1% of the males were colonised \nby Ureaplasma spp. and 3.9% by M. hominis  (practically all of \nwhom were coinfected with Ureaplasma spp.). These figures \nare somewhat lower than reported in earlier studies, in which \ncolonisation by Ureaplasma spp. also prevailed over M. homin -\nis [21-24]. Nevertheless, a high variability on genital mycoplas -\nma prevalence has been reported in part due to geographical \nand methodological differences [25]. Unlike other publications \nwhich report rates of up to 5% [21, 26], there were no positive \ncases of M. genitalium  in our patients. This could be explained \nbecause it\u2019s a population with a median age above 35-year-\nold (some studies report decreasing rates of colonisation by M. \nhominis  with age [27], asymptomatic and, possibly, more con -\nservative sexual behaviour.\nBesides the benefits that the eradication of genital my -\ncoplasma can have on the success of assisted reproduction, \nas already mentioned previously, it was also been shown that \npre-emptive antibiotic therapy of genital mycoplasma in col -\nonized pregnant women might represent a beneficial strategy \nto reduce premature labour and neonatal complications [28].\nAccording to the recommendations of therapeutic guide -\nlines, macrolides are the treatment of choice for Ureaplasma \nspp. infections, with doxycycline or levofloxacin as alterna -\ntives. For M. hominis,  the treatment of choice is doxycycline, \nwith quinolones as an alternative [29, 30]. As recommended in \nthese guidelines and taking into account the treatment sched -\nules used in studies in colonized women [21], azithromycin 1g/\nday single-dose was used to eradicate Ureaplasma spp. in both \nmembers of the couple when the male was positive. In addition \nto being a first-line option, the azithromycin regime simpli -\nfies treatment compliance. For the same reason, azithromycin \nwas also used in cases of Ureaplasma/M. hominis  coinfection. \nIn several studies, azithromycin is reported to be a highly ef -\nfective antibiotic against Ureaplasma spp., with a very low \npercentage of resistant strains [31-33]. However, the in vivo  \nresults obtained in our series using the treatment recommend -\ned for sexually transmitted infections (1 g single dose; www.\nvademecum.es) revealed the low efficacy of this macrolide. For \nthis reason, after the initial results, doxycycline was used as \nthe first choice (100 mg b.i.d. p.o., 7 days). Some reports have \ndemonstrated that a single dose of azithromycin is less effi -\ncient than azithromycin used over longer periods [34], and this \ncould be the reason behind its low efficacy in our series. Pos -\nsibly, also could contribute its bacteriostatic mechanisms and Prevalence of genital Mycoplasma  and response to eradication treatment in patients undergoing assisted \nreproductive techniquesE. Veiga, et al.\nRev Esp Quimioter 2019;32(4): 327-332331tion en assistance medicale a la procr\u00e9ation. Gynecol Obstet Fertil. \n2004; 32 (2): 135-39. doi: 10.1016/j.gyobfe.2003.11.017.\n8. Swenson CE, Toth A, O\u2019Leary WM. Ureaplasma urealyticum  and \nhuman infertility: the effect of antibiotic therapy on semen \nquality. Fertil Steril. 1979; 31 (6): 660-65. doi: 10.1016/S0015-\n0282(16)44057-4.\n9. Toth A, Lesser ML, Brooks C, Labriola D. Subsequent pregnancies \namong 161 couples treated for T-mycoplasma genital-tract in -\nfection. New Engl J Med. 1983; 308 (9): 505-507. doi: 10.1056/\nNEJM198303033080907.\n10. Kanakas N, Mantzavinos T, Boufidou F, Koumentakou I, Creatsas \nG. Ureaplasma urealyticum  in semen: is there any effect on in \nvitro fertilization outcome? Fertil Steril. 1999; 71 (3): 523-27. doi: \n10.1016/S0015-0282(98)00472-5.\n11. Imudia AN, Detti L, Pusacheck EE, Yelian FD, Diamond MP. The \nprevalence of Ureaplasma urealyticum, Mycoplasma hominis, \nChlamydia trachomatis  and Neisseria gonorrhoeae  infections, and \nrubella status on patients undergoing an initial infertility eval -\nuation. J Assist Reprod Genet. 2008; 25 (1): 43-6. doi: 10.1007/\ns10815-007-9192-z.\n12. Aydogan P, Hahyaoglu S, Sayqan S, Kaymak O, Mollamahmutoglu L, \nDanisman N. Does cervical Ureaplasma/Mycoplasma  colonization \nincrease the lower uterine segment bleeding risk during caesarean \nsection among patients with placenta previa? A cross-sectional \nstudy. Eur Rev Med Pharmacol Sci; 2014; 18 (16); 2243-7. PMID \n25219820.\n13. Knox CL, Cave DG, Farrell DJ, Eastment HT, Timms P. The role of \nUreaplasma urealyticum  in adverse pregnancy outcome. Aust \nN Z J Obstet Gynaecol. 1997; 37 (1): 45-51. doi: 10.1111/j.1479-\n828X.1997.tb02216.x\n14. Gdoura R, Kchaou W, Ammar-Keskes L, Chakroun N, Sellemi A, Zna -\nzen A, et al. Assessment of Chlamydia trachomatis, Ureaplasma \nurealyticum, Ureaplasma parvum, Mycoplasma hominis  and My-\ncoplasma genitalium  in semen and first voided urine specimens of \nasymptomatic male partners of sterile couples. J Androl. 2008; 29 \n(2): 198-206. doi: 10.2164/jandrol.107.003566.\n15. Donders GGG, Ruban K, Bellen G and Petricevic L. Mycoplasma/\nUreaplasma  infection in pregnancy: to screen or not to screen. J \nPerinat Med. 2017; 45 (5): 505-15. doi: 10.1515/jpm-2016-0111.\n16. Knox CL, Allan JA, Allan JM, Edirisinghe WR, Stenzel D, Lawrence FA, \net al. Ureaplasma parvum  and Ureaplasma urealyticum  are detect -\ned in semen after washing before assisted reproductive technology \nprocedures. Fertil Steril. 2003; 80 (4): 921-29. doi: 10.1016/S0015-\n0282(03)01125-7.\n17. Shalika S, Dugan K, Smith RD, Padilla SL. The effecct of positive \nsemen bacterial and Ureaplasma  cultures on in-vitro fertilization \nsuccess. Human Reprod. 1996; 11 (12): 2789-92. doi: 10.1093/ox -\nfordjournals.humrep.a019211.\n18. Zeyad A, Amor H, Hammadeh ME. The Impact of Bacterial Infec -\ntions on Human Spermatozoa. International Journal of Women\u2019s \nHealth and Reproduction Sciences. 2017; 5 (4): 243\u2013252. doi: \n10.15296/ijwhr.2017.43. \n19. Hannachi H, Elloumi H, Hamdoun M, Kacem K, Zhioua A, Bahri O.  In the case of patients who do not eliminate colonization \nin the first treatment regime, the benefit of initiating succes -\nsive alternative antibiotic treatments is debatable due to de -\nlayed onset of fertilization and the possible undesirable effects \non the vaginal microbiota that seems to play an important role \nin relation to female fertility [37, 38].\nFUNDING\nNone to declare\nCONFLICT OF INTEREST\nAuthors declare that they have no conflicts of interest.\nINFORMED CONSENT\nAll patients included in the study previously signed the in -\nformed consent document.\nREFERENCES\n1. Domingues D, Noguera F, and Tavira L. Papel que desempe\u00f1an mi -\ncoplasmas en las infecciones humanas. Act Med Port; 2005; 18: \n377-384. PMID 16611542.\n2. Breugelmans M, Vancutsem E, Naessens A, Laubach M, Folulon W. \nAssociation of abnormal vaginal flora and Ureaplasma  species as \nrisk factors for preterm birth: a cohort study. Acta Obstet Gynecol \nScand. 2010; 89 (2): 256-260. doi: 10.3109/00016340903418769.\n3. Tae K, Hye K, Soon MN. Detection of nanobacterianin patients \nwith chronic prostatitis and vaginitis by reverse transcriptase pol -\nymerase chain reaction. Korean J. Urol. 2011; 52 (3): 194-9. doi: \n10.4111/kju.2011.52.3.194. \n4. Capoccia R, Greub G, Baud D. Ureaplasma urealyticum, Mycoplas -\nma hominis  and adverse pregnancy outcomes. Curr Opin Infect Dis. \n2013; 26 (3): 231-240. doi: 10.1097/QCO.0b013e328360db58.\n5. Murtha AP, Edwards JM. The role of Mycoplasma  and Ureaplasma  \nin adverse pregnancy outcomes. Obstet Gynecol Clin N Am. 2014; \n41 (4): 615-27. doi: 10.1016/j.ogc.2014.08.010.\n6. Montagut JM, Lapretre S, Degoy J, Rousseau M. Ureaplasma  in se -\nmen and IVF. Human Reprod. 1991; 6 (5): 727-29. doi: 10.1093/\noxfordjournals.humrep.a137416.\n7. Wittemer C, Beattahar-Lebugle K, Ohl J, Rongi\u00e8res C, Viville S, \nNisand I. Colonisation bacterienne vaginale anormale et implanta -Men Women Couples\nAzithromycin 0 1 1\nDoxycycline 0 1 1Table 3  Number of therapeutic failures depending \non the antibiotic used for initial treatment \nin patients positive for M. hominisPrevalence of genital Mycoplasma  and response to eradication treatment in patients undergoing assisted \nreproductive techniquesE. Veiga, et al.\nRev Esp Quimioter 2019;32(4): 327-332332Mycoplasma hominis  in pregnant women. BMC Infect Dis. 2014; \n14: 171-177. doi: 10.1186/1471-2334-14-171.\n32. Schneider SC, Tinguely R, Droz S, Hilty M, Dona V, Bodmer T, et \nal. Antibiotic susceptibility and sequence type distribution of \nUreaplasma species isolated from genital samples in Switzer -\nland. Antimicrob Agents Chemother. 2015; 59 (10): 6026-31. doi: \n10.1128/AAC.00895-15.\n33. Lee MY, Kim MH, Lee WI, Kang SY , Jeon YL. Prevalence and Antibi -\notic Susceptibility of Mycoplasma hominis  and Ureaplasma urea -\nlyticum  in Pregnant Women. Yonsei Med J. 2016; 57 (5): 1271-75. \ndoi: 10.3349/ymj.2016.57.5.1271.\n34. Skerk V, Sch\u00f6nwald S, Krhen I, Rusinovic M, Strapac Z, Vukovic J. \nAzithromycin and doxycycline in the treatment of female patients \nwith acute urethral syndrome caused by Ureaplasma urealyticum : \nsignificance of duration of clinical symptoms. Drugs Exp Clin Res. \n2001; 27 (4): 135-39. PMID 11822223. \n35. Krausse R, Schubert S. In-Vitro activities of tetracyclines, mac -\nrolides, fluoroquinolone and clindadamycin against Mycoplasma \nhominis  and Ureaplasma spp  isolated in Germany over 20 years. \nClin Microbiol Infect. 2010; 16 (11): 1649-55. doi: 10.1111/j.1469-\n0691.2009.03155.x.\n36. P\u00f3nyai K, Ostorh\u00e1zi E, Farkas B, P\u00e1rducz L, Marschalk\u00f3 M, K\u00e1rp\u00e1ti S, \net al. Incidence and antibiotic susceptibility of genital mycoplasmas \nin sexually active individuals in Hungary. Eur J Clin Microbiol Infect \nDis. 2013; 32 (11): 1423-26. doi: 10.1007/s10096-013-1892-y.\n37. Sirota I, Zarek SM, Segars JH. Potential influence of the microbiome \non infertility and assisted reproductive technology. Semin Reprod \nMed. 2014; 32 (1): 35-42. doi: 10.1055/s-0033-1361821.\n38. Kroon SJ, Ravel J, Huston WM. Cervicovaginal microbiota, women\u2019s \nhealth, and reproductive outcomes. Fertil Steril. 2018, 110 (3): 327-\n336. doi: 10.1016/j.fertnstert.2018.06.036.Bacteriospermia: Effects on semen parameters. Gynecol Obstet Fer -\ntil Senol. 2018; 46 (6): 518-523. doi: 10.1016/j.gofs.2018.03.014.\n20. Acosta Boga B, Codina Grau MG, Matas Andreu L, Meseguer Peina -\ndo MA. Diagn\u00f3stico microbiol\u00f3gico de las infecciones por Myco -\nplasma spp . y Ureaplasma spp . Procedimientos en Microbiolog\u00eda \nCl\u00ednica Cap 40. Recomendaciones de la Sociedad Espa\u00f1ola de En -\nfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. 2011. \n21. Andrade-Rocha FT. Ureaplasma urealyticum  and Mycoplasma \nhominis  in men attending for routine semen analysis. Prevalence, \nincidence by age and clinical settings, influence on sperm charac -\nteristics, relationship with the leukocyte count and clinical value. \nUrol Int. 2003; 71 (4): 377-81. doi: 10.1159/000074089.\n22. Daxboeck F, Zitta S, Stadler M, Iro E, Krause R. Mycoplasma hominis  \nand Ureaplasma urealyt icum in patients with sterile pyuria. J In -\nfect. 2001; 51 (1): 54-8. doi: 10.1016/j.jinf.2004.06.010.\n23. Horner P, Donders G, Cusini M, Gomberg M, Jensen JS, Unemo \nM. Should we be testing for urogenital Mycoplasma hominis, \nUreaplasma  parvum and Ureaplasma urealyticum  in men and \nwomen? - a position statement from the European STI Guidelines \nEditorial Board. J Eur Acad Dermatol Venereol. 2018; 32 (11):1845-\n51. doi: 10.1111/jdv.15146.\n24. Kasprzykowska U, Sobieszcza \u0144ska B, Duda-Madej A, Secewicz A, \nNowicka J, Go \u015bciniak G. A twelve-year retrospective analysis of \nprevalence and antimicrobial susceptibility patterns of Ureaplasma  \nspp. and Mycoplasma hominis  in the province of Lower Silesia in \nPoland. Eur J Obstet Gynecol Reprod Biol. 2018; 220:44-49. doi: \n10.1016/j.ejogrb.2017.11.010.\n25. Seifoleslami M, Safari A, Khayyat Khameneie M. Prevalence of \nUreaplasma  urealyticum  and Mycoplasma hominis  in High Vaginal \nSwab Samples of Infertile Females. Iran Red Crescent Med J. 2015; \n17 (12): e16823. doi: 10.5812/ircmj.16823.\n26. Asenjo A, Kusters JG, Severs TT, JL. Mycoplasma genitalium  in \nSpain: prevalence of genital infection and frequency of resistance \nto macrolides. Enferm Infecc Microbiol Clin. 2018; 36 (3): 169-171. \ndoi: 10.1016/j.eimc.2017.01.006.\n27. Pignanelli S, Pulcrano G, Schiavone P, Lula VD, Catania MR. In vitro \nantimicrobial  susceptibility of Mycoplasma hominis  genital iso -\nlates. Indian J Dermatol Venerol. Leprol. 2015; 81 (3): 286-88. doi: \n10.4103/0378-6323.153520.\n28. Vouga M, Greub G, Prod\u00b4hom G, Durussel C, Roth-Kleiner M, Vasile -\nvsky, et al. Treatment of genital mycoplasma in colonized pregnant \nwomen in late pregnancy is associated with a lower rate of pre -\nmature labour and neonatal complications. Clin Microbiol Infect. \n2014; 20 (10): 1074-79. doi: 10.1111/1469-0691.12686.\n29. Horner P, Blee K, O\u00b4Mahoney C, Muir P, Evans C, Radkliffe K. On \nbehalf of the clinical effectiveness group of the British Association \nfor Sexual Health and HIV. 2015 UK national Guideline on the man -\nagement of non-gonococal urethritis. Int J STD & AIDS. 2016; 27 \n(2): 85-96. doi: 10.1177/0956462415586675.\n30. Mensa J, Gatell JM, Garc\u00eda JE. Gu\u00eda de terap\u00e9utica antimicrobiana. \nBarcelona: Ed Antares, 2017. \n31. Redelinghuys MJ, Ehlers MM, Dreyer AW, Lombaard HA, Kock MM. \nAntimicrobial susceptibility patterns of Ureaplasma  species and Rev Esp Quimioter 2019;32(4): 333-364333\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).ommendations, but only to give a multidisciplinary opinion on \ntopics that could be particularly debatable or controversial. \nThe paper reviews the main vaccine-preventable adult diseas -\nes, their clinical and economic impact, the possibilities of reducing \nthem with vaccination programmes and the difficulties in carrying \nthem out. The role of nursing, pharmacy services, patient associa -\ntions and the health administration itself in changing the current \nsituation was discussed. Prospects for new vaccines were discussed \nand we speculated on the future in this field. Finally, particularly \nrelevant ethical aspects in decision-making regarding vaccination \nwere discussed, which must be faced by both individuals and states.\nWe have tried to summarize, at the end of the presenta -\ntion of each question, the environment of opinion that was \nagreed with all the members of the table.\nKey words: adult vaccines, vaccination, Influenza, Hepatitis B, Hepatitis A, \nHuman Papillomavirus , Pneumococcus , Streptococcus  pneumoniae , Hae-\nmophilus  influenzae , Meningococcus, Ethics.\nVacunas para la prevenci\u00f3n de infecciones en \nadultos: art\u00edculo de opini\u00f3n sobre la situaci\u00f3n \nen Espa\u00f1a\nRESUMEN\nEl calendario de vacunaci\u00f3n infantil es bien conocido y \ngeneralmente bien implementado en los pa\u00edses desarrollados. ABSTRACT\nThe childhood immunization schedule is well known and \ngenerally well implemented in developed countries. For various \nreasons, the same is not true of vaccines aimed at preventing \ninfections in adults, in which vaccination coverage is incom -\nplete and generally very deficient.\nIn order to assess the situation of adult vaccination in \nSpain, the Fundaci\u00f3n de Ciencias de la Salud has brought to -\ngether a series of experts in different fields, including doctors, \nnurses, representatives of patient associations, health managers \nand economists, health authorities and journalists to deal with \nthis issue. The format was that of a round table in which a se -\nries of questions previously formulated by the coordinators were \nto be answered and debated. The document presented is not an \nexhaustive review of the topic, nor is it intended to make rec -Vaccines for the prevention of infections in adults: \nan opinion paper on the situation in Spain\n1Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Medicine \nDepartment, School of Medicine, Universidad Complutense de Madrid (UCM), Instituto de Investigaci\u00f3n Sanitaria Grego -\nrio Mara\u00f1\u00f3n, and CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain.\n2Pneumology Service. Hospital de la Princesa. Coordinator COPD strategy of the National Health Service. Madrid. Spain\n3Service of Preventive Medicine and Epidemiology. University Hospital Vall d\u2019Hebron. Barcelona. Spain.\n4Department of Microbiology. University of Valladolid. Department of Microbiology. University Hospital R\u00edo Hortega, \nValladolid. Spain\n5National Federation of Liver Transplant Patients (FNETH)\n6Public Health of the Canary Islands Health Service. Spanish Association of Vaccinology. Spain\n7Ciencias de la Salud Foundation. Madrid Spain.\n8National Association of Health Reporters (ANIS)\n9Vaccination Programs. Subdirecci\u00f3n de Promoci\u00f3n de la Salud y Vigilancia en Salud P\u00fablica. Ministry of Health. Madrid. \nSpain\n10Spanish Society of Geriatry and Gerontology. (SEGG). Spain\n11Working group in Immunology. Spanish Society of Family and Community Pharmacists (SEFAC). Madrid Spain.\n12Faculty of Nursing and Physiotherapy. Lleida University. L\u00e9rida. Spain\n13Complutense University. Clinical Microbiology and Infectious Disease Department. Hospital Gregorio Mara\u00f1on. Madrid. \nSpain.\n14Institute Choiseul. Madrid. Spain.\n15Department of Microbiology. University of Valladolid. Department of Microbiology. University Hospital, Valladolid.Spain\n16Health Preservation and Prevention Department. Catalonia Health Service. Barcelona, Spain.\n17Ciencias de la Salud Foundation. Madrid. SpainEmilio Bouza1\nJulio Ancochea-Berm\u00fadez2 \nMagda Campins3 \nJos\u00e9 Mar\u00eda Eir\u00f3s-Bouza4 \nJes\u00fas Fargas6 \nAm\u00f3s Jos\u00e9 Garc\u00eda Rojas6 \nDiego Gracia7 \nAlipio Guti\u00e9rrez S\u00e1nchez8 \nAurora Limia9 \nJos\u00e9 Antonio L\u00f3pez10 \nMar\u00eda del Carmen Magro11 \nGloria Mirada12 \nPatricia Mu\u00f1oz13 \nEduardo Olier14 \nRa\u00fal Ortiz de Lejarazu15 \nLuis Urbiztondo16 \nEsteban Palomo17\nCorrespondence:\nEmilio Bouza \nInstituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n.\nC/ Dr. Esquerdo, 46\n28007 Madrid, Spain\nPhone: +34- 91- 586 84 53/Fax: +34- 91- 504 49 06 \nE-mail: emilio.bouza@gmail.com\nEsteban Palomo\nDirector. Fundaci\u00f3n de Ciencias de la Salud.\nC/ Severo Ochoa, 2, \n28760 Tres Cantos. Madrid\nPhone +34 91 3530150Original\nArticle history\nReceived: 22 February 2019; Revision Requested: 23 March 2019; Revision Received: 15 April 2019; Accepted: 7 May 2019Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364334belong. This document is not intended to provide recommen -\ndations or guidelines, but simply to collect opinions.\nThe meeting was held in Madrid on April the 18th, 2018 \nand this document reflects the main questions, answers and \nconclusions of the meeting updated by the literature available \nup to May 2018.\nMETHODS\nBefore the meeting, the different participants were sent \nsome questions related to the situation of vaccines for adults \nin Spain, in general terms or in relation to some vaccines in \nparticular. Some questions especially pulsed the vision of these \nproblems on the part of particular groups as the nurses, the \nassociations of transplanted patients, the health economists or \nthe position and attitudes of the press. Each accepted question \nwas introduced and presented by one of the panel members \nand then discussed by all the participants trying to reach a \ncommon opinion or consensus.\nThe original document, conveniently edited and referenced, \nwas sent to all panel members for correction and final approval.\nQUESTION 1.- What are the most prevalent vac -\ncine-preventable diseases in adults?\nExposure:\nThe World Health Organization (W.H.O.) has listed the \nmost important diseases preventable by vaccines in adults (ta -\nble 1) [1]. Among them are several that do not currently rep -\nresent a problem in the developed world, precisely because of \nthe widespread use of vaccines among the population, so we \nwill not address them in this text. Examples are measles, rubel -\nla, mumps, tetanus, diphtheria, polio or rabies. It is important \nto note that, as recent experiences have shown [2], if a popu -\nlation\u2019s vaccination coverage is reduced, there is a clear risk of \noutbreaks of these diseases. WHO does not include in its list \nother diseases, also preventable by vaccines, but which either Por varias razones,no ocurre lo mismo en el caso de las va -\ncunas destinadas a prevenir las infecciones en adultos, en los \nque la cobertura vacunal es incompleta y generalmente muy \ndeficiente.\nCon el fin de evaluar la situaci\u00f3n de la vacunaci\u00f3n de adul -\ntos en Espa\u00f1a, la Fundaci\u00f3n de Ciencias de la Salud ha reunido \na una serie de expertos en diferentes campos, incluyendo m\u00e9d -\nicos, enfermeras, representantes de asociaciones de pacientes, \ngestores sanitarios,  economistas, autoridades sanitarias y \nperiodistas para discutir este asunto. El formato fue el de una \nmesa redonda en la que una serie de preguntas, formuladas \npreviamente por los coordinadores, deb\u00edan ser contestadas y \ndebatidas. El documento presentado no es una revisi\u00f3n ex -\nhaustiva del tema, ni tiene por objeto hacer recomendaciones, \nsimplemente pretende dar una opini\u00f3n multidisciplinar sobre \naspectos que pueden ser debatibles o controvertidos.  El doc -\numento revisa las principales enfermedades de los adultos que \npueden prevenirse con vacunas, su impacto cl\u00ednico y econ\u00f3m -\nico, las posibilidades de reducirlos con los programas de vacu -\nnaci\u00f3n y las dificultades para llevarlos a cabo. Se discuti\u00f3 el \npapel de la enfermer\u00eda, la farmacia, los servicios de salud, las \nasociaciones de pacientes y la propia administraci\u00f3n sanitaria \npara cambiar la situaci\u00f3n actual. Se evaluaron las perspecti -\nvas para nuevas vacunas y se especul\u00f3 sobre el  futuro en este \ncampo. Por \u00faltimo, se discutieron los aspectos \u00e9ticos especial -\nmente relevantes en la toma de decisiones con respecto a la \nvacunaci\u00f3n, que deben ser afrontados tanto por los individuos \ncomo por los estados.\nHemos intentado resumir, al final de la presentaci\u00f3n de \ncada pregunta, la opini\u00f3n que representaba el consenso de to -\ndos los miembros de la mesa.\nPalabras clave: Vacunas adultos, Vacunaci\u00f3n, Gripe, Hepatitis B, Hepatitis \nA, Papilomavirus , Neumococo , Streptococcus pneumoniae , Haemophilus \ninfluenzae , Meningococo, Etica.\nINTRODUCTION\nThe benefits that a child vaccination calendar has had in \nreducing Infectious Diseases during paediatric age and for the \nrest of life do not need to be highlighted. However, despite \nthe large number of infectious diseases with significant mor -\nbidity and mortality that can affect adults, and the availabil -\nity of vaccines for many of them, adult vaccination is often \nneglected. This negligence may be attributable to the patients \nthemselves, as well as to health-care professionals, and the ad -\nministration.\nIn order to examine the situation of this problem in Spain, \nthe Fundaci\u00f3n de Ciencias de la Salud has brought together, \nat a round table, both experts in different aspects of the sub -\nject as well as representatives of affected communities and the \nmedia. All participants were asked a series of previously agreed \nquestions to review the state of the art of each subject, with \nparticular emphasis on the situation in Spain and searching \nfor opportunities for improvement. The opinions expressed by \neach of the speakers are their own and do not necessarily rep -\nresent those of the Institution or Institutions to which they Measles\nRubella\nMumps\nPoliomyelitis\nHepatitis A\nHepatitis B\nInfluenza\nVaricella \nHerpes zoster \nRotavirusHuman Papillomavirus\nRabies\nTick-mediated encephalitis\nJapanese encephalitis\nHepatitis E\nPneumococcus\nHaemophilus influenzae  type b \nMeningococcus\nDiphtheriaWhooping cough\nCholera\nTyphoid fever\nTetanus\nTuberculosis\nMalaria\nDengueTable 1  Most prevalent diseases in adults \npreventable with vaccinesVaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364335caused by the Influenza virus, Varicella Zoster, Human Papillo -\nmavirus, pneumococcus ( Streptococcus pneumoniae ), hepati -\ntis B virus (HBV), meningococcus ( Neisseria meningitidis ) and \nHaemophilus influenzae  type b [3].\nTable 2 shows their incidence, some risk factors and the \nmorbidity and mortality associated with them. Whenever pos -\nsible, we have used figures provided by the CDC in order to \nharmonize them and recognizing that incidence and mortality \nfigures are estimates [4-16].no longer represent a threat (smallpox), or because a fully es -\ntablished and accepted vaccination system ( Bacillus anthracis , \nplague, Q fever) is not yet available.\nWe will mention here, by way of example, seven infections \nthat are vaccine-preventable but remain a challenge for adults \nin the developed world. The selection is based on the recent \nrecommendations of the North American Advisory Committee \non Immunization Practices (ACIP). These infections are, follow -\ning the same order of the mentioned recommendations, those Estimation of cases per yearEstimation of \ndeaths per yearMain Risk factors Morbidity Sequelae Source\nInfluenza 3-5,000,000 severe cases 650.000 Age, Chronic diseases,\nPregnancy\nHealth-Care-WorkerFever, malaise, \npneumoniaInfrequent [4]\nHerpes Zoster 972,580 in USA (30% life risk) 60/100,000 in \nadults >65 yearsAge, trauma, \nimmunosuppression, \nneoplasia, chronic medical \nconditionsRash, pain Neuralgia, \nmeningoencephalitis, \nmyelitis, vasculopathy, \nretinal necrosis[5]\nHPV 529,000 cervix neoplasia\n10-22% with normal Pap-smear274,000 Sexual intercourse, immune \ncompromisedAsymptomatic\nGenital and non-\ngenital wartsCervix carcinoma, \nvagina, vulva, \npenis, anus and \noropharyngeal \nrecurrent \npapillomatosis[6, 7]\nHepatitis B 257-350 million persons with \nchronic infection887,000 (2015) Mother-to-child \ntransmission, Drug users, \nhealth-care workers, sexual \ntransmissionHepatitis, Fulminant \nhepatitisChronic hepatitis, \ncirrhosis, hepatoma, \nextra hepatic \nmanifestations[8, 9]\nS. pneumoniae \u226565: 36.4/ 100.000\n <1 year: 34.2 /100,000 \nhematol. malignancies \n186/100,000 \nHIV 173/ 100,000 500,000 children \n< 5 yearsAge, chronic heart and \nlung disease, smoking and \naspleniaPneumonia, otitis, \nmeningitis, sepsis, \nendocarditis, other \ninfectionsSevere disabilities \nafter meningitis and \nendocarditis[10-12]\nMeningococcus 1.2 million 135,000 Age, closed communities, \ncertain medical conditions \n(asplenia, deficiency of \ncomplement components, \nHIV infection) and travelMeningitis, sepsis, \npneumonia, and \nother localized \ninfectionsCognitive impairment, \ndeafness, motor \nimpairment, seizures, \nvisual impairment, \nhydrocephalus, and \nlimb loss[13, 14]\nHaemophilus \ninfluenzae  type b8.13 million severe diseases 371,000 (2000)\n199,000 (2008)Age, immunosuppression \n(complement deficit, \nhypogammaglobulinemia, \nsickle cell anemia, asplenia, \nmalignancy, HIV), COPD, \nsmoking, alcoholism.Meningitis, \nepiglottitis, \npneumonia, \nempyema, \npericarditis, \nbacteraemia, septic \narthritis, and other \ninfectionsCognitive deficits and \nother serious sequelae \nin cases of meningitis.[15, 16]Table 2  Incidence, risk factors, morbidity and mortality of some infections preventable with vaccines.Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364336ease and others, stand out for their magni -\ntude. The number of deaths attributable to \nnotifiable infectious diseases in Spain in 2015 \nis estimated to be close to 28,000.\nThe recommendations of vaccines for \nadults are provided by the Health Department \nof the United States of America [3].\nDespite evidence of a drastic reduction in \nthe incidence, morbidity and mortality of vac -\ncine-preventable diseases since the late 19th \ncentury [23-25], American adults, as an exam -\nple of a developed nation, remain inadequate -\nly vaccinated [25-27].\nThe reasons include poor information, \nfear of undesirable effects, reluctance to use \nvaccines, low priority on the list of individual \nconcerns, cost, problems of access to vaccines \nand other [26-28].\nIt is estimated that since 1924, more \nthan 100 million cases of smallpox, measles, polio, mumps, ru -\nbella, hepatitis A, diphtheria and pertussis have been prevent -\ned.\nConsidering the period from 1980 to the present day, the \nreductions in incidence and mortality caused by some of the \naforementioned diseases exceed 90% and in some cases 99%. \nand vaccination is considered an efficient and cost-effective \nprocedure as a public health strategy [27, 28]. \nFollowing the line of argument of the previous question, \nthe potential for substantial reductions that could be achieved \nin the different diseases could be summarised as follows:\nInfluenza\nA study of 18 elderly cohorts in the United States of \nAmerica that collected 713,872 observational persons/-sea -\nsons estimated the effectiveness of Influenza vaccines as fol -\nlows: There was a 27% reduction in the risk of hospitalization \nfor pneumonia or Influenza and a 48% [29] reduction in the \nrisk of death for those vaccinated. These figures were main -\ntained for different age groups and risk subgroups. \nA historical cohort of England and Wales in people over \n64 years of age compares the rates of acute respiratory in -\nfection admissions and death from acute respiratory infec -\ntions in people vaccinated against Influenza (692,819 per -\nson-years) and in unvaccinated people (1,534,280 person/\nyears). The reduction in hospitalization was 21% and the \ndeath rate was reduced by 12% [30]. \nGross et al [31], in a meta-analysis of 20 cohort studies, \nestimate the effectiveness of influenza vaccination at 56% in \npreventing respiratory infections, 53% in preventing pneumo -\nnia, 50% in preventing hospitalizations, and 68% in preventing \ndeaths. In case-control studies, the prevention of hospitaliza -\ntion for pneumonia ranged from 32% to 45%; between 31% \nand 65% in preventing hospital deaths caused by pneumonia We must also mention the immense health expenditure \ninvolved in these preventable diseases. A few examples are \nworth mentioning. It is estimated that \u201cthe flu\u201d in the Unit -\ned States represents an annual expenditure of 10,400 million \nUS dollars only as direct costs for hospitalization and medical \nvisits of adults [17]. European sources refer to an expenditure \nattributable to influenza of 56.7 million euros per million in -\nhabitants [18].\nIn the case of pneumococcus, the cost of an episode of \npneumonia, meningitis and bacteraemia has been estimated \nat 6,283, 3,886 and 4,768 US dollars respectively [19]. Globally, \npneumococcal pneumonia costs the United States US$ 4.9 bil -\nlion annually, which increases by an additional US$ 324 million \nin the case of antimicrobial resistance [20]. Finally, the cost of \nbacterial meningitis in the event of sequelae has been estimat -\ned at \u00a3160,000-\u00a3200,000 in the first year after the episode and \n\u00a3590,000 - \u00a31,090,000 per person for the rest of his life, assum -\ning that the patient survives to the age of 70 years [21].\nConclusion:\nAt present, in the developed world, the 7 adult in -\nfections that could benefit most from a strict vaccina -\ntion schedule are those caused by: Influenza virus, Herpes \nZoster, Human Papillomavirus, Hepatitis B Virus, Pneu -\nmococcus, Meningococcus and Haemophilus influenzae \ntype b.\nQUESTION 2.- What proportion of vaccine-prevent -\nable diseases in adults could be reduced with currently \navailable vaccines? \nExposure:\nFigure 1 shows the incidence of vaccine-preventable dis -\neases in Spain published in 2015 [22]. Episodes of influenza, \nfollowed by chickenpox, whooping cough, mumps, invasive \npneumococcal disease, hepatitis A and B, meningococcal dis -Figure 1 Incidence of vaccine-preventable diseases in Spain (2015)\nVaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-36433711, 16 and 18 [40-43]. These results were maintained after 5 \nyears of follow-up [44].\nA vaccination with tetravalent vaccine, recommended \nthen only for girls between 11 and 12 years of age, with a res -\ncue for women between 13 and 26 years of age, was intro -\nduced in 2006 in the United States [45].\nOther recommendations have been added to this, that \ntake into account that there is an older population that can \nbenefit from this vaccine and that men are not excluded from \nthese benefits. However, information is being collected sug -\ngesting that the immunogenic capacity of these vaccines de -\ncreases when applied to populations over 19 years of age. To \nthe 2 and 4 serotypes vaccines, a 9-serotype vaccine has been \nadded more recently.\nFor all the above reasons, the current recommendations \nfor vaccination against HPV in the US ideally indicate it be -\ntween 11 and 12 years old, in both boys and girls, with a po -\ntential rescue until the age of 26 for those who did not receive \nit previously and particularly for groups at risk such as men \nwho have sex with men or immunocompromised men [ 45]. In \nSpain, the current recommendations of vaccination against \nHPV indicate 12 years old girls ( vaccinate only girls, with 2 \ndoses ) and some risk groups adult women (HIV, ICs (non-HIV) \n& conizated), in 13 autonomous regions [46].\nThe CDC of the United States of America estimates, with \ndata from 2008-2012, that about 30,700 episodes of cancer \nper year, 19,100 in women and 11,600 in men, can be attribut -\ned to HPV and that a correct vaccination could prevent 24,600 \ncancers in the U.S. population each year whether vaccinated \nwith bivalent or tetravalent vaccine, to which an additional \n3,800 cases could be added if vaccinated with new serotypes, \nwhich would add up to a potential prevention of 28,500 tu -\nmours if HPV vaccination is properly implemented, only in the \nUnited States of America [47]. Population studies in Denmark \nand Australia seem to confirm these assumptions [48-52].\nHepatitis B virus\nIn most European nations, the prevalence of chronic HBV is \nestimated at 0.5-0.7% of the general population. It is estimat -\ned that cirrhosis will develop in 20-30% of those infected with \nHBV, with another 25% developing hepatocarcinoma [8, 9, 53].\nHepatitis B vaccine is not strictly considered an adult vac -\ncine since it must be administered at paediatric age. It is rec -\nommended in adults only for those not previously vaccinated \nin which there is a medical, occupational or behavioural risk \nfactor or in non-immunized adults who lack these conditions \nand wish to be protected. The incidence of Hepatitis B in devel -\noped societies is already very low since the beginning of child -\nhood vaccination in 1991. It is estimated that the decrease in \nincidence has been 82%. Despite this, in 2015, the incidence of \nacute hepatitis B was 2.6 cases per 100,000 people aged 30-39 \nin the USA [54, 55].\nMedical indications for vaccination against HBV in the \nadult, not previously vaccinated, are primarily chronic renal or Influenza, between 43% and 50% in preventing deaths \nfrom any respiratory cause and between 27% and 30% in pre -\nventing deaths from any cause.\nHerpes Zoster\nIn Western countries, the incidence of shingles is approx -\nimately 11 cases per 1,000 inhabitants over 80 years of age/\nyear, compared to 1 to 3 episodes in people under 50 years \nof age [27]. A study carried out in the United States shows \nthat approximately 1 million cases of Zoster episodes occur in \nadults per year and that a high proportion of them developed \npost-herpetic neuralgia [5]. \nLal and colleagues [32] conducted a clinical trial in 18 \nnations on patients \u2265 50 years with two doses of VZV vac -\ncine two months apart, the results of which were stratified \nby decades of age (50 to 59, 60 to 69, and \u226570 years). Of \na total of 15,411 participants, 7,698 and 7,713 participants \nreceived the vaccine or placebo, respectively. During a fol -\nlow-up time of 3.2 years, herpes zoster was confirmed in 6 \nand 210 participants in the respective groups (incidence, 0.3 \nvs. 9.1 per 1,000 people/year). Overall, vaccine efficacy was \n97.2%. Adverse effects were minimal and there were no dif -\nferences between the two groups. In another prospective and \ncomparative study, that enrolled 13,900 evaluable partici -\npants (mean age, 75.6 years), observed over an average peri -\nod of 3.7 years, the efficacy of the vaccine in protecting from \nepisodes of zoster in patients over 70 years was 91.3% and \nagainst postherpetic neuralgia, 88.8% [33]. This data offers \nenormous possibilities for controlling the problem.\nHuman Papillomavirus\nNo example more clearly demonstrates the paradigm of \ninfection as a cause of cancer as in the case of the Human \nPapillomavirus (HPV). Infectious agents are estimated to cause \n17.8% of all cancers in the world and their main agents are \nHelicobacter pylori  (5.5% of the total), Hepatitis B and C virus -\nes (4.9%), EBV (1%), HIV along with Herpes viruses (0.9%) and \nHPV (5.2%) [6].\nThe last decade of the last century and the first decade \nof the present one have served to demonstrate the relation -\nship between HPV and cervical cancer in women, a cancer that \nconstitutes the second cause of death by neoplasia for women \nin the world [6, 34-38].\nIn a paper published in 2015, looking for HPV on tissues \narchived with different forms of human cancer, HPV was pres -\nent in 91% of cervical cancers, in 69% of vulva cancers, 75% \nof vaginal cancers, 63% of penile cancers, 89% and 93% of \nanal cancers in men and women respectively and 72 and 63%, \nrespectively, of oropharyngeal cancers in men and women [39].\nAfter 4 multicentric and multinational, similar design, \nclinical trials, a tetravalent vaccine against HPV was intro -\nduced. After a follow-up of 40 months, it showed a protection \nof almost 100% against genital warts, cervical cancer and the \npersistence of HPV types contained in the vaccine that were 6, Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364338sodes of infection. Of the 12 existing capsular groups, A, B, C, \nW, X and Y are the cause of most IMI episodes. IMI episodes \nare usually grouped into three life stages: childhood, adoles -\ncence, and a third group in people over the age of 65. The \nclassic quadrivalent vaccines include polysaccharide antigens \nfrom serogroups A, C, W and Y and induce specific antibody \nresponses in more than 90% of receptors [14].\nNone of these vaccines, however, offers protection \nagainst infection by N. meningitidis  serogroup B, which is nev -\nertheless the cause of more than 50% of meningococcal in -\nfections in different parts of the world, today. There are two \nvaccines against N. meningitidis type B on the market that are \nrecommended not only for children but also for adults with \nanatomic or functional asplenia, for those who have deficien -\ncies of complement components, people being treated with \neculizumab, microbiologists, and people exposed to epidemic \ninfection situations caused by this bacterium [61]. They con -\ntain protein antigens from the external membrane that have \nbeen incorporated with different techniques [62].\nGiven its recent introduction, the long-term impact ex -\nperience of this vaccine is still scarce. In outbreak situations \nthere has been a 42% reduction in expected cases. In the UK, \nthe efficacy of 4CMenB has been estimated at 83% after the \nadministration of the two doses [63, 64].\nIn a recent systematic review, the proportion of children \nand adolescents in whom seroconversion occurs at 30 days \nversus the original 4 strains was, respectively: 92% for strain \n44/76-SL, 91% for 5/99n, 84% for NZ98-254 and 87% for \nM10713. The incidence of serious adverse events in patients \nreceiving the 4CMenB vaccine was low (5.4 per 1,000 indi -\nviduals), although higher than other routine vaccines (1.2 per \n1,000 individuals)[65].\nHaemophilus influenzae  type b\nH. influenzae  type b is a well-known cause of meningitis \nand other invasive infections, usually accompanied by bacte -\nraemia. Most of them occur in children in whom the vaccine \nis recommended. In 2012, the rate of invasive Hib disease in \nEurope in children under 5 years of age was 0.19/100,000 chil -\ndren. In the United States, after the introduction of the vac -\ncine, the incidence of the disease has been reduced by 99% \n[15, 66] and remains below 0.27 cases/100,000 in children un -\nder 5 years estimated by the Healthy People project for 2020 \n[67, 68]. This has diverted the current focus of incidence to \nolder adults [69-71].\nIn adults, the H. influenzae  type b vaccine is recommend -\ned only in immunosuppressed patients at high risk of acquir -\ning this infection, including those with anatomic or function -\nal asplenia or who are scheduled for splenectomy, as well as \npatients with bone marrow transplants, including those pre -\nviously vaccinated, beginning 6-12 months after transplan -\ntation. This vaccine is not recommended for HIV-positive pa -\ntients at this time.\nIn conclusion, with the data summarized above, it is pos -failure (including haemodialysis), patients with chronic liver \ndiseases, diabetes mellitus and HIV infection. Professional indi -\ncations focus on health-care workers and security forces who \nmay be exposed to blood or body fluids and people with risky \nbehaviours such as parenteral drug users, those who have had \nmore than one different sexual contact in the last 6 months, \nmen who have sex with men and those who have had a recent \nSexually Transmitted Infection (STI).\nThe WHO aims to eliminate Hepatitis B by 2030, reducing \nchronic Hepatitis B infections by 90% and associated mortality \nby 65% [56].\nStreptococcus pneumoniae\nThe importance of Invasive Pneumococcal Disease (IPD) \ndoes not need to be highlighted and constitutes a very impor -\ntant cause of morbidity and mortality, mainly in the popula -\ntions of children and adults over 50 years of age.\nThe impact that conjugate pneumococcal vaccines have \nhad on the evolution of IPD in children is well known, with \nclear decreases in the overall incidence of episodes and par -\nticularly those caused by serotypes included in them [11].\nThe impact that has been achieved in the reduction of \nIPDs in the adult population is not so well known. On this as -\npect, a recent systematic review assesses the evolution of IPD \nbetween 2000 and 2016 using only articles written in English \nand collected in PubMed, finding 49 valid papers that met \nthe selection criteria. Most of them came from Canada, the \nUnited Kingdom or the United States of America and showed \nstatistically significant decreases in episodes of IPD after the \nintroduction of childhood vaccination. This indirect effect on \nolder populations was associated with coverage rates that had \nbeen achieved in different situations and particularly benefited \nthose over 65 years of age [12].\nIPD incidence reductions ranged from 61% as a combined \neffect of PCV7, PCV10 and PCV13 use in people over 65 years \nof age in Canada [12], with up to 21% reduction as an effect \nof the use of PCV7 and PCV13 in Israel [57].\nAn Alaskan study reported a significant reduction in IPD \nfollowing the introduction of PCV13 [58] but reduction did not \nreach statistical significance in other studies [59], one of them \nfrom Barcelona (Spain) [60]. In the latter case, mortality from \nIPD in people over 65 years of age did not change significant -\nly (24 vs. 22%); but mortality dependent on specific serotypes \nincluded in PCV7 did, which in three successive periods were \n4.94 vs. 3.58 vs. 2.45 deaths/100,000 population/year.\nNeisseria meningitidis\nN. meningitidis  (meningococcus) are Gram-negative, en -\ncapsulated bacteria that are grouped into pairs that cause \ninvasive meningococcal disease (IMI), characterized primarily \nby meningitis but also by other extrameningeal manifestations \nsuch as disseminated meningococcaemia. Mortality, in one \nform or another, can vary between 10 and 40% of the epi -Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-3643391930s. No serious effect associated with it has been demon -\nstrated but a hypothetical relationship between this product \nand autism or other neuropsychiatric diseases has caused a \ngreat damage to confidence in vaccines. Such an effect, we \ninsist, was never demonstrated and the work in question was \nwithdrawn for fraud [75-79].\nOther risks such as febrile seizures or immune thrombo -\ncytopenia are known but extremely rare. The FDA and the CDC \nmaintain a Vaccine Adverse Event Reporting System (VAERS) in \nthe United States of America where manufacturers and phy -\nsicians report about 30,000 adverse effects annually [80-82].\nIn this section we will try to respond specifically to the \nquestion posed in the adult population and in the vaccines \nthat we have selected as the most relevant and most discussed \nat the present time.\nInfluenza vaccine\nInfluenza vaccination in adults, particularly in peo -\nple over 65 years, has a somewhat higher incidence of local \nmanifestations (30%) than in the younger population. There \nis no evidence that the presence of systemic manifestations \nafter influenza vaccination is greater than in a population re -\nceiving placebo. A special mention is deserved for the risk of \ndeveloping Guillain-Barr\u00e9 syndrome, whose incidence in the \ngeneral population is about 10-20 cases per million inhabit -\nants. With some contradictory data, it is not clear that this rate \nis increased in the influenza vaccinated population nor that \nthere is a causal relationship between these two problems [83].\nA recent systematic review compares the results of influ -\nenza vaccination carried out with normal doses in young peo -\nple or with high doses in the elderly. Although the volume of \ninformation is scarce, high-dose vaccine would reduce the risk \nof influenza by 24%, without clearly being associated with a \nrisk of higher adverse effects [84].\nOlder patients receiving tetravalent influenza vaccines \nhad neither significant serious adverse effects nor a higher \nincidence of common adverse effects than trivalent vaccine \nrecipients [85].\nHuman Papillomavirus vaccines\nSerious adverse effects of HPV vaccines are minimal and \nrefer, in the vast majority of cases, to local manifestations of \npain or erythema. Occasionally, febrile episodes may occur \nthat rarely exceed a temperature of 39\u00b0C. In a safety study, 6 \ngirls had potentially immunomediated reactions (0.8%) such \nas reactive arthritis, idiopathic juvenile arthritis, erythema no -\ndosum, alopecia areata, ulcerative colitis and celiac disease, of \nwhich only one was possibly considered as related to the vac -\ncine [86]. \nThis safety profile is maintained in women who are vacci -\nnated between the ages of 15 and 55 years in which no serious \nadverse events attributable to the vaccine were detected with -\nin an observation period of 10 years [87].sible to imagine the added protection that would result from \nadequate immunization coverage. American adults have par -\nticularly poor immunization coverage against Influenza, hep -\natitis B, tetanus, and diphtheria/pertussis, which means that \nmillions of infections in the U.S. [26, 29] could be avoided with \nthe corresponding vaccines. One of the greatest risks is the \nassociation between influenza and pneumonia [28], for which \nvaccination coverage rates among adults did not reach 50%.\nThe consequences of all this is that some 50,000 Ameri -\ncans die annually from diseases that could have been prevent -\ned by vaccination and 99% of the deaths are in adults [27, 28].\nIn 2008, an estimated 4,500 people died in the U.S. from \ninvasive pneumococcal disease, the vast majority of whom \nwere adults over 35 years of age [72] \nIn terms of the reasons for this low coverage, in a recent \nsurvey, vaccines are perceived as a low health priority for both \ndoctors and patients and to be vaccinated is not required for \nthe vast majority of employment situations. Many adults are \nnot even aware that they need vaccines or the benefits of vac -\ncines, nor do they understand that booster doses of vaccines \nthey have received in the past may be necessary. In general, \nadults are aware that there are vaccines for influenza or tet -\nanus, however, only 36% of those vaccinated for tetanus re -\nceived a booster dose every 10 years. In the same survey, 56% \nof patients who knew there was a pneumococcal vaccine had \nnot had it because \u201cthe doctor did not recommend it\u201d. Added \nto this is the fear of vaccines, punctures and their effects, and \nin some cases the high cost of vaccines not covered by public \nservices or health insurers.\nConclusion:\nThe possibilities of reducing the problem with ade -\nquate vaccination in adults are always estimated to be \nabove 50% and often more than 90%. The savings in \nmorbidity, mortality and money would be immense if the \nvaccines were applied in all their indications and with an \nadequate vaccination calendar in adults.\nQUESTION 3.- What data is available on vaccine tol -\nerance in adults?\nExposure:\nLocal reactions at the injection site of parenterally admin -\nistered vaccines are common and may include pain, swelling, \nand erythema, usually of a moderate nature and of short dura -\ntion. Systemic manifestations such as fever, irritability, or rash \nmay also occur but are also rare and unimportant [73].\nSome vaccines contain traces of antibiotics such as ne -\nomycin or gelatin as in the case of the MMR vaccine, or egg \nproteins and can produce an allergic reaction in people with \nhypersensitivity to these substances. Anaphylactic reactions \nare estimated to occur in one out of every million doses ad -\nministered [74].\nThimerosal is a mercuric compound used to prevent \nbacterial and viral contamination of vaccines, used since the Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364340is pain at the injection site that occurs in less than 25% of \nvaccines. In much lower percentages there may be fever, ma -\nlaise, headaches, arthralgias and myalgias, generally mild and \nof short duration.\nSuspicions of a link between vaccination against hepatitis \nB and multiple sclerosis, raised in France, have not been con -\nfirmed in studies carried out in the United States of America \n[104-109].\nIn the case of the recombinant HBV vaccine using a new \nadjuvant (HepB-CpG), the adverse effects are similar to those \nfor the other vaccines [110], but suspicion has recently been \nraised that it may be associated with a higher incidence of my -\nocardial infarction in one of the three major clinical trials, as \nwell as new-onset autoimmune diseases [111].\nPneumococcal vaccines\nIn many developed countries, vaccination with the 23-va -\nlent pneumococcal vaccine is recommended to prevent IPD in \nadults over 50 years of age or with underlying diseases that \njustify the fact that it has been available for decades. Immuni -\nty declines with age and the revaccination recommendation is \nunder discussion. In a meta-analysis that includes 14 studies in \nvaccinated and revaccinated patients [112], most of them have \nsignificant biases, but local and general adverse effects during \nvaccination and revaccination were few and limited in time, \nalthough they were more frequent during the second vaccina -\ntion than during the first.\nFor conjugate vaccines, tolerance is also very good and \nserious adverse effects are minimal [113]. Most studies have \nfound no adverse reactions of particular interest, with the \ndoubt of an increase in asthmatic reactions in some of the \nstudies. The application of these vaccines to patients who have \npreviously received unconjugated vaccines does not increase \ntheir intolerance [114, 115].\nMeningococcal vaccines\nVaccines to prevent invasive meningococcal disease are \nusually given before adulthood and are only given in adults if \nthere is a particular risk of contracting this disease. This risk is \nparticularly important in travellers to hyperendemic areas of \nmeningococcal disease, in military personnel working in these \nareas, and for people frequently in contact with Neisseria \nmeningitidis , such as microbiologists. They are also indicated \nin individuals with functional or anatomical asplenia, patients \nwith complement deficiency, patients treated with eculizumab, \nmen that have sex with men and patients in some areas where \nthere is an epidemic outbreak of this disease in this population \ngroup.\nIn addition to the classic quadrivalent vaccines, there are \ntwo vaccines against Neisseria meningitidis  serotype B (Tru -\nmemba \u00ae and Bexsero\u00ae) that can be used in adults with risk \nfactors such as those mentioned above.\nThe most common adverse effects with tetravalent vaccines Serious adverse effects were also not detected in other \ngroups of adults who received the vaccine because they be -\nlonged to high-risk groups [88, 89] or during pregnancy [90]. \nThere is no evidence of increased risk of Guillain-Barr\u00e9 syn -\ndrome in the HPV vaccinated population [91].\nNonavalent vaccines are as harmless as tetravalent vac -\ncines and there is no difference between them in the incidence \nof headache, dizziness or tiredness [92].\nZoster vaccine\nThere are two vaccines available for the prevention of \nZoster in adults over 50 years of age: an older live attenuated \nvirus (ZVL) vaccine on the market, and a recombinant vaccine, \nproduced primarily with more recently introduced glycopro -\ntein E (RVZ) [93-99]. Although the two vaccines have not been \ncompared face-to-face in clinical trials, the efficacy of RZV \nseen in two clinical trials appears superior to that of ZVL. The \nprotection of ZVL Zoster is estimated at 70% [100], whereas \nin the case of RVZ the protection was 90 to 97% in two rand -\nomized clinical trials [33, 101].\nVaccines are preferably indicated for non-immunosup -\npressed individuals over the age of 50 and data on immuno -\nsuppressed individuals is limited. Safety data does not allow \nthese vaccines to be indicated in individuals with multiple \nsclerosis, rheumatoid arthritis and other autoimmune diseases \nbecause of the risk of the vaccines inducing flare-ups. RZV is \npreferred for vaccinating people who have immunosuppressed \nhome contacts. There are no contraindications to RZV vacci -\nnation for people who have had a previous Zoster more than \nthree years ago or who have previously received ZVL.\nThe incidence of local reactions is higher with RZV and \nconsists primarily of local pain at the injection site that on -\nly limits routine activities in 9% of recipients [33, 101]. The \nmost common systemic reactions to RZV are myalgia, tired -\nness, headaches, chills and fever that only limit daily activities \nin 10.8% of cases. The duration of these side effects is usually \nless than 3 days and do not prevent the vast majority of recip -\nients from receiving the second dose.\nThe ZVL vaccine is administered in single doses and its \nlocal and systemic effects are qualitatively similar to those \nof RVZ. However, 6 cases of acute retinal necrosis, uveitis or \nkeratitis with ZVL have been reported between 6 days and 2 \nmonths after vaccination. Contraindications to VZL include \nallergy to gelatin or neomycin, immunosuppression that may \nfacilitate dissemination of the vaccine strain, and pregnancy \n[102, 103].\nHepatitis B vaccine\nThere are several recombinant hepatitis B vaccines cur -\nrently available on the market and all of them are considered \nextraordinarily safe although the protection rate drops sub -\nstantially as administration takes place later in life.\nThe most important adverse effect with classic vaccines Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-36434148,277 cases in 2012 [128] [129]. In the United Kingdom there \nhas also been a significant rebound in recent cases, which \nreached 12 episodes per 100,000 people aged 15 and over in \n2012 [130]. There have also been major outbreaks of the dis -\nease in South America, Asia, Africa, Australia and New Zealand \nwith thousands of episodes published since 2008 and finally \na severe epidemic that continues since 2008 in West Darfur \n[131-136].\nIn Spain, vaccination with whole cell vaccine began in \n1975 and acellular vaccine was introduced in 2005. From 1998 \nto 2009, the numbers of whooping cough cases remained be -\nlow 1.5 episodes/100,000 population. But, those numbers have \nrisen dramatically in recent years and across all age groups \n[137]. The evolution of whooping cough in Spain between \n1982 and 2016 shows a recent upturn in the number of cas -\nes reaching 17.9 episodes / 100,000 inhabitants in 2016 and \ngrowing since 2010. The upturn affects all age groups.\nFernandez-Cano et al. analized the hospitalizated cases \nin Spain by whooping cough between 1997 and 2011, which \namounts to 8,331, of which 92% were children under 1 year \n[138]. The overall mortality was 0.56%, the vast majority of \nwhich occurs in infants who acquire the disease transmitted \nfrom their parents or siblings. The causes for this resurgence \nare the loss of natural and vaccinal immunity over time, the \nlower antigenic potency of acellular vaccines (DTaP), the scar -\ncity of mucosal immunity induction, greater clinical suspicion, \nimprovements in the use and precision of the techniques and \nthe genetic changes of Bordetella pertussis  that facilitate the \nescape from vaccine protection, along with the existence of \nstrains with higher toxin production. Whole cell vaccines \ndiffer from acellular vaccines in different aspects. They have \na protective efficacy ranging from 38-92% [139], prevent \nthe transmission of disease and infection, interrupt the car -\nrier state, confer a certain group immunity, induce a potent \nmucosal immunity and an immune response Th17. The acel -\nlular ones have an efficacy calculated between 71-85% [140], \nprotect from disease but not from infection, do not prevent \ncarrier status and allow transmission (experimental studies). \nThey do not confer group immunity, do not induce mucosal \nimmunity and produce a Th2-type immune response.\nConclusion:\nThere has been a clear increase in cases of whoop -\ning cough over the last decade, affecting all population \ngroups, including adults. The problem has multiple caus -\nes, one of which is the change to acellular vaccines, bet -\nter tolerated but with less permanence of immunogenic \ncapacity. Spain is no exception to the problem and has \nmultiplied its incidence of pertussis more than 10 times \nin the last decade.\nQUESTION 5. - What has been the reality of the re -\ncent flu vaccination campaign in Spain?\nExposure:\nThe reality of the 2017-2018 flu campaign in Spain is that include local pain and erythema, along with fever and headache \nas systemic effects. Although occasional cases of Guillain-Barr\u00e9 \nsyndrome have been reported following meningococcal vacci -\nnation, a clear causal association between these vaccines and \nthis syndrome has not been demonstrated [116, 117].\nIn the case of N. meningitis  serotype B vaccine, admin -\nistration to adults (microbiologists with occupational risk of \ninvasive meningococcal disease) showed local discomfort was \nfrequent but there were no serious adverse effects [118].\nHaemophilus influenzae  type b vaccine\nThe vaccine for the prevention of invasive disease caused \nby H. influenzae  type b is rarely administered in adulthood. The \nmost frequent reasons for this are the existence of anatomic \nor functional asplenia, HIV infection, humoral immunodefi -\nciency, defects of the complement chain, bone marrow trans -\nplant recipients and some patients with chemo or radiothera -\npy [119, 120]. Adverse effects of this vaccine in adults are very \nuncommon [121].\nConclusion:\nApart from local effects such as pain or systemic ef -\nfects such as general malaise or fever, of little signifi -\ncance and short duration, adult vaccines have shown a \nvery high degree of safety and a very low number of se -\nrious adverse effects. The very few hypersensitivity reac -\ntions described are generally related to substances added \nto preserve them, such as gelatin or neomycin.\nQUESTION 4.- What is the situation of whooping \ncough in adults and the elderly? How are things in Spain? \nExposure:\nWhooping cough or Pertussis is a disease caused by the \nbacterium Bordetella pertussis  that causes a respiratory infec -\ntion in childhood, characterized by violent attacks of spasmod -\nic cough that can last for weeks and are usually followed, in \nchildren, by post-episodium emesis. The only reservoir is hu -\nman and it is a highly contagious disease that can be fatal. \nTransmission in the close circle is very frequent but does not \nalways translate into a symptomatic clinical picture.\nThe introduction of a full-cell vaccine at the end of the \n1940s, for use in children, dropped the incidence in the United \nStates of America from about 250,000 cases per year in 1935 \nto about 1,000 cases per year in 1976 [122].\nThis vaccine was replaced by an acellular vaccine in 1997, \nbetter tolerated than the previous one, but against which the \nimmune response decreases at 5-10 years, resulting in a higher \nrisk of late infection in adolescents and adults [123-126].\nTherefore, we are witnessing a resurgence of this disease \nand in these circumstances; there are currently some 30 to 50 \nmillion cases of whooping cough in developing countries, of \nwhich some 300,000 cause death [127]. Some important out -\nbreaks have occurred in the United States that have reached \n25,827 episodes in 2004, 25,616 in 2005, 27,500 in 2010 and Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364342by Influenza A virus. (Spanish Influenza Surveillance System, \nApril 2018). Despite this, the effectiveness of the vaccine has \nbeen reasonable with a certain cross-response.\nIn Spain, inactivated vaccines have been available in their \ndifferent forms. Vaccines of fractionated viruses, subunits and \nadjuvant vaccines mainly and to a lesser extent, modern tetrav -\nalent with two B virus lineages, in addition to subtypes H1 and \nH3 of type A influenza virus. The viruses recommended by the \nWHO in the 2017-18 vaccine have been: A/Michigan/45/2015 \n(H1N1) pdm09-like virus; A/Hong Kong/4801/2014 (H3N2)-like \nvirus, B/Brisbane/60/2008-like virus (Victoria lineage). With the \nrecommendation that quadrivalent vaccines containing two B \nviruses in addition to the three previous viruses include a B/\nPhuket/3073/2013-like virus strain (of the Yamagata lineage).\nAlmost all the Autonomous Communities have vaccinated \nwith trivalent inactivated vaccines in any of the existing mo -\ndalities. This has left approximately 60% of the main viruses \nwithout specific homologous coverage, although, as explained \nabove, there has been some heterologous cross-protection.\nThe explanation for the use of trivalent vaccines instead \nof quadrivalent ones lies fundamentally in the price differenc -\nes between them. Spain, like other countries, has a very con -\nservative stance in this regard. The WHO has noted that in the \n2017/2018 season there were many hospitalizations among el -\nderly people caused by the influenza B virus of the lineage that \nwas not included in the classic trivalent vaccines. Although \nprice can be a barrier to implementation in countries with lim -\nited resources, due to the higher price of quadrivalents, WHO \nconsiders that given the total costs to the health sector, quad -\nrivalent vaccines can prove to be cost effective [144].\nAs far as its general explanation is concerned, the health -\ncare world tends to have a personal and simplistic knowledge \nabout Influenza, which, together with a lack of trust in a vac -\ncine that is not absolutely effective, means that it is not linked, \nas in other countries, to criteria of healthcare quality and effi -\nciency and does not appear constantly in the lifestyle and clin -\nical protocols of many common chronic diseases.\nAs for the challenges and possible future solutions, the \nfirst challenge in Spain lies in agreeing on a universal vaccina -\ntion indication or one almost similar to that of the USA, Cana -\nda or the UK. Only this indication has been shown to increase \ncoverage and therefore reduce risks and healthcare costs \n[145]. The current WHO coverage percentage targets (>75% \nin >64 years) do not achieve group protection (herd immunity) \nthat would be achieved with the US coverage targets (>80% in \nhealthy people) [146].\nOn the other hand, Spain, like many European countries, is \nfar from the coverage targets and does not include among its \nindications that of children between 2 and 5 years that exist, \nfor example, in Finland and the UK. In this sense, it is surprising \nthat countries with very low coverage of influenza vaccination \nin classic population groups (chronically ill, elderly, etc.) rec -\nommend vaccination in children as a more gestural measure \nthan fulfilled, since in many of them the influenza vaccine is \nnot free or reimbursed [142].it has been a real \u201cperfect storm\u201d with declining vaccination \nfigures, a multiple circulation of different types and subtypes \nof virus A, coupled with a predominance of type B command -\ning the seasonal epidemic, aggravated by the almost absolute \ndiscordance between the B virus lineage that has circulated in \nthe last seasonal epidemic 2017-2018 (Yamagata lineage) and \nthe content of the trivalent vaccines (Victoria lineage) admin -\nistered this season.\nSpanish flu vaccination figures are known almost every \nyear at the beginning of the following year\u2019s campaign, when \nthe different Autonomous Communities provided their data \nto the Ministry of Health. For the umpteenth consecutive year \nsince the 2009 pandemic, Spain shows a consecutive decrease \nin these figures. The only official global record available to \nSpain is for people over 65 years of age and indicates that the \nSpanish average for this population group stands at 55.5% \ncoverage far from the 65.7% of the 2009-2010 flu season; \nmaximum reached in the Spanish time series and twenty points \naway from the WHO set at 75% for \u2265 65 years. Only two Span -\nish communities, Castilla y Le\u00f3n and La Rioja, have exceeded \n60% of vaccination of their elderly. (Ministry of Health, Social \nServices and Equality, data from 2017).\nIn this regard, WHO has expressed concern that half of \nEuropean countries vaccinate less than 1 in three older people \n[141]. In this sense, the recommendations of many of the more \nand more extensive, detailed and individual European coun -\ntries recommendations reach lower real vaccination figures, \nwhich shows that extending vaccination indications to par -\nticular populations does not necessarily guarantee an increase \nin coverage [142].\nSpain, like most European countries, has included health \ncare workers in its guidelines for influenza vaccination for \nyears, but coverage in this strategic group is less than 40% \nand even lower. In general, there tends to be a certain parallel -\nism between vaccinated health-care workers and coverage in \na given community. Some Spanish publications have reliably \ndemonstrated an association between this fact and also the \nreasons associated with a higher frequency of vaccination in \nHealth-care workers [143].\nMuch more worrying is this vaccination in pregnant \nwomen; a priority population group for WHO, recommended \nin more than 90% of countries surveyed, barely reaches 10% \ncoverage in more than half of European countries despite the \ndemonstrated risk of severe influenza in pregnant women \nand the additional protection of the new-born by vaccinated \nmothers [142].\nThis year\u2019s seasonal influenza epidemic (2017-2018) has \nalso had some different peculiarities with respect to others, \nsuch as the slightly earlier onset than other times, the prom -\ninence of the B virus over the A viruses and the presence of a \nlineage (Yamagata) different from the content of the seasonal \nvaccine (Victoria lineage). A virus has also circulated, mostly of \nsubtype H3, strain A/Singapore/16-0019/2016 different from \nthat contained in the vaccine (A/Hong Kong/4801). This vac -\ncine H3 virus has accounted for only a third of the infections Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364343pneumococcal infection in adults (indirect protection). How -\never, until systematic vaccination of the child population is \nmaintained for several years, the use of PCV13 seems to be \njustified in adults at higher risk, as the prevention of pneumo -\ncoccal disease is based exclusively on the use of vaccines [ 155].\nIn Spain, S. pneumoniae  is the most frequently identified \npathogen in community-acquired pneumonia (CAP), causing \nup to 63.7% of cases in some series. During the period 2003-\n2007, a total of 75,932 deaths due to CAP were registered in \nadults aged 50 years or over and the incidence of CAP in our \ncountry in people over 65 is estimated at 14 cases per 1,000 \nperson-years (IC95% 12.7-15.3) and increases with age (29.4 \ncases per 1,000 person-years in people over 85 years). In ad -\ndition, it carries an important burden, as up to 75% of cases \nrequire hospital admission [155].\nWe have the pneumococcal polysaccharide 23 valent \nvaccine (PPV23), indicated for active immunization for the \nprevention of S. pneumoniae  disease in people older than 2 \nyears. In Spain, there are two authorised vaccines: Pneumo23 \n(pre-filled syringe) and Pneumovax23 (vial). In addition, conju -\ngate pneumococcal vaccines are available, 7, 10 and 13 valents \nindicated for active immunization for the prevention of Inva -\nsive Pneumococcal Disease (IPD), pneumonia and Acute Otitis \nMedia (AOM) caused by S. pneumoniae  in children and adoles -\ncents aged 6 weeks to 17 years and for the prevention of IPD in \nadults \u2265 18 years and older. The conjugate vaccines authorised \nin Spain are Synflorix \u00ae and Prevenar \u00ae [156].\nIn Spain it is estimated that approximately 50% of the \npopulation over 50 years of age has risk factors for pneumo -\ncoccal disease and would be candidates for vaccination [157]. \nThe impact of polysaccharide vaccines have shown only a mod -\nest reduction in hospitalizations, ICU admissions, and death in \nelderly patients diagnosed with CAP [158]. On the contrary, \nthe impact of the use of conjugate vaccines in children on the \nincidence of disease by vaccine serotypes in adults has been \ndemonstrated by C\u00e1mara et al [159]. The PPV23 has shown a \ngood safety profile both as primary doses and after the ad -\nministration of booster doses, but does not generate immune \nmemory, with antibody levels decreasing over time, causing a \nphenomenon of immune tolerance, and also does not act on \nnasopharyngeal colonization. However, the conjugate vaccines \n(PCV13) generate a more potent immune response and a great -\ner impact by acting on nasopharyngeal colonization.\nPrior to the introduction of PCV7 in children, a study in \n10 European countries, including Spain, evaluated the cost-ef -\nfectiveness of PPV23 in preventing IPD in adults, which was \nfound acceptable in all countries. For Spain, the cost-effective -\nness rate per QALY (Quality of Life Adjusted Life-Year Earned) \namong adults aged 65 and over was estimated at 9,187 euros.\nUsing the CAPiTA study efficacy data, the CAPA study \nserotype coverage data and the CMBD 2010-13 incidence of \npneumococcal disease, it determined that the use of PCV13 in 5 \nyears would hope to avoid in a cohort between 65 and 69 years \nof age 10,360 cases of IPD, 699 deaths, 14,736 years of life \ngained that only in direct costs would represent an accumu -The next challenge is the development of vaccines with \nelongated immunity in order to increase the immunizing po -\ntency and its spectrum of effectiveness against different virus -\nes, thus avoiding the problem of flu variation or lengthening \nthe period of influenza revaccinations. These vaccines have \nbeen denominated by the WHO as NGIV (Next Generation In -\nfluenza Vaccines) that has elaborated and published some ob -\njectives to 5 and 10 years. Some of them are easier to achieve \nand reach; others may require more time [147]. Among these \nfuture vaccines are the popularly-called \u201cuniversal flu vac -\ncines\u201d claimed by different authors [148, 149].\nThe approaches to these vaccines are multiple and not all \nhave the same degree of experimental development. The viral \ntargets against which they are directed include, in order of de -\nvelopment, the M2 protein, the chimera haemagglutinins, the \ninclusion of neuraminidase and nucleoprotein (NP), the anti -\nbodies against the stem of the haemagglutinin in serial admin -\nistration, etc. [150, 151].\nUntil these challenges are met, the low coverage of influ -\nenza in many European countries, especially those in the East, \nmust be addressed by clarifying misunderstandings among the \npopulation, doctors and health-care administrators homoge -\nneously throughout the Union [152]. This is the only way to \nincrease the coverage in the elderly and people with chronic \ndiseases and add other population groups with scarce or tes -\ntimonial coverage (pregnant women and children) reaching at \nleast the 75% targets set by the WHO [153]. Until we reach the \nHoly Grail of an almost universal flu vaccine, there are quite a \nfew preliminary goals to be met [154].\nConclusion:\nThe proportion of people over the age of 65 vacci -\nnated against influenza in Spain continues to decline and \nis far from a coverage of more than 75% of the popula -\ntion WHO objectives. The situation in populations such \nas health care workers, pregnant women and children is \nregrettable and does not reach significant figures. There \nare very important challenges in the flu vaccination until \nthe Holy Grail of an almost universal vaccine against this \nvirus is reached.  Vaccination of children is effective not \nonly in the prevention of hospitalizations but also in in -\ndirect herd immunity in older people before much greater \ncoverage is achieved.\nQUESTION 6.- What is the situation of pneumococcal \nvaccination in Spain? \nExposure:\nS. pneumoniae  infection is a major cause of morbidi -\nty and mortality worldwide and the pneumococcal disease is \npotentially preventable by vaccination in the world. According \nto WHO estimates, S. pneumoniae  causes 1.6 million deaths \nannually; the disease preventable by vaccines that causes the \nmost mortality, with the youngest children and older adults \nbeing the most affected. Probably, routine childhood vacci -\nnation could prevent morbidity and mortality associated with Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364344systems vaccinology, use of new adjuvants and delivery mo -\ndalities, heterologous vaccination, polysaccharide to protein \nconjugation and adversomics. Among the innovative routes \nof administration: edible, mucous, and transcutaneous. And as \nnew types of vaccines: recombinant (with or without vectors), \nnucleic acid, peptide, attenuated and molecularly inactivated, \nreordered virus (reassorted) and adapted to the cold [162].\nThe antiviral vaccines that are at a more advanced level of \nresearch development include those aimed at the prevention \nof infection by Cytomegalovirus (CMV) in stem cell transplan -\ntation, recurrent infection by Herpes Simplex (HSV) and Vari -\ncella-Zoster Virus (VZV). At the same level of development are \nframed different flu vaccines, against Respiratory Syncytial Vi -\nrus (RSV), new modalities of triple virus (Measles-Rubella-Pa -\nrotiditis) and those aimed at the prevention of HPV and HIV, \nwhose search is a relevant challenge, with high budgets and \ngreat media attention [163]. Of the \u201cemerging\u201d agents it seems \nappropriate to cite Dengue, Ebola and Zika. Dengue is based \non another flavivirus (yellow fever), which is attenuated and \nrecombined with genes from the premembrane and the enve -\nlopes of wild strains of the different serotypes [164].\nThe Ebola outbreak in 2014 has accelerated the develop -\nment of vaccines, being an adenovirus derived from chimpan -\nzee (ChiAd3) that encodes the glycoprotein of the species Zaire \n(GP EBOV), which has become the vector of the same at an ad -\nvanced stage Zika is working on vaccines that can activate the \nresponse B and T together and also include Dengue [165, 166].\nAmong the antibacterial vaccines, those against staphy -\nlococcal infection (due to S aureus  which includes several an -\ntigens, given its host adaptation systems that allow it to col -\nonize numerous niches and elude the immune system) stand \nout [167], as well as those against pneumococcal infection \n(recombinant vaccines), conjugate anti-meningococcal vac -\ncines, and against Streptococcus agalactiae, H. influenzae,  and \nClostridium difficile . [168].\nOf the parasitic diseases that present a strong research \ninvestment, Malaria, Chagas Disease and Leishmaniasis stand \nout, the latter being autochthonous in our country. Vaccines \nare developed with recombinant antigens, by vectors (adenovi -\nrus or vaccinia), DNA vaccines and a heterologous vaccination \nstrategy through induction by plasmidic DNA and a later re -\ninforcement with a viral vector (adenovirus) or with recombi -\nnant proteins adjuvated with IL-2 and cytokines [169].\nWhich of the research vaccines will be most useful \nin Spain?\nThe conventional meaning of \u201cusefulness\u201d refers to the \ncapacity of a measure (in this case a vaccine) to serve or to \nbe used for a specific purpose. The criteria that must prevail \nin order to implement \u201cuseful\u201d vaccination strategies in our \nenvironment must assess the economic and social impact of \nprevention programs. To this end, at least two entities are in -\nvolved that combine healthcare and preventive activity in each \nRegional Management of the health system: the \u201cDirecciones lated net saving of 3.8 million euros at constant prices (4.9 at \ncurrent prices), being efficient for the National Health System \nof Spain.\nPPV23 is financed by all the Autonomous Communities \nin Spain, in risk groups and systematically for people over 60 \nyears in each Autonomous Community. Only 5 Autonomous \nCommunities (Castilla Le\u00f3n, Madrid, Galicia, Asturias and La \nRioja) finance in their calendar the vaccination of adults with a \nvalent conjugate vaccine from 60-65 years of age. The fact that \nit is not financed does not mean that it cannot be recommend -\ned. In fact, the Ministry of Health, Social Services and Equality \nitself, in the review document published by the Working Group \non Vaccination against pneumococcus in risk groups of the \nPresentation of Programmes and Registration of Vaccinations \nand approved by the Public Health Commission in June 2015, \nurges physicians that \u201cit is necessary to adequately inform the \nelderly and/or those belonging to at-risk groups of the possibil -\nities of vaccination against pneumococcus (...)\u201d. In those cases \nin which the vaccine recommended by the health authorities \nis the PPV23, it is necessary not only to inform that the choice \nof the vaccine obeys public health criteria, but that the PCV13 \nalso exists and is marketed, which, although it is not financed \nin all cases, is not contraindicated [156].\nConclusion:\nInvasive pneumococcal infection in Spain is a very \nimportant cause of morbidity and mortality in adults and \nthe elderly. Although the polyvalent polysaccharide vac -\ncine has shown only a modest impact in reducing hospi -\ntal admissions and deaths, conjugate vaccines applied to \nchildren have a greater impact on the adult population. \nThe financing of these vaccines does not follow a homo -\ngeneous pattern in the different Autonomous Communi -\nties of Spain.\nQUESTION 7. - What is the future of Vaccine Clinical \nResearch?\nExposure:\nAccording to a report issued by a prestigious consorti -\num of manufacturers and researchers, almost three hundred \nvaccines are in the development phase, half of them aimed at \ninfectious diseases [160]. The dynamism of this field of knowl -\nedge is illustrated by the fact that access to PubMed through \nthe terms \u201cvaccines research\u201d currently offers one hundred \nand thirteen thousand references [161]. To offer a structured \nview of the topic, we will try to answer four questions.\nWhat vaccines are in Phase 3 clinical trials at the \npresent time?\nThe field of infectious diseases includes vaccines against \nbacteria, viruses, fungi and parasites, which employ various \nproduction strategies and techniques. Those aimed at iden -\ntifying new protective antigens include inverse vaccinology, \nstructural vaccinology and immunomics; those aimed at ac -\nquiring or enhancing immunogenicity include vaccinomics, Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364345It is possible to introduce new vaccines from the modal -\nities of economic evaluation in the field of health. These can \nbe summarised in two types of techniques: analysis where \nthe measurement of the effect is collected in monetary units \n(Cost-Benefit Analysis) and analysis where the measurement \nof the effect is collected in non-monetary units, where the \nCost-Utility Analysis (CUA) is inscribed. Specifically, in a CUA \n(to which the second question referred) we compare two or \nmore alternatives in relation to its costs and results, expressed \nin terms of utility units or quality of life, according to the user\u2019s \nperception. The unit of measurement can be the QALY (Quality \nAdjusted Life Year) or AVAC (Quality Adjusted Life Years); this \nmeasure relates the years of life that the individual would en -\njoy (thanks to a health intervention) with the quality of life of \nthat extra period [171].\nA particularly attractive field will be to apply these eval -\nuation models from vaccinomics, studying individual pheno -\ntypes and genotypes, correlating genetic polymorphisms with \na certain predisposition to suffer the infection, a singular im -\nmune response, an adjusted vaccine dosage, an adequate ad -\nministration route or quantifying the probability of suffering \nan adverse effect [162]. This will lead to the possibility of de -\nsigning vaccines for each individual or group that are safer, \ncheaper and easier to conserve/administer, against prevalent \nand emerging pathogens such as those mentioned above.\nConclusion:\nAn enormous number of Phase 3 clinical trials are \ncurrently studying the effectiveness of new vaccines, ap -\nproximately half of which are aimed at controlling infec -\ntious diseases. These include vaccines for viral, bacterial \nand parasitic processes, and their future application will \ndepend on very diverse factors that must consider the \nsize of the problem, the effectiveness of the vaccine, its \ntolerance, and economic aspects of unquestionable im -\nportance.\nQUESTION 8.- What is the administration\u2019s vision of \nvaccines in Spain?\nExposure:\nFollowing the transfer of public health competencies from \nthe State to the Autonomous Communities (AA.CC.), between \n1979 and 1985, and through the General Health Law 14/1986, \nthe \u201cInterterritorial Council of the National Health System, ICN -\nHS (Consejo Interterritorial del Sistema Nacional de Salud)\u201d was \ncreated as a permanent body for coordination, cooperation and \ncommunication between the State and the AA.CC. In this way, \nthe Ministry of Health, Social Services and Equality coordinates \nand harmonizes health strategies in order to maintain equity \nand cohesion in access to health services. [172].\nThe Committee on Vaccination Programme and Registries, \ncreated in 1991, advises the Public Health Commission of the \nICNHS from a scientific and technical point of view in making \ndecisions on vaccination programmes in Spain [173]. Vaccina -\ntion in risk groups and healthy adults is currently being re -Generales de Asistencia y Salud P\u00fablica\u201d of the different Au -\ntonomous Communities. Among others, we could consider \nfrom the assistance both the assessment of the real burden \nof each disease, identified by the Basic Minimum Data Set to \nhospital discharge and scientific literature; and have a system \nof access to \u201cbig-data\u201d that allows a quantification of the most \nprevalent infectious diseases. Public Health and Preventive \nMedicine should define vaccination priorities by age segments \nand patient groups. From the managerial point of view, it is \npertinent to implement economic evaluation studies with ro -\nbust and consolidated models that allow to endorse the deci -\nsions adopted and render accounts with transparency. \nIn our country, in addition to those commented by the \nprevious speakers, priority would be given to those against \nRSV, CMV and other Herpesviruses. Among the bacterial \nones, it would be desirable to promote those directed against \nStaphylococcus aureus  and C. difficile .\nWhat problems are foreseen for its future implemen -\ntation?\nThe definition of health-care priorities represents a chal -\nlenge that presupposes equity, access to the system and budg -\netary availability. Among the actors that will have a joint im -\npact on its application and, consequently, on the reduction of \nthe problems for its application, it is worth mentioning:\nFirstly, the Pharmaceutical Companies which, through \ntheir R+D+I strategies, develop and manufacture effective and \nsafe vaccines and contribute to their post-marketing implan -\ntation/surveillance. Secondly, basic researchers, contributing \nnew concepts and technologies and connecting with groups \nthat apply their findings. Thirdly, health-care professionals \nwho advise the population on their benefits and develop vac -\ncination programs. Investment in continuing education will \nnever be weighed sufficiently. In Spain, Primary Care exhibits \nexemplary behaviour in achieving recommendations and cov -\nerage that place us in paediatrics among the most advanced \ncountries [170], a fact that should be taken advantage of in \nthe vaccinology of adults and patients with special indications. \nFourthly, the necessary involvement of the media in the dis -\nsemination of truthful and responsible information in support \nof vaccination campaigns should be highlighted. Finally, it is \nopportune to point out the role of the Health Authorities, who \ndefine the conditions of use and ensure access to vaccines and \ntheir implementation, provide budget, support and promote \nvaccination policies. Likewise, they must preserve the protag -\nonism and independence of the Regulatory Agencies, which \nevaluate and control their effectiveness, safety and quality.\nWhat impact will they have on the problems they aim \nto reduce?\nIt is clear that the purpose of any vaccination strategy is \nto measure its capacity to reduce the burden of disease to be \nprevented, to reduce its morbidity and to avoid its potential \nmortality.Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364346Should there be some others? \nAt the moment, vaccination recommendations for differ -\nent risk groups and healthy adults are in the final phase of the \nevaluation process at the ICNHS. The evaluation of vaccina -\ntion recommendations against shingles in healthy adults and \nmeningococcal disease will begin with 2018.\nWhat are the major differences between Autonomous \nCommunities?\nIn recent years, the ICNHS has worked to reach a broad \nconsensus on vaccination recommendations aimed at the \nchild population, reflected in the common childhood vac -\ncination schedule. Although there has also been joint work \non the recommendations for certain vaccines in risk groups, \nsome AA.CC have extended the age of vaccination and the \nuse of certain vaccines to certain population groups. The \nmain differences relate to the age of influenza vaccination, \ntype of vaccination used for routine pneumococcal and risk \ngroup vaccination, and human papillomavirus (HPV) vaccina -\ntion in certain risk groups.\nWhat can be improved and what is needed to do so?\nSome of the aspects to be improved in terms of vaccina -\ntion policy in general and in terms of vaccination in adults, in \nparticular, would include the following:\n- Recommendations on vaccination programs are agreed \nby consensus in the ICNHS. However, sometimes these recom -\nmendations may not be followed by all AA.CCs. Unilateral deci -\nsions different than those agreed in the ICNHS may cause con -\nfusion in the population and the healthcare workers. Political \ncommitment and institutional loyalty are required to maintain \nagreements adopted within an institution, the ICNHS, of which \nall the Autonomous Communities are a part.\n- In order to improve confidence in the decisions adopted \nby the ICNHS, it would be necessary to find mechanisms for \nparticipation in the proposal of recommendations from the \ndifferent stakeholders involved in vaccination, as well as great -\ner transparency and communication between them.\n- There is a need for greater awareness of the benefits \nthat vaccination programs bring to the health of the popu -\nlation, establishing communication strategies aimed at health \nprofessionals and the general population.\nConclusion:\nThe authorisation of vaccines in Spain is mainly car -\nried out at European Union level. Most of the vaccines \nauthorised in Spain are for use in a wide range of ages \nincluding adults, with some exceptions authorised only \nfor children or for the erderly. They are financed in any \nage group, as long as they are included into the current \nvaccination schedule, approved by the Interterritorial \nCouncil of the National Health System or the Autono -\nmous Communities, with few differences between them. \nThroughout 2018, the evaluation of vaccination recom -viewed within the ICNHS. These recommendations, which are \nstill in the consultation phase, are expected to be agreed in \n2018.\nVaccines for adults authorised in Spain.\nVaccines are authorised through national or centralised \nprocedures, the latter coordinated at European Union (EU) lev -\nel and the most widely used at present. The Spanish Agency \nfor Medicines and Health Products (AEMPS), existing under the \nMinistry of Health, Social Services and Equality, is the regula -\ntory body that participates together with the other EU coun -\ntries in the evaluation of medicines dossiers in the European \nMedicines Agency (EMA) [174-176].\nMost of the vaccines authorized in Spain are for use in \na wide range of ages including adults, with the exception of \ncombined vaccines that contain high loads of diphtheria tox -\noid and components against whooping cough (D and Pa), ro -\ntavirus vaccines (up to 24 or 32 weeks depending on the prod -\nuct), attenuated influenza (2 to 18 years), shingles (from 50 \nyears of age and older), ten serotypes pneumococcal conjugate \nvaccine (6 weeks to 5 years of age) and H. influenzae type b (2 \nto 5 years of age) [177].\nIt is important to distinguish between the authorization \nand the recommendation of vaccines. In the evaluation for \nvaccine authorization, it is considered that the benefit/risk ra -\ntio is favourable. To establish vaccination recommendations, it \nis necessary to consider other additional criteria, such as the \nepidemiological characteristics of the disease to be prevented, \nthe pattern and target group to obtain the expected benefits \nin the population, indirect adverse effects of its use, imple -\nmentation aspects and economic aspects.\nThe recommendations for vaccination in adults approved \nfrom the ICNHS currently include:\n- Systematic vaccination in \u2265 65 years against tetanus \nand diphtheria (Td), influenza and pneumococcus (VPP23). \n Between the ages of 15 and 64, any contact with the \nhealth system should be used to review vaccination and up -\ndate it in case of susceptibility, especially Td, MMR (measles, \nmumps and rubella) and varicella; and in young adults, hepati -\ntis B, meningococcus C and HPV.\n- In addition, people of any age with risk conditions, the \nrelevance of recommending DTap, hepatitis A, hepatitis B, con -\njugated meningococcal, conjugated pneumococcal and influ -\nenza vaccines should be taken into account.\nHow are vaccines financed in Spain?\nAccording to current legislation, referring to the portfolio \nof common services in the NHS, \u201cvaccinations are covered in \nall age groups and, where appropriate, risk groups, according \nto the current vaccination schedule approved by the ICNHS \nand the competent health administrations, as well as those \nthat may be indicated, in general population or risk groups, for \nsituations that epidemiologically advise it\u201d. Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364347considered safe, although diphtheria-toxin antibody levels \nmay fall more rapidly than in the normal population. Booster \ndoses with tetanus diphtheria toxoid should be given at least \nevery 10 years [186, 187]. The ACIP recommends that booster \ndoses be made with a triple vaccine including tetanus toxoid, \ndiphtheria toxoid and acellular pertussis (Tdap) type Boostrix \u00ae \nor Adacel \u00ae for all adults older than 19 years in which a de -\ncrease in immunity is suspected.\nIn relation to polio, given the situation close to the erad -\nication of poliomyelitis, only transplant recipients who could \nbe exposed due to travel or risk would require prevention with \ninactivated vaccine, in case of doubt of previous vaccination, \nand only a booster dose is recommended if the risk of exposure \ncontinues, once in a lifetime [188-190].\nSolid organ transplant recipients should receive pneumo -\ncoccal polysaccharide vaccine 23 valent, and conjugate vaccine \n10 or 13 valent, but it is interesting that the recommendations \ndepend on the vaccines previously received and the order of \nthe vaccinations. For those who have not previously received \neither of the two, we recommend first the conjugate followed \nby the 23 valent, at least 8 weeks apart [191]. For those who \nhave previously received one or more doses of 23 valent vac -\ncine, a single dose of separate conjugate vaccine a minimum \nof one year after the 23 valent vaccine is recommended. Fi -\nnally, for those who have received previous conjugate vaccine \nand require other doses of 23 valent vaccine, a delay of at least \n8 weeks from the administration of the conjugate, and not less \nthan 5 years from the last dose of 23 valent, is desirable.\nThe relatively low incidence of H. influenzae  type b pneu -\nmonia in adult transplant recipients and the poor immunogen -\nic response that occurs with the vaccine do not make this one \nan essential vaccine for this population group [192, 193]. The \nsame occurs with the meningococcal vaccine in this popula -\ntion. Among adults, there is a low incidence of meningococcal \ninfection in SOT patients and the response to it is also poorly \nknown [194]. The vaccine is therefore reserved for those with \nparticular risk factors for contracting the disease. When indi -\ncated, it seems reasonable to opt for a conjugate vaccine [179].\nAll SOT that are Anti-HBs negative should be vaccinated \nagainst HBV. The population with chronic HBV liver disease in \nthe post-transplant period has a high rate of post-transplant \ncomplications and a high rate of related mortality [195-197]. \nTherefore, if after the usual three doses a rate of antibodies \n> 10mIU/ml is not reached in this population, a second cycle \nshould be repeated. The response to HBV vaccine is quite varia -\nble when done in post-transplantation and also in cirrhotic pa -\ntients, vaccinated at any time, which makes it necessary to pe -\nriodically re-check the level of protective antibodies [198-203].\nWith regard to Hepatitis A (HAV), vaccination is mandato -\nry for all unvaccinated transplant recipients, whether children \nor adults, since there is an increased risk of fulminant liver fail -\nure when contracting hepatitis A in a SOT recipient. The anti -\nbody response is also more limited in time than in the normal \npopulation and vaccination should therefore be attempted pri -\nor to transplantation, whenever possible [204-207].mendations against herpes zoster in healthy adults and \ninvasive meningococcal disease will begin.\nQUESTION 9.- What is the vision on vaccination of \na group of affected people such as patients with Solid \nOrgan Transplants?\nExposure:\nFirst of all, it would be appropriate to highlight, as an idea \nfor discussion, the potential role of vaccines as a mechanism \nto avoid solid organ transplants (SOT). We do not know a pre -\ncise answer to this question, but it is enough to recall, as an \nexample, that a substantial proportion of liver transplants are \na consequence of the evolution of hepatitis B and therefore \npotentially avoidable in almost 100% of cases.\nPreventing infection is a key element in SOT patients, since \nit is clear that infections contribute to the morbidity and mor -\ntality of these patients and often to graft loss. Prevention is \nalso necessary because many avoidable infections either have \nno medical treatment or patients respond poorly to it. Immu -\nnization in these patients, with frank immunosuppression, also \nhas its particularities since, generally, vaccines made with live \nattenuated agents cannot be administered, in addition to the \nability to mount an adequate immune response being limited \nin some situations [178].\nThe International and National Societies have issued \nGuidelines with recommendations for Immunization in this \npopulation both in the paediatric age and for adults that in -\nclude their health and personal contacts. [120, 179, 180]. \nIdeally, vaccines should be given before transplantation to \nachieve the greatest possible immune response. During this \nperiod, the patient may receive vaccines with live attenuat -\ned agents (measles, mumps, rubella, chickenpox, etc.) that \nthey will not be able to receive if administration is made after \ntransplantation.\nIn the post-transplant period, vaccinations are generally \navoided in the first two to six months after transplantation, \nduring the period of maximum immunosuppression. An excep -\ntion to this rule is the case of Influenza, in which vaccination is \njustified after the first month post-transplant with inactivated \ninfluenza virus vaccines [181].\nIt is known that influenza is more severe in the popula -\ntion with SOT, occurs more frequently with pneumonia, causes \nmore intensive care admissions and more deaths than in the \nnon-transplanted population [182]. Vaccine protection is low -\ner than in the immunocompetent population and administra -\ntion of higher antigenic doses in this population is associated \nwith a better immune response [183, 184]. A Spanish group \nhas demonstrated the best efficacy of a second dose (booster) \nof inactivated flu vaccine, 5 weeks after the first, in the trans -\nplanted population [185].\nFor other inactivated vaccines, a summary of the situation \nwould be as follows:\nVaccination guidelines for diphtheria and tetanus should \nbe the same as in the normal population, and vaccines are Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364348Health Authorities, so that they issue recommendations on \nvaccination in adults belonging to risk groups, and that these \nare as homogeneous as possible, and duly supported by sci -\nentific evidence. They must collaborate with the health-care \nauthorities to ensure that the health professional is the first \ndefender of vaccines and to provide agile mechanisms for con -\nsultation with those professionals who are better prepared in \nthe field of prevention. In Spain there are several scientific so -\ncieties that have specific sections or working groups dedicated \nto vaccines groups. The Spanish Vaccinology Association (AEV) \nworks specifically and monographically on the topic.\nIt is a non-profit Medical-Scientific Association, constitut -\ned under Law 191/1964, of 24 December. Its general objective \nis to protect health by means of primary and, where appropri -\nate, secondary prevention actions against immunopreventable \ninfectious diseases, with biological preparations for immunisa -\ntion practices, thereby contributing to better life expectancy \nand quality of life for citizens, with special reference to the \nchild population and risk groups by age, immunocompromised \npeople, people with occupational risks, international travel and \nbasic diseases, increasing the quality of life of the population.\nThe aims of the Association include:\na) To disseminate scientific advances in the area of \u201cArtifi -\ncial, active and passive acquired immunity\u201d and to promote the \ndevelopment of knowledge of immunobiological vaccines and \npreparations for infectious diseases.\nb) To permanently review medical, clinical, epidemiologi -\ncal, immunobiological research and cost-benefit analysis crite -\nria in order to make judgments that may be useful for a ration -\nal use and in accordance with the socio-sanitary development \nin the aforementioned preparations, in the practice of Health \nSciences professionals, both private practice and at the service \nof the Administrations.\nc) To expand the Vaccination Programs recommended by \nthe Health-Care Authorities to support the coverages, as well \nas to foment the evaluation of the same ones and to stimulate \nthe Pharmacovigilance in the use of the preparations.\nd) To organize, sponsor and promote conferences, courses, \ncongresses and meetings in order to disseminate and update \nthe knowledge that is being incorporated into Vaccinology, \nwith expression of technological development in this field of \nHealth Sciences.\ne) To promote research in Vaccinology, cooperating where \nnecessary, in the Projects at the Design and Planning level, \nstimulating the streamlining at the level of the Clinical Re -\nsearch Ethics Committee of the Welfare Network.\nf) To raise awareness on the importance of the correct use \nof immunization practices to social agents (politicians, media, \ngeneral population) bearing in mind the competences of the \ndifferent Public Administrations including Foreign Health.\ng) To establish relations with those National, International \nand International Scientific Societies with thematic affinity, as \nwell as with the Health Administrations with competences in \nthis professional or Regulatory praxis, creating meeting spac -With regard to the HPV vaccine, it is a known fact that \ninfection with this virus is associated with a risk of up to 100 \ntimes greater incidence of cervical neoplasms in transplanted \nwomen and anogenital cancers in men. Therefore, those who \nhave vaccination criteria, regardless of whether or not they \nhave been transplanted, should receive the HPV vaccine. If \nthey have already been transplanted, it is advisable to wait 3-6 \nmonths after the transplant. The immunogenicity of the HPV \nvaccine in this population is not well known but the risks-ben -\nefits incline to the recommendation. In the future, indications \nmay be extended to groups of transplanted adults who are not \nin the age ranges in which the vaccine is now indicated [179, \n208-210].\nRZV was immunogenic in patients with solid tumors re -\nceiving immunosuppressive chemotherapies. Humoral and \ncell-mediated immune responses persisted 1 year after vacci -\nnation and no safety concerns were identified [211].\nAt the time of writing this document, there is no recom -\nmendation for vaccination against Zoster with the recom -\nbinant vaccine in the population with SOT, but at least two \nclinical trials are underway in this population group that will \nshortly clarify its indications that seem favourable [212]. In pa -\ntients with hematopoietic transplantation, the result of a clin -\nical trial has just been published that proves its efficacy and \ngood tolerance [213].\nTo conclude, we should remember that the responsibility \nfor implementing the vaccine schedule in transplant patients \nis often diluted between the transplant team of the patient, \nthe family and community medicine teams that also follow the \ncases and transplant patient organizations. International da -\nta show that there are clear opportunities to improve the im -\nplementation of the vaccine schedule in this population [214, \n215]. Our opinion is that this dilution of responsibilities is also \na frequent reason for omissions or forgetfulness in the vacci -\nnation calendar of patients with SOT in our environment.\nConclusion:\nAdult transplanted patients constitute a very par -\nticular group in relation to the prevention of diseases \nthrough vaccines, for several reasons. Firstly, because \nthey cannot receive vaccines produced with attenuated \nmicro-organisms in the post-transplant period. Second -\nly, because the immune response is not the same as in \nthe non-immunosuppressed population. Finally, some \nvaccines should be administered in this population with \nhigher doses and at different rates. Despite the high level \nof the transplant system in Spain, there is an opportunity \nto improve coordination when implementing a rigorous \nvaccine schedule in solid organ transplant recipients.\nQUESTION 10.- What is the role and work of profes -\nsional and scientific associations / societies specifically \ndedicated to vaccines?\nExposure:\nThe Scientific Societies must provide evidence to the Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364349In a study conducted in Israel, the role of the flu vaccine \nnurse in gaining acceptance of the flu vaccine among those \nrecommended for vaccination is demonstrated [223]. The re -\nminder role of certain programmes on the at-risk population, \ncarried out by doctors and nurses, has proved effective [224]. \nIn the case of the pneumococcal vaccine, a study carried out \nin Hong Kong, showed that a brief process of health educa -\ntion, lasting only 3 minutes, carried out by nurses, increased \nacceptance and coverage with pneumococcal vaccine from 48 \nto 57% [225].\nNursing can also play a relevant role in detecting cases \neligible for pneumococcal vaccination during hospital admis -\nsion for any reason, and so a CDC-sponsored study increased \nthe vaccination rate from 19% to 74% after implementing a \nscreening program and vaccination offer [226].\nAnother example of the potential nursing work in the ac -\nceptance by school girls and their families, through a simple \nreminder call of the convenience of getting vaccinated against \nHPV [227]. This work may be particularly necessary when it is \ncarried out in particularly defenceless groups or in social exclu -\nsion. This is the case of vaccination against hepatitis B, where \nthe role of nursing has also been shown to be fundamental, \nparticularly by ensuring, through a follow-up programme, that \npatients complete their third dose of vaccine [228].\nThe literature collects a miscellany of situations in which \nthe role of nursing is key in the global vaccination process, \nboth in poor and developed countries and with vaccines of a \ndifferent nature, including polio [229-231].\nIt seems, therefore, that this would be a very appropri -\nate area, due to the characteristics we have mentioned, for the \ncreation of consultations, or vaccine promotion groups, par -\nticularly coordinated by nurses, although we have not been \nable to find concrete examples in the professional literature \nstudying (with the appropriate methodology) the clinical, eco -\nnomic and social impact of their introduction.\nConclusion:\nVaccination, and particularly adult vaccination, is one \nof the paradigms of the work and competence of nursing. \nMany studies demonstrate the effectiveness of nursing \nintervention in different groups, with different vaccines \nand with different impacts. Nursing has to promote and \nmanage all adult vaccines and their complete vaccination \nschedule, and in our opinion, this work is a very clear ar -\nea for nursing consultations or working groups managed \nby nurses.\nQUESTION 12.- What is the role of Pharmacy Services \nin the vaccination of adults? \nExposure:\nThe Community Pharmacist plays, or must play, an essen -\ntial role in adult vaccination. Not only in aspects such as the \ncorrect conservation and storage of vaccines, but also in all \naspects related to tolerance and safety of vaccination. There \nis the possibility of making a clear contribution to health edu -es between professionals of different levels and disciplines, for \nwhat is related to this scientific field.\nh) To cooperate in those Programmes of Health Dissemina -\ntion and Information and Education for Health (EPS) in which \ntopics on vaccines and other immunobiological preparations \nof social, scientific or journalistic interest can be submitted for \ndebate.\ni) To carry out Publications (printed, digital, Web), to sum -\nmon scholarships or aids for national and foreign research \nstudies, to organize Prizes, Courses or Seminars, or any other \naction conducive to metializing the previous points.\nThe activity of the Spanish Vaccinology Association is \nnot restricted exclusively to promoting the scientific technical \nknowledge of its members but is open to any other possible \nbeneficiary who meets the conditions and characters required \nby the nature of its own purposes.\nThe activity of the Association may also consist of the \ncollection and management of funds and patronage for the \ngranting of Scholarships or Grants for studies and research, \nthe organisation of Awards, Courses and Seminars, grants for \nall kinds of Institutions and other activities that the Governing \nBody considers appropriate for the strict fulfilment of its aims.\nConclusion:\nThere are several Scientific Societies that have spe -\ncific sections or working groups dedicated to vaccines in \nSpain. The Spanish Vaccinology Association (AEV) works \nspecifically in the field of vaccines and its objectives are \naimed at promoting knowledge, research and the appro -\npriate use of vaccines as a means of immunoprevention.\nQUESTION 11.- What is the role of nursing in pro -\nmoting health with vaccines in adults?\nExposure:\nHealth promotion, as part of the comprehensive care pro -\ncess, is the essence of nursing. This process includes, in addi -\ntion to promotion, assistance (primary and specialized), pre -\nvention (primary, secondary and tertiary) and social adaptation \n(rehabilitation and integration). At any of these levels, health \neducation is a key instrument [216, 217]. The concept of nurs -\ning care has also evolved from a disease-oriented care system \nto a preventive and health promotion system [218]. According \nto the World Health Organization at the 9th World Health Pro -\nmotion Conference, \u201cgetting vaccinated\u201d is one of the 12 tips \nfor good health. It therefore integrates vaccines into healthy \nlifestyles [219, 220].\nThe role of nursing, specifically in the field of promo -\ntion and administration of vaccines, is very broad and varies \nfrom recruitment of vaccination subsidiaries to conviction \ncampaigns, continuing education and follow-up. As in other \ngroups, the knowledge and skills of nurses, both graduated \nand school nurses, in the problem of vaccination, still offer op -\nportunities for improvement in both groups today and in high -\nly developed countries such as Finland [221, 222].Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364350from 72 to 93% of the candidates in one institution [244].\nSimilar experiences have been carried out in countries \nother than the United States [245-252], but we have not been \nable to find information on the activity and impact of promot -\ning vaccination in Spanish pharmacy services and offices.\nConclusion:\nBoth hospital pharmacy departments and Community \nPharmacy offices can do a great deal in infection preven -\ntion and health education from their respective depart -\nments, working to promote the proper use of vaccines in \nadults. In the United States, a high percentage of these \nservices have such programs, and the data in the litera -\nture show a clear impact on vaccination rates and educa -\ntional capacity. We have not been able to find data on the \nquantitative and qualitative importance of this activity in \npharmacy departments and pharmacy offices in Spain.\nQUESTION 13.- What is the economic value of vac -\ncines, as seen by a health economist?\nExposure:\nThe Choiseul Institute has recently produced two publica -\ntions proposing \u201cA Vaccine Strategy for Spain\u201d [253], and as -\nsessing \u201cThe economic impact of vaccines\u201d [254], of which we \nsummarise some aspects in the following lines.\nHealth expenditure in Spain has been reduced to below \n6% of Gross Domestic Product (GDP) in 2018 according to \nthe General State Budget (not yet approved). This means that \nSpain is not among the leading European countries in \u201cper \ncapita\u201d health-care spending but is in a second place that it \nshares with Italy. In a way, this situation is aggravated by the \ndispersion that exists in the different Autonomous Commu -\nnities (AA.CC.). The fact that health policies have been trans -\nferred to AA.CC. adds to the inequality between the different \nregions of Spain.\nOn the other hand, it is interesting to note one of the \nproblems that are not normally analysed, such as the effect on \nthe economy of absenteeism due to illness. Although there is \nno very recent data, that provided by Eurostat in 2012 of the \n13,000 million euros representing temporary incapacity says \nenough. An influenza episode, for example, results in a worker, \non average, to take sick leave for five days. The cost of this \nincapacity represents more than 20% of health expenditure, \npart of which could be covered by prevention policies. This is \nwhere vaccines come in; an area which, like many others in \nhealth-care policy, has suffered significant cuts. Suffice it to \nsay that spending on vaccines is around 1.8% of total pharma -\nceutical spending in Spain. This quantity is clearly insufficient \nif the benefits of vaccination are considered.\nThe vaccination policy in young people is well known. In \nthis chapter, Spain is among the most advanced countries in \nthe world with coverage rates above 95%. However, vaccina -\ntion must be considered as a policy during all ages of life. And \nhere, the situation is frankly improvable. It is enough to look at \nvaccination data for those over 18 years of age, or older. Cov -cation from the Community Pharmacy. This must be done not \nonly in relation to the vaccines of regular use, but also in those \nthat are needed occasionally as it is the case of some vaccines \nfor travellers. If this is not the case, it is due, in our opinion, to \nthe lack of necessary training and the necessary coordination \nwith other structures. The attitude of the Community Phar -\nmacist as a health-care agent is changing significantly for the \nbenefit of the patient, not only in Spain, but also in numerous \ncountries of the European Union and beyond.\nThe wide network of pharmacies distributed uniformly \nthroughout Spain can undoubtedly help to increase the vac -\ncination coverage of the adult population along with oth -\ner health-care centres. We must not forget that an average \nSpaniard goes to the pharmacy 7 times more frequently than \nto any other health centre or medical consult.\nAt the Community Pharmacy, it is possible to identify \nand guide risk patients who may benefit from vaccination, \nstrengthen the recruitment of people included in these risk \ngroups by collaborating with other health professionals and \ninvolve the pharmacy in health education, transmitting truth -\nful and clear information on the importance of vaccination to \nprevent different diseases. In addition, it is easy to carry out \npharmacovigilance work from the Community Pharmacy. An -\nother important objective is to fight against the \u201canti-vaccine\u201d \nphilosophy from which some elements of the supposedly bet -\nter educated classes are not free.\nThe other area that we must discuss is the role of the \nHospital Pharmacy Department in the immunization policy \nof the population. The hospital pharmacy is currently one of \nthe points with the highest volume of data on patients in the \nhospital, not only from their own information but for being \nthe coordinating node of many other databases to create cam -\npaigns and strategies based on combination and confrontation \nof the data. Alert campaigns to doctors and nurses responsible \nfor certain patients with risk factors of certain diseases can \nvery well be done with a warning from the pharmacy servic -\nes. Taking advantage of admission to the hospital to facilitate \nsuch vaccination is a perfectly feasible contribution. In the \nUnited States of America, the \u201cpharmacy-delivered immuniza -\ntion services\u201d or groups that promote vaccination based on the \npharmacy department are well known. One recent study esti -\nmates that they administer an additional 6.2 million doses of \nflu vaccine and 3.5 million additional pneumococcal vaccines \neach year [232]. Something similar happens with Community \nPharmacies. A recent evaluation estimates that almost 80% of \nthem in the U.S. offer and promote the use of at least one \nvaccine that can be administered at the pharmacy itself [233-\n235].\nThere are data on the effectiveness of such vaccination \nprograms implemented from pharmacy, community or hospi -\ntal services, which have demonstrated effectiveness in influen -\nza, pneumococcal infection and HPV fundamentally [236-243]. \nA good example in the case of influenza and invasive pneu -\nmococcal infection is a working group created by a pharmacy \ntechnician and a nurse that increased influenza vaccination Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364351enormous economic effects because it affects work perfor -\nmance and other aspects that are undoubtedly very relevant. \nIn all this, public authorities must be sensitive to the times.\nConclusion:\nThe money spent on vaccines should not be seen as \nan expense but as an investment. In strictly economic \nterms, it is estimated that every euro spent on vaccines \nhas a return of 4 euros to a country\u2019s economy. Each \npathogen against which a vaccine protects cost an esti -\nmated \u20ac44 to \u20ac226. The implementation of a programme \nof only 6 vaccines in the 72 poorest countries of the \nworld would have the effect of preventing the death of \n6.4 million children and 426 million episodes of illness in \nthe next 10 years and would mean a saving of 151,000 \nmillion dollars, as a result of less spending on diseases \nand greater productivity.\nQUESTION 14.- What is the role of the press in the \npromotion of Health through vaccines?\nExposure:\nThe role of the press in the vaccination of adults and \nchildren should focus on conveying to the population the im -\nportance of this fact and its repercussions as a major public \nhealth issue. The press should demand from the health author -\nities, beyond information, a commitment to adopt measures to \nguarantee access for adults, on equal terms, to all the neces -\nsary vaccines. Furthermore, it should call on the responsibility \nof scientific societies to promote the implementation of a ho -\nmogeneous adult vaccination schedule for the whole country.\nIn addition to these general principles, it is also pertinent \nto comment on the news that leads to the dissemination of \nvaccine hoaxes, particularly via the Internet. In a study con -\nducted between July 2014 and September 2017, researchers \nfollowed thousands of tweets, proving that many of them had \norigins similar to those that tried to influence the electoral \nprocess in 2016 in the United States of America. In general, \nthey try to project the image of a public opinion much more \ndivided than it actually is about the safety or insecurity of \navailable vaccines. The study shows that the vast majority of \nAmerican society believes that vaccines are safe and effective.\nThe reluctance of some parents to allow their children \nto be vaccinated is another issue in which the press can play \na very important role, just providing proper information. In \ngeneral, parents who do so tend to make three kinds of ar -\nguments: some believe that their children are at little risk of \ndiseases such as polio, measles or tetanus because others are \nvaccinated already. Others believe that many of the diseases \nthat vaccines prevent are not really too serious, such as chick -\nenpox or measles itself. Finally, there is a group of parents \nwhose primary concern is the incidence of adverse effects such \nas autism. The press, offering truthful and rigorous informa -\ntion and fleeing sensationalism, can do an extraordinary job in \nthis sense as well [256-266].\nIn conclusion, we would like to convey our opinion to erage in adolescents is estimated at 79% and in adulthood at \n57% [254]. Not to mention the laxity that health professionals \nthemselves have when it comes to getting vaccinated, an as -\npect that requires special attention.\nThe results of phase I of the DOVE study published in 2011 \nin the journal of Health Affairs conclude that with a package \nof only 6 vaccines, the death of 6.4 million children could be \navoided over the following 10 years, to which should be add -\ned the disappearance of 426 million episodes of disease. Eco -\nnomically, the potential savings for the 72 poorest countries, \nif such a vaccination program were to be implemented, would \nmean saving 151,000 million dollars, the result of less spend -\ning on diseases and greater productivity [255].\nIt has been proven that vaccination, a healthy life, and \none would also say, life expectancy itself, are related aspects \nthat translate into well-being for individuals while providing \nvery positive effects on the economy of any country. People \nwith deteriorated health produce less, consume less, increase \npublic spending, affect the public deficit and have effects on \nforeign trade, because buying less weakens exports, and pro -\nducing less affects, in some way, on exports; in short, harm the \nproduction of goods and services of the country and, there -\nfore, deteriorate global wealth. The importance of vaccination \nin a country\u2019s wealth is therefore evident. A European calcu -\nlation estimates that for every euro invested in health-care, \na return of 4 euros is obtained and that 5 years of increase in \nlife expectancy has an impact on the GDP of an annual 0.5% \nincrease in developed countries. In Spain, it is estimated that \nfor every euro invested in vaccines, \u20ac22 is saved in direct and \nindirect costs.\nVaccinating a person throughout his or her life is calculat -\ned at a variable cost of between \u20ac443 and \u20ac3,953 per person \nat a cost of \u20ac44 to \u20ac226 per \u201cprotected\u201d pathogen [255].\nThere are also other no less important considerations, \nsuch as new vaccines that address new health problems. At \nthis point, it is important to highlight the fact that the phar -\nmaceutical industry is one of the most R+D-intensive, this be -\ning necessary for the production of new solutions to specific \nhealth-care problems. One of them has to do, for example, \nwith changes in the patterns of sexual relations, due to rela -\ntionships occurring at increasingly younger ages and without \nthe proper precautions, to which has been added the new \nproblem that comes from the famous \u201cmorning-after pill\u201d, \nwhich is proven to be used without any medical control and \nwhich, in the long run, according to many experts, could have \nincidence in breast cancers. However, going back to vaccines, it \nis important to point out the HPV vaccine, which is now on the \nvaccination calendar for young women, but not for men. Giv -\nen the promiscuity in young people, the difference in criteria \nfrom one European country to another, the \u201cErasmus effect\u201d, \nand other considerations, this is a problem that, without being \napparently serious, also affects boys in a multitude of health \nproblems that affect the physical and, above all, the psycho -\nlogical area. This is an aspect of vaccination policy that calls \nfor review. This aspect, moreover, without being deadly, has Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364352In fact, ethics has never questioned the legality of this \ntype of service. The problems have started very recently. In the \ncase of armies, one of the reasons has been the progressive \ncomplication and technification of military tasks, which can \nno longer be covered by non-specialized personnel, which has \nforced the professionalization not only of military command -\ners but of the militia in general.\nBut in addition to these reasons that we can call technical \nor professional, there are others that depend on culture. We \nlive in a liberal culture, where perhaps the most appreciated \nvalue is freedom. It is, of course, about individual freedom, in \nsuch a way that all the orders coming from any instance out -\nside the person are questioned by principle.\nOn the other hand, Western culture generally puts free -\ndom at the service of maximum utility or maximum personal \ninterest. This means that the idea of the collective interest has \nlost much of its previous strength, and that today it clearly \nconflicts with the individual interest inasmuch as the search \nfor that collective interest may result in some damage to the \nindividual himself.\nThus, the great moral conflict of compulsory vaccination \nis the conflict between the collective or common good and the \nindividual good. As long as the protection of the former can \nput the latter at risk, there are criticisms that individual rights \nare being violated which are inviolable.\nThe two values at stake or, in these cases, in conflict, are \ncollective benefit vs. individual benefit. In all classical ethics it \nwas assumed that the first of these values had priority over the \nsecond. Aristotle says it at the beginning of his Politics , and \nit became an undisputed principle, which was self-evident. It \nwas a clear \u201cdeontological principle\u201d, which was soon justified \nby criteria of natural law and even divine law.\nBut as of the 18th century, a new approach was devel -\noped, not deontological but \u201cteleological\u201d; that of utilitari -\nanism. The only moral obligation is to maximize utilities, and \ntherefore the question is whether the utilities of the individual \nbenefit are superior to those of the public benefit or not. Act \nUtilitarianism calculates utility \u201cact by act\u201d. This means that \nthe usefulness of an individual\u2019s vaccination must be calcu -\nlated both for the community and for the individual himself. \nIf the vaccine entails serious risks, even if its probability is very \nlow, it is normal that the usefulness of vaccinating a single \nindividual is socially or collectively very small, and that the \nusefulness of avoiding the individual risk of secondary effects \nmay be greater. Knowingly or not, this is how most objectors \nto social vaccination reason.\nThere is another utilitarianism called Rule Utilitarianism. \nIt seeks to optimize the usefulness not of each act, but of \neach norm or rule. In the case of compulsory vaccination, the \nrule says that collective vaccination has a great social bene -\nfit, even though it may entail some individual risks, which, in \nsome very extraordinary cases, may become serious. But Rule \nUtilitarianism does not easily eliminate Act Utilitarianism. The \nresult is that the rational utilitarianist will look for others to \nact according to Rule Utilitarianism whilst he decides accord -point out that the press is an excellent vehicle for transmitting \npublic demands to the political class, which must legislate on \nthe financing of vaccines so that their application is feasible \nfor all those who need them.\nConclusion:\nThe role of the press in the subject of vaccination is \npotentially multiple. It must contribute to disseminating \ntruthful and rigorous information to the population, pro -\nmoting the acceptance of essential Public Health meas -\nures. The media must contribute to the elimination of \nhoaxes and misinformation and create social pressure in \nfavour of making legislative decisions that, as in the case \nof vaccines, have a great impact on individual and collec -\ntive health.\nQUESTION 15.- What ethical aspects deserve to be \nparticularly highlighted in the policy of using vaccines for \nthe prevention of infections in adults?\nExposure:\nVaccination has raised ethical issues from the very begin -\nning. But this does not mean that these problems have always \nbeen the same. Quite the opposite is true, that each era has \nposed its own problems.\nWhen Jenner fine-tuned the antivariolic vaccination pro -\ncedure and wanted to spread it and generalize it to the whole \npopulation, the problem arose as to whether it was correct to \ninoculate, in healthy people, a very serious disease and from \nwhich more than 30% of those affected died. This was the \ngreat debate in the final years of the 18th century and the first \ndecades of the 19th century.\nIn the middle of that century another problem arose. \nFaced with the cholera epidemics that filled the entire century, \nJaime Ferr\u00e1n fine-tuned his controversial vaccine. Here the de -\nbate was mainly scientific, and the question was whether this \nvaccine was effective and safe enough to be extended to the \nwhole population.\nToday there is no question about the effectiveness and \nsafety of vaccines. But it happens that, precisely because they \nare effective, they have side effects, which in some cases can \nbe serious. And the problem that arises is whether the State \ncan make a vaccine obligatory, which, although there is no \ndoubt that it has a clear collective benefit, can nevertheless be \nharmful at an individual level.\nFor obvious reasons, in the following lines we are going to \nfocus on the analysis of this last problem, that of the obligato -\nry nature of vaccines.\nUntil very modern times it was never doubted that the \nState had the power to oblige people to provide services, not \nonly financially or in terms of goods, but also personally or in \nterms of their own lives, in certain cases in which the good of \nthe community was at serious risk. Such has always been the \ncase of the obligatory nature of military service and of actively \nintervening in actions of war, even at the risk of one\u2019s own life.Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364353and Abrahamic root religions. This is the basis of Western nat -\nuralism, which although it has been very positive in many as -\npects of our culture, also has highly problematic and negative \nconsequences, such as the conversion of the order of nature \ninto a criterion of morality. At present, this moral prejudice is \nat the basis of many of the \u201cecological\u201d movements.\nBut as pernicious to ethics as deontological naturalism \nhas been teleological utilitarianism, of which we have al -\nready spoken, the moral obligations of human beings are not \naimed solely at optimizing individual benefits. We are social \nbeings, we benefit from social life which, obviously, has the \nright to demand certain benefits by reciprocity. These must be \nas harmless as possible to individual goods, and that is why \nvaccines should be made compulsory only in exceptional cases. \nBut we must all assume our duty to contribute to the common \nor collective good, even assuming, in exceptional cases, vital \nrisks. Whoever does not act in this way must be seen for what \nhe is, a \u201cnon-solidarity\u201d subject, a \u201cprofiteer\u201d or, simply, a \u201cfree -\nloader\u201d. In 1714, a British physician and philosopher, Bernard \nMandeville, published a famous book with the following title: \nThe Fable of Bees, or How Private Vices Make Prosperity Public . \nIt is a classic topic in liberal culture thereafter. Some time later, \nin 1759, Adam Smith brought to light his great book of ethics, \nthe Theory of Moral Sentiments . In the part entitled \u201cFrom the \nEffect of Utility on the Sentiment of Approval,\u201d he wrote: \u201cThe \nrich consume barely more than the poor, and despite their \nnatural selfishness and greed, even though they seek only their \nown convenience, even though the only aim they set them -\nselves is the satisfaction of their own vain and insatiable de -\nsires, they divide with the poor the fruit of all their properties. \nAn invisible hand leads them to realize almost the same distri -\nbution of things necessary for life that would have taken place \nif the earth had been divided into equal portions among all its \ninhabitants, and so without pretending it, without knowing it, \nthey promote the interest of society\u201d. Hence the importance \nthat this invisible hand ended up having in the other great \nwork written by Adam Smith, this one on political economy, \nAn investigation on the nature and cause of the wealth of na -\ntions , published in 1776. Does such an invisible hand exist? \nDoes it fix everything? Does it make private vices contribute \nto public prosperity? Sometimes yes, but not in all cases. Both \nsituations occur in the world of vaccines. In some of them, the \npure individual interest in tackling the ills of the disease pro -\ntects even those not directly vaccinated and thus contributes \nto the collective benefit. This is the case of the Sabin vaccine \nagainst the polio virus. By seeking individual protection, the \nimmunization of other individuals is indirectly achieved (\u201cherd \neffect\u201d). These are win-win situations, so studied in game the -\nory. It is unreasonable to collaborate on a collective good if \none does not take personal advantage of it. The problem is that \nthis is not always achieved, because there are times when it is \nnecessary to lose something individually in order to maximize \nthe collective benefit. The analysis of these situations has been \nworrying theoreticians for a long time, from Pareto to Nash. \nMancur Olson\u2019s study of this type of social behaviour in his \nbook The Logic of Collective Action: Public Goods and the The -ing to Act Utilitarianism. This is the case of the \u201cfreeloader\u201d, \nwho takes advantage of the altruism of others to increase the \nusefulness of his own selfishness. For example, if everyone is \nvaccinated, my child will not be infected with the disease, and \ntherefore I do not need to vaccinate him, thus avoiding dis -\ncomfort and possible side effects. It is the same as when it is \nforbidden to fill swimming pools with water during a very dry \nsummer, but a someone decides to fill his because this con -\nsumption is almost imperceptible, as long as the others respect \nthe rule. I take advantage of the respect of the rule of others, \nat the same time that I decide not to respect it.\nWhat has been said about compulsory vaccination chang -\nes when vaccination is free, in such a way that it is advised but \nnot obligatory. In those cases, which are the most frequent, \nthe conflicting values are, in general, the balance between \nbenefit and risk, that is to say, between the prevention of a \npotential serious disease on the one hand and the risk of sec -\nondary effects of the vaccine on the other. These are obviously \ntwo distinct manifestations of non-maleficence: preventing \nsomething that is in our hands and that is maleficent on the \none hand and, on the other hand, avoiding or not carrying out \nsomething that can be, though certainly with a low probability.\nThis conflict is more apparent than real. This is due to the \nfact that clinical research into vaccines allows us to have sci -\nentific evidence that the benefit of the disease it prevents, or \nthe harm it avoids, is far greater than the harm from the side \neffects of the vaccine itself, and this in the individual himself. \nTherefore, now we are not talking about collective benefit \nversus individual benefit, but we are comparing the individu -\nal benefit of getting vaccinated and avoiding a serious illness \nversus the benefit of not getting vaccinated and avoiding the \nside effects of the vaccine, whilst accepting the risk that the \nperson may suffer a serious illness. This is therefore a utilitar -\nian calculation, and not a \u201cRule\u201d but an \u201cAct\u201d. And it is clear \nthat in vaccines, utilitarian calculus is always on the side of \nvaccinating, because its benefits are much greater than the \nrisks assumed.\nSo far, we have appealed to the language of values and \nconflicts of values. We have approached analysis as a choice \nbetween different values. This is what is usually done in ethics. \nHowever, it is not the ideal procedure. The optimal solution is \nnever in the extreme courses but in the intermediate ones.\nIt is sometimes said that between vaccinating and not \nvaccinating, there are no intermediate courses. But that is not \nthe case. This is a typical bias in the decision-making process \nthat we human beings commit with unusual frequency.\nThe optimal intermediate course is citizen education and \nthe promotion of responsibility. Most of the objections to vac -\ncination are due to false prejudices, which an adequate delib -\neration allows, in most cases, to overcome.\nOne of the most common prejudices is that of \u201cnatural -\nism\u201d, i.e. natural is good and artificial is bad. This, however \nparadoxical it may seem, is in the collective unconscious of \nour culture. Ethics was born as a scientific discipline in Greece \nfrom this principle, which later reinforced Stoic philosophy Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364354ligatory vaccines in children, or Italy, where the presentation \nof the health booklet attesting to the application of the twelve \ntypes of vaccines required by law is required upon entry in -\nto kindergarten or school. The argument put forward by the \nSpanish scientific societies is that, with the current procedure, \nvery high percentages of vaccination are achieved, even higher \nthan that achieved in some other country through compulsory \nvaccination. This is a markedly consequentialist criterion. And \nwhile the consequences are an important factor in moral rea -\nsoning, they are not the only one. There are also the principles; \nin this case, that of justice, the equitable distribution of bur -\ndens. We must not endorse voluntarism and altruism, which \nis basically a pure duty of justice. The invisible hand, as Adam \nSmith rightly said, gets \u201calmost\u201d the same distribution as jus -\ntice does. But only \u201calmost\u201d.\nConclusion:\nWe receive many benefits from the community, and \nthat is why we are also obliged to contribute to the col -\nlective good with different types of benefits. It is nec -\nessary to do everything humanly possible so that these \nare the least possible, not only in number but also in se -\nverity. But when it is necessary to distribute risks, it is \nnot possible to trust everything to the voluntary will of \nthose who, for whatever reasons, are willing to assume \nthem freely and voluntarily. Because this, in a collateral \nway, encourages the proliferation of freeloaders. Public \nburdens must be distributed equitably, otherwise they \ncannot be considered fair. When persuasive measures do \nnot fully cover health objectives, as in the case of several \nvaccines, the only right thing to do is to make them ob -\nligatory. The rest is a serious dereliction of duty.\nTRANSPARENCY DECLARATIONS/POTENTIAL \nCONFLICTS OF INTEREST\nThe authors declare no conflicts of interest. This publica -\ntion was financed by GSK and the authors have not received \nany fee for their collaboration.\nREFERENCES\n1. World Health Organization . Global Vaccine Plan 2010-2020. Gene -\nva, 2012. 2017\n2. World Health Organization. 16th Meeting of the SAGE Polio \nWorking Group. http://www.who.int/immunization//sage/meet -\nings/2017/april/1_Final_report_Clarke_april3.pdf\n3. Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Recommended \nImmunization Schedule for Adults Aged 19 Years or Older, United \nStates, 2017. Ann Intern Med. 2017;166(3):209-19. DOI: 10.7326/\nm16-2936\n4. Uhart M, Bricout H, Clay E, Largeron N.  Public health and eco -\nnomic impact of seasonal influenza vaccination with quadriva -\nlent influenza vaccines compared to trivalent influenza vaccines \nin Europe. Hum Vaccin Immunother. 2016;12(9):2259-68. DOI: ory of Groups  (1965) is a classic. The study of the case of the \n\u201csponger\u201d, \u201cstowaway\u201d, \u201cparasite\u201d or free-rider, the one who \ntries to go unnoticed to take advantage of the collective ben -\nefit, without contributing to it in its aliquot part, also comes \nfrom the theory of games: \u201cIf everyone gets vaccinated, then \nI don\u2019t have to, because the germ won\u2019t be able to live and \nspread.\u201d\nThe problem increases by degree when the individual loss \ndoes not consist so much in the discomfort of the very fact of \nvaccination, but as the possibility of some more serious and \npersistent effect on the life of the person being vaccinated. \nThere is also a paradigmatic example of this: the human small -\npox vaccine, which managed to eradicate this very serious dis -\nease from the face of the earth. In addition to the discomfort \ninherent in its application, there were extremely rare encepha -\nlitis, but with permanent and often serious sequelae. It should \nbe remembered that antivariolic vaccination was compulsory \nuntil the eradication of the disease in 1980. The argument \nfor requiring vaccination, even knowing that a small group of \npeople would be harmed by it, was one of \u201cpublic health\u201d. The \nrisk had to be taken that individual health might be affected \nfor public health reasons. It was a social benefit, a contribution \nto the collective good like others, including the obligation of \nmilitary service or the defence of the country in the event of \nwar.\nToday, in Spain, there is no vaccine that is compulsory. \nThere is a very positive reason for doing so. The use of per -\nsuasive methods is always preferable to coercive measures, es -\npecially in our liberal societies, where it is getting worse and \nworse that someone has to suffer harm for reasons of public \nbenefit. We all understand well and are willing to collaborate \nin win-win situations, but we resist by all means at our dis -\nposal those in which the collective good requires a sacrifice, \nsometimes serious, very serious, of certain individuals. These \nare the lose-win situations. Someone has to lose, and we try \nby all means not to be us, although we are delighted to receive \nthe positive social consequences generated by the sacrifice of \nothers. The paradigmatic case is that of wars. With which we \nbecome, velis nolis, freeloaders.\nThe ethical consequences of this type of behaviour are \nevident. We receive many benefits from the community, and \nthat is why we are also obliged to contribute to the collec -\ntive good with different types of sacrifices. It is necessary to do \neverything humanly possible so that these are the least possi -\nble, not only in number but also in gravity. But it is no longer \nso clear that the solution, when it is necessary to distribute \nrisks, consists in trusting everything to the voluntary will of \nthose who, for whatever reasons, are willing to assume them \nfreely and voluntarily. Because this, in a collateral way, en -\ncourages the proliferation of freeloaders. Public burdens must \nbe distributed equitably, otherwise they cannot be considered \nfair. When persuasive measures do not fully cover health ob -\njectives, as in the case of several vaccines, the only right thing \nto do is to make them obligatory. The rest is a serious dere -\nliction of duty. This seems to have been understood by other \ncountries, such as France, where there are currently eleven ob -Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364355and costs associated with pneumonia in the United States during \n2008\u20132014. BMC Health Serv Res. 2018;18(1):715.doi: 10.1186/\ns12913-018-3529-4\n21. Wright C, Wordsworth R, Glennie L. Counting the cost of meningo -\ncoccal disease : scenarios of severe meningitis and septicemia. Pae -\ndiatr Drugs. 2013;15(1):49-58. DOI: 10.1007/s40272-012-0006-0\n22.  Centro Nacional de Epidemiolog\u00eda. CIBER Epidemiolog\u00eda y Salud \nP\u00fablica (CIBERESP). Instituto de Salud Carlos III. Resultados de la \nVigilancia Epidemiol\u00f3gica de las enfermedades transmisibles. In -\nforme anual 2015. Madrid, 2017.\n23. Williams WW, Hickson MA, Kane MA, Kendal AP, Spika JS, Hinman \nAR. Immunization policies and vaccine coverage among adults. The \nrisk for missed opportunities. Ann Intern Med. 1988;108(4):616-25. \n24. Williams WW, Lu PJ, O\u2019Halloran A, Kim DK, Grohskopf LA, Pilishvili \nT, et al. Surveillance of Vaccination Coverage among Adult Popula -\ntions - United States, 2015. MMWR Surveill Summ. 2017;66(11):1-\n28. DOI: 10.15585/mmwr.ss6611a1\n25. Ventola CL. Immunization in the United States: Recommendations, \nBarriers, and Measures to Improve Compliance: Part 2: Adult Vacci -\nnations. P t. 2016;41(8):492-506. PMC4959618\n26. Esposito S, Durando P, Bosis S, Ansaldi F, Tagliabue C, Icardi G. Vac -\ncine-preventable diseases: from paediatric to adult targets. Eur J \nIntern Med. 2014;25(3):203-12. DOI: 10.1016/j.ejim.2013.12.004\n27. Poland GA, Schaffner W, Hopkins RH, Jr., Health USDo, Human S. \nImmunization guidelines in the United States: new vaccines and \nnew recommendations for children, adolescents, and adults. Vac -\ncine. 2013;31(42):4689-93. DOI: 10.1016/j.vaccine.2013.03.031\n28. Anderson EL. Recommended solutions to the barriers to immuniza -\ntion in children and adults. Mo Med. 2014;111(4):344-8. \n29.  Nichol KL, Nordin J D, Nelson D B, Mullooly J P,Hak E.  Effectiveness \nof influenza vaccine in the community-dwelling elderly. N Engl J \nMed. 2007;357(14):1373-81. doi: 10.1056/NEJMoa070844\n30. Mangtani P, Cumberland P, Hodgson CR, Roberts JA, Cutts FT, \nHall AJ. A cohort study of the effectiveness of influenza vaccine \nin older people, performed using the United Kingdom general \npractice research database. J Infect Dis. 2004;190(1):1-10. DOI: \n10.1086/421274\n31. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The \nefficacy of influenza vaccine in elderly persons. A meta-analysis \nand review of the literature. Ann Intern Med. 1995;123(7):518-27. \n32. Lal H, Cunningham AL, Heineman TC. Adjuvanted Herpes Zoster \nSubunit Vaccine in Older Adults. N Engl J Med. 2015;373(16):1576-\n7. DOI: 10.1056/NEJMc1508392\n33. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domin -\ngo J, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults \n70 Years of Age or Older. N Engl J Med. 2016;375(11):1019-32. DOI: \n10.1056/NEJMoa1603800\n34. Tilston P. Anal human papillomavirus and anal cancer. J Clin Pathol. \n1997;50(8):625-34. PMC500098\n35. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal re -\nlation between human papillomavirus and cervical cancer. J Clin \nPathol. 2002;55(4):244-65. PMC176962910.1080/21645515.2016.1180490\n5. Le P, Rothberg MB. Cost-Effectiveness of Herpes Zoster Vaccine for \nPersons Aged 50 Years. Ann Intern Med. 2015;163(7):489-97. DOI: \n10.7326/m15-0093\n6. Parkin DM. The global health burden of infection-associated can -\ncers in the year 2002. Int J Cancer. 2006;118(12):3030-44. DOI: \n10.1002/ijc.21731\n7. No authors listed. Human papillomavirus and cervical cancer. Lan -\ncet. 1988;1(8588):756-8.\n8. Schweitze A, Horn J, Mikolajczyk R, Krause G, Ott J. Estimations of \nworldwide prevalence of chronic hepatitis B virus infection: a sys -\ntematic review of data published between 1965 and 2013. Lancet. \n2015;386:1546-55. \n9. Blachier M, Leleu H, Peck-Radosavljevic M, Valla D, Roudot-Thoraval \nF. The burden of liver disease in Europe: a review of available epide -\nmiological data. J Hepatol 2013;58:593-608. \n10. Thorrington D, Andrews N, Stowe J, Miller E, van Hoek AJ. Elucidat -\ning the impact of the pneumococcal conjugate vaccine programme \non pneumonia, sepsis and otitis media hospital admissions in Eng -\nland using a composite control. BMC Med. 2018;16(1):13. DOI: \n10.1186/s12916-018-1004-z\n11. Tsaban G, Ben-Shimol S. Indirect (herd) protection, following pneu -\nmococcal conjugated vaccines introduction: A systematic review of \nthe literature. Vaccine. 2017;35(22):2882-91. DOI: 10.1016/j.vac -\ncine.2017.04.032\n12. Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, et al. \nPneumococcal vaccination programs and the burden of invasive \npneumococcal disease in Ontario, Canada, 1995-2011. Vaccine. \n2013;31(49):5863-71. DOI: 10.1016/j.vaccine.2013.09.049\n13. Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. Quad -\nrivalent meningococcal vaccination of adults: phase III compari -\nson of an investigational conjugate vaccine, MenACWY-CRM, \nwith the licensed vaccine, Menactra. Clin Vaccine Immunol. \n2009;16(12):1810-5. DOI: 10.1128/cvi.00207-09\n14. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Esko -\nla J, et al. Global epidemiology of meningococcal disease. Popul \nHealth Metr. 2013;11(1):17. doi: 10.1186/1478-7954-11-17.\n15. Adams AI, Barron AO. Pertussis in Sydney: an indicator of the prob -\nlem facing health educators. Med J Aust. 1966;1(2):41-5. \n16. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, \net al. Decline of childhood Haemophilus influenzae type b (Hib) dis -\nease in the Hib vaccine era. Jama. 1993;269(2):221-6. \n17.  Putri WCWS, Muscatello DJ, Stockwell MS, Newall AT. Econom -\nic burden of seasonal influenza in the United States. Vaccine. \n2018;36(27):3960-3966. doi: 10.1016/j.vaccine.2018.05.057.\n18.  European CDC. Factsheet about seasonal influenza.. https://ecdec.\neuropa.eu/en/seasonal-influenza8facts/factsheet. 2017.\n19. Calderon C, Dennis R. Economic cost of community-acquired \npneumonia, meningitis and bacteremia in an adult population \nthat required hospitalization in Bogota, Colombia. Biomedica. \n2014;34(1):92-101. DOI: 10.1590/s0120-41572014000100012\n20.  Tong S, Amand C, Kieffer A, Moe H.Trends in healthcare utilization Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364356dence of cervical lesions in Danish women before and after imple -\nmentation of a national HPV vaccination program. Cancer Causes \nControl. 2014;25(7):915-22. DOI: 10.1007/s10552-014-0392-4\n50. Baldur-Felskov B, Munk C, Nielsen TS, Dehlendorff C, Kirschner B, \nJunge J, et al. Trends in the incidence of cervical cancer and severe \nprecancerous lesions in Denmark, 1997-2012. Cancer Causes Con -\ntrol. 2015;26(8):1105-16. DOI: 10.1007/s10552-015-0603-7\n51. Gertig DM, Brotherton JM, Saville M. Measuring human papilloma -\nvirus (HPV) vaccination coverage and the role of the National HPV \nVaccination Program Register, Australia. Sex Health. 2011;8(2):171-\n8. DOI: 10.1071/sh10001\n52. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, \nSaville AM. Impact of a population-based HPV vaccination pro -\ngram on cervical abnormalities: a data linkage study. BMC Med. \n2013;11:227. DOI: 10.1186/1741-7015-11-227\n53. Prevention CfDCa. Yellow Book. Hepatitis B. 2016. https://ww -\nwnccdcgov/travel/yellowbook/2016/infectious-diseases-relat -\ned-totravel/hepatitis-b#4621  2 \n54. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis \n- United States, 2007. MMWR Surveill Summ. 2009;58(3):1-27. \n55. Iqbal K, Klevens RM, Kainer MA, Baumgartner J, Gerard K, Pois -\nsant T, et al. Epidemiology of Acute Hepatitis B in the United States \nFrom Population-Based Surveillance, 2006-2011. Clin Infect Dis. \n2015;61(4):584-92. DOI: 10.1093/cid/civ332\n56. World Health Organization. Combating hepatitis B and C to reach \nelimination by 2030 \n57. Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, \net al. Early impact of PCV7/PCV13 sequential introduction to the \nnational pediatric immunization plan, on adult invasive pneu -\nmococcal disease: A nationwide surveillance study. Vaccine. \n2015;33(9):1135-42. DOI: 10.1016/j.vaccine.2015.01.030\n58. Bruce MG, Singleton R, Bulkow L, Rudolph K, Zulz T, Gounder P, \net al. Impact of the 13-valent pneumococcal conjugate vaccine \n(pcv13) on invasive pneumococcal disease and carriage in Alaska. \nVaccine. 2015;33(38):4813-9. DOI: 10.1016/j.vaccine.2015.07.080\n59. Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, \net al. Serotype distribution of invasive in Canada after the introduc -\ntion of the 13-valent pneumococcal conjugate vaccine, 2010-2012. \nCan J Microbiol. 2013;59(12):778-88. DOI: 10.1139/cjm-2013-0614\n60. Grau I, Ardanuy C, Cubero M, Benitez MA, Linares J, Pallares R. \nDeclining mortality from adult pneumococcal infections linked to \nchildren\u2019s vaccination. J Infect. 2016;72(4):439-49. DOI: 10.1016/j.\njinf.2016.01.011\n61. No author listed. Adult immunization. Med Lett Drugs Ther. \n2018;60(1546):73-82. \n62. Wang NY, Pollard AJ. The next chapter for group B meningo -\ncoccal vaccines. Crit Rev Microbiol. 2018;44(1):95-111. DOI: \n10.1080/1040841x.2017.1329276\n63. Parikh SR, Campbell H, Beebeejaun K, Ribeiro S, Gray SJ, Borrow R, \net al. Meningococcal Group W Disease in Infants and Potential Pre -\nvention by Vaccination. Emerg Infect Dis. 2016;22(8):1505-7. DOI: \n10.3201/eid2208.16012836. Dawar M, Deeks S, Dobson S. Human papillomavirus vaccines launch \na new era in cervical cancer prevention. Cmaj. 2007;177(5):456-61. \nDOI: 10.1503/cmaj.070771\n37. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wachold -\ner S. Human papillomavirus and cervical cancer. Lancet. \n2007;370(9590):890-907. DOI: 10.1016/s0140-6736(07)61416-0\n38. Palma DA, Nichols AC. Human papillomavirus in head and neck \ncancer. Cmaj. 2014;186(5):370. DOI: 10.1503/cmaj.130849\n39. Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, \nLyu CW, et al. US assessment of HPV types in cancers: implica -\ntions for current and 9-valent HPV vaccines. J Natl Cancer Inst. \n2015;107(6):djv086. DOI: 10.1093/jnci/djv086\n40. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. \nEfficacy of human papillomavirus-16 vaccine to prevent cervical in -\ntraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. \n2006;107(1):18-27. DOI: 10.1097/01.AOG.0000192397.41191.fb\n41. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et \nal. Prophylactic quadrivalent human papillomavirus (types 6, 11, \n16, and 18) L1 virus-like particle vaccine in young women: a ran -\ndomised double-blind placebo-controlled multicentre phase II \nefficacy trial. Lancet Oncol. 2005;6(5):271-8. DOI: 10.1016/s1470-\n2045(05)70101-7\n42. Sattler C, editor Efficacy of a prophylactic quadrivalent human \npapillomavirus (HPV) (types 6,11,16,18) L1 virus-like particle (VLP) \nvaccine for prevention of cervical dysplasia and external genital le -\nsions (EGL). 45th Interscience Conference on Antimicrobial Agents \nand Chemnotherapy 2005; Washington DC.\n43. Skjelkdestad F, editor Prophylactic quadrivalent human papilloma -\nvirus (HPV) (Types 6,11, 16, 18) L1 virus-like particle (VPL) vaccine \n(GardasilTM) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk \nAbstract LB-8a. 43rd Infectious Disease S ociety of America; 2005; \nSan Francisco.\n44. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, \net al. High sustained efficacy of a prophylactic quadrivalent hu -\nman papillomavirus types 6/11/16/18 L1 virus-like particle vaccine \nthrough 5 years of follow-up. Br J Cancer. 2006;95(11):1459-66. \nDOI: 10.1038/sj.bjc.6603469\n45. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger \nER. Quadrivalent Human Papillomavirus Vaccine: Recommenda -\ntions of the Advisory Committee on Immunization Practices (ACIP). \nMMWR Recomm Rep. 2007;56(Rr-2):1-24. \n46. Calendario de Vacunaci\u00f3n del Consejo Interterritorial https://www.\nmscbs.gob.es/profesionales/saludPublica/prevPromocion/vacuna -\nciones/Calendario2018.htm\n47. Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson \nTD, et al. Human Papillomavirus-Associated Cancers - United States, \n2008-2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661-6. \nDOI: 10.15585/mmwr.mm6526a1\n48. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact \nof human papillomavirus vaccination on cervical neoplasia--na -\ntionwide follow-up of young Danish women. J Natl Cancer Inst. \n2014;106(3):djt460. DOI: 10.1093/jnci/djt460\n49. Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK. Inci -Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-36435710.1056/NEJMoa071434\n77. Godlee F, Smith J, Marcovitch H. Wakefield\u2019s article linking MMR \nvaccine and autism was fraudulent. Bmj. 2011;342:c7452. DOI: \n10.1136/bmj.c7452\n78. Wakefield AJ. Measles, mumps, and rubella vaccination and autism. \nN Engl J Med. 2003;348(10):951-4; author reply -4. \n79. Wakefield AJ, Harvey P, Linnell J. MMR--responding to retraction. \nLancet. 2004;363(9417):1327-8; discussion 8. DOI: 10.1016/s0140-\n6736(04)16017-0\n80. Hambidge SJ, Ross C, Shoup JA, Wain K, Narwaney K, Breslin K, et \nal. Integration of data from a safety net health care system into \nthe Vaccine Safety Datalink. Vaccine. 2017;35(9):1329-34. DOI: \n10.1016/j.vaccine.2017.01.027\n81. Izurieta HS, Moro PL, Chen RT. Hospital-based collaboration for ep -\nidemiological investigation of vaccine safety: A potential solution \nfor low and middle-income countries? Vaccine. 2018;36(3):345-6. \nDOI: 10.1016/j.vaccine.2017.10.003\n82. Lei J, Balakrishnan MR, Gidudu JF, Zuber PLF. Use of a new glob -\nal indicator for vaccine safety surveillance and trends in adverse \nevents following immunization reporting 2000-2015. Vaccine. \n2018;36(12):1577-82. DOI: 10.1016/j.vaccine.2018.02.012\n83. Rowhani-Rahbar A, Klein NP, Baxter R. Assessing the safety of in -\nfluenza vaccination in specific populations: children and the elder -\nly. Expert Rev Vaccines. 2012;11(8):973-84. DOI: 10.1586/erv.12.66\n84. Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Set -\nta AM, et al. Efficacy and safety of high-dose influenza vaccine \nin elderly adults: A systematic review and meta-analysis. Vaccine. \n2017;35(21):2775-80. DOI: 10.1016/j.vaccine.2017.03.092\n85. Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. \nImmunogenicity and safety of inactivated quadrivalent influenza \nvaccine in adults: A systematic review and meta-analysis of ran -\ndomised controlled trials. Vaccine. 2016;34(35):4092-102. DOI: \n10.1016/j.vaccine.2016.06.064\n86. Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, et al. Comparative \nimmunogenicity and safety of human papillomavirus (HPV)-16/18 \nAS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine adminis -\ntered according to 2- and 3-dose schedules in girls aged 9-14 years: \nResults to month 12 from a randomized trial. Hum Vaccin Immuno -\nther. 2015;11(7):1689-702. DOI: 10.1080/21645515.2015.1050570\n87. Schwarz TF, Galaj A, Spaczynski M, Wysocki J, Kaufmann AM, \nPoncelet S, et al. Ten-year immune persistence and safety of the \nHPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-\n55 years of age. Cancer Med. 2017;6(11):2723-31. DOI: 10.1002/\ncam4.1155\n88. Hidalgo-Tenorio C, Ramirez-Taboada J, Gil-Anguita C, Esquivias J, \nOmar-Mohamed-Balgahata M, SamPedro A, et al. Safety and im -\nmunogenicity of the quadrivalent human papillomavirus (qHPV) \nvaccine in HIV-positive Spanish men who have sex with men \n(MSM). AIDS Res Ther. 2017;14:34. DOI: 10.1186/s12981-017-\n0160-0\n89. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, \nChatterjee A, Lazcano-Ponce E, et al. Efficacy, safety, and immuno -\ngenicity of the human papillomavirus 16/18 AS04-adjuvanted vac -64. Parikh SR, Newbold L, Slater S, Stella M, Moschioni M, Lucidarme \nJ, et al. Meningococcal serogroup B strain coverage of the mul -\nticomponent 4CMenB vaccine with corresponding regional distri -\nbution and clinical characteristics in England, Wales, and North -\nern Ireland, 2007-08 and 2014-15: a qualitative and quantitative \nassessment. Lancet Infect Dis. 2017;17(7):754-62. DOI: 10.1016/\ns1473-3099(17)30170-6\n65. Flacco ME, Manzoli L, Rosso A, Marzuillo C, Bergamini M, Stefa -\nnati A, et al. Immunogenicity and safety of the multicomponent \nmeningococcal B vaccine (4CMenB) in children and adoles -\ncents: a systematic review and meta-analysis. Lancet Infect Dis. \n2018;18(4):461-72. DOI: 10.1016/s1473-3099(18)30048-3\n66. Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. \nHaemophilus influenzae invasive disease in the United States, \n1994-1995: near disappearance of a vaccine-preventable child -\nhood disease. Emerg Infect Dis. 1998;4(2):229-37. DOI: 10.3201/\neid0402.980210\n67. No author listed. From the Centers for Disease Control and Preven -\ntion. Progress toward elimination of Haemophilus influenzae type b \ninvasive disease among infants and children-- United States, 1998-\n2000. Jama. 2002;287(17):2206-7. \n68. No author listed. Progress toward elimination of Haemophi -\nlus influenzae type b invasive disease among infants and chil -\ndren--United States, 1998-2000. MMWR Morb Mortal Wkly Rep. \n2002;51(11):234-7. \n69. MacNeil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, \net al. Current epidemiology and trends in invasive Haemophilus \ninfluenzae disease--United States, 1989-2008. Clin Infect Dis. \n2011;53(12):1230-6. DOI: 10.1093/cid/cir735\n70. Blain A, MacNeil J, Wang X, Bennett N, Farley MM, Harrison LH, et \nal. Invasive Haemophilus influenzae Disease in Adults >/=65 Years, \nUnited States, 2011. Open Forum Infect Dis. 2014;1(2):ofu044. DOI: \n10.1093/ofid/ofu044\n71. Livorsi DJ, Macneil JR, Cohn AC, Bareta J, Zansky S, Petit S, et al. \nInvasive Haemophilus influenzae in the United States, 1999-2008: \nepidemiology and outcomes. J Infect. 2012;65(6):496-504. DOI: \n10.1016/j.jinf.2012.08.005\n72. Maine LL, Knapp KK, Scheckelhoff DJ. Pharmacists and techni -\ncians can enhance patient care even more once national pol -\nicies, practices, and priorities are aligned. Health Aff (Millwood). \n2013;32(11):1956-62. DOI: 10.1377/hlthaff.2013.0529\n73. Spencer JP, Trondsen Pawlowski RH, Thomas S. Vaccine Ad -\nverse Events: Separating Myth from Reality. Am Fam Physician. \n2017;95(12):786-94. \n74. Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Bless -\ning-Moore J, et al. Adverse reactions to vaccines practice parame -\nter 2012 update. J Allergy Clin Immunol. 2012;130(1):25-43. DOI: \n10.1016/j.jaci.2012.04.003\n75. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in child -\nhood vaccines. Pediatrics. 2001;107(5):1147-54. \n76. Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen \nVL, et al. Early thimerosal exposure and neuropsychological out -\ncomes at 7 to 10 years. N Engl J Med. 2007;357(13):1281-92. DOI: Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364358post-marketing safety experience. Vaccine. 2017;35(52):7231-9. \nDOI: 10.1016/j.vaccine.2017.11.013\n104. Shaw FE, Jr., Graham DJ, Guess HA, Milstien JB, Johnson JM, Schatz \nGC, et al. Postmarketing surveillance for neurologic adverse events \nreported after hepatitis B vaccination. Experience of the first three \nyears. Am J Epidemiol. 1988;127(2):337-52. \n105. McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, \nWainwright K. Frequency of adverse reactions to hepatitis B vac -\ncine in 43,618 persons. Am J Med. 1992;92(3):254-6. \n106. Niu MT, Davis DM, Ellenberg S. Recombinant hepatitis B vacci -\nnation of neonates and infants: emerging safety data from the \nVaccine Adverse Event Reporting System. Pediatr Infect Dis J. \n1996;15(9):771-6. \n107. Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Bro -\ndovicz K, et al. Hepatitis B vaccination and the risk of multi -\nple sclerosis. N Engl J Med. 2001;344(5):327-32. DOI: 10.1056/\nnejm200102013440502\n108. Hall A, Kane M, Roure C, Meheus A. Multiple sclerosis and hepatitis \nB vaccine? Vaccine. 1999;17(20-21):2473-5. \n109. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccina -\ntions and the risk of relapse in multiple sclerosis. Vaccines in Multi -\nple Sclerosis Study Group. N Engl J Med. 2001;344(5):319-26. DOI: \n10.1056/nejm200102013440501\n110. Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. \nRecommendations of the Advisory Committee on Immunization \nPractices for Use of a Hepatitis B Vaccine with a Novel Adjuvant. \nMMWR Morb Mortal Wkly Rep. 2018;67(15):455-8. DOI: 10.15585/\nmmwr.mm6715a5\n111. BLA Clinical Review Memorandum, 2017. https://www.fda.gov/\ndownloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/\nUCM590189.pdf  (Accessed on May 10, 2018). [Internet]. 2018.\n112. Remschmidt C, Harder T, Wichmann O, Bogdan C, Falkenhorst G. \nEffectiveness, immunogenicity and safety of 23-valent pneu -\nmococcal polysaccharide vaccine revaccinations in the elderly: a \nsystematic review. BMC Infect Dis. 2016;16(1):711. DOI: 10.1186/\ns12879-016-2040-y\n113. Solanki BB, Juergens C, Chopada MB, Supe P, Sundaraiyer V, Le \nDren-Narayanin N, et al. Safety and immunogenicity of a 13-va -\nlent pneumococcal conjugate vaccine in adults 50 to 65 years \nof age in India: An open-label trial. Hum Vaccin Immunother. \n2017;13(9):2065-71. DOI: 10.1080/21645515.2017.1331796\n114. Destefano F, Pfeifer D, Nohynek H. Safety profile of pneumococcal \nconjugate vaccines: systematic review of pre- and post-licensure \ndata. Bull World Health Organ. 2008;86(5):373-80. PMC2647448\n115. Urbancikova I, Prymula R, Goldblatt D, Roalfe L, Prymulova K, Ko -\nsina P. Immunogenicity and safety of a booster dose of the 13-va -\nlent pneumococcal conjugate vaccine in children primed with the \n10-valent or 13-valent pneumococcal conjugate vaccine in the \nCzech Republic and Slovakia. Vaccine. 2017;35(38):5186-93. DOI: \n10.1016/j.vaccine.2017.07.103\n116. Centers for Disease Control and Prevention (CDC). Notice to read -\ners: Recommendation from the Advisory Committee on Immuniza -\ntion Practices (ACIP) for use of quadrivalent meningococcal conju -cine in women older than 25 years: 7-year follow-up of the phase 3, \ndouble-blind, randomised controlled VIVIANE study. Lancet Infect \nDis. 2016;16(10):1154-68. DOI: 10.1016/s1473-3099(16)30120-7\n90. Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI, et al. Safety \nof quadrivalent human papillomavirus vaccine (Gardasil) in preg -\nnancy: adverse events among non-manufacturer reports in the \nVaccine Adverse Event Reporting System, 2006-2013. Vaccine. \n2015;33(4):519-22. DOI: 10.1016/j.vaccine.2014.11.047\n91. Gee J, Sukumaran L, Weintraub E. Risk of Guillain-Barre Syndrome \nfollowing quadrivalent human papillomavirus vaccine in the Vac -\ncine Safety Datalink. Vaccine. 2017;35(43):5756-8. DOI: 10.1016/j.\nvaccine.2017.09.009\n92. Costa APF, Cobucci RNO, da Silva JM, da Costa Lima PH, Giral -\ndo PC, Goncalves AK. Safety of Human Papillomavirus 9-Valent \nVaccine: A Meta-Analysis of Randomized Trials. J Immunol Res. \n2017;2017:3736201. DOI: 10.1155/2017/3736201\n93. Sacks HS. In adults \u226570 years of age, an adjuvanted herpes zoster \nsubunit vaccine reduced herpes zoster at a mean 3.7 years. Ann \nIntern Med. 2017;166(2):Jc5. DOI: 10.7326/acpjc-2017-166-2-005\n94. Parrino J, McNeil SA, Lawrence SJ, Kimby E, Pagnoni MF, Stek JE, \net al. Safety and immunogenicity of inactivated varicella-zoster \nvirus vaccine in adults with hematologic malignancies receiv -\ning treatment with anti-CD20 monoclonal antibodies. Vaccine. \n2017;35(14):1764-9. DOI: 10.1016/j.vaccine.2016.10.055\n95. Oxman MN, Levin MJ. Vaccination against Herpes Zoster and Pos -\ntherpetic Neuralgia. J Infect Dis. 2008;197 Suppl 2:S228-36. DOI: \n10.1086/522159\n96. Herpes zoster vaccine (Zostavax). Med Lett Drugs Ther. \n2006;48(1243):73-4. \n97. Vazquez M, Shapiro ED. Varicella vaccine and infection with vari -\ncella-zoster virus. N Engl J Med. 2005;352(5):439-40. DOI: 10.1056/\nNEJMp048320\n98. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, \net al. A vaccine to prevent herpes zoster and postherpetic neuralgia \nin older adults. N Engl J Med. 2005;352(22):2271-84. DOI: 10.1056/\nNEJMoa051016\n99. Kessler KM. A vaccine to prevent herpes zoster. N Engl J Med. \n2005;353(13):1414-5; author reply -5. DOI: 10.1056/NEJMc051795\n100. Schmader KE, Levin MJ, Gnann JW, Jr., McNeil SA, Vesikari T, Betts \nRF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine \nin persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922-8. DOI: \n10.1093/cid/cir970\n101. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, \nHwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit \nvaccine in older adults. N Engl J Med. 2015;372(22):2087-96. DOI: \n10.1056/NEJMoa1501184\n102. Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, \net al. The Safety and Immunogenicity of Live Zoster Vaccination in \nPatients With Rheumatoid Arthritis Before Starting Tofacitinib: A \nRandomized Phase II Trial. Arthritis Rheumatol. 2017;69(10):1969-\n77. DOI: 10.1002/art.40187\n103. Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, An -\nnunziato PW, et al. Herpes zoster vaccine live: A 10year review of Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364359lance pertussis data with changing diagnostic and immunization \npractices: the case of the state of Sao Paulo, Brazil. BMC Infect Dis. \n2018;18(1):126. DOI: 10.1186/s12879-018-3004-1\n132. Alamaw SD, Kassa AW, Gelaw YA. Pertussis outbreak investigation \nof Mekdela district, South Wollo zone, Amhara region, North-West \nEthiopia. BMC Res Notes. 2017;10(1):420. DOI: 10.1186/s13104-\n017-2735-1\n133. Saul N, Gilmour R, Spokes P. Annual vaccine-preventable disease \nreport for New South Wales, Australia, 2014. Western Pac Surveill \nResponse J. 2017;8(2):5-11. DOI: 10.5365/wpsar.2016.7.3.006\n134. Bailon H, Leon-Janampa N, Padilla C, Hozbor D. Increase in pertus -\nsis cases along with high prevalence of two emerging genotypes \nof Bordetella pertussis in Peru, 2012. BMC Infect Dis. 2016;16:422. \nDOI: 10.1186/s12879-016-1700-2\n135. Aslanabadi A, Ghabili K, Shad K, Khalili M, Sajadi MM. Emergence \nof whooping cough: notes from three early epidemics in Persia. \nLancet Infect Dis. 2015;15(12):1480-4. DOI: 10.1016/s1473-\n3099(15)00292-3\n136. Javed S, Said F, Eqani SA, Bokhari H. Bordetella parapertussis out -\nbreak in Bisham, Pakistan in 2009-2010: fallout of the 9/11 syn -\ndrome. Epidemiol Infect. 2015;143(12):2619-23. DOI: 10.1017/\ns0950268814003732\n137. Sizaire V, Garrido-Estepa M, Masa-Calles J, Martinez de Aragon MV. \nIncrease of pertussis incidence in 2010 to 2012 after 12 years of \nlow circulation in Spain. Euro Surveill. 2014;19(32). \n138. Fernandez-Cano MI, Armadans-Gil L, Alvarez-Bartolome M, Rodri -\ngo-Pendas JA, Campins-Marti M. [Hospitalization due to whoop -\ning cough in Spain (1997-2011)]. Enferm Infecc Microbiol Clin. \n2014;32(10):638-42. DOI: 10.1016/j.eimc.2013.11.006\n139. Heininger U. Pertussis: what the pediatric infectious disease spe -\ncialist should know. Pediatr Infect Dis J. 2012;31(1):78-9. DOI: \n10.1097/INF.0b013e31823b034e\n140. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for \npreventing whooping cough in children. Cochrane Database Syst \nRev. 2012(3):Cd001478. DOI: 10.1002/14651858.CD001478.pub5\n141. WHO Europe/ECDC joint statement. Low uptake of seasonal in -\nfluenza vaccination in Europe may jeopardize capacity to protect \npeople in next pandemic. http://wwweurowhoint/en/media-centre/\nsections/press-releases/2018/who-europeecdc-joint-statement . \n2018. \n142. Jorgensen P, Mereckiene J, Cotter S, Johansen K, Tsolova S, Brown C. \nHow close are countries of the WHO European Region to achieving \nthe goal of vaccinating 75% of key risk groups against influenza? \nResults from national surveys on seasonal influenza vaccination \nprogrammes, 2008/2009 to 2014/2015. Vaccine. 2018;36(4):442-\n52. DOI: 10.1016/j.vaccine.2017.12.019\n143. Godoy P, Castilla J, Mayoral JM, Martin V, Astray J, Torner N, et \nal. Influenza vaccination of primary healthcare physicians may be \nassociated with vaccination in their patients: a vaccination cover -\nage study. BMC Fam Pract. 2015;16:44. DOI: 10.1186/s12875-015-\n0259-0\n144. Word Health Organization. http://www.euro.who.int/en/\nhealth-topics/communicable-diseases/influenza/news/gate vaccine (MCV4) in children aged 2--10 years at increased risk \nfor invasive meningococcal disease. MMWR Morb Mortal Wkly Rep \n2007;56:1265. \n117. Centers for Disease Control and Prevention (CDC). Updated recom -\nmendations for use of meningococcal conjugate vaccines --- Ad -\nvisory Committee on Immunization Practices (ACIP), 2010. MMWR \nMorb Mortal Wkly Rep. 2011;60(3):72-6. \n118. Hong E, Terrade A, Taha MK. Immunogenicity and safe -\nty among laboratory workers vaccinated with Bexsero(R) \nvaccine. Hum Vaccin Immunother. 2017;13(3):645-8. DOI: \n10.1080/21645515.2016.1241358\n119. Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N. Preven -\ntion and control of haemophilus influenzae type b disease: recom -\nmendations of the advisory committee on immunization practices \n(ACIP). MMWR Recomm Rep. 2014;63(Rr-01):1-14. \n120. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et \nal. 2013 IDSA clinical practice guideline for vaccination of the im -\nmunocompromised host. Clin Infect Dis. 2014;58(3):e44-100. DOI: \n10.1093/cid/cit684\n121. Lottenbach KR, Granoff DM, Barenkamp SJ, Powers DC, Kennedy \nD, Irby-Moore S, et al. Safety and immunogenicity of haemophilus \ninfluenzae type B polysaccharide or conjugate vaccines in an el -\nderly adult population. J Am Geriatr Soc. 2004;52(11):1883-7. DOI: \n10.1111/j.1532-5415.2004.52511.x\n122. (CDC) CfDCaP. Pertussis--United States, 1997-2000. MMWR Morb \nMortal Wkly Rep. 2002;51(4):73-6. \n123. Lambert HJ. Epidemiology of a small Pertussis outbreak in Kent \ncounty, Michigan. Public Health Rep. 1965;80:365-9. PMC1919641\n124. Jenkinson D. Duration of effectiveness of pertussis vaccine: evi -\ndence from a 10 year community study. Br Med J (Clin Res Ed). \n1988;296(6622):612-4. PMC2545243\n125. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and \nrates of adverse reactions associated with DTP and DT immuniza -\ntions in infants and children. Pediatrics. 1981;68(5):650-60. \n126. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for \npreventing whooping cough in children. Cochrane Database Syst \nRev. 2014(9):Cd001478. DOI: 10.1002/14651858.CD001478.pub6\n127. Prevention. Pertussis (Whooping Cough). Pertussis in Other Coun -\ntries. http://www.cdc.gov/pertussis/countries.html .\n128. Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, \net al. Prevention of Pertussis, Tetanus, and Diphtheria with Vac -\ncines in the United States: Recommendations of the Advisory Com -\nmittee on Immunization Practices (ACIP). MMWR Recomm Rep. \n2018;67(2):1-44. DOI: 10.15585/mmwr.rr6702a1\n129. MMMWR. Notifiable Diseases and Mortality Tables. http://www.\ncdc.gov/mmwr/preview/mmwrhtml/mm6115md.htm?s_ci -\nd=mm6115md_w  2012.\n130. Amirthalingam G, Gupta S, Campbell H. Pertussis immunisation and \ncontrol in England and Wales, 1957 to 2012: a historical review. \nEuro Surveill. 2013;18(38). \n131. Fernandes EG, Sartori AMC, de Soarez PC, Carvalhanas T, Rodrigues \nM, Novaes HMD. Challenges of interpreting epidemiologic surveil -Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364360158. Dominguez A, Soldevila N, Toledo D, Torner N, Force L, Perez MJ, \net al. Effectiveness of 23-valent pneumococcal polysaccharide \nvaccination in preventing community-acquired pneumonia hospi -\ntalization and severe outcomes in the elderly in Spain. PLoS One. \n2017;12(2):e0171943. DOI: 10.1371/journal.pone.0171943\n159. Camara J, Marimon JM, Cercenado E, Larrosa N, Quesada MD, Fon -\ntanals D, et al. Decrease of invasive pneumococcal disease (IPD) \nin adults after introduction of pneumococcal 13-valent conjugate \nvaccine in Spain. PLoS One. 2017;12(4):e0175224. DOI: 10.1371/\njournal.pone.0175224\n160. Pharmaceutical Research and Manufacturers of America. VAC -\nCINES: HARNESSING SCIENCE TO DRIVE INNOVATION FOR PA -\nTIENTS. https://wwwphrmaorg/report/2017-state-of-vaccines . \n2017;Assessed march 24, 2018. \n161. PubMed. https://www.ncbi.nlm.nih.gov/pubmed/?term=vac -\ncines+research  [assessed April 1st 2018]. 2018.\n162. Gonz\u00e1lez-Romo. F, Picazo. FJ. El desarrollo de nuevas vacunas. . En -\nferm Infecc Microbiol Clin. 2015;33:557-68. \n163. Gao Y, McKay PF, Mann JFS. Advances in HIV-1 Vaccine Develop -\nment. Viruses. 2018;10(4). DOI: 10.3390/v10040167\n164. Tian YS, Zhou Y, Takagi T, Kameoka M, Kawashita N. Dengue Vi -\nrus and Its Inhibitors: A Brief Review. Chem Pharm Bull (Tokyo). \n2018;66(3):191-206. DOI: 10.1248/cpb.c17-00794\n165. Ewer K, Sebastian S, Spencer AJ, Gilbert S, Hill AVS, Lambe T. \nChimpanzee adenoviral vectors as vaccines for outbreak path -\nogens. Hum Vaccin Immunother. 2017;13(12):3020-32. DOI: \n10.1080/21645515.2017.1383575\n166. Roth C, Delgado FG, Simon-Loriere E, Sakuntabhai A. Immune Re -\nsponses to Dengue and Zika Viruses-Guidance for T Cell Vaccine \nDevelopment. Int J Environ Res Public Health. 2018;15(2). DOI: \n10.3390/ijerph15020385\n167. Goldmann O, Medina E. strategies to evade the host acquired im -\nmune response. Int J Med Microbiol. 2018;308(6):625-30. DOI: \n10.1016/j.ijmm.2017.09.013\n168. Bruxelle JF, Pechine S, Collignon A. Immunization Strategies Against \nClostridium difficile. Adv Exp Med Biol. 2018;1050:197-225. DOI: \n10.1007/978-3-319-72799-8_12\n169. Zucca M, Scutera S, Savoia D. New chemotherapeutic strategies \nagainst malaria, leishmaniasis and trypanosomiases. Curr Med \nChem. 2013;20(4):502-26. \n170. Moreno-Perez D, Alvarez Garcia FJ, Alvarez Aldean J, Cilleruelo \nOrtega MJ, Garces Sanchez M, Garcia Sanchez N, et al. [Immuni -\nsation schedule of the Spanish Association of Paediatrics: 2018 \nrecommendations]. An Pediatr (Barc). 2018;88(1):53.e1-.e9. DOI: \n10.1016/j.anpedi.2017.10.001\n171. Cabezas Pascual CF, P\u00e9rez Rubio A, Eiros Bouza JM, Cort\u00e9s Lorenzo \nI. Cien cuestiones b\u00e1sicas de Econom\u00eda de la Salud y Evaluaciones \nEcon\u00f3micas. In: (ed). EA, editor. I. Valladolid: Iglesias Comunicaci\u00f3n; \n2017.\n172. Ministerio de Sanidad SSeI. Consejo Interterritorial. Introducci\u00f3n y \nmarco legal. Ley 14/1986, de 25 de abril, General de Sanidad (LGS) y \ndisposiciones de desarrollo. https://wwwmsssigobes/organizacion/\nconsejoInterterri/introduccionhtm  [assessed April 5th, 2018]. 1986. news/2018/6/is-european-region-ready-to-respond-to-next-in -\nfluenza-pandemic  accessed 28 June 2018. \n145. Ortiz de Lejarazu R, Tamames S. [Influenza vaccination. Effective -\nness of current vaccines and future challenges]. Enferm Infecc Mi -\ncrobiol Clin. 2015;33(7):480-90. DOI: 10.1016/j.eimc.2015.06.011\n146. Plans-Rubio P. The vaccination coverage required to establish herd \nimmunity against influenza viruses. Prev Med. 2012;55(1):72-7. \nDOI: 10.1016/j.ypmed.2012.02.015\n147. Ortiz JR, Hickling J, Jones R, Donabedian A, Engelhardt OG, Katz \nJM, et al. Report on eighth WHO meeting on development of in -\nfluenza vaccines that induce broadly protective and long-lasting \nimmune responses: Chicago, USA, 23-24 August 2016. Vaccine. \n2018;36(7):932-8. DOI: 10.1016/j.vaccine.2017.11.061\n148. Paules CI, Sullivan SG, Subbarao K, Fauci AS. Chasing Seasonal In -\nfluenza - The Need for a Universal Influenza Vaccine. N Engl J Med. \n2018;378(1):7-9. DOI: 10.1056/NEJMp1714916\n149. Osterhaus A, Fouchier R, Rimmelzwaan G. Towards univer -\nsal influenza vaccines? Philos Trans R Soc Lond B Biol Sci. \n2011;366(1579):2766-73. DOI: 10.1098/rstb.2011.0102\n150. Scorza FB, Pardi N. New Kids on the Block: RNA-Based Influen -\nza Virus Vaccines. Vaccines (Basel). 2018;6(2). DOI: 10.3390/vac -\ncines6020020\n151. Krammer F, Palese P. Influenza virus hemagglutinin stalk-based \nantibodies and vaccines. Curr Opin Virol. 2013;3(5):521-30. DOI: \n10.1016/j.coviro.2013.07.007\n152. Kassianos G, Blank P, Falup-Pecurariu O, Kuchar E, Kyncl J, De \nLejarazu RO, et al. Influenza vaccination: key facts for general \npractitioners in Europe-a synthesis by European experts based on \nnational guidelines and best practices in the United Kingdom and \nthe Netherlands. Drugs Context. 2016;5:212293. DOI: 10.7573/\ndic.212293\n153. Blank PR, van Essen GA, Ortiz de Lejarazu R, Kyncl J, Nitsch-\nOsuch A, Kuchar EP, et al. Impact of European vaccination poli -\ncies on seasonal influenza vaccination coverage rates: An up -\ndate seven years later. Hum Vaccin Immunother. 2018:1-9. DOI: \n10.1080/21645515.2018.1489948\n154. Rudolph W, Ben Yedidia T. A universal influenza vaccine: where are \nwe in the pursuit of this \u201cHoly Grail\u201d? Hum Vaccin. 2011;7(1):10-1. \n155. Gonzalez-Romo F, Picazo JJ, Garcia Rojas A, Labrador Horrillo M, \nBarrios V, Magro MC, et al. Consenso sobre la vacunaci\u00f3n anti-neu -\nmoc\u00f3cica en el adulto por riesgo de edad y patolog\u00eda de base. Ac -\ntualizaci\u00f3n 2017. Rev Esp Quimioter. 2017;30(2):142-68. PMID: \n28198169 \n156. Ministerio de Sanidad SSeI. Grupo de trabajo vacunaci\u00f3n frente a \nneumococo en grupos de riesgo 2015 de la Ponencia de Programas \ny Registro de Vacunaciones. Utilizaci\u00f3n de la vacuna frente a neu -\nmococo en grupos de riesgo. Comisi\u00f3n de Salud P\u00fablica del Consejo \nInterterritorial del Sistema Nacional de Salud. 2015. \n157. Ochoa-Gondar O, Hospital I, Vila-Corcoles A, Aragon M, Jariod M, \nde Diego C, et al. Prevalence of high, medium and low-risk med -\nical conditions for pneumococcal vaccination in Catalonian mid -\ndle-aged and older adults: a population-based study. BMC Public \nHealth. 2017;17(1):610. DOI: 10.1186/s12889-017-4529-8Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-3643612014;16(6):871-7. DOI: 10.1111/tid.12288\n187. Broeders EN, Wissing KM, Ghisdal L, Lemy A, Hoang AD, Vereer -\nstraeten P, et al. Large decrease of anti-tetanus anatoxin and an -\nti-pneumococcal antibodies at one year after renal transplantation. \nClin Nephrol. 2013;79(4):313-7. DOI: 10.5414/cn107779\n188. Prevots DR, Burr RK, Sutter RW, Murphy TV. Poliomyelitis preven -\ntion in the United States. Updated recommendations of the Adviso -\nry Committee on Immunization Practices (ACIP). MMWR Recomm \nRep. 2000;49(Rr-5):1-22; quiz CE1-7. \n189. Brandao LGP, Santoro-Lopes G, Oliveira SS, da Silva EE, do Brasil \nP. Seroprevalence of antibodies against the three serotypes of po -\nliovirus and IPV vaccine response in adult solid organ transplant \ncandidates. Vaccine. 2018;36(31):4681-6. DOI: 10.1016/j.vac -\ncine.2018.06.031\n190. Ljungman P, Aschan J, Gustafsson B, Lewensohn-Fuchs I, Winiarski \nJ, Ringden O. Long-term immunity to poliovirus after vaccination \nof allogeneic stem cell transplant recipients. Bone Marrow Trans -\nplant. 2004;34(12):1067-9. DOI: 10.1038/sj.bmt.1704678\n191. No author listed. Use of 13-valent pneumococcal conjugate vac -\ncine and 23-valent pneumococcal polysaccharide vaccine for \nadults with immunocompromising conditions: recommendations \nof the Advisory Committee on Immunization Practices (ACIP). \nMMWR Morb Mortal Wkly Rep. 2012;61(40):816-9. \n192. Sever MS, Yildiz A, Eraksoy H, Badur S, Yuksel-Onel D, Gorcin B, et \nal. Immune response to Haemophilus influenzae type B vaccina -\ntion in renal transplant recipients with well-functioning allografts. \nNephron. 1999;81(1):55-9. DOI: 10.1159/000045246\n193. Pao M, Papadopoulos EB, Chou J, Glenn H, Castro-Malaspina H, \nJakubowski AA, et al. Response to pneumococcal (PNCRM7) and \nhaemophilus influenzae conjugate vaccines (HIB) in pediatric and \nadult recipients of an allogeneic hematopoietic cell transplantation \n(alloHCT). Biol Blood Marrow Transplant. 2008;14(9):1022-30. DOI: \n10.1016/j.bbmt.2008.06.012\n194. Wyplosz B, Derradji O, Hong E, Francois H, Durrbach A, Duclos-\nVallee JC, et al. Low immunogenicity of quadrivalent meningococ -\ncal vaccines in solid organ transplant recipients. Transpl Infect Dis. \n2015;17(2):322-7. DOI: 10.1111/tid.12359\n195. Wedemeyer H, Pethig K, Wagner D, Flemming P, Oppelt P, Petzold \nDR, et al. Long-term outcome of chronic hepatitis B in heart trans -\nplant recipients. Transplantation. 1998;66(10):1347-53. \n196. Pessoa MG, Terrault NA, Ferrell LD, Detmer J, Kolberg J, Collins ML, \net al. Hepatitis after liver transplantation: the role of the known \nand unknown viruses. Liver Transpl Surg. 1998;4(6):461-8. \n197. Kliem V, Ringe B, Holhorst K, Frei U. Kidney transplantation in hep -\natitis B surface antigen carriers. Clin Investig. 1994;72(12):1000-6. \n198. Chung RT, Feng S, Delmonico FL. Approach to the management of \nallograft recipients following the detection of hepatitis B virus in \nthe prospective organ donor. Am J Transplant. 2001;1(2):185-91. \n199. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis \nB vaccination in cirrhotic patients waiting for liver transplantation. \nCan J Gastroenterol. 2000;14 Suppl B:59b-62b. \n200. Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J. \nVaccination against hepatitis B virus in cirrhotic patients on liv -173. Espa\u00f1a. Gd. Real Decreto 1030/2006, de 15 de septiembre, por el \nque se establece la cartera de servicios comunes del Sistema Na -\ncional de Salud y el procedimiento para su actualizaci\u00f3n., \n174. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Vacu -\nnas de uso humano autorizadas en Espa\u00f1a. . https://wwwaemps -\ngobes/medicamentosUsoHumano/vacunas/autorizadasEspana/\nhomehtm  [consultado el 5 de abril de 2018]. \n175. European Medicines Agency. Authorisation of medicines. . \nAvailable at http://wwwemaeuropaeu/ema/indexjsp?curl=pag -\nes/about_us/general/general_content_000109jsp &mid=W -\nC0b01ac0580028a47  [consulted April 5, 2018]. \n176. European Medicines Agency. Marketing authorisation. Avail -\nable at: http://wwwemaeuropaeu/ema/indexjsp?curl=pages/\nregulation/general/general_content_001595jsp &mid=W -\nC0b01ac0580b18a3d  [Colsulted April 5 2018]\n177. Ministerio de Sanidad SSeI. Vacunas y programas de vacunaci\u00f3n. \nAvailable at: http://wwwmsssigobes/profesionales/saludPublica/\nprevPromocion/vacunaciones/homehtm  [assessed  April 5th, 2018]\n178. Chong PP, Avery RK. A Comprehensive Review of Immuniza -\ntion Practices in Solid Organ Transplant and Hematopoietic Stem \nCell Transplant Recipients. Clin Ther. 2017;39(8):1581-98. DOI: \n10.1016/j.clinthera.2017.07.005\n179. Danziger-Isakov L, Kumar D. Vaccination in solid organ transplan -\ntation. Am J Transplant. 2013;13 Suppl 4:311-7. DOI: 10.1111/\najt.12122\n180. Danziger-Isakov L, Posfay-Barbe KM. Optimal approach to immuni -\nzation in pediatric solid organ transplantation. Pediatr Transplant. \n2012;16(7):680-3. DOI: 10.1111/j.1399-3046.2012.01689.x\n181. Hirzel C, Kumar D. Influenza vaccine strategies for solid organ \ntransplant recipients. Curr Opin Infect Dis. 2018;31(4):309-15. DOI: \n10.1097/qco.0000000000000461\n182. Kumar D, Ferreira VH, Blumberg E, Silveira F, Cordero E, Perez-Rome -\nro P, et al. A Five-year Prospective Multi-center Evaluation of Influ -\nenza Infection in Transplant Recipients. Clin Infect Dis. 2018. DOI: \n10.1093/cid/ciy294\n183. Natori Y, Shiotsuka M, Slomovic J, Hoschler K, Ferreira V, Ashton \nP, et al. A Double-Blind, Randomized Trial of High-Dose vs Stand -\nard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Re -\ncipients. Clin Infect Dis. 2018;66(11):1698-704. DOI: 10.1093/cid/\ncix1082\n184. Natori Y, Shiotsuka M, Slomovic J, Hoschler K, Ferreira V, Ashton P, \net al. A Double Blind Randomized Trial of High Dose vs. Standard \nDose Influenza Vaccine in Adult Solid Organ Transplant Recipients. \nClin Infect Dis. 2017. DOI: 10.1093/cid/cix1082\n185. Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavalda J, \nMoreno A, et al. Two Doses of Inactivated Influenza Vaccine Im -\nprove Immune Response in Solid Organ Transplant Recipients: Re -\nsults of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial. \nClin Infect Dis. 2017;64(7):829-38. DOI: 10.1093/cid/ciw855\n186. Rohde KA, Cunningham KC, Henriquez KM, Nielsen AR, Worzella \nSL, Hayney MS. A cross-sectional study of tetanus and diphtheria \nantibody concentrations post vaccination among lung transplant \npatients compared with healthy individuals. Transpl Infect Dis. Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364362tion. Curr Opin Infect Dis. 2014;27(4):329-35. DOI: 10.1097/\nqco.0000000000000078\n215. Berben L, Denhaerynck K, Schaub S, De Geest S. Prevalence and cor -\nrelates of influenza vaccination among kidney transplant patients. \nProg Transplant. 2009;19(4):312-7. \n216.  Formaci\u00f3n en Promoci\u00f3n y Educaci\u00f3n para la Salud. Informe del \nGrupo de Trabajo de Promoci\u00f3n de la Salud a la Comisi\u00f3n de Salud \nP\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. \nOctubre 2003. [Internet]. 2003.\n217. Glosario de Promoci\u00f3n de la Salud (OMS). 1998. [Internet]. 1998.\n218.  Marco de competencias del CIE para la enfermera generalista. [In -\nternet]. 2003.\n219. Carta de Ottawa para el Fomento de la Salud. Primera Conferencia \nInternacional sobre Fomento de la Salud, Ottawa. [Internet]. 1986.\n220. Organizaci\u00f3n Mundial de la Salud. Promoci\u00f3n de la Salud. 9\u00aa Conferen -\ncia Mundial de Promoci\u00f3n de la Salud, Shanghai (2016). Available at: \nhttp://wwwwhoint/healthpromotion/conferences/9gchp/es/  2016. \n221. Nikula A, Puukka P, Leino-Kilpi H. Vaccination competence of grad -\nuating public health nurse students and nurses. Nurse Educ Today. \n2012;32(8):850-6. DOI: 10.1016/j.nedt.2011.10.008\n222. Nikula A, Nohynek H, Puukka P, Leino-Kilpi H. Vaccination com -\npetence of graduating public health nurse students. Nurse Educ \nToday. 2011;31(4):361-7. DOI: 10.1016/j.nedt.2010.07.007\n223. Bar-Tal Y, Barnoy S. Factors influencing the decision to comply with \nnurse recommendations to take or avoid influenza vaccination. \nNurs Inq. 2016;23(4):338-45. DOI: 10.1111/nin.12145\n224. Hutchison BG. Effect of computer-generated nurse/physician re -\nminders on influenza immunization among seniors. Fam Med. \n1989;21(6):433-7. \n225. Chan SS, Leung DY, Leung AY, Lam C, Hung I, Chu D, et al. A \nnurse-delivered brief health education intervention to improve \npneumococcal vaccination rate among older patients with chron -\nic diseases: a cluster randomized controlled trial. Int J Nurs Stud. \n2015;52(1):317-24. DOI: 10.1016/j.ijnurstu.2014.06.008\n226. Smith JG, Metzger NL. Evaluation of pneumococcal vaccination \nrates after vaccine protocol changes and nurse education in a ter -\ntiary care teaching hospital. J Manag Care Pharm. 2011;17(9):701-\n8. DOI: 10.18553/jmcp.2011.17.9.701\n227. Whelan NW, Steenbeek A, Martin-Misener R, Scott J, Smith B, \nD\u2019Angelo-Scott H. Engaging parents and schools improves uptake \nof the human papillomavirus (HPV) vaccine: examining the role \nof the public health nurse. Vaccine. 2014;32(36):4665-71. DOI: \n10.1016/j.vaccine.2014.06.026\n228. Nyamathi A, Liu Y, Marfisee M, Shoptaw S, Gregerson P, Saab S, et \nal. Effects of a nurse-managed program on hepatitis A and B vac -\ncine completion among homeless adults. Nurs Res. 2009;58(1):13-\n22. DOI: 10.1097/NNR.0b013e3181902b93\n229. Nowalk MP, Tabbarah M, Hart JA, Fox DE, Raymund M, Wilson SA, \net al. Office manager and nurse perspectives on facilitators of adult \nimmunization. Am J Manag Care. 2009;15(10):755-60. \n230. Nowalk MP, Zimmerman RK, Feghali J. Missed opportunities for \nadult immunization in diverse primary care office settings. Vaccine. er transplant waiting list. Liver Transpl. 2000;6(4):440-2. DOI: \n10.1053/jlts.2000.8313\n201. Barcena R, Fernandez-Braso M, Urman J, Lopez-San Roman A, del \nCampo S, Moreno N, et al. Response to hepatitis B virus vaccine in \npatients transplanted for HBV-related liver disease under specific \ngammaglobulin prophylaxis. Transplant Proc. 1999;31(6):2459-60. \n202. Loinaz C, de Juanes JR, Gonzalez EM, Lopez A, Lumbreras C, Gomez \nR, et al. Hepatitis B vaccination results in 140 liver transplant recip -\nients. Hepatogastroenterology. 1997;44(13):235-8. \n203. Serrano B, Bayas JM, Bruni L, Diez C. Solid organ transplantation \nand response to vaccination. Vaccine. 2007;25(42):7331-8. DOI: \n10.1016/j.vaccine.2007.08.031\n204. No author listed. Prevention of hepatitis A through active or passive im -\nmunization: Recommendations of the Advisory Committee on Immuni -\nzation Practices (ACIP). MMWR Recomm Rep. 1999;48(Rr-12):1-37. \n205. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. \nFulminant hepatitis associated with hepatitis A virus superinfection \nin patients with chronic hepatitis C. N Engl J Med. 1998;338(5):286-\n90. DOI: 10.1056/nejm199801293380503\n206. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters \nB. Serious hepatitis A: an analysis of patients hospitalized dur -\ning an urban epidemic in the United States. Ann Intern Med. \n1998;128(2):111-4. \n207. Arslan M, Wiesner RH, Poterucha JJ, Gross JB, Jr., Zein NN. Hepa -\ntitis A antibodies in liver transplant recipients: evidence for loss of \nimmunity posttransplantation. Liver Transpl. 2000;6(2):191-5. DOI: \n10.1002/lt.500060216\n208. Chin-Hong PV, Kwak EJ. Human papillomavirus in solid organ \ntransplantation. Am J Transplant. 2013;13 Suppl 4:189-200. DOI: \n10.1111/ajt.12142\n209. Kumar D, Unger ER, Panicker G, Medvedev P, Wilson L, Humar A. \nImmunogenicity of quadrivalent human papillomavirus vaccine in \norgan transplant recipients. Am J Transplant. 2013;13(9):2411-7. \nDOI: 10.1111/ajt.12329\n210. Kwak EJ, Julian K. Human papillomavirus infection in solid organ \ntransplant recipients. Am J Transplant. 2009;9 Suppl 4:S151-60. \nDOI: 10.1111/j.1600-6143.2009.02906.x\n211. Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira \nB, Jung KH, Rodriguez Moreno JF, et al. Immunogenicity and safety \nof the adjuvanted recombinant zoster vaccine in patients with solid \ntumors, vaccinated before or during chemotherapy: A randomized \ntrial. Cancer. 2019. DOI: 10.1002/cncr.31909\n212. Wang L, Verschuuren EAM, van Leer-Buter CC, Bakker SJL, de Joode \nAAE, Westra J, et al. Herpes Zoster and Immunogenicity and Safe -\nty of Zoster Vaccines in Transplant Patients: A Narrative Review \nof the Literature. Front Immunol. 2018;9:1632. DOI: 10.3389/fim -\nmu.2018.01632\n213. Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam \nSA, et al. Inactivated varicella zoster vaccine in autologous hae -\nmopoietic stem-cell transplant recipients: an international, multi -\ncentre, randomised, double-blind, placebo-controlled trial. Lancet. \n2018;391(10135):2116-27. DOI: 10.1016/s0140-6736(18)30631-7\n214. Kumar D. Immunizations following solid-organ transplanta -Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364363245. Voidazan S, Morariu SH, Tarcea M, Moldovan H, Curticapian I, Do -\nbreanu M. Human Papillomavirus (HPV) Infection and HPV Vacci -\nnation: Assessing the Level of Knowledge among Students of the \nUniversity of Medicine and Pharmacy of Tirgu Mures, Romania. \nActa Dermatovenerol Croat. 2016;24(3):193-202. \n246. Anderson C, Thornley T. Who uses pharmacy for flu vaccinations? \nPopulation profiling through a UK pharmacy chain. Int J Clin \nPharm. 2016;38(2):218-22. DOI: 10.1007/s11096-016-0255-z\n247. Maharajan MK, Rajiah K, Sze Fang KN, Lui LY. Cervical Cancer \nPrevention in Malaysia: Knowledge and Attitude of Undergrad -\nuate Pharmacy Students Towards Human Papillomavirus In -\nfection, Screening and Vaccination in Malaysia. J Cancer Educ. \n2017;32(1):166-74. DOI: 10.1007/s13187-015-0957-2\n248. Poulose S, Cheriyan E, Cheriyan R, Weeratunga D, Adham M. Phar -\nmacist-administered influenza vaccine in a community pharmacy: \nA patient experience survey. Can Pharm J (Ott). 2015;148(2):64-7. \nDOI: 10.1177/1715163515569344\n249. Comboroure JC, Mueller JE. [Perception of vaccination and role of \nthe pharmacist: A survey among final year pharmacy students in \nFrance]. Ann Pharm Fr. 2014;72(2):122-31. DOI: 10.1016/j.phar -\nma.2013.10.001\n250. Hook S, Windle J. Community pharmacy influenza immunisation \nincreases vaccine uptake and gains public approval. Aust N Z J Pub -\nlic Health. 2013;37(5):489-90. DOI: 10.1111/1753-6405.12109\n251. Banh HL. Alberta pharmacy students administer vaccinations in \nthe University Annual Influenza Campaign. Can Pharm J (Ott). \n2012;145(3):112-5. DOI: 10.3821/145.3.cpj112\n252. Al-lela OQ, Bahari MB, Elkalmi RM, Jawad Awadh AI. Incorporating \nan immunization course in the pharmacy curriculum: Malaysian \nexperience. Am J Pharm Educ. 2012;76(10):206. DOI: 10.5688/\najpe7610206\n253. Olier E. Una estrategia vacunal para Espa\u00f1a. Notas estrat\u00e9gicas del \nInstituto Choiseul ISSN 2444-4006. 2017. \n254. Choiseul I. El impacto econ\u00f3mico de las vacunas. Madrid: Instituto \nChoiseul ISSN 2444-4006; 2017.\n255. Stack ML, Ozawa S, Bishai DM, Mirelman A, Tam Y, Niessen L, et \nal. Estimated Economic Benefits During The \u2018Decade Of Vaccines\u2019 \nInclude Treatment Savings, Gains In Labor Productivity. Health Aff \n(Millwood). 2011;30(6):1021\u20138. \n256. Davies PD. Vaccine given bad press. Bmj. 1993;307(6902):506. \nPMC1678807\n257. Freed GL, Katz SL, Clark SJ. Safety of vaccinations. Miss America, the \nmedia, and public health. Jama. 1996;276(23):1869-72. \n258. Cohn V. Vaccines and risks. The responsibility of the media, scien -\ntists, and clinicians. Jama. 1996;276(23):1917-8. \n259. Eavey RD. Vaccine safety, media reporting, and Miss America. Jama. \n1997;278(4):290-1. \n260. Anderson P. Another media scare about MMR vaccine hits Britain. \nBmj. 1999;318(7198):1578. PMC1115967\n261. Danovaro-Holliday MC, Wood AL, LeBaron CW. Rotavirus vaccine \nand the news media, 1987-2001. Jama. 2002;287(11):1455-62. \n262. Dobson R. Media misled the public over the MMR vaccine, study says. 2004;22(25-26):3457-63. DOI: 10.1016/j.vaccine.2004.02.022\n231. Nowalk MP, Bardella IJ, Zimmerman RK, Shen S. The physician\u2019s of -\nfice: can it influence adult immunization rates? Am J Manag Care. \n2004;10(1):13-9. \n232. Patel AR, Breck AB, Law MR. The impact of pharmacy-based im -\nmunization services on the likelihood of immunization in the \nUnited States. J Am Pharm Assoc (2003). 2018. DOI: 10.1016/j.\njaph.2018.05.011\n233. Westrick SC, Patterson BJ, Kader MS, Rashid S, Buck PO, Rothholz \nMC. National survey of pharmacy-based immunization services. \nVaccine. 2018. DOI: 10.1016/j.vaccine.2018.07.027\n234. Lin JL, Bacci JL, Reynolds MJ, Li Y, Firebaugh RG, Odegard PS. Com -\nparison of two training methods in community pharmacy: Project \nVACCINATE. J Am Pharm Assoc (2003). 2018;58(4s):S94-S100.e3. \nDOI: 10.1016/j.japh.2018.04.003\n235. Alsabbagh MW, Church D, Wenger L, Papastergiou J, Raman-Wilms \nL, Schneider E, et al. Pharmacy patron perspectives of community \npharmacist administered influenza vaccinations. Res Social Adm \nPharm. 2018. DOI: 10.1016/j.sapharm.2018.04.015\n236. Hohmeier KC, Randolph DD, Smith CT, Hagemann TM. A mul -\ntimodal approach to improving human papillomavirus vac -\ncination in a community pharmacy setting. SAGE Open Med. \n2016;4:2050312116682128. DOI: 10.1177/2050312116682128\n237. Calo WA, Gilkey MB, Shah P, Marciniak MW, Brewer NT. Parents\u2019 \nwillingness to get human papillomavirus vaccination for their ad -\nolescent children at a pharmacy. Prev Med. 2017;99:251-6. DOI: \n10.1016/j.ypmed.2017.02.003\n238. Pickren E, Crane B. Impact on CDC Guideline Compliance After Incor -\nporating Pharmacy in a Pneumococcal Vaccination Screening Process. \nHosp Pharm. 2016;51(11):894-900. DOI: 10.1310/hpj5111-894\n239. Long AG, Roberts CM, Hayney MS. Pharmacy student involve -\nment with increasing human papillomavirus (HPV) vaccination \namong international college students. J Am Pharm Assoc (2003). \n2017;57(1):127-8. DOI: 10.1016/j.japh.2016.11.009\n240. Rhodes LA, Branham AR, Dalton EE, Moose JS, Marciniak MW. Im -\nplementation of a vaccine screening program at an independent \ncommunity pharmacy. J Am Pharm Assoc (2003). 2017;57(2):222-\n8. DOI: 10.1016/j.japh.2016.10.009\n241. Kirkdale CL, Nebout G, Megerlin F, Thornley T. Benefits of phar -\nmacist-led flu vaccination services in community pharmacy. Ann \nPharm Fr. 2017;75(1):3-8. DOI: 10.1016/j.pharma.2016.08.005\n242. Chun GJ, Sautter JM, Patterson BJ, McGhan WF. Diffusion of \nPharmacy-Based Influenza Vaccination Over Time in the United \nStates. Am J Public Health. 2016;106(6):1099-100. DOI: 10.2105/\najph.2016.303142\n243. Rawson SJ, Conway JH, Hayney MS. Addressing vaccine hesitan -\ncy in the pharmacy. J Am Pharm Assoc (2003). 2016;56(2):209-10. \nDOI: 10.1016/j.japh.2016.02.008\n244. Hill JD, Anderegg SV, Couldry RJ. Development of a Pharmacy \nTechnician-Driven Program to Improve Vaccination Rates at an \nAcademic Medical Center. Hosp Pharm. 2017;52(9):617-22. DOI: \n10.1177/0018578717722788Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain E. Bouza, et al.\nRev Esp Quimioter 2019;32(4): 333-364364Bmj. 2003;326(7399):1107. DOI: 10.1136/bmj.326.7399.1107-a\n263. Ma KK, Schaffner W, Colmenares C, Howser J, Jones J, Poehling \nKA. Influenza vaccinations of young children increased with media \ncoverage in 2003. Pediatrics. 2006;117(2):e157-63. DOI: 10.1542/\npeds.2005-1079\n264. Smith MJ, Ellenberg SS, Bell LM, Rubin DM. Media coverage of \nthe measles-mumps-rubella vaccine and autism controversy and \nits relationship to MMR immunization rates in the United States. \nPediatrics. 2008;121(4):e836-43. DOI: 10.1542/peds.2007-1760\n265. Roehr B. Media induced anti-vaccination sentiment can even affect \nhealth workers, vaccine researcher says. Bmj. 2012;344:e1563. DOI: \n10.1136/bmj.e1563\n266. Glanz JM, Wagner NM, Narwaney KJ, Kraus CR, Shoup JA, Xu S, et \nal. Web-based Social Media Intervention to Increase Vaccine Ac -\nceptance: A Randomized Controlled Trial. Pediatrics. 2017;140(6). \nDOI: 10.1542/peds.2017-1117Rev Esp Quimioter 2019;32(4): 365-369365\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Comparaci\u00f3n de dos m\u00e9todos que eluden \nla lisis celular y la extracci\u00f3n de prote\u00ednas \npara la identificaci\u00f3n de bacterias crecidas \nen hemocultivos mediante espectrometr\u00eda de \nmasas MALDI-TOF\nRESUMEN\nObjetivo. La espectrometr\u00eda de masas MALDI-TOF se utili -\nza com\u00fanmente para la identificaci\u00f3n r\u00e1pida de bacterias cre -\ncidas en hemocultivos (HC). Hemos comparado el rendimiento \nde dos procedimientos, uno que incluye un paso previo del en -\nriquecimiento en caldo coraz\u00f3n-cerebro y el otro un m\u00e9todo \ndirecto que usa tubos vacutainer con gel separador (DI), para la \nidentificaci\u00f3n de bacterias a partir de hemocultivos mediante \nMALDI-TOF MS.\nMaterial y m\u00e9todos. Analizamos prospectivamente un \ntotal de 145 HC no consecutivos (68 con crecimiento de bacte -\nrias gramnegativas y 77 de cocos grampositivos).\nResultados. Un total de 82% y 49% de los aislamientos \nfueron identificados correctamente a nivel de especie por los \ndos m\u00e9todos, respectivamente.\nConclusi\u00f3n. El rendimiento del m\u00e9todo de pre-enriqueci -\nmiento en caldo coraz\u00f3n-cerebro fue mejor que el del m\u00e9todo \nDI para la identificaci\u00f3n de la pr\u00e1ctica totalidad de las especies \nbacterianas incluidas en el panel de estudio.\nPalabras clave: MALDI-TOF MS; hemocultivo; identificaci\u00f3n bacteriana.ABSTRACT\nObjective. Matrix-assisted laser desorption/ionization \ntime-of-flight mass-spectrometry (MALDI-TOF MS) is wide -\nly used for fast identification of bacteria from blood cultures \n(BC). We compared the performance of two procedures, one \nincluding a pre-enrichment step in brain heart infusion and \nthe other a direct method using vacutainer separator gel tubes \n(DI), for identification of bacteria from blood cultures by MAL -\nDI-TOF MS. \nMaterial and methods. We first prepared a train -\ning set of 20 simulated bacteremia specimens, including 10 \nGram-negative and 10 Gram-positive species. A total of 145 \nnon-consecutive BCs flagged as positive (68 Gram-negative \nrods, and 77 Gram-positive cocci) were prospectively analyzed \n(validation set). \nResults. A total of 82% and 49% of isolates were cor -\nrectly identified to the species level by the respective methods.\nConclusion. The pre-enrichment method outperformed \nthe DI method for identification of virtually all bacterial spe -\ncies included in the panels.\nKey words: MALDI-TOF M; blood culture; bacterial identification.Comparison of two methods skipping cell lysis and \nprotein extraction for identification of bacteria from \nblood cultures by matrix-assisted laser desorption/\nionization time-of-flight mass-spectrometry \n1Microbiology Service, Hospital Cl\u00ednico Universitario, Fundaci\u00f3n INCLIVA, Valencia, Spain.\n2Department of Microbiology, School of Medicine, University of Valencia, Spain.Ignacio Torres1\nEstela Gim\u00e9nez1\nDixie Huntley1 \nMireia Mart\u00ednez1\nJavier Colomina1\nDavid Navarro1,2\nCorrespondence:\nDavid Navarro, Microbiology Service, Hospital Cl\u00ednico Universitario, and Department of Micro -\nbiology, School of Medicine.\nAv. Blasco Ib\u00e1\u00f1ez 17, 46010 Valencia, Spain. \nTel: 34(96)3864657\nFax: 34(96)3864173\nEmail: david.navarro@uv.esBrief report\nArticle history\nReceived: 17 January 2019; Revision Requested: 18 February 2019; Revision Received: 18 February  019; Accepted: 25 April 2019Comparison of two methods skipping cell lysis and protein extraction for identification of bacteria from \nblood cultures by matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry I. Torres, et al.\nRev Esp Quimioter 2019;32(4): 365-369366continuous-monitoring blood culturing instrument (BACTEC\u2122 \nFX; BD). The isolates had been grown overnight on chocolate \nagar medium (BD) at 36 \u00b0C in air with 5% CO 2 using a Heracell \n240i CO 2 incubator, (Thermo Fisher Scientific, Langenselbold, \nGermany). The bacterial inocula were prepared in sterile saline. \nThe concentration of bacteria was determined by the quantita -\ntive plating method prior to inoculation into the blood culture \nbottles. Next, a total of 145 non-consecutive BCs flagged as \npositive and collected between September 2017 and May 2018 \nfrom unique adult (n=138) or pediatric (n=7) patients were \nprospectively analyzed (validation set). Only monomicrobial \nBCs were selected for this study. All coagulase-negative staph -\nylococci (CNS) included in the panel were deemed be clinical -\nly significant. Positive BCs were processed for MALDI-TOF MS \nidentification following two different protocols, performed in \nparallel: our pre-cultivation protocol [7] and a DI method. For \nthe former method, a volume of 50 \u00b5l of blood culture was in -\noculated into a volume of 500 \u00b5l of BHI (Oxoid Limited, Hamp -\nshire, United Kingdom) in sterile vials and incubated at 36 \u00b0C in \nair with 5% CO 2 for 2-4 h. Then the vials were centrifuged at \n13,000 rpm for 2 min, the supernatants discarded, and the pel -\nlets used for MALDI-TOF MS analyses, as previously described \n[7]; for the latter method, a volume of 8.0 ml of BCs was trans -\nferred with a syringe to a serum separator tube (Vacutainer \n8.5 ml SST Plus; Beckton Dickinson-BD- New Jersey, USA) and \ncentrifuged at 3,600 rpm for 15 minutes at room temperature. \nThe supernatant was aspirated with caution to avoid disrupt -\ning the formed pellet of bacteria present at the surface of the \npolymeric gel. \nPositive BCs were subcultured overnight on chocolate \nagar following our routine diagnostic protocol, and the grow -\ning biomass was used for MALDI-TOF MS identification. The INTRODUCTION\nMatrix-assisted laser desorption/ionization time-of-flight \nmass-spectrometry (MALDI-TOF MS) is widely used for fast \nidentification of bacteria from blood cultures (BC) [1]. For the \nsake of simplicity, several methods skipping blood cell lysis and \nprotein extraction have been developed for this purpose, using \neither bacteria directly pelleted by centrifugation from BCs - \nDI methods [2-5], or bacteria harvested following a pre-culti -\nvation step in solid [6] or liquid [7] media. \nWe previously developed a simple method by which pos -\nitive BCs were subjected to short-term enrichment in brain \nheart infusion broth (BHI) prior to MALDI-TOF MS analysis \n(ENR method), and showed that it outperformed pre-incuba -\ntion in blood agar in terms of efficiency and speed in identify -\ning a wide array of bacterial species, in particular Gram-neg -\native bacteria [7]. Here, we compared the performance of our \nprocedure with a DI method from positive BCs collected in \nvacutainer tubes with separator gels. \nMATERIAL AND METHODS\nWe first prepared a training set of 20 simulated bacter -\nemia specimens. Bacteria, including 10 Gram-negative and \n10 Gram-positive species (table 1), were selected from cry -\nopreserved stocks of clinical isolates recovered during the \npreceding year, in accordance with a protocol approved by \nour institutional review board. Bacterial isolates were spiked \ninto blood culture bottles (BACTEC\u2122 Plus Aerobic/F and Plus \nAnaerobic/F medium bottles, Becton Dickinson and Company, \nNew Jersey, USA) at 103 CFU/ml and incubated in automated \nIsolates in the panel (n) Accurate identification following pre-\nenrichment in Brain Heart Infusion brothAccurate identification by direct processing \nof blood cultures\nno. of isolates (%) no. of isolates (%)\nAll (20) 15 (75) 9 (45)\nEnterobacteriaceae  (5) 5 (100) 5 (100)\nEscherichia  coli (2) 2 (100) 2 (100)\nKlebsiella  pneumoniae  (2) 2 (100) 2 (100)\nEnterobacter  cloacae  (1) 1 (100) 1 (100)\nPseudomonas aeruginosa  (5) 2 (40) 0 (0)\nStaphylococcus  aureus  (5) 3 (60) 1 (20)\nStreptococcus/Enterococcus  spp. (5) 5 (100) 3 (60)\nEnterococcus faecalis  (2) 2 (100) 1 (50)\nEnterococcus faecium  (1) 1 (100) 0 (0)\nStreptococcus pneumoniae  (1) 1 (100) 1 (100)\nStreptococcus agalactiae  (1) 1 (100) 1 (100)Table 1  Performance of two methods for identifying bacteria to the species level from \nblood cultures by matrix-assisted laser desorption/ionization time-of-flight \nmass-spectrometry: training setComparison of two methods skipping cell lysis and protein extraction for identification of bacteria from \nblood cultures by matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry I. Torres, et al.\nRev Esp Quimioter 2019;32(4): 365-369367from Biomeriuex, L\u2019Etoile, France or BD Phoenix BD system, BD) \nor 16S rRNA gene sequencing.\nRESULTS\nAs shown in table 1, bacterial species in the training set \nwere successfully identified in 75% of cases after pre-cul -\ntivation in BHI and 45% of cases by direct BC processing. \n(P=<0.001 by a chi-square test). Species accounting for this spectra were acquired using the Microflex LT system (Bruker \nDaltonics, Bremen, Germany) and analyzed on MALDI BIOTYP -\nER 3.3 (Bruker Daltonics) software. MALDI-TOF MS analyses \nwere performed in triplicate on the same target slide. Criteria \nfor successful identification were met when the spectral score \nof at least one of the three spots was \u2265 2.0 (species level) and \n\u2265 1.7 (genus level), as recommended by the manufacturer.\nDiscordant results were resolved using commercially \navailable phenotypic methods (Vitek2, or API test strips, both Isolates in the panel  (n) Time to positive \nblood culture \nafter incubation \n(hours)Accurate identification fo -\nllowing pre-enrichment in Brain \nHeart Infusion broth\nno. of isolates (%)Incubation time in \nBrain Heart Infusion \nbroth (hours)Accurate identification by \ndirect processing of blood \ncultures\nno. of isolates (%)\nAll (145) 12.3 119 (82) 2.9 72 (49)\nEnterobacteriaceae  (58) 11.5 55 (94.8) 2.4 44 (75.8)\nEscherichia  coli (31) 11.3 29 (93.5) 2.1 25 (80.6)\nKlebsiella pneumoniae  (13) 11.9 12 (92.3) 2.2 12 (92.3)\nEnterobacter cloacae  (7) 11.6 7 (100) 2.8 3 (42.8)\nProteus mirabilis  (4) 13.9 4 (100) 2.7 1 (25)\nCitrobacter koseri  (1) 6.8 1 (100) 2.5 1 (100)\nEnterobacter kobei  (1) 10.2 1 (100) 2.0 1 (100)\nSerratia marcescens  (1) 6.9 1 (100) 2.5 1 (100)\nNon-fermenting Gram-negative rods (10) 13.6 7 (70) 3.8 6 (60)\nPseudomonas aeruginosa  (9) 13.9 7 (77.8) 3.9 6 (66.7)\nPseudomonas putida  (1) 11.2 0 (0) 3.0 0 (0)\nStaphylococcus spp. (37) 12.8 24 (64.8) 3.4 5 (13.5)\nStaphylococcus aureus  (12) 12.4 8 (66.7) 3.4 2 (16.7)\nStaphylococcus hominis  (10) 13.2 7 (70) 3.6 1 (10)\nStaphylococcus epidermidis  (9) 13.5 7 (77.7) 3.2 1 (11.1)\nStaphylococcus haemolyticus  (4) 12.0 2 (50) 3.4 0 (0)\nStaphylococcus capitis  (2) 12.7 0 (0) 2.7 1 (50)\nStreptococcus spp./Enterococcus spp. (38) 12.6 33 (86.8) 2.9 17 (44.7)\nEnterococcus faecium  (11) 13.0 10 (90.9) 2.7 5 (45.4)\nEnterococcus faecalis  (7) 14.7 5 (71.4) 3.5 3 (42.8)\nStreptococcus pneumoniae  (7) 10.6 6 (85.7) 2.9 4 (57.1)\nStreptococcus pyogenes  (5) 11.3 5 (100) 2.8 3 (69)\nStreptococcus anginosus  (3) 13.3 3 (100) 2.7 0 (0)\nStreptoptococcus  oralis (2) 13.1 2 (100) 2.0 0 (0)\nEnterococcus  hirae (1) 11.0 1 (100) 3.5 1 (100)\nStreptococcus  agalactiae  (1) 11.9 1 (100) 3.0 1 (100)\nStreptococcus  parasanguinis  (1) 12.8 0 (0) 2.5 0 (0)\nGemella morbillorum  (2) 13.7 0 (0) 2.0 0 (0)Table 2  Performance of two methods for identification to the species level of bacteria \nfrom blood cultures by matrix-assisted laser desorption/ionization time-of-\nflight mass-spectrometry: validation setComparison of two methods skipping cell lysis and protein extraction for identification of bacteria from \nblood cultures by matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry I. Torres, et al.\nRev Esp Quimioter 2019;32(4): 365-369368difference were Pseudomonas aeruginosa , Staphylococcus \naureus  and Enterococcus spp. These results were largely repro -\nduced in the validation set (table 2). In fact, the ENR meth -\nod identified 82% of isolates to the species level, whereas \nonly 49% could be identified by the DI method ( P=<0.001 \nby a chi-square test). Both methods performed better with \nGram-negative rods, particularly Enterobacteriaceae , than \nwith Gram-positive cocci. The ENR method was more success -\nful with all bacterial species included in the panel, except for \nStaphylococcus capitis  (n=1). The DI method\u2019s performance \nwas hampered by its failure to accurately identify a large num -\nber of Gram-positive cocci ( Staphylococcus  spp., 86.5%, Ente-\nrococcus  spp., 52%, and Streptococcus spp., 57%). \nAll Gram-negative rods except Pseudomonas putida  were \nsuccessfully identified to the genus level by both methods. As \nfor Gram-positive cocci, 5 (2 Staphylococcus capitis , 2 Gemel -\nla morbillorum and 1 Streptococcus parasanguinis ) and 12 (4 \nStaphylococcus haemolyticus , 3 Streptococcus anginosus, 2 \nStreptococcus oralis,  2 Gemella morbillorum and 1 Strepto -\ncoccus parasanguinis ) were not accurately named to the ge -\nnus level by the ENR and DI methods, respectively.\nDISCUSSION\nA number of studies have evaluated DI methods avoiding \nblood cell lysis and protein extraction [2-5], and to our knowl -\nedge, only one of these used vacutainer separator gels tubes \n[5]. Overall, the rate of accurate identification to the species \nlevel varied widely across these studies (between 50% and \n98%), although all consistently showed a better performance \nfor Gram-negative than for Gram-positive bacteria. The disa -\ngreement among these studies may be attributable to the use \nof different starting volumes of blood for pelleting bacteria (1 \nto 6 ml), the speed of the centrifugation steps to remove blood \ncells, the spectrum of bacteria subjected to analysis, the plat -\nform used for MALDI-TOF MS analysis, and the stringency of \nthe cut-off spectral scores for species identification. \nOur study further emphasizes that DI methods struggle \nto identify Gram-positive bacterial species correctly (strepto -\ncocci in particular), even when employing large volumes of \nblood; consequently, cell lysis and protein extraction prior to \nMALDI-TOF MS are warranted to enhance efficiency [8]. This \ndoes not appear to be the case for Gram-negative bacteria, \nin particular for those belonging to Enterobacteriaceae , for \nwhich the DI method performed reasonably well, in line with \na previous study also using vacutainer separator gels tubes but \nperform reasonably well for Enterobacteriaceae , in line with a \nprevious study also using vacutainer separator gels tubes [7]. \nNevertheless, the DI method evaluated herein was clearly out -\nperformed by our pre-enrichment method for identification of \nvirtually all bacterial species included in the panels. The ma -\nnipulation that is inherent to the pre-enrichment method we \npropose entails the risk of contamination, although this was \nnegligible in our series, perhaps due to the training of the per -\nsonnel in charge. In this sense, whether  the simple incubation/\nagitation of positive blood culture bottles during a comparable time period, this practically minimizing the risk of contami -\nnations, would have resulted in a bacterial identification rate \ncomparable to that achieved by our method merits further \ninvestigation. Work addressing this issue is currently under -\nway. Advantages of DI procedures in comparison with pre-en -\nrichment methods include faster bacterial identification and \nlower risk of contamination by saprophytic bacteria. Whether \nor not the delay in bacterial identification has a tangible im -\npact on patient outcomes remains to be investigated. Given \nthe good performance of the DI method evaluated herein for \nthe identification of Enterobacteriaceae  and its rather limited \nsuccess rate for identification of non-fermenting Gram-neg -\native bacilli and Gram-positive cocci when compared to that \nof the pre-enrichment method, a mixed strategy, by which \none method or another would be used according the bacterial \nmorphotype observed on Gram stain smear preparations may \nfind its place in the work flow for positive blood cultures.  \nACKNOWLEDGEMENTS \nEstela Gim\u00e9nez holds a R\u00edo Hortega research contract \nfrom the Carlos III Health Institute (ISCIII) (Ref. CM16/00200). \nWe thank BD for the kind donation of vacutainer gel tubes \nused in this study.\nFUNDING \nNone to declare\nCONFLICT OF INTEREST\nThe authors declare that they have no conflicts of interest.\nREFERENCES\n1.  Faron ML, Buchan BW, Ledeboer NA. Matrix-Assisted Laser De -\nsorption    Ionization-Time of Flight Mass Spectrometry for Use \nwith Positive Blood Cultures: Methodology, Performance, and \nOptimization. J Clin Microbiol 2017; 55:3328-38. DOI: 10.1128/\nJCM.00868-17\n2.  Juiz PM, Almela M, Melci\u00f3n C, Campo I, Esteban C, Pitart C, et al. \nA comparative study of two different methods of sample prepa -\nration for positive blood cultures for the rapid identification \nof bacteria using MALDI-TOF MS. Eur J Clin Microbiol Infect Dis \n2012;31:1353-8. DOI: 10.1007/s10096-011-1449-x\n3.  La Scola B, Raoult D. Direct identification of bacteria in positive \nblood culture bottles by matrix-assisted laser desorption ionisation \ntimeof-flight mass spectrometry. PLoS One  2009; 4:e8041. DOI: \n10.1371/journal.pone.0008041\n4.  Maelegheer K, Nulens E . Same-day identification and antibiotic \nsusceptibility testing on positive blood cultures: a simple and inex -\npensive procedure. Eur J Clin Microbiol Infect Dis  2017; 36:681-7. \nDOI: 10.1007/s10096-016-2849-8\n5.  Wimmer JL, Long SW, Cernoch P, Land GA, Davis JR, Musser JM, Comparison of two methods skipping cell lysis and protein extraction for identification of bacteria from \nblood cultures by matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry I. Torres, et al.\nRev Esp Quimioter 2019;32(4): 365-369369et al. Strategy for rapid identification and antibiotic susceptibility \ntesting of gram-negative bacteria directly recovered from posi -\ntive blood cultures using the Bruker MALDI Biotyper and the BD \nPhoenix system . J Clin Microbiol 2012;50:2452-4. DOI: 10.1128/\nJCM.00409-12\n6.  Idelevich EA, Sch\u00fcle I, Gr\u00fcnastel B, W\u00fcllenweber J, Peters G, Becker \nK. Rapid identification of microorganisms from positive blood cul -\ntures by MALDI-TOF mass spectrometry subsequent to very short-\nterm incubation on solid medium. Clin Microbiol Infect 2014; 20 : \n1001\u20136. DOI: 10.1111/1469-0691.12640\n7.  Torres I, Gimenez E, Pascual T, Bueno F, Huntley D, Mart\u00ednez M, et \nal. Short-term incubation of positive blood cultures in brain-heart \ninfusion broth accelerates identification of bacteria by matrix-as -\nsisted laser desorption/ionization time-of-flight mass-spectrome -\ntry. J Med Microbiol 2017;66:1752-8. DOI: 10.1099/jmm.0.000643\n8.  Florio W, Tavanti A, Barnini S, Ghelardi E, Lupetti A. Recent Advanc -\nes and Ongoing Challenges in the Diagnosis of Microbial Infections \nby MALDI-TOF Mass Spectrometry. Front Microbiol 2018;9:1097. \nDOI: 10.3389/fmicb.2018.01097Rev Esp Quimioter 2019;32(4): 370-374370\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Evaluation of a rapid assay for detection of \nPBP2a Staphylococcus aureus\nABSTRACT \nBackground.  Methicillin-resistant Staphylococcus aureus  \n(MRSA) is a significant pathogen causing both health-care-\nassociated and community-acquired infection. Rapid and ac -\ncurate detection of this pathogen is crucial for the use of ap -\npropriate antimicrobial therapy and the control of nosocomial \nspread. \nMethods.  A total of 107 S. aureus  strains were assayed \nfor methicillin resistance: Vitek2\u00ae (bioM\u00e9rieux), CHROMa -\ngarTM MRSA II (BD Becton Dickinson), disk diffusion in agar \nfor cefoxitin 30 \u00b5g and immunochromatography PBP2a SA \nCulture Colony Test (AlereTM). The results of conventional tests \nwere compared with the \u201cgold standard\u201d PCR test for mecA  \ngene.\nResults.  Sensitivity and specificity were: disk diffusion for \ncefoxitin 100% and 100% respectively, Vitek2\u00ae 100 and 100%, \nCHROMagarTM MRSA II 100 and 96%, and ICPBP2a detection \n98,25% and 100%. \nConclusion.  ICPBP2a Culture Colony Test (AlereTM) is fast, \nefficient and economical technique for detection of penicillin \nbinding protein 2a (PBP2a) from isolates. This assay is a useful \ntool for the management of hospital outbreaks.\nKeywords: PBP2a, Methicillin-resistant Staphylococcus aureus , immuno -\nchromatography\nINTRODUCCI\u00d3N\nStaphylococcus aureus es un microorganismo que fre -\ncuentemente coloniza la piel del hombre sano, pero que tam -\nbi\u00e9n est\u00e1 involucrado en infecciones tanto de origen comu -RESUMEN \nIntroducci\u00f3n.  En los \u00faltimos a\u00f1os se ha producido un \nincremento de las infecciones producidas por Staphylococcus \naureus  resistente a meticilina (SARM). En comparaci\u00f3n con las \nproducidas por S. aureus  sensible a meticilina (SASM), las in -\nfecciones por SARM requieren estancias hospitalarias m\u00e1s pro -\nlongadas y presentan mayor mortalidad. La detecci\u00f3n r\u00e1pida \nde la resistencia a la meticilina por la adquisici\u00f3n del gen mecA  \nque codifica la prote\u00edna fijadora de penicilina (PBP2a) es crucial \npara evitar la diseminaci\u00f3n nosocomial e instaurar una correcta \nterapia antimicrobiana. Nos proponemos evaluar el test inmu -\nnocromatogr\u00e1fico r\u00e1pido para la detecci\u00f3n de PBP2a directa -\nmente de colonias de S. aureus , PBP2a SA Culture Colony Test\u00ae \n(ICPBP2a).\nMaterial y m\u00e9todos.  En 107 cepas de S. aureus  se estudi\u00f3 \nla resistencia a meticilina mediante las siguientes pruebas: el \nsistema automatizado Vitek2\u00ae (bioM\u00e9rieux), CHROMagar MRSA \nII\u00ae (BD Becton Dickinson ), difusi\u00f3n con disco de cefoxitina, la \nICPBP2a (AlereTM) y como m\u00e9todo de referencia, la detecci\u00f3n \nmolecular del gen mecA . \nResultados.  La sensibilidad y especificidad para las prue -\nbas de detecci\u00f3n fueron para la difusi\u00f3n en agar con disco \nde cefoxitina 100% y 100% respectivamente, Vitek2\u00ae 100% \ny 100%, CHROMagarTM MRSA II 100% y 96%, y la ICPBP2a \n98,25% y 100%. \nConclusi\u00f3n.  La inmunocromatograf\u00eda para la detecci\u00f3n \nde PBP2a es una t\u00e9cnica r\u00e1pida, f\u00e1cil y econ\u00f3mica. Resulta \nmuy \u00fatil para el manejo de brotes hospitalarios.\nPalabras clave: PBP2a, Staphylococcus aureus  resistente a meticilina, in -\nmunocromatograf\u00eda.Evaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n \nde PBP2a en Staphylococcus aureus\nServicio de Microbiolog\u00eda. UGC Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva. Hospital Regional Uni -\nversitario de M\u00e1lagaRoc\u00edo S\u00e1inz-Rodr\u00edguez \nInmaculada de Toro-\nPeinado\nMiriam Valverde-Troya\nM\u00aa Pilar Berm\u00fadez Ru\u00edz\nBego\u00f1a Palop-Borr\u00e1s\nCorrespondencia:\nBego\u00f1a Palop-Borr\u00e1s\nServicio de Microbiolog\u00eda\nHospital Regional Universitario de M\u00e1laga \nAvda. Carlos Haya, s/n 29010 M\u00e1laga \nE-mail: bpalop@hotmail.comOriginal breve\nArticle history\nReceived: 15 February 2019; Revision Requested: 21 March 2019; Revision Received: 17 April 2019; Accepted: 25 April 2019Evaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n de PBP2a en Staphylococcus aureus R. S\u00e1inz-Rodr\u00edguez, et al.\nRev Esp Quimioter 2019;32(4): 370-374371De las 107 cepas de S. aureus  se aislaron 93 (86,91%) de \nmuestras cl\u00ednicas: 78 de sangre (83,87%), 4 abscesos (4,30%), \n1 biopsia (1,07%), 4 broncoaspirados (4,30%), y 6 exudados de \nherida (6,45%). Y las 14 restantes de frotis nasales para estudio \nde portadores (13,08%). \nLas muestras se trabajaron seg\u00fan los protocolos norma -\nlizados del laboratorio que incluyen: Cultivo en medios no \nselectivos y espec\u00edficos y estudios de identificaci\u00f3n utilizando \nespectrometr\u00eda de masas MALDI TOF (Bruker\u00ae), y la sensibilidad \nmediante el sistema comercial automatizado Vitek2\u00ae (bioM\u00e9 -\nrieux). Los resultados de sensibilidad antimicrobiana se inter -\npretaron siguiendo los criterios EUCAST 2015-2018.\nAdem\u00e1s, a todas ellas se les realiz\u00f3 siembra en medio cro -\nmog\u00e9nico CHROMagar MRSA II (BD Becton Dickinson) con \nlectura a las 24 y 48 horas, estudio de resistencia fenot\u00edpico \nutilizando m\u00e9todo de difusi\u00f3n con disco de cefoxitina, inmu -\nnocromatograf\u00eda para la detecci\u00f3n de PBP2a utilizando el test \nPBP2a SA Culture Colony y adem\u00e1s estudio molecular de de -\ntecci\u00f3n de gen mecA , para lo que se utilizaron 2 procedimien -\ntos: 52 cepas aisladas en muestras de sangre (a\u00f1os 2015-2017) \nse enviaron al Centro Nacional de Microbiolog\u00eda (CNM) para \nestudio de tipificaci\u00f3n. Y a las 55 cepas restantes se les realiz\u00f3 \nen el Laboratorio de Microbiolog\u00eda del HRU de M\u00e1laga el estu -\ndio molecular para la detecci\u00f3n del gen mecA. \nInmunocromatograf\u00eda PBP2a SA.  Se trata de un inmu -\nnoensayo cromatogr\u00e1fico cualitativo para la detecci\u00f3n r\u00e1pida \nde la prote\u00edna de fijaci\u00f3n de la penicilina 2a (PBP2a) en co -\nlonias previamente identificadas, como ayuda para identifi -\ncar S.aureus  resistente a la meticilina (SARM). Se basa en la \ntecnolog\u00eda de membrana de nitrocelulosa donde se fijan los \nanticuerpos monoclonales recombinantes (rFabs) altamente \nsensibles y una prote\u00edna de control. Se realiz\u00f3 siguiendo las in -\ndicaciones del fabricante. Los resultados se leen visualmente al \ncabo de 5 minutos.\nM\u00e9todos moleculares.  Del total de 78 cepas recuperadas a \npartir de hemocultivos, se enviaron 52 al CNM de Majadahonda \n(Madrid) donde se les realiz\u00f3, entre otras t\u00e9cnicas, una tipifica -\nci\u00f3n del casete cromos\u00f3mico estafiloc\u00f3cico mec (SCCmec) me -\ndiante una PCR m\u00faltiple que gener\u00f3 un patr\u00f3n de amplificaci\u00f3n \nespec\u00edfico para cada tipo estructural de SCCmec [11].\nLas 55 cepas restantes se trabajaron en el Laboratorio de \nMicrobiolog\u00eda del HRU de M\u00e1laga donde se les realiz\u00f3 en pri -\nmer lugar una extracci\u00f3n automatizada de ADN con el sistema \nMagcore\u00ae y una posterior PCR a tiempo real SmartCycler (Ce -\npheid\u00ae) utilizando el kit RealCycler SAMAPV (Progenie Molecu -\nlar\u00ae) que detecta el gen mecA , la toxina leucocidina de Panton-\nValentine (PVL) y el ADN (gen NUC) de S. aureus .\nRESULTADOS\nDel total de 107 cepas de S. aureus , se identificaron por \nm\u00e9todos moleculares 57 (53,27%) SARM y 50 (46,73%) SASM. nitario como hospitalario. Es una de las principales causas de \ninfecciones en la piel, tejidos blandos y huesos, adem\u00e1s de bac -\nteriemias y sepsis [1].\nS. aureus  adquiere la resistencia a meticilina y a otros \n\u03b2-lact\u00e1micos principalmente por el gen mecA,  que codifica la \nproducci\u00f3n de una prote\u00edna de uni\u00f3n a penicilina suplemen -\ntaria, PBP2a o 2\u2019, que se expresa de manera homog\u00e9nea o \nheterog\u00e9nea, y menos frecuentemente por el gen mecC  [2]. S. \naureus resistente a meticilina (SARM) es un pat\u00f3geno nosoco -\nmial de gran importancia a nivel mundial y ha incrementado la \nfrecuencia de infecciones adquiridas en la comunidad con una \nsignificativa morbi-mortalidad [1,3].\nDistintos estudios indican que, seg\u00fan las tasas de morta -\nlidad, las cepas de SARM son m\u00e1s virulentas que las cepas de \nS.aureus  susceptibles a la meticilina (SASM)[4].\nSeg\u00fan los datos proporcionados por el ECDC en 2017, el \nn\u00famero de aislamientos invasivos de SARM es variable para los \ndistintos pa\u00edses europeos (entre el 1% y el 44,4%), y dentro \nde estos, Espa\u00f1a se ha mantenido con cifras importantes del \n25,3% y que han ido en ligero aumento en estos \u00faltimos a\u00f1os \n(22,1% en 2014, 25,3 % en 2015, 25,8% en 2016) [5]. En nues -\ntro medio es por tanto de crucial importancia el conocimiento \nde la susceptibilidad a meticilina para instaurar el tratamiento \nemp\u00edrico correcto, teniendo en cuenta que el uso de la vanco -\nmicina, que ser\u00eda la alternativa en caso de SARM[6], se asocia \ncon una tasa de mortalidad m\u00e1s alta que los \u03b2-lact\u00e1micos en el \ntratamiento de la bacteriemia por SASM [7]. Adem\u00e1s, permite \nque los pacientes reciban una terapia antimicrobiana dirigida \nm\u00e1s r\u00e1pidamente con las implicaciones que conlleva en salud \nen infecciones graves como las bacteriemias por SARM [8,9].\nTodos estos datos demuestran la importancia de la detec -\nci\u00f3n temprana de estas cepas de SARM para instaurar un co -\nrrecto y r\u00e1pido tratamiento.\nCl\u00e1sicamente, la sensibilidad a la meticilina se determina por \nlas pruebas de susceptibilidad en disco o con m\u00e9todos automa -\ntizados, pero todos ellos necesitan al menos 24-48 horas para su \nrealizaci\u00f3n a partir del aislamiento en placa de S.aureus [2]. La \nincorporaci\u00f3n de m\u00e9todos moleculares ha permitido agilizar es -\ntos resultados, pero se trata de m\u00e9todos caros y de mayor com -\nplejidad t\u00e9cnica. Los m\u00e9todos inmunocromatogr\u00e1ficos son una \nalternativa a los anteriores, ya que se trata de m\u00e9todos r\u00e1pidos y \nde f\u00e1cil utilizaci\u00f3n en el laboratorio de Microbiolog\u00eda [10]. \nEn el presente trabajo evaluamos la incorporaci\u00f3n de \nPBP2a SA Culture Colony Test (Alere ahora Abbott) para la de -\ntecci\u00f3n de la meticilin-resistencia de S.aureus  aislados en nues -\ntro laboratorio.\nMATERIAL Y M\u00c9TODOS\nSe han incluido en el estudio 107 cepas de S.aureus  aisla -\ndas a partir de muestras cl\u00ednicas y de frotis nasales para estu -\ndios de vigilancia de pacientes atendidos en el Hospital Regio -\nnal Universitario (HRU) de M\u00e1laga, en el periodo comprendido \nentre el 1 de agosto de 2015 al 31 de agosto de 2018. Evaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n de PBP2a en Staphylococcus aureus R. S\u00e1inz-Rodr\u00edguez, et al.\nRev Esp Quimioter 2019;32(4): 370-374372la excepci\u00f3n de uno de los aislamientos de SARM que resul -\nt\u00f3 indeterminado. Este hecho podr\u00eda deberse a que seg\u00fan el \nfabricante (Alere Technical Services), los resultados no v\u00e1lidos \ngeneralmente se deben a cantidades excesivas de PBP2a que \nse unen al conjugado y evitan que aparezca la l\u00ednea de control \n[12]. Otros autores [13] describen falsos positivos en pruebas \nrealizadas a partir de hemocultivos con part\u00edculas de carb\u00f3n.\nEn situaciones de brotes hospitalarios en los que es nece -\nsaria una respuesta r\u00e1pida para evitar la diseminaci\u00f3n de este \npat\u00f3geno, es de gran relevancia poder disponer de una t\u00e9cnica \ncapaz de identificar estas cepas de una forma r\u00e1pida y sencilla, \ngenerando un gran beneficio en t\u00e9rminos socio-sanitarios ya \nque facilita aislamientos precoces y tratamientos eficaces. Las \npruebas moleculares son \u00f3ptimas para este fin, pero requieren \nequipo, instalaciones adecuadas, personal capacitado para su \nrealizaci\u00f3n y recursos econ\u00f3micos que no est\u00e1n disponibles en \ntodos los hospitales.\nLa utilizaci\u00f3n de cefoxitina en lugar de oxacilina como an -\ntibi\u00f3tico de elecci\u00f3n tiene la ventaja de ser mejor inductor de la \nexpresi\u00f3n del gen mecA , y detecta mejor las poblaciones SARM \nde bajo nivel de resistencia, clasificadas err\u00f3neamente como \nSASM [2].\nEl sistema autom\u00e1tico Vitek2\u00ae presenta excelentes resul -\ntados y la ventaja de mayor rapidez frente al medio cromog\u00e9 -\nnico CHROMagar MRSA II y la difusi\u00f3n en disco de cefoxitina, \nya que se obtienen los resultados a partir de las 7 horas [14].\nCHROMagar MRSA II demuestra ser \u00fatil como t\u00e9cnica de \nscreening en la b\u00fasqueda de portadores nasales de SARM, con \nlectura de las placas a las 24 y 48 horas, aunque la sensibilidad \naumenta poco tras la reincubaci\u00f3n [15] pero a costa de la p\u00e9r -\ndida de eficacia. Algunos autores y con muestras de hemocul -\ntivos acortan este tiempo y obtienen id\u00e9nticos resultados a las \n12 y a las 24 horas, 96 % de sensibilidad y 100% especificidad \n[16]. Las 2 muestras discordantes crec\u00edan en el medio cromo -\ng\u00e9nico pero, sin embargo el resto de pruebas eran negativas. \nAlgunos autores [17] describen que la sensibilidad de estos me -\ndios disminuye cuando se trata de cepas heterorresistentes y la \nespecificidad en cepas con CMI borderline.\nLa principal debilidad que presenta esta prueba inmuno -\ncromatogr\u00e1fica es que s\u00f3lo est\u00e1 validada para su realizaci\u00f3n \nsobre colonias aisladas de S.aureus a partir de medios s\u00f3lidos, \nlo que retrasa la informaci\u00f3n 24 horas. Dupieux et al [9] la uti -\nlizaron con estafilococos coagulasa negativos demostrando la \nnecesidad de inducci\u00f3n con cefoxitina para obtener buenos Entre los 57 aislamientos de SARM, se detect\u00f3 el gen codifican -\nte de la PVL en el 5,26% (2 abscesos, 1 biopsia).\nLos resultados obtenidos en el sistema Vitek2\u00ae tuvieron \nuna concordancia del 100% con el m\u00e9todo de referencia. Las \n57 cepas de SARM mostraban concentraciones de oxacilina \u22654 \n\u00b5g/ml y el test de cefoxitina positivo. La prueba de difusi\u00f3n con \ndisco de cefoxitina present\u00f3 un halo de inhibici\u00f3n \u226421 mm en \nlas 57 cepas de SARM. \nEn el medio cromog\u00e9nico CHROMagar MRSA II crecieron \n59 cepas (2 de ellas SASM) y no crecieron 48/50 SASM. 2 cepas \nidentificadas como SASM crecieron en el medio cromog\u00e9nico \n(tabla 1).\nICPBP2a fue positiva en 56/57 SARM y negativa en 50/50 \nSASM. Una de las pruebas realizadas result\u00f3 indeterminada. Del \ntotal de 106 pruebas consideradas como v\u00e1lidas coincidieron \ncon los resultados obtenidos en el sistema Vitek2\u00ae y la prueba \nde difusi\u00f3n con disco de cefoxitina en el 100% de los casos \n(tabla 2).\nDISCUSI\u00d3N\nEn los \u00faltimos a\u00f1os y con el fin de controlar la disemi -\nnaci\u00f3n de SAMR en los hospitales fundamentalmente, se han \nimplantado distintas t\u00e9cnicas r\u00e1pidas, como la ICPBP2a. El test \ninmunocromatogr\u00e1fico es de f\u00e1cil realizaci\u00f3n y al no necesitar \nning\u00fan equipamiento espec\u00edfico es accesible a todos los tipos \nde laboratorios. Adem\u00e1s, los resultados son f\u00e1cilmente evi -\ndenciables, de hecho, todos los resultados fueron v\u00e1lidos con n\u00ba de aislado Tipo de muestra Vitek2 OXA Disco Cefoxitina CHROMagar MRSA II IC PBP2a mecA PLV\n31 Absceso S \u2264 0,25 S + - - -\n34 Absceso S \u2264 0,25 S + - - -Tabla 1  Aislados discordantes\nS = sensible\nPrueba Sensibilidad Especificidad\nDisco Cefoxitina57/57\n100%50/50\n100%\nVitek257/57\n100%50/50\n100%\nCHROMagar MRSA II57/57\n100%48/50\n96%\nICPBP2a56/57\n98,25%50/50\n100%Tabla 2  Sensibilidad y especificidad de las \npruebas.Evaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n de PBP2a en Staphylococcus aureus R. S\u00e1inz-Rodr\u00edguez, et al.\nRev Esp Quimioter 2019;32(4): 370-374373(EARS-Net) 2017. Disponible en: https://ecdc.europa.eu/en/publi -\ncations-data/surveillance-antimicrobial-resistance-europe-2017\n6. Rao S N, Wang S K, Gonzalez-Zamora J, Hanson A P, Polisetty R S, \nand Singhm K. Improving time to optimal Staphylococcus aureus  \ntreatment using a penicillin-binding protein 2a assay. J Med Mi -\ncrobiol 2016; 65: 1452\u20131455. DOI: 10.1099/jmm.0.000365.\n7. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD et al. Outcome \nof vancomycin treatment in patients with methicillin-susceptible \nStaphylococcus  aureus  bacteremia. Antimicrob Agents Chemother \n2008; 52: 192-7. DOI: 10.1128/AAC.00700-07.\n8. Nicolsen N C, LeCroy N, Lecroy N, Alby K, Martin K E, Laux J, et \nal. Clinical outcomes with rapid detection of methicillin-resistant \nand methicillin-susceptible Staphylococcus aureus  isolates from \nroutine blood cultures. J Clin Microbiol 2013; 51: 4126\u20134129. DOI: \n10.1128/JCM.01667-13.\n9. Dupieux C, Trouillet-Assant S, Tasse J, Freydi\u00e8re A M, Raulin O, \nRoure-Sobas Ch, Salord H, et al. Evaluation of a commercial im -\nmunochromatographic assay for rapid routine identification of \nPBP2a-positive Staphylococcus aureus  and coagulase-negative \nstaphylococci. Diagn Microbiol Infect Dis2016; 86: 262\u2013264. DOI: \n10.1016/j.diagmicrobio.2016.08.012.\n10. Arnold A R, Burnham C A D, Ford B A, Lawhon S D, McAllister S K, \nLonsway D, et al. Evaluation of an immunochromatographic assay \nfor rapid detection of Penicillin-Binding Protein 2a in human and \nanimal Staphylococcus intermedius  group, Staphylococcus lugdu -\nnensis , and Staphylococcus schleiferi  clinical isolates. J Clin Micro -\nbiol 2016; 54 (3):745-748. DOI: 10.1128/JCM.02869-15.\n11. Oliveira Dc, A Tomasz and H. de Lencastre. Multiplex PCR strategy \nfor rapid identification of structural types and variants of the mec \nelement in methicillin-resistant Staphylococcus aureus . Antimi -\ncrob. Agents Chemother 2002; 46:2155-2161. PMID: 12069968.\n12. Trienski T L, Barrett H L, Pasquale T R, DiPersio J R and File T M. \nEvaluation and use of a rapid Staphylococcus aureus  assay by an \nantimicrobial stewardship program. Am J Health Syst Pharm 2013; \n70 (21):1908-1912. DOI: 10.2146/ajhp130118.\n13. Heraud S, Freydiere A M, Doleans-Jordheim A, Bes M, Tristan A, \nVandenesch F, et al. Direct Identification of Staphylococcus au -\nreus and Determination of Methicillin Susceptibility From Positive \nBlood-Culture Bottles in a Bact/ALERT System Using Binax Now \nS. aureus and PBP2a Tests. Ann Lab Med 2015; 35:454-457. DOI: \n10.3343/alm.2015.35.4.454.\n14. Acosta-P\u00e9rez G, Rodr\u00edguez-\u00c1brego G, Longoria-Revilla E, Castro-\nMussot M E. Evaluaci\u00f3n de cuatro m\u00e9todos para la detecci\u00f3n de \nStaphylococcus aureus  meticilino-resistente de muestras cl\u00ednicas \nen un hospital regional. Salud Publica Mex 2012; 54:1-6. PMID: \n22286822.\n15. Wendt C, Havill N L, Chapin K C, Boyce J M, Dickenson R, Eigner \nU, Schutt S and Fahr A M. Evaluation of a New Selective Medium, \nBD BBL CHROMagar MRSA II, for Detection of Methicillin-Resistant \nStaphylococcus aureus  in Different Specimens. J Clin Microbiol \n2010; 48(6): 2223\u20132227. DOI: 10.1128/JCM.02374-09.\n16. Chihara S, Hayden M K, Minogue-Corbett E, and Singh K . Shorte -\nned Time to Identify Staphylococcus  Species from Blood Cultures resultados. Existen estudios que realizan la prueba a partir de \nmuestra directa de hemocultivos positivos obteniendo buenos \nresultados [18]. Otros tambi\u00e9n los obtienen realizando la iden -\ntificaci\u00f3n por espectrometr\u00eda de masas (MALDI TOF, Bruker) \na partir de microcolonias a las pocas horas del subcultivo de \nlos hemocultivos positivos y la detecci\u00f3n de PBP 2a cuando se \ntrata de S.aureus [19] produciendo resultados en unas cuantas \nhoras de gran repercusi\u00f3n en el manejo del paciente.\nLa inmunocromatograf\u00eda Alere\u00ae para detecci\u00f3n r\u00e1pida de \nPBP2a resulta ser por tanto una prueba de f\u00e1cil implementa -\nci\u00f3n a nivel t\u00e9cnico [20], r\u00e1pida, segura y econ\u00f3mica que puede \nutilizarse en los laboratorios de Microbiolog\u00eda para confirmar la \nresistencia a meticilina mediada por el gen mecA .\nAGRADECIMIENTOS\nLos autores agradecen al Laboratorio de Infecciones intra -\nhospitalarias del Centro Nacional de Microbiolog\u00eda (Instituto de \nSalud Carlos III) por la tipificaci\u00f3n de las cepas enviadas y al Dr. \nFederico Rom\u00e1n Alonso, responsable del mismo por la revisi\u00f3n \nde las mismas. \nFINANCIACI\u00d3N\nLos autores declaran no haber recibido financiaci\u00f3n para la \nrealizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan conflicto de inte -\nreses.\nBIBLIOGRAF\u00cdA\n1. Tong S Y C, Davis J S, Eichenberger E, Holland T L, Vance G. Fowler V \nG. Staphylococcus aureus  Infections: Epidemiology, Pathophysio -\nlogy, Clinical Manifestations, and Management. Clin Microbiol Rev \n2015; 28(3): 603-661. DOI: 10.1128/CMR.00134-14.\n2. Morosini MI, Cercenado E, Ardanuy C, Torres C. Detecci\u00f3n fenot\u00edpi -\nca de mecanismos de resistencia en microorganismos grampositi -\nvos. Enf Infec Microbiol Clin 2012; 30(6): 325-332. DOI: 10.1016/j.\neimc.2011.09.009.\n3. Han Z, Lautenbach E, Fishman N, Nachamkin I. Evaluation of man -\nnitol salt agar, CHROMagar Staph aureus and CHROMagar MRSA \nfor detection of meticilin-resistant Staphylococcus aureus  from \nnasal swab specimens. J Med Microbiol 2007; 58: 43-46. DOI: \n10.1099/jmm.0.46777-0.\n4. Melzer M, Eykyn S J, Gransden W R, Chinn S. Is Methicillin-Resis -\ntant Staphylococcus aureus More Virulent than Methicillin-Sus -\nceptible S. aureus ? A Comparative Cohort Study of British Patients \nwith Nosocomial Infection and Bacteremia. Clin Infect Dis 2003; \n37(11): 1453\u20131460. DOI: 10.1086/379321.\n5. Surveillance of antimicrobial resistance in Europe Annual report \nof the European Antimicrobial Resistance Surveillance Network Evaluaci\u00f3n de una prueba r\u00e1pida para la detecci\u00f3n de PBP2a en Staphylococcus aureus R. S\u00e1inz-Rodr\u00edguez, et al.\nRev Esp Quimioter 2019;32(4): 370-374374and Methicillin Resistance Testing Using CHROMAgar. Int J Micro -\nbiol 2009; 65: 626\u2013631. DOI: 10.1155/2009/636502\n17. Datta P, Gulati N, Singla N, Rani Vasdeva H, Bala K, Chander J, et al. \nEvaluation of various methods for the detection of meticillin-re -\nsistant Staphylococcus aureus  strains and susceptibility patterns. J \nMed Microbiol 2011; 60:1613-1616. DOI: 10.1099/jmm.0.032219-\n0.\n18. Kong H, Tong L, Zhang W, Fu Y, Li X. Combined use of the Binax -\nNOW Staphylococcus aureus  test with the Clearview PBP2a assay \nfor the early detection of methicillin-resistant S. aureus  from po -\nsitive blood culture. Diag Microbiol Infect Dis 2014; 78:226\u2013228. \nDOI: 10.1016/j.diagmicrobio.2013.11.018.\n19. Delport J A, Mohorovic I, Burn S, McCormick J K, Schaus D, Lanni -\ngan R and Michael John M. Rapid detection of meticillin-resistant \nStaphylococcus aureus  bacteraemia using combined three-hour \nshort-incubation matrixassisted laser desorption/ionization time-\nof-flight MS identification and Alere Culture Colony PBP2a de -\ntection test. J Med Microbiol 2016; 65: 626-631. DOI: 10.1099/\njmm.0.000285.\n20. Tasse J, Dupieux C, Caillon J, Lanotte P, Lamy B, Aissa N et al. Rapid \nbench identification of methicillin-sensitive and methicillin-resis -\ntant Staphylococcus aureus : A multicenter comparative evaluation \nof Alere PBP2a Culture Colony Test (Alere) Versus Slidex MRSA de -\ntection (bioM\u00e9rieux). Diag Microbiol Infect Dis 2016; 85:419-421. \nDOI: 10.1016/j.diagmicrobio.2016.04.008.Rev Esp Quimioter 2019;32(4): 375-378375\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).susceptibility data of strains isolated from pregnant women \nwith AB as representation of women with community-acquired \nUAC.\nKeywords: uncomplicated UTI, antibiotic resistance, asymptomatic bacte -\nriuria, pregnant women\n\u00bfEs posible extrapolar las tasas de \nresistencia de Escherichia coli  de bacteriurias \nasintom\u00e1ticas en gestantes a las de E. coli  en \nITU no complicada adquirida en la comunidad?\nRESUMEN\nObjetivos.  El tratamiento en atenci\u00f3n primaria de las in -\nfecciones del tracto urinario no complicadas es generalmente \nemp\u00edrico sin solicitar urocultivo y basado en datos de resisten -\ncia sesgados procedentes de pacientes seleccionados, muchos \nde ellos con factores de riesgo de aislamiento de microorganis -\nmos resistentes. Con el fin de solventar el d\u00e9ficit de informaci\u00f3n \nsobre las tasas de resistencia reales en ITU no complicada, com -\nparamos el fenotipo antimicrobiano y genotipo de aislados de \nEscherichia coli  procedentes de mujeres embarazadas con bac -\nteriuria asintom\u00e1tica (cultivo siempre realizado) con aquellos \nprocedentes de mujeres con cistitis aguda no complicada (cul -\ntivo raramente realizado) de diferentes grupos de edad. \nMaterial y m\u00e9todos . Entre septiembre de 2017 y marzo \nde 2018 se recogieron aleatoriamente 103 orinas de mujeres \nembarazadas con edades entre 16 y 47 a\u00f1os con bacteriuria \nasintom\u00e1tica (BA) (n=42), mujeres no hospitalizadas en el mis -\nmo rango de edad con cistitis aguda no complicada (CANC) \n(n=31) y mujeres mayores de 47 a\u00f1os no hospitalizadas con \nCANC (n=30). La identificaci\u00f3n bacteriana se realiz\u00f3 por es -\npectrometr\u00eda de masas y el antibiograma por microdiluci\u00f3n en \ncaldo. La tipificaci\u00f3n gen\u00e9tica se llevo a cabo por electroforesis \nen gel por campo pulsado. ABSTRACT\nObjective.  Treatment of uncomplicated urinary tract in -\nfections in primary care is generally empirical without request -\ning urine culture and based on biased resistance data collected \nfrom selected patients, most of them having risk factors for the \nisolation of resistant microorganisms. In order to overcome the \nlack of information on the real resistance rates in uncomplicat -\ned UTI, we compared antimicrobial phenotype and genotype of \nEscherichia coli  isolated from pregnant women with asympto -\nmatic bacteriuria (culture always performed) with those from \nwomen with uncomplicated acute cystitis (culture rarely per -\nformed) of different age groups. \nMaterial and methods.  Between September 2017 and \nMarch 2018, 103 urines were randomly collected from preg -\nnant women aged between 16 and 47 with asymptomatic \nbacteriuria (AB) (n=42), not hospitalized women in the same \nage range with uncomplicated acute cystitis (UAC) (n=31) and \nwomen older than 47 not hospitalized with UAC (n=30). Bacte -\nria identification was performed using mass spectrometry and \nthe antibiogram by broth microdilution. Genetic typification \nwas carried out by pulsed-field gel electrophoresis.\nResults . There are no significant differences between the \ngroups of patients in the antibiotic susceptibility. Likewise, \nas expected, a wide genetic diversity is observed among the \nstrains of E. coli  studied without significant differences be -\ntween the three groups. \nConclusions . We propose a simple model that could pro -\nvide better guidance for selection of empirical antimicrobial \ntherapy for non-pregnant women with UAC than do generic \nhospital antibiogram data based on reliably extrapolating the Is it possible to extrapolate the rates of resistance \nof Escherichia coli  from asymptomatic bacteriuria \nin pregnant women to those of E. coli in \nuncomplicated community-acquired UTI?\n1Servicio Microbiolog\u00eda, Hospital Universitario de Getafe, Madrid, Spain.\n2Laboratorio de Referencia e Investigaci\u00f3n en Resistencia a Antibi\u00f3ticos e Infecciones Relacionadas con la Asistencia Sa -\nnitaria, Centro Nacional de Microbiolog\u00eda, Majadahonda, Madrid, Spain.\n3Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI), Spain.Alejandra Asenjo1\nMart\u00edn C. Grados1\nJes\u00fas Oteo-Iglesias2,3\nJuan-Ignacio Al\u00f3s1\nCorrespondence:\nJuan-Ignacio Al\u00f3s\nServicio Microbiolog\u00eda, Hospital Universitario de Getafe, Madrid, Spain.\nPhone: +34 916833541\nE-mail:nachoalos@telefonica.netBrief report\nArticle history\nReceived: 25 March 2019; Revision Requested: 14 April 2019; Revision Received: 29 April 2019; Accepted: 7 May 2019Is it possible to extrapolate the rates of resistance of Escherichia coli  from asymptomatic bacteriuria in \npregnant women to those of E. coli  in uncomplicated community-acquired UTI?A. Asenjo, et al.\nRev Esp Quimioter 2019;32(4): 375-378376lected. The samples were from women which, after reviewing \ntheir clinical history, met the inclusion criteria:\n\u2013 Pregnant women aged between 16 and 47 at the end of \nthe first trimester or beginning of the second trimester with \nasymptomatic bacteriuria (AB), considering this term when \n>105 UFC/ml of E. coli were isolated. \n\u2013 Not hospitalized in the same age range with uncompli -\ncated acute cystitis (UAC) and the isolation of >103 UFC/ml of \nE. coli .\n\u2013 Older than 47 not hospitalized with UAC and the isolation \nof >103 UFC/ml of E. coli .\nFrom the first group, 42 strains of E. coli were collected, \nfrom the second, 31 and from the third, 30. \nBacteria identification was performed using mass spec -\ntrometry (MALDITOF) and the antibiogram by broth microdilu -\ntion (MicroScan panels). Genetic typification was carried out by \npulsed-field gel electrophoresis (PFGE) following digestion with \nthe restriction endonuclease XbaI with the purpose of measur -\ning the genetic variation between the strains of the different \npatient groups.\nIn addition, cumulative susceptibility data of adults from \nprimary care with significant isolation of E. coli  in urine cul -\ntures during 2017 were obtained from our laboratory computer \nsystem.\nData were introduced in a database created for the study. \nThe results of PFGE were analyzed with InfoQuestFP, using a \ncut-off point of 85% similarity, and the diversity index was \ncalculated [8]. \nTo test the statistically significant differences in the sus -\nceptibility and genetic variability of the strains among the 3 \nstudy groups, either the chi-square test or Fisher\u2019s exact test \nwas performed. When the p-value was inferior to the alpha \nerror (5%), a statistical significance was considered. \nThe project was approved by the Ethics Committee (CEIm \n18/19)\nRESULTS\nThe strains studied showed high susceptibility rates to all \nthe antimicrobials tested except to ampicillin with no signifi -\ncant differences between the different groups (table 1).\nInterestingly, when the susceptibility data of the total \nUAC strains of the study (n=103) are compared with the 2017 \ncumulative laboratory data (n=2,328), significant differences \nwere observed in the susceptibility of E. coli  to ampicillin (p = \n0.008), cefotaxime (p=0.03), cotrimoxazole (p = 0.002), nalidix -\nic acid (p = 0.01), ciprofloxacin (p = 0.001) and to gentamicin \n(p = 0.008) (table 2).\nWe observed 90 unique PFGE-profiles (34 from E. coli \nisolates of the AB group, 29 from the strains of patients with \nUAC aged between 16 and 47, and 27 from strains of the \ngroup older than 47 with UAC). The diversity index of the set \nof E coli isolates was 87.38%. In table 3 the unique PFGE-pro -Resultados.  No hay diferencias significativas en la sensib -\nilidad antibi\u00f3tica entre los grupos de pacientes. De igual forma, \ny seg\u00fan lo esperado, se observ\u00f3 una amplia diversidad gen\u00e9tica \nentre las cepas de E. coli estudiadas sin diferencias significati -\nvas entre los diferentes grupos. \nConclusiones.  Proponemos un modelo sencillo que po -\ndr\u00eda orientar mejor que los datos generales del hospital en la \nselecci\u00f3n del tratamiento antimicrobiano emp\u00edrico de mujeres \nno embarazadas con CANC, basado en extrapolar los datos de \nsensibilidad de cepas aisladas de mujeres embarazadas con BA \ncomo representaci\u00f3n de mujeres con CANC adquirida en la co -\nmunidad.\nPalabras clave: ITU no complicada, Resistencia antimicrobiana, bacteriuria \nasintom\u00e1tica, mujer embarazada\nINTRODUCTION\nUncomplicated urinary tract infections (UTIs), mainly cys -\ntitis, are a frequent cause of primary care consultation. Escher -\nichia coli  is the microorganism most frequently involved [1]. \nTreatment is generally empirical and based on local susceptibil -\nity data without requesting urine culture [2-4].\nThese susceptibility data are based on the urine cultures \nsubmitted to laboratories but a high percentage of uncom -\nplicated UTIs are treated empirically without performing a \nurine culture. In addition, many of these urine samples are \nfrom selected patients (with complicated UTI or with previ -\nous failed treatments), most of them having risk factors for \nthe isolation of resistant microorganisms [5]. Therefore, the \nempirical treatment prescribed for uncomplicated cystitis is \nbased on biased resistance data, which are in most cases from \nstrains that cause complicated or recurrent UTIs that have \nbeen shown to be more resistant [6]. Real and representative \ndata are required. \nThe guidelines for the management of pregnant women \nrecommend to screen with urine culture for asymptomatic \nbacteriuria at the end of the first trimester or beginning of the \nsecond trimester [7]. This enables us to have reliable suscepti -\nbility results of E. coli  isolated in this population, which could \nbe representative of the population with uncomplicated UTI of \nsimilar or higher age.\nThe objective of the study, in order to overcome the lack of \ninformation on the real resistance rates in uncomplicated UTI, \nwas to validate the hypothesis that there is no difference in \npopulation or susceptibility between E. coli  isolated from urine \ncultures of pregnant women with asymptomatic bacteriuria \nand those isolated from women with uncomplicated acute \ncystitis of different age groups. If so, a susceptibility pattern of \nE. coli  causing uncomplicated cystitis could be obtained easily \nand inexpensively.\nMATERIALS AND METHODS\nBetween September 2017 and March 2018, 103 urines \nsubmitted to the microbiology laboratory were randomly col -Is it possible to extrapolate the rates of resistance of Escherichia coli  from asymptomatic bacteriuria in \npregnant women to those of E. coli  in uncomplicated community-acquired UTI?A. Asenjo, et al.\nRev Esp Quimioter 2019;32(4): 375-378377files found are reported separately by the different groups of \npatients studied. There were no significant differences in the \nnumber of profiles. \nDISCUSSION\nTan TY et al. provide evidence that laboratory antibiotic \nsusceptibility reporting has a direct influence on antibiotic \nprescribing [9, 10]. Previous studies have shown that the sus -\nceptibility data of uropathogens provided by laboratories are \nnot representative of those of uncomplicated UTI, leading to \nan overestimation of local resistance rates and the consequent \ninappropriate use of antibiotics in empirical treatment [11-13].\nIn our experience, we also observed significant differences \nafter comparing the results obtained in this study with the cu -\nmulative laboratory UTI susceptibility data. \nFollowing our local patterns and according to the guide -\nlines recommendation not to use an antibiotic as empirical \ntreatment in uncomplicated cystitis when the resistance is \ngreater than 20%, ciprofloxacin (73.75% of susceptibility), \ncotrimoxazole (68.38% of susceptibility) or ampicillin (43.77% \nof susceptibility) could not be used as empirical treatment of \nUAC. However, taking into account the results of this research, \nthe options for empirical treatment in women with uncompli -\ncated UTI would be extended since all antibiotics could be used \nwith the exception of ampicillin.\nThere are no significant differences between the groups \nof patients in the antibiotic susceptibility tested. Likewise, a \nwide genetic diversity is observed among the strains of E. coli  \nstudied without significant differences between isolates from \nwomen with AB and those from women with UAC acquired in \nthe community regardless of patient\u2019s age. The genetic diver -\nsity found in most of the strains studied after performing the \npulsed field is the expected in community-acquired UTI [14].Antimicrobial agent AB\n(n=42)UAC\n(16-46 years)\n(n=31)UAC\n (>47 years)\n(n=30)p\nAB vs UAC (16-46 years)p\nAB vs UAC (>47 years)\nAmpicillin 54.14% 67.74% 53.33% 0.36 0.75\nAmoxicillin clavulanate 93.02% 93.55% 90.00% 0.91 0.67\nCefotaxime 100.00% 100.00% 100.00% 1 1\nFosfomycin 100.00% 96.77% 100.00% 0.42 1\nCotrimoxazol 83.72% 83.87% 90.00% 0.83 0.59\nNalidixic acid 86.05% 77.42% 76.67% 0.22 0.20\nCiprofloxacin 95.35% 96.77% 86.67% 0.83 0.07\nGentamicin 93.02% 100.00% 100.00% 0.26 0.26Table 1  Percentage of susceptibility of the 103 grouped strains studied and comparison \nbetween groups\nAB: asymptomatic bacteriuria; UAC: uncomplicated acute cystitis\nAntimicrobial agent % susceptiblity\n(n=2,328)UAC\n(n=61)p\nAmpicillin 43.77% 60.66% 0.008\nAmoxicillin clavulanate 85.09% 91.8% 0.14\nCefotaxime 93.40% 100% 0.03\nFosfomycin 97.42% 98.36% 0.65\nCotrimoxazol 68.38% 86.88% 0.002\nNalidixic acid 61.68% 77.05% 0.01\nCiprofloxacin 73.75% 91.8% 0.001\nGentamicin 91.67% 100% 0.008Table 2  Cumulative susceptibility data of significant \nisolates of E. coli  in adults during 2017 in \ncomparison with those of UAC.\nUAC: uncomplicated acute cystitis\nA potential limitation of the study is the small sample size, \nbut it takes long time to recover strains of E. coli  from pregnant \nwomen with ABU. \nWe conclude that strains of E. coli  from pregnant women \nwith AB are similar in both genetic diversity and antimicrobi -\nal phenotype to those of women with UAC regardless of age. \nGiven that E. coli urine isolates from all pregnant women with \nAB are generated routinely, we propose a reasonable, econom -\nical and simple model that could provide better guidance for \nselection of empirical antimicrobial therapy for non-pregnant \nwomen with UAC than do generic hospital antibiogram data. \nThis model is based on reliably extrapolating the susceptibility \ndata of strains isolated from pregnant women with AB as rep -\nresentation of women with community-acquired UAC.Is it possible to extrapolate the rates of resistance of Escherichia coli  from asymptomatic bacteriuria in \npregnant women to those of E. coli  in uncomplicated community-acquired UTI?A. Asenjo, et al.\nRev Esp Quimioter 2019;32(4): 375-378378Infectious Diseases Society of America guidelines for the diagnosis \nand treatment of asymptomatic bacteriuria in adults. Clin Infect \nDis. 2005;40:643-54. DOI: 10.1086/427507\n8.  Gastmeier P, Schwab F, B\u00e4rwolff S, R\u00fcden H, Grundmann H. Cor -\nrelation between the genetic diversity of nosocomial pathogens \nand their survival time in intensive care units. J Hosp Infect. \n2006;62:181-6. DOI: 10.1016/j.jhin.2005.08.010\n9.  Tan TY, McNulty C, Charlett A, Nessa N, Kelly C, Beswick T . Lab-\noratory antibiotic susceptibility reporting and antibiotic prescrib -\ning in general practice. J Antimicrob Chemother. 2003;51:379-84. \nPMID:12562706\n10.  McNulty CA, Lasseter GM, Charlett A, Lovering A, Howell-Jones R, \nMacgowan A,Thomas M . Does laboratory antibiotic susceptibility \nreporting influence primary care prescribing in urinary tract infec -\ntion and other infections?. J Antimicrob Chemother. 2011;66:1396-\n404. DOI: 10.1093/jac/dkr088\n11.  Jorgensen S,  Zurayk M, Yeung S, Terry J, Dunn M, Nieberg P, et \nal. Emergency Department Urinary Antibiograms Differ by Specif -\nic Patient Group. J Clin Microbiol. 2017;55:2629-36. DOI: 10.1128/\nJCM.00481-17\n12.  Hudepohl NJ, Cunha CB, Mermel LA. Antibiotic Prescribing for \nUrinary Tract Infections in the Emergency Department Based on \nLocal Antibiotic Resistance Patterns: Implications for Antimicro -\nbial Stewardship. Infect Control Hosp Epidemiol. 2016;37:359-60. \nDOI:10.1017/ice.2015.283\n13.  Chin TL, McNulty C, Beck C, MacGowan A. Antimicrobial resistance \nsurveillance in urinary tract infections in primary care. J Antimicrob \nChemother. 2016;71:2723-8. DOI: 10.1093/jac/dkw223\n14.  Arbeit RD, Arthur M, Dunn R, Kim C, Selander RK, Goldstein R. \nResolution of recent evolutionary divergence among Escherichia \ncoli from related lineages: the application of pulsed field electro -\nphoresis to molecular epidemiology. J Infect Dis. 1990;161:230-5. \nPMID:1967621FUNDING\nThis study was supported in part by Fundaci\u00f3n Soria Mel -\nguizo. The funders had no role in study design, data collection and \ninterpretation, or the decision to submit the work for publication.\nCONFLICTS OF INTEREST\nThe authors declare that there are no conflicts of interest\nREFERENCES\n1.  de Cueto M, Aliaga L, Al\u00f3s JI, Canut A, Los-Arcos I, Mart\u00ednez JA, et \nal. Executive summary of the diagnosis and treatment of urinary \ntract infection: Guidelines of the Spanish Society of Clinical \nMicrobiology and Infectious Diseases (SEIMC). Enferm Infecc \nMicrobiol Clin. 2017;35:314-20. DOI: 10.1016/j.eimc.2016.11.005\n2.  Hillier S, Bell J, Heginbothom M, Roberts Z, Dunstan F, Howard A, \net al.  When do general practitioners request urine specimens for \nmicrobiology analysis? The applicability of antibiotic resistance \nsurveillance based on routinely collected data. J Antimicrob \nChemother. 2006;58:1303-6. DOI: 10.1093/jac/dkl432\n3.  Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, et al. Interna -\ntional clinical practice guidelines for the treatment of acute un -\ncomplicated cystitis and pyelonephritis in women: A 2010 update \nby the Infectious Diseases Society of America and the European \nSociety for Microbiology and Infectious Diseases. Clin Infect Dis. \n2011;52:e103-20. DOI: 10.1093/cid/ciq257\n4.  Livermore DM, Pearson A. Antibiotic resistance: location, location, \nlocation. Clin Microbiol Infect. 13 Suppl 2007;2:7-16. DOI: 10.1111/\nj.1469-0691.2007.01724.x\n5.  Schmiemann G, G\u00e1gyor I, Hummers-Pradier E, Bleidorn J. Resist -\nance profiles of urinary tract infections in general practice--an ob -\nservational study. BMC Urol. 2012;12:33. DOI: 10.1186/1471-2490-\n12-33\n6.  Ti TY, Kumarasinghe G, Taylor MB, Tan SL, Ee A, Chua C, Low A. What \nis true community-acquired urinary tract infection? Comparison of \npathogens identified in urine from routine outpatient specimens \nand from community clinics in a prospective study. Eur J Clin Mi -\ncrobiol Infect Dis. 2003;22:242-5. DOI: 10.1007/s10096-003-0893-\n7\n7.  Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. AB\n(n=42)UAC\n(16-46 years)\n(n=31)UAC \n(>47 years)\n(n=32)p\nAB vs UAC (16-46 years)p\nAB vs UAC (>47 years)\nUnique profiles (n) 34 29 27 0.12 0.70\nDiversity index 80.95% 93.55% 90.00% - -Table 3  Unique genetic profiles found in the 103 grouped strains studied and comparison  \nbetween groups.\nAB: asymptomatic bacteriuria; UAC: uncomplicated acute cystitisRev Esp Quimioter 2019;32(4): 379-380379\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).mera vez a los 8 meses de edad con episodios de lesiones cut\u00e1 -\nneas urticariformes recurrentes, asociando, a la edad de 4 a\u00f1os, \nedema facial e infecciones conjuntivales y \u00f3ticas de repetici\u00f3n. \nDesde los 18 a\u00f1os experimentaba adem\u00e1s brotes autolimitados \nde artritis de grandes articulaciones, requiriendo a lo largo de \nsu vida m\u00faltiples ciclos de tratamiento con esteroides.\nTras la confirmaci\u00f3n gen\u00e9tica del diagn\u00f3stico de CAPS \ny con el objetivo de iniciar tratamiento inmunosupresor con \nanti-interleukina 1 (anakinra) se deriv\u00f3 desde la Unidad de En -\nfermedades Autoinmunes Sist\u00e9micas de la Unidad de Gesti\u00f3n \nCl\u00ednica de Medicina Interna a la Unidad de Vacunas del Servi -\ncio de Medicina Preventiva y Salud P\u00fablica del propio centro. \nUna vez all\u00ed, se revis\u00f3 la historia vacunal y se realiz\u00f3 una sero -\nlog\u00eda basal. La paciente hab\u00eda recibido la vacunaci\u00f3n sistem\u00e1ti -\nca infantil correcta para su edad. En la tabla 1 se presentan los \nresultados serol\u00f3gicos.\nTeniendo en cuenta lo anterior, y dado que la paciente no \nestaba recibiendo tratamiento inmunosupresor, se program\u00f3 \nla vacunaci\u00f3n inicial con vacuna triple v\u00edrica y hepatitis B. La \nvacuna frente al virus de la hepatitis A no fue administrada en Sr. Editor:\nLos pacientes con enfermedades autoinflamatorias sist\u00e9 -\nmicas pueden estar en situaci\u00f3n de inmunosupresi\u00f3n, sobre \ntodo como consecuencia de los tratamientos que precisan. \nEsto condiciona un mayor riesgo de padecer enfermedades in -\nfecciosas, habiendo sido ampliamente demostrado en la litera -\ntura cient\u00edfica el beneficio de la vacunaci\u00f3n en este grupo [1]. \nLa seguridad de las vacunas es un hecho contrastado con \nuna s\u00f3lida base de evidencia cient\u00edfica [2].  Los ensayos cl\u00ednicos, \nas\u00ed como los controles de calidad durante su fabricaci\u00f3n, hacen \nque se hayan convertido en f\u00e1rmacos seguros [3]. A pesar de lo \nanterior, el manejo de las vacunas en los pacientes inmunode -\nprimidos debe llevarse a cabo en Unidades de Vacunas especia -\nlizadas. La monitorizaci\u00f3n de las reacciones adversas asociadas \na la vacunaci\u00f3n es de especial inter\u00e9s para la Farmacovigilancia. \nEn ocasiones, se han descrito reacciones adversas postvacunales \nen los pacientes inmunodeprimidos, por lo que la valoraci\u00f3n del \nbeneficio-riesgo debe estar siempre presente [4].\nSe plantea el caso de la reactivaci\u00f3n de la patolog\u00eda de \nbase de una paciente tras la vacunaci\u00f3n con triple v\u00edrica (sa -\nrampi\u00f3n, rubeola y parotiditis) y vacuna frente al virus de la \nhepatitis B. La paciente deb\u00eda actualizar su calendario vacunal \npor ser candidata a tratamiento inmunosupresor:\nSe trata de una mujer de 22 a\u00f1os con diagn\u00f3stico cl\u00ednico \nde s\u00edndrome peri\u00f3dico asociado a criopirinas (CAPS), clasifica -\ndo como fenotipo Muckle-Wells. Esta patolog\u00eda se caracteriza \npor una mutaci\u00f3n en el gen NLRP3 que se traduce en una ac -\ntivaci\u00f3n del inflamosoma con aumento en la s\u00edntesis de inter -\nleukina 1 beta (IL-1B), actual diana terap\u00e9utica de anticuerpos \nmonoclonales como el anakinra, canakinumab y rilonacept [5]. \nEn el caso de la paciente, la enfermedad se manifest\u00f3 por pri -Reactivaci\u00f3n del s\u00edndrome peri\u00f3dico asociado a \ncriopirinas tras la vacunaci\u00f3n en una paciente \ncandidata a inmunosupresi\u00f3n\n1Servicio de Medicina Preventiva y Salud P\u00fablica. Hospital Vital \u00c1lvarez Buylla. Asturias.\n2Unidad de Enfermedades Autoinmunes Sist\u00e9micas. Unidad de Gesti\u00f3n Cl\u00ednica de Medicina Interna. Hospital Universitario \nCentral de Asturias.\n3Servicio de Medicina Preventiva y Salud P\u00fablica. Hospital Universitario de La Princesa. Madrid.\n4Servicio de Alergolog\u00eda. Hospital Universitario Central de Asturias.\n5Servicio de Medicina Preventiva y Salud P\u00fablica. Hospital Valle del Nal\u00f3n. Asturias.\n6Servicio de Vigilancia Epidemiol\u00f3gica. Direcci\u00f3n General de Salud P\u00fablica. Consejer\u00eda de Sanidad del Principado de As -\nturias.Mar\u00eda Fern\u00e1ndez-Prada1\nJessica Rugeles-Ni\u00f1o2\nLuc\u00eda Su\u00e1rez-P\u00e9rez2\nMiguel Ruiz-\u00c1lvarez3\nJos\u00e9 Bernardino L\u00f3pez-\nD\u00edaz2\nJuan Fern\u00e1ndez-Madera4\nCarmen Mart\u00ednez-Ortega5\nIsmael Huerta-Gonz\u00e1lez6\nCorrespondencia:\nMar\u00eda Fern\u00e1ndez-Prada. \nServicio de Medicina Preventiva y Salud P\u00fablica. Hospital Vital \u00c1lvarez Buylla. Mieres, Asturias, \nEspa\u00f1a. Vistalegre 1B, 33619. \nTfno.: (+34) 678120248\nE-mail: mariafdezprada@gmail.comCarta al Director\nArticle history\nReceived: 3 September 2018; Accepted: 14 November 2018\nAnt\u00edgeno Determinaci\u00f3n Resultado\nVaricela IgG Positivo\nSarampi\u00f3n IgG Negativo \nHepatitis B antiHBs Negativo (2,0 UI/ml)\nantiHBc total Negativo\nHBsAg Negativo \nHepatitis A IgG Negativo Tabla 1  Serolog\u00eda basal (prevacunal). IgG: \ninmunoglobulina G; antiHBs: anticuerpos \nfrente al ant\u00edgeno de superficie; antiHBc \ntotal: anticuerpos totales frente al \nant\u00edgeno core; HBsAg: ant\u00edgeno de \nsuperficie.Reactivaci\u00f3n del s\u00edndrome peri\u00f3dico asociado a criopirinas tras la vacunaci\u00f3n en una paciente candidata a \ninmunosupresi\u00f3nM. Fern\u00e1ndez-Prada, et al.\nRev Esp Quimioter 2019;32(4): 379-380380CONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan conflicto de inter\u00e9s.\nBIBLIOGRAF\u00cdA\n1. Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E et \nal. Vaccination recommendations for the adult immunosuppressed \npatient: A systematic review and comprehensive field synopsis. J \nAutoimmun. 2017;80:10-27.  doi: 10.1016/j.jaut.2017.03.011.\n2. Centers for Disease Control and Prevention. Epidemiology and Pre -\nvention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, \nWolfe S, eds. 13th ed., Supplement. Washington D.C. Public Health \nFoundation, 2017.\n3. Cunningham AL, Gar\u00e7on N, Leo O, Friedland LR, Strugnell R, Lau -\np\u00e8ze B et al. Vaccine development: from concept to early testing. \nVaccine 2016;34:6655-64. doi: 10.1016/j.vaccine.2016.10.016.\n4. Fern\u00e1ndez-Prada M, Brandy-Garc\u00eda AM, Rodr\u00edguez-Fonseca OD, \n\u00c1lvarez-Arg\u00fcelles ME, Mel\u00f3n-Garc\u00eda S. Varicela por virus vacunal \nen un paciente en tratamiento con metotrexato. Rev Esp Quimio -\nter.2017;5:1-3. PMID: 28422472.\n5. Ar\u00f3stegui J. Enfermedades autoinflamatorias sist\u00e9micas he -\nreditarias. Reumatol Clin. 2011;7(1):45-50. doi:10.1016/j.reu -\nma.2010.01.010\n6. Walker UA, Hoffman HM, Williams R, Kuemmerle-Deschner J, Haw -\nkins PN. Brief Report: Severe Inflammation Following Vaccination \nAgainst Streptococcus pneumoniae  in Patients With Cryopyrin-\nAssociated Periodic Syndromes. Arthritis Rheumatol. 2016;68:516-\n20. doi: 10.1002/art.39482.\n7. Walker UA, Volksbeck L, Juemmerle-Deschner J. Flare of a Cryo -\npyrin-associated Periodic Syndrome Following Vaccination with \nNeisseria meningitidis  Polysaccharides. J Rheumatol. 2018;45:878-\n9. doi: 10.3899/jrheum.171037.ese momento por desabastecimiento y las antineumoc\u00f3cicas \nfueron descartadas al estar descrita la reactivaci\u00f3n del CAPS \ntras la administraci\u00f3n de la conjugada de 13 serotipos y polisa -\nc\u00e1rida de 23 serotipos [6].\nA las 24 horas de la administraci\u00f3n de estas vacunas la pa -\nciente experiment\u00f3 un cuadro cl\u00ednico caracterizado por fiebre de \nhasta 38\u00baC, artralgias y rash urticariforme generalizado, compa -\ntible con un brote de la patolog\u00eda de base. Se prescribi\u00f3 un ciclo \ncorto de corticoides (deflazacort 30mg/d\u00eda en pauta descenden -\nte), persistiendo los s\u00edntomas hasta 6 d\u00edas. El cuadro se resolvi\u00f3 \npor completo a los 20 d\u00edas, aproximadamente, sin complicacio -\nnes ni secuelas. La figura 1 muestra el rash urticariforme inicial \ny la evoluci\u00f3n en d\u00edas sucesivos. De acuerdo con la paciente y \nel Servicio de Medicina Interna desde la Unidad de Vacunas, se \ndecidi\u00f3 interrumpir el calendario de vacunaci\u00f3n programado\nA pesar de que existen publicaciones relacionadas con el \nempeoramiento del CAPS y la vacunaci\u00f3n antineumoc\u00f3cica y an -\ntimeningoc\u00f3cica [6, 7], hasta el momento no se hab\u00edan descrito \ncasos relacionados con las vacunas triple v\u00edrica y hepatitis B. Cabe \nla posibilidad de que la estimulaci\u00f3n del sistema inmune con la \nvacunaci\u00f3n en general, y no con ciertas vacunas espec\u00edficamente, \nprovoque alteraciones en las personas con dicha patolog\u00eda. Inclu -\nso, en base a esta experiencia, los autores plantean que, dado que \nla paciente inici\u00f3 los s\u00edntomas a los 8 meses de edad, pero no fue \ndiagnosticada hasta los 18 a\u00f1os, algunos de los brotes peri\u00f3dicos \nde la infancia y la adolescencia quiz\u00e1 hayan podido desencadenar -\nse en el contexto de la vacunaci\u00f3n sistem\u00e1tica infantil. Sin embar -\ngo, esta hip\u00f3tesis resulta dif\u00edcil de confirmar.\nEl caso fue notificado al Sistema de Farmacovigilancia \n(n\u00famero 03-600302).\nFINANCIACI\u00d3N \nLos autores declaran no haber recibido financiaci\u00f3n para \nla realizaci\u00f3n de este estudio. Figura 1 Secuencia cl\u00ednica postvacunal\nRev Esp Quimioter 2019;32(3): 381-383381\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).men for diagnosis of meningoencephalitis. In brain computed \ntomography scan there was not any sing of occupying lesion \nor increased intracerebral pressure. Cerebrospinal fluid (CSF) \nwas semi-clear and colorless with mild elevated protein level \nof 75 mg/dl, red blood cells of 17/mm3, white blood cells of \n170/mm3, of which 65% were neutorophils, glucose level of 89 \nmg/dl with simultaneous blood sugar of 117 mg/dl and lactate \ndehydrogenase level of 64 U/L. The result of initial CSF gram \nstain was positive for Gram-positive delicate and filamentous \nmicroorganisms suggestive of nocardiosis.Sir, \nNocardia  is a gram-positive bacillus, which is the cause of \nvarious diseases such as cutaneous, ocular and central nervous \nsystem (CNS) infections in both immunocompetent and im -\nmune-compromised patients [1]. The range of these diseases \ncan be from a sub-clinical infection to a life-threatening dis -\neases [2]. These infections especially CNS infections are more \nhappens in immunocompromised patients [1, 2]. On the other \nhand over the past several years the number of immunocom -\npromised patients are increased [1]. Nocardial meningitis is \nvery rare and may be associated with or without a brain ab -\nscess. \nIn this paper, we describe a man with Beh\u00e7et disease who \nwas on corticosteroid, and experienced meningitis caused by \nNocardia farcinica . \nA 38 years old man admitted with complaints of fever, \nnausea, vomiting, frontal headache and hemiplegia on left side \nand decreased level of consciousness. \nOn admission the patient has temperature of 4oC, his \nblood pressure was 190/110, pulse rate was 115 beats/min; \nrespiratory rate was 20/min; and his oxygen saturation de -\ngree was 92%. The forces of lower limbs had been decreased \nto 3/5. In eyes there was horizontal nystagmus and in left eye \nthe movement of the globe to medial and lateral sides was dis -\nturbed; but no papilledema was seen in examination of both \nsides. \nThe patient was a known case of Beh\u00e7et disease since 4 \nyears ago, and was on 20 mg prednisolone daily since that \ntime. At first, with this primary information; vancomycin, mer -\nopenem and aciclovir, were prescribed as an antiobiotic regi -Nocardia farcinica  isolated meningitis in a patient \nwith Beh\u00e7et\u2019s disease: case report and literature \nreview\n1Assistant Professor of infectious diseases, Acquired immunodeficiency reseach center, Isfahan university of medical \nsciences, Isfahan, Iran \n2Resident of infectious disease ward, Department of Infectious Diseases, Infectious Diseases and Tropical Medicine Re -\nsearch Center, Isfahan University of Medical Sciences, Isfahan, Iran.Kiana Shirani1\nFatemeh Mohajeri2\nCorrespondence:\nFatemeh Mohajeri\nDepartment of Infectious Diseases, Infectious Diseases and Tropical Medicine Research Cen -\nter, Isfahan University of Medical Sciences, Isfahan, Iran.\nE-mail: fatemeh.mohajeri183@gmail.comLetter to the Editor\nArticle history\nReceived: 18 October 2018; Revision Requested: 9 January 2019; Revision Received: 18 January 2019; Accepted: 11 February 2019\nFigure 1  Diffuse signal change as high in T2W \nat limited view of brain stem is seen \ninvolving pons and medulla without \nobvious mass effect\nNocardia farcinica  isolated meningitis in a patient with Beh\u00e7et\u2019s disease: case report and literature review Kiana Shirani, et al.\nRev Esp Quimioter 2019;32(3): 381-383382gle-organ infection is manifested as pulmonary as the most \ncommon (39% in hospitalized patients), followed by CNS in -\nfection (9%) in nocardial infections [7]. CNS nocardial infec -\ntion is an uncommon disease and carrying a high mortality \nrate [8]. In our cases we did not find any other site of infection \nin the body and therefore we concluded that \u201cisolated men -\ningitis\u201d is the most probable diagnosis in this patient; which \nis really a rare incident. Although, isolated CNS infections, as \nabscesses in spinal cord and brain without extra-CNS involve -\nment are reported [9]; but there is not any report of Isolated \nand /or pure nocardial meningitis similar to our case. Isolated \nnocardial meningitis may progress to CNS abscess; therefore \nearly diagnosis can prevent of abscess formation and the bet -\nter prognosis will be achieved in these patients. \nIn every immune-compromised patient who has referred \nby CNS infection; thinking about nocardial CNS infection as a \ndifferential diagnosis would be logic.\nFUNDING \nNone to declare\nCONFLICT OF INTERESTS\nThe authors declare that they have no conflict of interest\nREFERENCES\n1. Conville PS, Brown JM, Steigerwalt AG, Lee JW, Byrer DE, Anderson \nVL, et al. Nocardia veterana as a pathogen in North American pa -\ntients. J Clin Microbiol. 2003;41(6):2560-8. PMID:12791881. DOI: \n10.1128/JCM.41.6.2560\u20132568.2003\n2. Abreu C, Rocha-Pereira N, Sarmento A, Magro F. Nocardia infec -\ntions among immunomodulated inflammatory bowel disease pa -\ntients: a review. World J Gastroenterol. 2015;21(21):6491-8. DOI: \n10.3748/wjg.v21.i21.6491\n3. Duque \u00c1IA, Salas PAO, Oviedo JMP, Mora A, Ruales F. Meningo -\nencefalitis por Nocardia spp.: Reporte de un caso y revisi\u00f3n de la \nliteratura. Infectio. 2014;18(3):109-15. https://doi.org/10.1016/j.\ninfect.2014.02.005\n4. Al-Araji A, Kidd DP. Neuro-Beh\u00e7et\u2019s disease: epidemiology, clinical \ncharacteristics, and management. Lancet Neurol. 2009;8(2):192-\n204. DOI: 10.1016/S1474-4422(09)70015-8\n5. Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, \nConstantinescu CS, et al. Diagnosis and management of Neuro-Be -\nh\u00e7et\u2019s disease: international consensus recommendations. J Neurol. \n2014;261(9):1662-76. DOI: 10.1007/s00415-013-7209-3.\n6. Rafiei N, Peri AM, Righi E, Harris P, Paterson DL. Central nervous \nsystem nocardiosis in Queensland: a report of 20 cases and review \nof the literature. Medicine (Baltimore). 2016;95(46):e5255.\n7. Beaman BL, Beaman L. Nocardia  species: host-parasite relation -\nships. Clin Microbiol Rev. 1994;7(2):213-64. PMID: 8055469\n8. Sharma M, Anthony C, Hsu CC-T, Maclean C, Martens N. Dissem -According to the sign and symptoms of the patient and \nCSF pattern, antibiotic regimen was changed to meropenem \nand intravenous co-trimoxazole (to treat nocardial meningitis). \nBrain magnetic resonance venography result was in nor -\nmal limit and in brain magnetic resonance imaging high T2/ \nflair signal intensity lesions were shown in medulla oblongata, \npons and brain; which could be suggestive for demyelinating \nor vasculitis disorders (figure 1).\nA few days later, CSF culture was reported positive for \nNocardia  species (figure 2); therefore PCR for Nocardia  spe-\ncies was performed and the result was positive for N. farcinica . \nFortunately after 10 days; the general condition of the patient \nbecame better and improvement of headache and neurolog -\nic sign and symptoms were achieved. Intravenous antibiotics \nwere continued for 6 weeks in hospital and after that the pa -\ntient was discharged with oral antibiotics (cotrimoxazol, cefix -\nime and amoxicillin-clavulanic acid) for up to 9 months. After \nthat cotrimoxazol was continued for 3 months later. Now after \none year the patient is on cotrimoxazol yet, and he has not any \nproblem and feels completely well. \nNocardiosis is an opportunistic infection that affects \nmainly immune-compromised patients, especially the patients \nwith cell-mediated immunity such as acquired immunodefi -\nciency syndrome [3]. Neuro-Beh\u00e7et\u2019s disease (NBD), is one of \nthe most dangerous and serious complications of the Beh\u00e7et\u2019s \ndisease which is described in some papers [4]. One of the crite -\nria for NBD diagnosis is \u201cno better explanation for neurological \nfindings\u201d [5], and in our patient CSF smear, culture and PCR \nwere positive for N. farcinica . \nIn some reports of systemic nocardial infections, CNS in -\nfection is seen in up to 44% [6]. Beaman et al. reported sin -Figure 2  Branched and pink colored bacilli in \nacid fast stained smear\nNocardia farcinica  isolated meningitis in a patient with Beh\u00e7et\u2019s disease: case report and literature review Kiana Shirani, et al.\nRev Esp Quimioter 2019;32(3): 381-383383inated Cerebral and Intradural Extramedullary Spinal Nocardiosis \nin an Immunocompetent Patient. Eur J Case Report Intern Med. \n2015;2(4). DOI: 10.12890/2015_000207\n9. Durmaz R, Atasoy MA, Durmaz G, Adapinar B, Arslanta \u015f A, Ay -\ndinli A, et al. Multiple nocardial abscesses of cerebrum, cerebel -\nlum and spinal cord, causing quadriplegia. Clin Neurol Neurosurg. \n2001;103(1):59-62. PMID: 11311481Rev Esp Quimioter 2019;32(4): 384-386384\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).completed 12 weeks without remarkable side effects. There is \nno general agreement based on solid evidence regarding for \nhow long should treatment after debridement and implant \nretention in prosthetic joint infection (PJI) caused by common \nmicroorganisms, so solid recommendations on behalf of PJI \ncaused by rare microorganisms as in the case presented, are \ndefinitely lacking [1]. Fourteen months after withdrawing \nlevofloxacin, there are no clinical signs of recurrence, and CRP \nvalues remain normal. \nPasteurella  spp. is a genera of small gram-negative \nnonflagellated coccobacilli often found as part as the normal \nmicrobiota of oral and upper respiratory tracts of animals \nand humans. It is isolated from human infections associated \nto dog bites and 75% percent of cat bites. Humans acquire \nP. multocida  not only through bites, but through scratches, \neven without skin or mucosal breakdown. Phenotypic \ncharacterization of P.multocida  was traditionally based \non morphology and biochemical characteristics, but their \naccuracy was low. 16S rDNA sequencing and MALDI-TOF are \nbetter for identification at the genus and species level [2-4].\nMethicillin-susceptible Staphylococcus aureus, Klebsiella \noxytoca, Pantoea agglomerans, Bergeyella zoohelcum and \nPasteurella multocida, were isolated from cat\u00b4s sample. Why \nthe patient\u00b4s prosthesis became infected by P. multocida  and \nno by the other bacteria? Multiple virulence factors, including \ngenes encoding capsule, lipopolysaccharide, outer membrane \nproteins, iron acquisition genes, thiamine metabolism \ngenes, and the adhesion/Flp pilus assembly gene cluster \n(tadZABCDEFG) are present in P. multocida . Homologs of \nthe tad gene locus are also present in many Pasteurellaceae, \nplaying key roles in biofilm formation, colonization, and \npathogenesis [5]. P. multocida  can produce in vitro biofilm, \nalthough a case of PJI due to a non-biofilm-producing strain \nof P. multocida  has been described [6]. \nIn order to try to evaluate phylogenetic relationship \nbetween the patient\u00b4s P. multocida  and the cat\u00b4s sample Sir, \nA 92-year-old woman with a total knee arthroplasty \nperformed 10 years ago was admitted with a story of 3 \ndays of fever, pain and joint effusion in the left knee, which \nensued abruptly. Routine blood analysis showed leukocytosis \n(12,500 leucocytes/mm3, 88% polymorphonuclear-PMN-), \nand elevated C reactive protein (202 mg/L \u2013CRP-). Two sets of \nblood cultures and a urine culture were obtained. A diagnostic \narthrocentesis was performed, revealing purulent effusion \n(40,200 leucocytes/mm3, 94% PMN, undetectable glucose). No \nmicroorganisms were observed on gram stain. \nMeropenem and vancomycin were started. The patient \nunderwent surgery 72h after hospital admission: Capsulotomy, \nalong with debridement and replacement of prosthetic mobile \nelements (tibial polyethylene and patella) with prosthesis \nretention, and lavage with 9 liters of sterile solution [1] were \nperformed.\nSynovial fluid and surgical samples were transported and \nplated immediately and [1] yielded Pasteurella multocida  after \n24h of incubation, which was identified by Matrix-associated \nlaser desorption/ ionization-time of flight mass spectrometry \n(Vitek MS, BioMerieux, Database V3). Blood and urine cultures \nwere negative. Anamnesis revealed that the patient owned a \ncat, which used to scratch and lick patients\u00b4 legs. An oral swab \nof the patient\u00b4s cat was obtained and plated. \nOnce Pasteurella  was identified and susceptibility profile \ndetermined, treatment was switched to i.v ampicillin plus oral \nlevofloxacin. CRP levels fell from 238 mg/L (normal range, \n0-5 mg/L) in the day of surgery to 18 after twelve days, when \nshe was discharged on oral levofloxacin. At the sixth week \nafter surgery, CRP values had normalized, and the patient Acute zoonotic total knee prosthetic joint infection \ndue to Pasteurella multocida  treated successfully \nwith debridement, irrigation and antibiotics without \nprosthesis removal\n1Microbiology. Hospital Universitario de Burgos, Spain. \n2Infectious Diseases Unit, Internal Medicine. Hospital Universitario de Burgos, Spain.\n3Traumatology and Orthopedic Surgery. Hospital Universitario de Burgos, Spain.Maria Pilar Ortega Lafont1\nLuis Buz\u00f3n Mart\u00edn2\nLedicia \u00c1lvarez Paredes1\nMar\u00eda Mora Fern\u00e1ndez3\nAntonio Rodr\u00edguez P\u00e9rez3\nMiguel \u00c1ngel Mor\u00e1n \nRodr\u00edguez2\nCorrespondence:\nMaria Pilar Ortega Lafont\nMicrobiology. Hospital Universitario de Burgos, Spain. \nFax: 0034 947282722\nE-mail: portegal@saludcastillayleon.esLetter to the Editor\nArticle history\nReceived: 15 January 2019; Revision Requested: 6 February 2019; Revision Received: 19 March 2019; Accepted: 25 March 2019Acute zoonotic total knee prosthetic joint infection due to Pasteurella multocida  treated successfully with \ndebridement, irrigation and antibiotics without prosthesis removalM. P. Ortega Lafont, et al.\nRev Esp Quimioter 2019;32(4): 384-386385easy recovery from joint effusion samples and a relationship \nwith close contact with dogs or cats. The case presented \nrepresents, therefore, an archetypal example [8].\nIn these 32 cases, about half were treated with prosthesis \nremoval. This series suggests that surgical lavage, debridement \nand prosthesis retention combined with optimal targeted \nantimicrobial therapy is enough, thus avoiding two steps \nexchange procedure, an impression supported by the case \npresented. All of the cases, whatever the surgical approach \nperformed, were successfully cured [8]. Penicillins and \ndoxycycline were the drugs most commonly used followed \nby fluoroquinolones. Our experience, along with previously \nreported data, suggests that monotherapy along with \nappropriate surgical drainage is enough for treating acute \nperiprosthetic infections caused by P. multocida  in most cases.isolate, samples from another cat not related to the index case \nand samples from another patient with P. multocida  infection \nwere collected, and MALDI-TOF was used (RUO database). In \norder to avoid biases, each isolate was analyzed under identical \nexperimental conditions [7]. Main spectrum projection showed \nthat patient\u2019s and her cat\u00b4s isolates were very similar, and \ndiffered from the unrelated isolates, pointing to a possible \nethiopathogenical link between the infected patient\u00b4s prosthesis \nand her cat\u00b4s oral flora. Nevertheless, the mass distance between \nall of them, related and unrelated samples, was close (figure 1). \nSince 1975, only 32 cases of PJI due to P. multocida \nhave been reported. Almost every case diagnosed share some \ncommon features: abrupt late onset infections with a median \ntime of 7.6 years after implantation, absence of documented \nbacteremia in most cases, very intense inflammatory reaction, Figure1   Relationship of Pasteurella multocida isolated from the case patient \n(patient 1), patient\u2019s cat (cat 1) and another unrelated strains (patient 2 \nand cat 2) by matrix-assisted laser desorption/ionization-time of flight \nmass spectrometry dendrograms and clustering (mass/ charge)\nSpectrometry dendrogram showing clustering of patient and cat\u00b4s isolates of Pasteurella multocida .Acute zoonotic total knee prosthetic joint infection due to Pasteurella multocida  treated successfully with \ndebridement, irrigation and antibiotics without prosthesis removalM. P. Ortega Lafont, et al.\nRev Esp Quimioter 2019;32(4): 384-386386FUNDING \nNone to declare\nCONFLICTS OF INTEREST\nThe authors declare that there are no conflicts of interest\nREFERENCES\n1 Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg \nJM, et al. Diagnosis and management of prosthetic joint infection: \nClinical Practice Guidelines by the Infectious Diseases Society of \nAmerica. Clin Infect Dis 2013; 56(1): e1-25. PMID: 23223583\n2. Wilson BA, Ho M. Pasteurella multocida:  from zoonosis to cellu -\nlar microbiology. Clin Microbiol Rev 2013; 26(3): 631-55. PMID: \n23824375\n3. Zangenah S, G\u00fclery\u00fcz G, Bor\u00e4ng S, Ullberg M, Bergman A et al. \nIdentification of clinical Pasteurella isolates by MALDI-TOF -- \na comparison with VITEK 2 and conventional microbiological \nmethods. Diagn Microbiol Infect Dis 2013; 77(2):96-8. PMID: \n23824375. \n4. Dewhirst FE, Paster BJ, Olsen I, Fraser GJ. Phylogeny of 54 \nrepresentative strains of species in the family Pasteurellaceae as \ndetermined by comparison of 16S rRNA sequences. J Bacteriol \n1992; 174(6): 2002-13. PMID: 23886788.\n5. Harper M, Boyce JD, and Adler B. Pasteurella multocida  \npathogenesis: 125 years after Pasteur. FEMS Microbiol Lett 2006; \n265(1):1-10. PMID: 1548238.\n6. Roman\u00f2 CL, De Vecchi E, Vassena C, Manzi G, Drago L. A case of a \nlate and atypical knee prosthetic infection by no-biofilm producer \nPasteurella multocida  strain identified by pyrosequencing. Pol J \nMicrobiol 2013; 62:435\u20138. PMID: 17101417.\n7. Culebrasa E, \u00c1lvarez-Buyllab A, Artacho Reinoso MJ, Lepe A. Studies \nof bacterial typing with MALDI-TOF. Enferm Infecc Microbiol Clin \n2016; 34(Supl 2):42-6. PMID: 24730139.\n8. Honnorat E, Seng P, Savini H, Pinelli PO, Simon F, Stein A. \nProsthetic joint infection caused by Pasteurella multocida : a case \nseries and review of literature . BMC Infect Dis 2016; 16(1):435. \nPMID: 27544345.Rev Esp Quimioter 2019;32(4): 387-389387\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).En este contexto se decide iniciar TARGA con dolutegravir \n50 mg/d\u00eda junto a tenofovir/emtricitabina 300/200 mg/d\u00eda. La \npaciente evoluciona favorablemente, con mejor\u00eda del labora -\ntorio y siete semanas despu\u00e9s se documenta del Western blot \nreactivo. Se observ\u00f3 una excelente respuesta virol\u00f3gica con un \ndescenso de la CV a 151 copias/ml (2.18 log10) y ascenso del \nrecuento de linfocitos T-CD4 (tabla 1).\nDos meses posteriores al inicio del TARGA present\u00f3 ame -\nnorrea con test de embarazo positivo y ecograf\u00eda obst\u00e9trica \nque informaba gesta de 8 semanas. Se decidi\u00f3 continuar mis -\nmo esquema de tratamiento seg\u00fan las recomendaciones del \nmomento, presentando CV indetectable durante todo el em -\nbarazo, el cual curs\u00f3 sin intercurrencias cl\u00ednicas u obst\u00e9tricas, \npresentando parto vaginal a las 40 semanas de gestaci\u00f3n. Pa -\nri\u00f3 un reci\u00e9n nacido masculino sano con estudios virol\u00f3gicos \n(PCR en ADN proviral) negativos al momento del nacimiento, a \nlos 2 y 6 meses de vida. \nEn virtud del beneficio cl\u00ednico sobre el paciente, la posibili -\ndad de disminuir el desarrollo de reservorios y el riesgo de tras -\nmisi\u00f3n a terceros, las recomendaciones internacionales reco -\nmiendan el tratamiento precoz de la infecci\u00f3n aguda por VIH, \ncon un f\u00e1rmaco de alta barrera gen\u00e9tica y con eficacia frente \na viremias elevadas como es el caso de nuestra paciente [3, 5]. \nPor la eficacia y perfil de seguridad que muestra dolutegravir \nfrente a otros TARGA [6, 7], se decidi\u00f3 iniciar tratamiento con \neste f\u00e1rmaco con muy buena respuesta virol\u00f3gica (descenso de \n4.9 log10 en 4 semanas) y cl\u00ednica (desaparici\u00f3n de los s\u00ednto -\nmas). Esto fue de suma importancia teniendo en cuenta que \nla paciente qued\u00f3 embarazada al poco tiempo del diagn\u00f3sti -\nco y comenzar la gestaci\u00f3n con supresi\u00f3n virol\u00f3gica reduce a \n<1% el riesgo de trasmisi\u00f3n vertical. La paciente fue asistida \nantes del alerta emitida por diferentes agencias regulatorias en \nfunci\u00f3n de los resultados del estudio Tsepamo donde se docu -\nment\u00f3 una potencial asociaci\u00f3n entre defectos del tubo neural \ny exposici\u00f3n a dolutegravir al momento de la concepci\u00f3n [9]. \nEn este contexto se requiere de estudios prospectivos que con -\nfirmen o refuten esta potencial asociaci\u00f3n con defectos con -Sr. Editor: \nA pesar de las intervenciones integrales para la preven -\nci\u00f3n de la infecci\u00f3n por VIH y del impacto de la terapia antirre -\ntroviral de gran eficacia (TARGA), todav\u00eda hay dos millones de \nnuevos casos de VIH en adultos cada a\u00f1o [1]. Esta incidencia es \ndebido en gran parte a los fallos en la detecci\u00f3n de los casos \nagudos y, por lo tanto, en su tratamiento precoz [2]. La infec -\nci\u00f3n aguda por VIH se define como el conjunto de fen\u00f3menos \ninmunol\u00f3gicos y virol\u00f3gicos que ocurren entre la adquisici\u00f3n \nviral y la emergencia de anticuerpos espec\u00edficos [3].\nPresentamos el caso de una paciente femenina de 29 a\u00f1os \nque consult\u00f3 por s\u00edndrome febril de 3 semanas de evoluci\u00f3n. \nAl interrogatorio refer\u00eda cambio de pareja sexual reciente. En \nel examen f\u00edsico presentaba abdomen doloroso a la palpaci\u00f3n \nsuperficial en hipogastrio y el laboratorio evidenciaba leve tri -\ncitopenia (tabla 1). Se interna para estudio y descartar patolo -\ng\u00eda quir\u00fargica. \nLa ecograf\u00eda ginecol\u00f3gica no presentaba alteraciones y la \ntomograf\u00eda de t\u00f3rax, abdomen y pelvis presentaba m\u00faltiples \nadenopat\u00edas en regi\u00f3n inguinal y retroperitoneales. \nAl ingreso presenta resultados discordantes de serolog\u00eda \nde VIH, con test r\u00e1pido de VIH (Alere Determinetm HIV-1/2) ne -\ngativo, Elisa de 4a generaci\u00f3n positivo (Bayer\u00ae) y Western blot \nindeterminado (detecci\u00f3n exclusivamente de banda GP 160). Se \nrealiza carga viral (CV) que informa >10.000.000 copias/ml (rea -\nliz\u00e1ndose t\u00e9cnicas de diluci\u00f3n se precisa su valor en 12.100.000 \ncopias/ml, 7.08 log10), confirmando el cuadro como s\u00edndrome re -\ntroviral agudo, estadio de Fiebing 2 [4]. A los 3 d\u00edas se repite test \nr\u00e1pido que resulta negativo y nuevo Elisa que resulta positivo \ncon aumento de la relaci\u00f3n de positividad. La prueba de resis -\ntencia genot\u00edpica basal no evidencia mutaciones.Uso de dolutegravir en infecci\u00f3n aguda por VIH-1: \nprimer caso reportado\n1Unidad de infectolog\u00eda, Hospital General de Agudos Cosme Argerich, Buenos Aires, Argentina \n2Laboratorio Central, Hospital General de Agudos Cosme Argerich, Buenos Aires, Argentina Franco Garibaldi1\nMarcia Pozzati2\nClaudia Rodriguez1\nDiego Cecchini1\nCorrespondencia:\nFranco Garibaldi  \nHospital General de Agudos Cosme Argerich,  \nAlmirante Brown 240, Buenos Aires 1155AHD, Argentina. \nTel: +54 11 4121-0828.\nFax: +54 11 4307-5952.\nE-mail: franco.garibaldi@hotmail.comCarta al Director\nArticle history\nReceived: 22 January 2019; Accepted: 11 March 2019Uso de dolutegravir en infecci\u00f3n aguda por VIH-1: primer caso reportado F. Garibaldi, et al.\nRev Esp Quimioter 2019;32(4): 387-389388BIBLIOGRAF\u00cdA\n1. UNAIDS. Prevention gap report. 2016. http://www.unaids.org/si -\ntes/default/files/media_asset/2016-prevention-gap-report_en.pdf  \n[acceso: 20 de octubre 2018]\n2. Dehne KL, Dallabetta G, Wilson D, Garnett GP, Laga M, Benomar E, \net al. HIV prevention 2020: a framework for delivery and a call for \naction. Lancet HIV. 2016;3(7): e323\u201332. PMID:27365207\n3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Gui -\ndelines for the Use of Antiretroviral Agents in Adults and Adoles -\ncents Living with HIV. Department of Health and Human Services. \nhttp://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.\npdf. [acceso: 20 de octubre 2017]\n4. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infec -\ntion. N Engl JMed. 2011;364(20):1943-54. PMCID: PMC3771113.\n5. WHO. Consolidated guidelines on the use of antiretroviral drugs \nfortreating and preventing HIV infection: recommendations for a \npublic health approach. 2nd ed. Geneva: World Health Organiza -\ntion; 2016 Sep. https://www.who.int/hiv/pub/arv/arv-2016/en/  [ac-\nceso: 20 de octubre 2017]\n6. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. \nSPRING-2 Study Group. Once-daily dolutegravir versus raltegravir \nin antiretroviral-naive adults with HIV-1 infection: 48 week results \nfrom the randomised, double-blind, non-inferiority SPRING-2 stu -\ndy. Lancet. 2013;381(9868):735-43. PMID: 23306000.\n7. Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry \nK, et al. Once-daily dolutegravir is superior to once daily darunavir/\nritonavir in treatment-na\u00efve HIV-1-positive individuals: 96 week g\u00e9nitos, siendo actualmente un f\u00e1rmaco recomendado en la \ngestaci\u00f3n fuera del primer trimestre [8].\nHasta nuestro conocimiento, este es el primer reporte que \ndescribe el descenso de la CV en el contexto de una infecci\u00f3n \naguda por VIH con dolutegravir, donde destacamos que se par -\nti\u00f3 de una viremia basal extremada elevada, por encima del \npunto de corte de la t\u00e9cnica. El r\u00e1pido control de la viremia \nen el contexto de la seroconversi\u00f3n es de fundamental impor -\ntancia tanto para la salud del paciente individual como para la \nprevenci\u00f3n de la trasmisi\u00f3n a terceros, requiri\u00e9ndose ensayos \ncl\u00ednicos que documenten el mejor TARGA para indicar en este \nescenario cl\u00ednico. \nAGRADECIMIENTOS\nA la Bioq. Claudia F Nieto, Laboratorio Central, Hospital \nGeneral de Agudos Cosme Argerich.\nEste caso cl\u00ednico fue presentado en parte en el VII Congre -\nso Internacional de Infectolog\u00eda Pedi\u00e1trica y Vacunas, Buenos \nAires Argentina, 19 \u2013 20 de abril de 2018. Poster # 102 \nFINANCIACI\u00d3N\nLos autores declaran no haber recibido financiaci\u00f3n para la \nrealizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan conflicto de intereses.D\u00eda 1 D\u00eda 2 D\u00eda 5 D\u00eda 7 Semana 2 Semana 5 Semana 7\nTest r\u00e1pido Negativo Negativo Negativo Negativo Positivo\nElisa Positivo Positivo Positivo Positivo Positivo\nRelaci\u00f3n de positividad (ELISA) 40 40 238\nWestern Blot GP 160 GP 160/ GP 120/ GP 41/ GP 24\nCarga viral (copias/ml) 12.100.000 151\nCarga viral (log10) 7,08 2,18\nCD4 (cel/ul) 576 1.253\nHematocrito (%) 29,9 32,5 32 33 37,1\nHemoglobina (g/dl) 9,9 11 10,8 11,9 12,4\nGlobulos blancos (cel/mm3) 4.000 3.900 3.500 3.500 10.100\nNeutr\u00f3filos (%) 62 53 39.5 37 55\nLinfocitos (%) 30 43 9.8 55 36\nPlaquetas (cel/mm3) 107.000 97.000 93.000 98.000 224.000\nTARGA SI\nPrueba de resistencia (genotipo) SITabla 1  Evoluci\u00f3n de par\u00e1metros de laboratorio en una paciente que inicia TARGA con dolutegravir \ndurante infecci\u00f3n aguda por VIH.Uso de dolutegravir en infecci\u00f3n aguda por VIH-1: primer caso reportado F. Garibaldi, et al.\nRev Esp Quimioter 2019;32(4): 387-389389results from FLAMINGO. J Int AIDS Soc. 2014;17(4 Suppl 3):19490. \nPMCID: PMC4224885.\n8. World Health Organization. Potential safety issue affecting women \nliving with HIV using dolutegravir at the time of conception. Ge -\nneva, Switzerland. May 18, 2018. http://www.who.int/medicines/\npublications/drugalerts/Statement_on_DTG_18May_2018final.pdf  \n[acceso: 15 de septiembre de 2018]\n9. Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolu -\ntegravir Treatment from the Time of Conception. N Engl J Med. \n2018;379(10):979-981. PMID: 30037297Rev Esp Quimioter 2019;32(4): 390-392390\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).ciencia renal oligoanurica, precisando sesiones intermitentes \nde hemodiafiltraci\u00f3n veno-venosa continua. Adem\u00e1s, requiri\u00f3 \nventilaci\u00f3n mec\u00e1nica prolongada debido a un cuadro de neu -\nmon\u00eda precoz asociada a la misma, que evolucion\u00f3 a distr\u00e9s \nrespiratorio agudo. Por otro lado, present\u00f3 numerosas compli -\ncaciones infecciosas de tipo nosocomial, asociadas a la venti -\nlaci\u00f3n mec\u00e1nica, secundarias al cat\u00e9ter venoso central y a la \nherida quir\u00fargica, entre otras, recibiendo una amplia terapia \nantibi\u00f3tica (tabla 1).\nAl cabo de 3 meses de ingreso (d\u00eda 93), el paciente pre -\nsent\u00f3 febr\u00edcula (37,8\u00b0 C) con ligero descenso de plaquetas \n(128.000/\u00b5l), con repunte de PCR (8,9 mg/dl) y procalcitonina \n(0,7 ng/ml). Se cursaron hemocultivos y se asoci\u00f3 de manera \nemp\u00edrica amikacina, al tratamiento antibi\u00f3tico ya instaurado \n(meropenem + tigeciclina). Al cabo de 2 d\u00edas present\u00f3 empeo -\nramiento cl\u00ednico en forma de shock s\u00e9ptico, fibrilaci\u00f3n auri -\ncular, hipotensi\u00f3n refractaria a noradrenalina e insuficiencia \nrenal oligoan\u00farica. Anal\u00edticamente destac\u00f3: plaquetopenia \n(69.000/\u00b5l), leucopenia (2.800/\u00b5l), PCR 20,6 mg/dl e \u00edndice de \nQuick 45%. Al d\u00eda siguiente, se recibe resultados de hemo -\ncultivos previos, positivos para E. meningoseptica . El m\u00e9todo \nempleado en la identificaci\u00f3n fue el sistema de espectrometr\u00eda \nde masas \u201cMatrix-Assisted Laser Desorption/Ionization time of \nFlight\u201d (MALDI-TOF). Se confirm\u00f3 identificaci\u00f3n de E. menin -\ngoseptica  repitiendo cultivo, pero no se realiz\u00f3 confirmaci\u00f3n \nmediante secuenciaci\u00f3n gen\u00f3mica del ARNr 16s. Se retir\u00f3 la \namikacina y se inici\u00f3, a la espera de resultado de antibiograma, \nrifampicina y cotrimoxazol (tabla 2). Al cabo de 24 h, el pacien -\nte present\u00f3 mala evoluci\u00f3n con fallo multiorg\u00e1nico refractario, \nsiendo finalmente \u00e9xitus.\nE. meningoseptica  es considerado un pat\u00f3geno oportunis -\nta, que presenta resistencia a la mayor\u00eda de antibi\u00f3ticos dirigi -\ndos frente a gramnegativos. Posee dos tipos de \u03b2-lactamasas \n(\u03b2-lactamasa de espectro extendido de tipo A y metalo \n\u03b2-lactamasa de tipo B), que le confieren resistencia intr\u00ednseca \na betalact\u00e1micos y carbapen\u00e9micos y reducen la actividad de \npolimixinas, aminoglucosidos y tigeciclina [3]. Parad\u00f3jicamen -Sr. Editor:  Elizabethkingia meningoseptica, antiguamente \ndenominada Flavobacterium meningosepticum  y posterior -\nmente reclasificada como Chryseobacterium meningosep -\nticum, es un bacilo gramnegativo, aer\u00f3bico, no fermentador, \ninm\u00f3vil y ubicuo, ampliamente distribuido en la naturaleza [1]. \nLa mayor\u00eda de las infecciones producidas por E. meningosepti -\nca, a pesar de no estar presente en la microflora humana, son \nde origen nosocomial, consider\u00e1ndose un pat\u00f3geno emergen -\nte, de ambiente hospitalario [2]. Su genoma est\u00e1 constituido \npor genes que le confieren capacidad de formar biofilms y \nsobrevivir durante tiempos prolongados [3]. Se han documen -\ntado colonizaciones de material sanitario como, respiradores, \nnebulizadores, cat\u00e9teres intravasculares, adem\u00e1s de soluciones \nsalinas de lavado y desinfectantes como la clorhexidina [4].\nPor otro lado, la presentaci\u00f3n cl\u00ednica de las infecciones de \nE. meningoseptica , incluye casos de bacteriemia y sepsis, neu -\nmon\u00eda, infecciones de piel y partes blandas (como celulitis y \nfascitis necrotizante), osteomielitis e infecci\u00f3n prot\u00e9sica, en -\ndocarditis, endoftalmitis, absceso abdominal y peritonitis [5, 6]. \nPresentamos un caso de sepsis/shock s\u00e9ptico secundario a E. \nmeningoseptica en un paciente postquir\u00fargico con una estan -\ncia prolongada en la unidad de cuidados intensivos.\nPaciente var\u00f3n de 69 a\u00f1os de edad, con antecedentes de \ndiabetes, obesidad e hipertensi\u00f3n arterial, que acude a Urgen -\ncias el 22 de mayo de 2018, por cl\u00ednica de s\u00edndrome coronario \nagudo y crisis hipertensiva. Fue diagnosticado de enfermedad \ncoronaria de dos vasos y aneurisma de aorta tor\u00e1cica, practi -\nc\u00e1ndose doble bypass aorto-coronario y recambio de la aor -\nta tor\u00e1cica. El postoperatorio estuvo marcado por etapas de \ninestabilidad hemodin\u00e1mica requiriendo noradrenalina en \nvarias ocasiones, con fases de fibrilaci\u00f3n auricular e insufi -Shock s\u00e9ptico secundario a Elizabethkingia \nmeningoseptica : descripci\u00f3n de un caso\n1Servicio de Farmacia. Hospital Quir\u00f3n Barcelona. Barcelona\n2Unidad de Cuidados Intensivos. Hospital Quir\u00f3n Barcelona. BarcelonaDavid Brandariz N\u00fa\u00f1ez1\nPaula Rodr\u00edguez Pedreira2\nVirginia Hern\u00e1ndez \nCorredoira1\nJoaquin Puig Forcada2\nFrancisco J Gurri Hernand2\nArturo S Boix Boix2\nCorrespondencia:\nDavid Brandariz N\u00fa\u00f1ez\nServicio de Farmacia. Hospital Quir\u00f3n Barcelona. Barcelona\nTfno.: 637762900.\nE-mail: vrandariz@gmail.comCarta al Director\nArticle history\nReceived: 22 January 2019; Accepted: 4 March 2019Shock s\u00e9ptico secundario a Elizabethkingia meningoseptica : descripci\u00f3n de un caso D. Brandariz N\u00fa\u00f1ez, et al.\nRev Esp Quimioter 2019;32(4): 390-392391(43-54,4%) [9], similar a otros bacilos gramnegativos multirre -\nsistentes [10], donde la elecci\u00f3n de tratamiento inapropiado y \nel estado de shock en el momento de presentaci\u00f3n, son facto -\nres predictores independientes de mortalidad [2]. \nEntre los factores de riesgo relacionados con E. meningo -\nseptica se incluyen, diabetes mellitus, malignidad, corticote -\nrapia, neutropenia, hemodi\u00e1lisis, estancia hospitalaria prolon -\ngada y la exposici\u00f3n previa a m\u00faltiples antibi\u00f3ticos dirigidos \nfrente a bacterias gramnegativas [3]. Nuestro paciente era dia -\nb\u00e9tico, tuvo etapas de neutropenia, necesit\u00f3 sesiones de he -\nmodiafiltraci\u00f3n y recibi\u00f3 una presi\u00f3n antibi\u00f3tica considerable \ndurante un ingreso prolongado, superior a 3 meses. \nE. meningoseptica  es un pat\u00f3geno multirresistente, con una \nelevada mortalidad. Ser\u00eda aconsejable potenciar medidas desti -\nnadas al control y prevenci\u00f3n de brotes e infecciones nosoco -\nmiales. Debido a la falta de consenso en el tratamiento emp\u00edrico, \nel manejo deber\u00eda ser en funci\u00f3n de los resultados de la sensibili -\ndad del antibiograma. En infecciones causadas por bacilos gram -\nnegativos que no responden a tratamientos emp\u00edricos de amplio \nespectro, se deber\u00eda sospechar de E. meningoseptica.\nFINANCIACI\u00d3N\nLos autores declaran no haber recibido financiaci\u00f3n para la \nrealizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan conflicto de intereses.te, muestra susceptibilidad a antibi\u00f3ticos empleados en el tra -\ntamiento de bacterias grampositivas, como rifampicina, vanco -\nmicina, quinolonas, y cotrimoxazol [7]. El perfil de resistencias \nvar\u00eda seg\u00fan las series publicadas, siendo cotrimoxazol (91%), \nlevofloxacino (81%), y rifampicina (87%) los antibi\u00f3ticos con \nmejor perfil de sensibilidad  [2, 8]. No existe un consenso sobre \nel tratamiento emp\u00edrico de E. meningoseptica , donde la mayo -\nr\u00eda de autores sugieren que el uso de antibi\u00f3ticos deber\u00eda ser \nen funci\u00f3n de los resultados de la sensibilidad del antibiogra -\nma. En el caso de nuestro paciente, de todos los antibi\u00f3ticos \ntestados, E. meningoseptica , solo fue sensible a cotrimoxazol.\nE. meningoseptica  tiene una tasa de mortalidad elevada D\u00eda ingreso Infecci\u00f3n Muestra Microorganismo implicado Tratamiento antibi\u00f3tico dirigido\n15 Bacteriemia Hemocultivo Enterobacter aerogenes Meropenem\n21 Bacteriemia Punta de cat\u00e9ter Pseudomonas aeruginosa Meropenem\n36 Bacteriemia Hemocultivo Pseudomonas aeruginosa  productora de \ncarbapenemasaCiprofloxacino (i.v) + amikacina + cefepima\n42 Traqueobronquitis Aspirado traqueal Pseudomonas aeruginosa  MR Amikacina + colistina (i.v)\n46 Colitis pseudomembranosa Coprocultivo Clostridium difficile Metronidazol (i.v) + vancomicina (oral + \nrectal)\n51 Bacteriemia cat\u00e9ter Hemocultivo Streptococcus mitis Teicoplanina\n62 Traqueobronquitis Aspirado traqueal Stenotrophomonas maltophilia Cotrimoxazol (i.v) + ceftazidima + \ntobramicina (inhalada)\n78 Colitis Citomegalovirus 1 ganciclovir \u2192 2 foscarnet\n83 Infecci\u00f3n de herida quir\u00fargica \n(esternotomia)Cultivo de exudado Enterobacter aerogenes  MR Meropenem + tigeciclina\n85 Bacteriemia Hemocultivo Klebsiella pneumoniae  MR (productora de \ncarbapenemasa OXA 48 y BLEE)Tigeciclina\n93 Bacteriemia/shock s\u00e9ptico Hemocultivo Elizabethkingia meningoseptica Rifampicina (i.v) + cotrimoxazol (i.v)Tabla 1  Evoluci\u00f3n de la infecci\u00f3n del paciente durante el ingreso\nMR: multirresistente, BLEE: betalactamasa de espectro extendido, i.v: intravenosa\nAntibi\u00f3tico CMI (mg/L) Sensibilidad\nAmikacina \u226564 Resistente\nCefepima \u226564 Resistente\nCeftazidima \u226564 Resistente\nCiprofloxacino \u22654 Resistente\nGentamicina \u226516 Resistente\nImipenem \u226516 Resistente\nPiperacilina/tazobactam \u2265128 Resistente\nTrimetroprim/sulfametoxazol 80 SensibleTabla 2  Antibiograma de la cepa de \nElizabethkingia meningosepticaShock s\u00e9ptico secundario a Elizabethkingia meningoseptica : descripci\u00f3n de un caso D. Brandariz N\u00fa\u00f1ez, et al.\nRev Esp Quimioter 2019;32(4): 390-392392BIBLIOGRAF\u00cdA\n1. Kim KK, Kim MK, Lim JH, Park HY, Lee ST. Transfer of Chryseobac -\nterium meningosepticum  and Chryseobacterium miricola  to Eliza-\nbethkingia  gen. nov. as Elizabethkingia meningoseptica  comb. nov. \nand Elizabehtkingia miricola  comb. nov. Int J Syst Evol Microbiol. \n2005; 55:1287-1293. PMID: 15879269\n2. Hsu MS, Liao CH, Huang YT,  Liu CY, Yang CJ, Kao KL, et al. Clinical \nfeatures, antimicrobial susceptibilities, and outcomes of Elizabeth -\nkingia meningoseptica  (Chryseobacterium meningosepticum ) bac -\nteriemia at medical center in Taiwan, 1999-2006. Eur J Clin Micro -\nbiol Infect Dis. 2011; 30: 1271-1278. PMID: 21461847\n3. Ceyhan M, Yildirim I, Tekeli A, Yurdakok M, Us E, Altun B, et al. A \nChryseobacterium meningosepticum outbreak observed in 3 clus -\nters involving both neonatal and non-neonatal pedriatic patients. \nAm J Infect Control. 2008; 36:453-457. PMID: 18675153\n4. Coyle-Gilchrist MM, Crewe P, Roberts G. Flavobacterium meningo -\nsepticum  in the hospital enviroment . J Clin Pathol. 1976; 29:1921-\n1927. PMID: 977783 \n5. Pereira GH, de Oliveira Garcia D, Abboud CS, Barbosa VL, Silva PS. \nNosocomial Infections caused by Elizabethkingia meningoseptica : \nan emergent pathogen. Braz J Infect Dis. 2013; 17(5): 606-9. PMID: \n24055393\n6. Ratnamani MS, Rao R. Elizabethkingia meningoseptica : Emerging \nnosocomial pathogen in bedside hemodialysis patients. Indian J \nCrit Care Med. 2013; 2:13-15. PMID: 24339643\n7. Jung SH, Lee B, Mirrakhimov AE, Hussain N. Septic shock caused \nby Elizabethkingia meningoseptica : a case report and review of lite -\nrature. Case Reports 2013;2013:bcr2013009066. PMID: 23559661\n8. Kirby JT, Sader HS, Walsh TR, Jones RN. Antimicrobial susceptibility \nand epidemiology of a worldwide collection of Chryseobacterium \nspp: report from the Sentry Antimicrobial Surveillance program \n(1997-2001). J Clin Microbiol. 2004; 42:445-448. PMID: 14715802\n9. Huang YC, Lin YT, Wang DF. Comparison of the therapeutic efficacy \nof fluoroquinolone and non-fluoroquinolone treatment in patients \nwith Elizabethkingia meningoseptica  bacteraemia. Int J Amtimicro -\nbial Agent. 2018; 51:47-51. PMID: 28668676\n10. Huang Y-C, Wu PF, Lin YT, Wang FD. Comparison of clinical cha -\nracteristics of bacteremia from Elizabethkingia meningoseptica  \nand other carbapenem-resistant, non-fermenting Gram-negative \nbacilli at a tertiary medical center. J Microbiol Immunol Infect. \n2019;52(2):304-311. Doi: 10.1016/j.jmii.2018.06.007Rev Esp Quimioter 2019;32(4): 393-394393\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).(hemoglobina 8,6 g/dl, 400 leucocitos/\u00b5l con 180 neutr\u00f3filos \nabsolutos y 5.000 plaquetas/\u00b5l), con PCR de 89 mg/l (valor nor -\nmal: 0-5 mg/l) y procalcitonina de 0,59 ng/ml (valor normal: \n0-0,5 ng/ml). La radiograf\u00eda de t\u00f3rax fue normal. Se recogieron \nhemocultivos y con el diagn\u00f3stico de pancitopenia posquimio -\nterapia y neutropenia febril grave se inici\u00f3 tratamiento antimi -\ncrobiano emp\u00edrico con ceftazidima (2 g iv/8h) y daptomicina (6 \nmg/kg/24h). El hemocultivo evidenci\u00f3 el crecimiento de A. oris \n\u2014identificado mediante espectrometr\u00eda de masas (MALDI-TOF, \nBruker\u00ae) \u2014 y se realiz\u00f3 un TC cervico-toraco-abdomino-p\u00e9lvico \nque descart\u00f3 complicaciones locales. La sensibilidad antibi\u00f3tica \nse realiz\u00f3 mediante los puntos de corte indicados en el Clini -\ncal and Laboratory Standards Institute (CLSI). El microorganis -\nmo fue sensible a los siguientes antibi\u00f3ticos: penicilina (CMI \n= 0,094 mg/L), amoxicilina-clavul\u00e1nico (CMI = 0,094 mg/L), \nimipenem (CMI = 0,12 mg/L), clindamicina (CMI= 0,5 mg/L). \nMetronidazol (CMI > 256 mg/L) se catalog\u00f3 como resistente. \nSe desescal\u00f3 a amoxicilina-clavul\u00e1nico (875/125 mg iv/8h) du -\nrante 1 semana, con negativizaci\u00f3n de los hemocultivos a los 4 \nd\u00edas de inicio del tratamiento. Posteriormente, se realiz\u00f3 tera -\npia secuencial de mantenimiento con amoxicilina-clavul\u00e1nico \n(875/125 mg vo/8h) durante 6 meses sin evidencia de recidiva.\nSe han descrito distintos factores de riesgo para desarrollar \ninfecci\u00f3n por Actinomyces  como deterioro del sistema inmune \n(infecci\u00f3n por VIH, quimioterapia y toma cr\u00f3nica de esteroi -\ndes), cuerpos extra\u00f1os \u2014en especial dispositivos intrauterinos\u2014 \ny procedimientos quir\u00fargicos en especial la cirug\u00eda abdominal \ny manipulaci\u00f3n dental. La marcada presencia de A. oris e n la \nflora de la cavidad bucal, su poca virulencia y la inusual pre -\nsencia de estos g\u00e9rmenes en hemocultivo obliga a pensar en \nla disrupci\u00f3n de la barrera mucosa como factor fundamental \nen su papel pat\u00f3geno. En este sentido, distintos estudios [5] \nhan puesto en relieve la presencia de bacteriemia por A. oris \ndespu\u00e9s de manipulaciones dentales, por lo que la valoraci\u00f3n \nminuciosa en busca de enfermedad bucodental podr\u00eda ser pe -\nrentorio en el estudio de una bacteriemia en el contexto de una \nneutropenia febril.Sr. Editor : Actynomices spp. \u2014del griego aktinos (rayo) y \nmykes (hongo) en referencia a su aspecto microsc\u00f3pico\u2014 son \nbacilos grampositivos de forma filamentosa o ramificada, anae -\nrobios, no \u00e1cido-alcohol resistentes. Se consideran microbiota \nhabitual de las mucosas, en especial, de la orofaringe, tracto \ngenital femenino y tubo digestivo [1].\nHasta hace relativamente poco, la clasificaci\u00f3n de Actyno -\nmices spp. se realizaba mediante las diferencias en las pruebas \nfenot\u00edpicas convencionales. En los \u00faltimos a\u00f1os, gracias a las \nt\u00e9cnicas genot\u00edpicas de identificaci\u00f3n, se han conseguido gran -\ndes avances taxon\u00f3micos con redefinici\u00f3n e identificaci\u00f3n de \nnuevas especies. Henssge et al [2]. propusieron reclasificar las \ngenoespecies 2 y WVA 963 de Actynomices naeslundi  en Acty-\nnomices oris y Actinomyces johnsonii, respectivamente. \nLa bacteriemia por Actynomices spp. es una forma de ac -\ntinomicosis poco frecuente. Hasta donde hemos podido saber, \nexisten escasas referencias bibliogr\u00e1ficas [3] sobre el particular. \nUna de las especies implicadas en bacteriemia ha sido A. naes -\nlundi [4], sin embargo \u2014tras la reclasificaci\u00f3n de una de sus ge -\nnoespecies en A. oris \u2014 hemos encontrado escasas referencias \n[5] (buscadores PubMed y Medline, palabras clave bacteremia, \ninfection y Actynomices oris) acerca de su participaci\u00f3n como \nagente causal de infecci\u00f3n. \nSe presenta un caso de una bacteriemia por A. oris en una \npaciente un paciente en tratamiento quimioter\u00e1pico.\nVar\u00f3n de 32 a\u00f1os, diagnosticado de medulobalastoma \nlocalizado en tratamiento quimioter\u00e1pico con cisplatino, vin -\ncristina y ciclofosfamida. Ingres\u00f3 por fiebre de 39\u00baC y mal \nestado general, 20 d\u00edas despu\u00e9s de recibir el \u00faltimo ciclo de \nquimioterapia. En la exploraci\u00f3n f\u00edsica destacaba la presencia \npalidez cut\u00e1nea y anal\u00edticamente presentaba una pancitopenia Bacteriemia por Actynomices oris\n1Servicio de Medicina Interna. Hospital cl\u00ednico Universitario de Valladolid, Espa\u00f1a. \n2Unidad de Enfermedades Infecciosas. Servicio de Medicina Interna. Hospital cl\u00ednico Universitario de Valladolid, Espa\u00f1a. Javier Miguel Mart\u00edn \nGuerra1\nMiguel Mart\u00edn Asenjo1\nClaudia Iglesias P\u00e9rez1\nCarlos Jes\u00fas Due\u00f1as \nGuti\u00e9rrez1,2\nCorrespondencia:\nJavier Miguel Mart\u00edn Guerra\nHospital Cl\u00ednico Universitario de Valladolid. Avda. Ram\u00f3n y Cajal, 1. 47005. Valladolid (Espa\u00f1a) \nTfno.: 660376561\nE-mail: javi6vega@hotmail.comCarta al Director\nArticle history\nReceived: 10 February 2019; Revision Requested: 4 March 2019; Revision Received: 26 March 2019; Accepted: 13 April 2019Bacteriemia por Actynomices oris J. M. Mart\u00edn Guerra, et al.\nRev Esp Quimioter 2019;32(4): 393-3943947. Smith AJ, Hall V, Thakker B, Gemmell CG. Antimicrobial suscepti -\nbility testing of Actinomyces species with 12 antimicrobial agents. \nJ Antimicrob Chemother. 2005;56:407-9 DOI: 10.1093/jac/dki206\n8. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernan -\ndez HT. Comparative in vitro susceptibilities of 396 unusual anae -\nrobic strains to tigecycline and eight other antimicrobial agents. \nAntimicrob Agents Chemother. 2006;50:3507-13 DOI: 10.1128/\nAAC.00499-06\n9. Goldstein EJ1, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fer -\nnandez HT, Bryskier A. Comparative in vitro activities of XRP 2868, \npristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, \nlinezolid, clarithromycin, telithromycin, clindamycin, and am -\npicillin against anaerobic gram-positive species, actinomycetes, \nand lactobacilli. Antimicrob Agents Chemother. 2005;49:408-13. \nDOI:10.1128/AAC.49.1.408-413.2005\n10. Tyrrell KL1, Citron DM, Warren YA, Goldstein EJ. In vitro activity \nof TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, \nagainst 377 strains of anaerobic bacteria and 34 strains of Coryne -\nbacterium  species. Antimicrob Agents Chemother. 2012;56:2194-7. \nDOI: 10.1128/AAC.06274-11Aunque Actinomyces spp. suelen ser sensibles a penicili -\nnas, se recomienda identificar la especie en cuesti\u00f3n. A parte de \nla resistencia intr\u00ednseca a metronidazol [6], se han descrito re -\nsistencias particulares en algunas especies como A. europaeus  \n(ceftriaxona, clindamicina, macr\u00f3lidos, ciprofloxacino y/o ta -\nzobactam) y A. turicensis (clindamicina, tetraciclinas, macr\u00f3 -\nlidos, ciprofloxacino y/o linezolid) . Ambas especies son las m\u00e1s \nresistentes [7]. Adem\u00e1s  se han observado CMIs elevadas para \ndistintos antimicrobianos en cepas de A. funkei  (tetraciclina), \nA. israelii  (linezolid) y A. odontolyticus (clindamicina) [3, 8-10]. \nLa duraci\u00f3n del tratamiento \u2014y en especial en la bacterie -\nmia\u2014 no est\u00e1 bien establecido, pero se han considerado trata -\nmientos muy prolongados, incluso de un a\u00f1o.\nLa bacteriemia por A. oris  justifica una exhaustiva valo -\nraci\u00f3n bucodental. Queda patente la escasa experiencia en el \nmanejo de bacteriemia por Actynomices spp., lo que nos obli -\ngar\u00eda a dise\u00f1ar estudios multic\u00e9ntricos e internacionales que \naportasen evidencia al respecto.\nFINANCIACI\u00d3N\nLos autores declaran no haber recibido financiaci\u00f3n para la \nrealizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan conflicto de inte -\nreses.\nBIBLIOGRAF\u00cdA\n1. Betriu C, Picazo JJ. Actinomicosis. Med Clin (Barcelona). \n1999;113:422-7. PMID 10562956\n2. Henssge U, Do T, Radford DR, Gilbert SC, Clark D, Beighton D. Emen -\nded description of Actinomyces naeslundii  and descriptions of Ac-\ntinomyces oris  sp. nov. and Actinomyces johnsonii sp. nov., pre -\nviously identified as Actinomyces naeslundii  genospecies 1, 2 and \nWVA 963. Int J Syst Evol Microbiol. 2009.59:509-16. DOI:10.1099/\nijs.0.000950-0\n3. K\u00f6n\u00f6nen E, Wade WG. Actinomyces  and related organisms in hu -\nman infections. Clin Microbiol Rev. 2015;28:419-42.DOI: 10.1128/\nCMR.00100-14 \n4. De Keyser R, Ram A, Dasanu CA. A Curious Case of Actinomyces \nnaeslundii  bacteremia in a patient with metastatic pancreatic can -\ncer. Conn Med. 2016;80:417-18. PMID: 29782130\n5. Akbulut Y, Goymen M, Zer Y, Buyuktas Manay A.Investigation \nof bacteremia after debonding procedures.Acta Odontol Scand. \n2018;76:314-19. DOI: 10.1080/00016357.2018.1451654\n6. Wade WG, K\u00f6n\u00f6nen E. Propionibacterium , Lactobacillus , Acti-\nnomyces , and other non-spore-forming anaerobic gram-positive \nrods, p 817\u2013833. In Versalovic J, Carroll KC, Funke G, Jorgensen JH, \nLandry ML, Warnock DW (ed), Manual of clinical microbiology, 10th \ned. 2011. ASM Press, Washington, DC. Rev Esp Quimioter 2019;32(4): 395-397395\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).unremarkable. The patient had a favorable clinical response, \nbeing discharged after two weeks of fluconazole at the same \ndose. \nIn June, he was re-admitted with fever and hyporexia for \nover a month. Blood cultures were drawn, yielding a recurrent \nC. glabrata . Micafungin 100 mg/day was initiated, and follow-\nup blood cultures were sterile after five days. Nevertheless, \nthe transesophageal echocardiogram (TEE) showed prosthetic \naortic valve endocarditis and aortic abscess. The dose of \nmicafungin was increased to 150 mg/day and combined with \nfluconazole 400 mg/day. Although surgical debridement was \nrecommended, conservative management was preferred due \nto the patient\u00b4s high operative risk. \nWithin a month of antifungals, he presented clinical signs \nof treatment failure with severe aortic valve deterioration, \nrequiring urgent valve replacement. Heart valve cultures yielded \ntwo morphologically different strains of C. glabrata , being one of \nthem phenotypically resistant to echinocandins. Treatment was \nswitched to liposomal amphotericin B (3 mg/kg/day) combined \nwith fluconazole 800mg/day. Unfortunately, the patient acquired \na ventilator-associated pneumonia due to Pseudomonas \naeruginosa  a week after surgery and died of refractory septic \nshock. \nThe antifungal susceptibility results of all Candida  isolates \nwere performed according to EUCAST EDef 7.3  [6] and are \nsummarized in table 1. Hot spots 1 and 2 of the FKS1  and FKS2  \ngenes  were sequenced and the isolate showing resistance to \nechinocandins harbored a point mutation in the FKS2  gene. \nThere were two C. glabrata  strains from blood culture and \ntwo morphologically different strains from the heart valve \nculture. Nevertheless, all of them proved to be identical after \nmicrosatellite genotyping [7], which suggests secondary \nacquisition of resistance during treatment. Also, all C. glabrata  \nisolates were tested in a Galleria mellonella  model [7] and \nshowed no differences in terms of growth kinetics or virulence \n(data not shown). Sir,\nCandida glabrata  is a major agent of invasive candidiasis \nand its incidence is on the rise [1]. Overall rates of echinocandin \nresistance among C. glabrata  blood isolates vary according to \nregion, ranging from <1% in Europe to over 10 % in some \nhospitals located in the United States of America [1]. These \nisolates usually harbor mutations in hot spot regions of the \nFKS genes, which confer resistance after long-term exposure \nto echinocandins [1, 2]. Moreover, there is an additional \nconcern regarding C. glabrata  strains because of their capacity \nof rapidly acquiring antifungal resistance during treatment [3]. \nCandida  endocarditis is an infrequent entity, being C. \nglabrata  specifically responsible for about 0.2% of all cases \nof infectious endocarditis [4]. Despite its low prevalence, \nCandida  endocarditis remains a difficult-to-treat infection, \nentailing a poor prognosis for most patients [5]. Furthermore, \ninfections by strains with  FKS mutations are independently \nassociated with treatment failure and even higher mortality \nrates [3]. To the best of our knowledge, this is the first report \nof endocarditis caused by a strain of C. glabrata  that acquired \nresistance to echinocandins during treatment. \nAn 80-year-old male with a prosthetic aortic valve \nreplacement in 2011 was admitted in December 2015 due \nto a community acquired pneumonia. He responded well to \ntreatment but remained hospitalized because of recurrent \nepisodes of gastrointestinal bleeding. By March, he presented \nwith fever, diarrhea, and positive blood cultures for Clostridium \nperfringens  and Candida glabrata . Antibiotics and intravenous \nfluconazole 400mg/day were started adjusted to renal \nfunction, which recovered shortly. Abdominal perforation was \nexcluded and the imaging screening for infection source was Infectious endocarditis caused by Candida glabrata : \nevidence of in vivo  development of echinocandin \nresistance\n1Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Calle \nDoctor Esquerdo, 46, 28007, Madrid, Spain.\n2Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Calle Doctor Esquerdo, 46, 28007, Madrid, Spain.\n3CIBER de Enfermedades Respirat\u00f3rias (CIBERES CB06/06/0058), Av. Monforte de Lemos, 3-5. Pabell\u00f3n 11, Planta 0, \n28029, Madrid, Spain.\n4Department of Medicine, Facultad de Medicina, Universidad Complutense de Madrid, Plaza Ram\u00f3n y Cajal, s/n. Ciudad \nUniversitaria, 28040, Madrid, Spain.Caroline Agnelli1,2\nJesus Guinea1,2,3,4\nMaricela Valerio1,2\nPilar Escribano1,2,4\nEmilio Bouza1,2,3,4\nPatricia Mu\u00f1oz1,2,3,4\nCorrespondence:\nCaroline Agnelli\nDepartment of Clinical Microbiology and Infectious Diseases\nHospital General Universitario Gregorio Mara\u00f1\u00f3n\nCalle Doctor Esquerdo 46, 28007, Madrid, Spain. \nPhone: +34 915868453. -  Fax: +34 915044906. \nE-mail: agnelli.carol@gmail.comLetter to the Editor\nArticle history\nReceived: 10 February 2019; Revision Requested: 6 March 2019; Revision Received: 13 April 2019; Accepted: 19 April 2019Infectious endocarditis caused by Candida glabrata : evidence of in vivo  development of echinocandin \nresistanceC. Agnelli, et al.\nRev Esp Quimioter 2019;32(4): 395-397396endocarditis, should have antifungal susceptibility testing of \nall invasive isolates to promptly detect resistant strains.\nEven though echinocandins are highly active against \nCandida  biofilms, infections with a high microbial burden \nin sites of poor drug penetration may contribute to the \nemergence of resistant strains [1]. In addition, biofilm \nformation creates an ideal environment to harbor resistant \nmutants [12]. This could explain why one of the isolates from \nthe heart valve acquired an FKS2  mutation, whereas those \nfrom blood \u2013 where the concentration of micafungin is much \nhigher \u2013 remained fully susceptible to antifungals. In this \ncontext, high-dose echinocandin combined with liposomal \namphotericin B could have been more effective against \nbiofilm formation, potentially avoiding the development of \nechinocandin resistance [13]. Furthermore, C. glabrata  strains \nwith FKS mutation seem to have a fitness cost and may \nregain full susceptibility to echinocandins after treatment \nwith echinocandins is suspended [14]. Thus, improving \nantifungal prescribing practices may contribute to prevent the \ndevelopment and the spread of resistant clones [14]. \nIn conclusion, we describe a case of recurrent candidemia \nby C. glabrata  complicated with endocarditis by a strain that \ndeveloped resistance to echinocandins during treatment. This \nreport highlights the importance of performing antifungal \nsusceptibility testing of all invasive isolates to pursue the Relevant aspects may have potentially contributed to \ninfection recurrence. First, the patient might have received a \nlower dose of fluconazole than the one recommended for C. \nglabrata  in current guidelines [8]. He presented a very unstable \nrenal function, which presumably required more frequent \ndose adjustments. Although not routinely recommended, \nfluconazole therapeutic drug monitoring (TDM) could have \nbeen useful, especially for microorganisms with higher minimal \ninhibitory concentration (MIC) values [9]. Second, our patient \nhad diarrhea and intermittent gastrointestinal bleeding, \nfacilitating Candida  gastrointestinal translocation. In fact, the \ngastrointestinal tract is known to be a reservoir for Candida  \nand a potential source of antifungal resistance due to irregular \ndrug penetration [1,10]. Noteworthy, the most common source \nof late recurrent candidemia is intra-abdominal, followed by \nendocarditis [11]. \nTo the best of our knowledge, this is the first report of \nIE with an echinocandin-resistant Candida glabrata  isolate, \nthough the incidence of such event is probably underestimated \nfor several reasons. First, not all patients undergo surgery, so \nvalve cultures are not routinely available. Second, susceptibility \ntesting is hardly ever performed in strains other than those \nisolated from blood. Testing several isolates would increase \nthe chances to point out the resistant strain in cases caused \nby both susceptible and resistant Candida . Thus, we believe \nthat complex biofilm-related infections, such as Candida  Sample Date Species Amphotericin B Fluconazole Voriconazole Posaconazole Micafungin Anidulafungin FKS2\nBlood culture 2016 Mar 22 C. glabrata 0.25 2 0.25 0.5 \u22640.015 0.03 WT\nBlood culture 2016 Jun 06 C. glabrata 0.125 4 0.125 0.5 \u22640.015 0.03 WT\nHeart valve culture 2016 Jul 05 C. glabrata 0.125 8 0.25 0.5 \u22640.015 0.03 WT\n0.125 2 0.125 0.25 2a1aS663PTable 1  Antifungal susceptibility and analysis of FKS2 gene mutations of Candida isolates from a patient \nwith recurrent candidemia and infectious endocarditis by Candida  glabrata\nAntifungal susceptibility testing was performed according to EUCAST EDef 7.3 [6] The minimal inhibitory concentrations are expressed in mg/L. All isolates were suscep -\ntible to amphotericin B, voriconazole, posaconazole, and susceptible dose-dependent to fluconazole. aAntifungal resistance according to EUCAST EDef 7.3 [6] breakpoints \nfor micafungin and anidulafungin.\nFigure 1  Disease progression of recurrent candidemia by C. glabrata  complicated \nwith endocarditis and development of echinocandin resistance during \nantifungal treatment\nInfectious endocarditis caused by Candida glabrata : evidence of in vivo  development of echinocandin \nresistanceC. Agnelli, et al.\nRev Esp Quimioter 2019;32(4): 395-3973979. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, \nHope WW. Therapeutic drug monitoring (TDM) of antifungal \nagents: guidelines from the British Society for Medical Mycology. J \nAntimicrob Chemother 2014;69:1162\u201376. doi:10.1093/jac/dkt508.\n10. Healey KR, Nagasaki Y, Zimmerman M, Kordalewska M, Park \nS, Zhao Y, et al. The Gastrointestinal Tract Is a Major Source of \nEchinocandin Drug Resistance in a Murine Model of Candida \nglabrata  Colonization and Systemic Dissemination. Antimicrob \nAgents Chemother 2017;61:e01412-17. doi:10.1128/AAC.01412-\n17.\n11. Mu\u00f1oz P, Vena A, Valerio M, \u00c1lvarez-Ur\u00eda A, Guinea J, Escribano P, \net al. Risk factors for late recurrent candidaemia. A retrospective \nmatched case-control study. Clin Microbiol Infect 2016;22:277.\ne11-20. doi:10.1016/j.cmi.2015.10.023.\n12. Grosset M, Desnos-Ollivier M, Godet C, Kauffmann-Lacroix C, \nCazenave-Roblot F. Recurrent episodes of Candidemia due to \nCandida glabrata , Candida tropicalis  and Candida albicans  \nwith acquired echinocandin resistance. Med Mycol Case Rep \n2016;14:20\u20133. doi:10.1016/j.mmcr.2016.12.004.\n13. Marcos-Zambrano LJ, G\u00f3mez-Perosanz M, Escribano P, Zaragoza \nO, Bouza E, Guinea J. Biofilm Production and Antibiofilm Activity \nof Echinocandins and Liposomal Amphotericin B in Echinocandin-\nResistant Yeast Species. Antimicrob Agents Chemother \n2016;60:3579\u201386. doi:10.1128/AAC.03065-15.\n14. Imbert S, Castain L, Pons A, Jacob S, Meyer I, Palous M, et al. \nDiscontinuation of echinocandin and azole treatments led to the \ndisappearance of an FKS alteration but not azole resistance during \nclonal Candida glabrata  persistent candidaemia. Clin Microbiol \nInfect 2016;22:891 e5-891 e8. doi:S1198-743X(16)30263-4 \n[pii]10.1016/j.cmi.2016.07.025.diagnosis of resistant mutants.  Moreover, antifungal \nstewardship programs are warranted to optimize therapeutic \nmanagement and thus, prevent the development of resistant \nstrains.\nFUNDING\nThis work was supported by Coordena\u00e7\u00e3o de \nAperfei\u00e7oamento de Pessoal de N\u00edvel Superior (CAPES) \nFoundation, Brazil / PDSE [88881.187981/2018-01 to C.A.], and \nFondo de Investigaci\u00f3n Sanitaria (FIS PI16/01012), Instituto de \nSalud Carlos III [CPI15/00115 to P.E. and CPII15/00006 to J.G.].  \nCONFLICTS OF INTEREST\nThe authors declare that they have no conflicts of interest.\nREFERENCES \n1. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The \nglobal problem of antifungal resistance: prevalence, mechanisms, \nand management. Lancet Infect Dis 2017;17:e383\u201392. doi:10.1016/\nS1473-3099(17)30316-X.\n2. Shields RK, Nguyen MH, Press EG, Cumbie R, Driscoll E, Pasculle \nAW, et al. Rate of FKS Mutations among Consecutive Candida  \nIsolates Causing Bloodstream Infection. Antimicrob Agents \nChemother 2015;59:7465\u201370. doi:10.1128/AAC.01973-15.\n3. Barber AE, Weber M, Kaerger K, Linde J, G\u00f6lz H, Duerschmied D, et \nal. Comparative Genomics of Serial Candida glabrata  Isolates and \nthe Rapid Acquisition of Echinocandin Resistance during Therapy. \nAntimicrob Agents Chemother 2019;63:e01628-18. doi:10.1128/\nAAC.01628-18.\n4. Baddley JW, Benjamin DK, Patel M, Mir\u00f3 J, Athan E, Barsic B, et \nal. Candida  infective endocarditis. Eur J Clin Microbiol Infect Dis \n2008;27:519\u201329. doi:10.1007/s10096-008-0466-x.\n5. Lefort A, Chartier L, Sendid B, Wolff M, Mainardi J-L, Podglajen I, et \nal. Diagnosis, management and outcome of Candida  endocarditis. \nClin Microbiol Infect 2012;18:E99\u2013109. doi:10.1111/J.1469-\n0691.2012.03764.X.\n6. Arendrup MC, Meletiadis J, Mouton JW, Guinea J, Cuenca-Estrella \nM, Lagrou K, et al. EUCAST technical note on isavuconazole \nbreakpoints for Aspergillus , itraconazole breakpoints for Candida  \nand updates for the antifungal susceptibility testing method \ndocuments. Clin Microbiol Infect 2016;22:571.e1-571.e4. \ndoi:10.1016/j.cmi.2016.01.017.\n7. Bordallo-Cardona M\u00c1, Marcos-Zambrano LJ, S\u00e1nchez-Carrillo C, \nde la Pedrosa EGG, Cant\u00f3n R, Bouza E, et al. Mutant Prevention \nConcentration and Mutant Selection Window of Micafungin and \nAnidulafungin in Clinical Candida glabrata  Isolates. Antimicrob \nAgents Chemother 2018;62. doi:10.1128/AAC.01982-17.\n8. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-\nZeichner L, et al. Clinical Practice Guideline for the Management \nof Candidiasis: 2016 Update by the Infectious Diseases Society of \nAmerica. Clin Infect Dis 2016;62:e1-50. doi:10.1093/cid/civ933.Rev Esp Quimioter 2019;32(4): 398-399398\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).favorable, resolvi\u00e9ndose satisfactoriamente los episodios infec -\nciosos de v\u00edas respiratorias altas. \nTras recibir la muestra del contenido purulento en el Ser -\nvicio de Microbiolog\u00eda, se sembr\u00f3 en dos placas de agar sangre \n(Biom\u00e9rieux\u00ae) (una incubada en aerobiosis y otra en anae -\nrobiosis) a 36\u00baC y agar chocolate (Biom\u00e9rieux\u00ae) incubado a \n37\u00baC en atm\u00f3sfera con 5% de CO2. A las 48 horas se observ\u00f3 \nel crecimiento en cultivo puro de colonias de peque\u00f1o tama -\n\u00f1o (aproximadamente 1mm de di\u00e1metro) en agar chocolate y \nen agar sangre incubado en anaerobiosis. La espectrometr\u00eda \nde masas MALDI-TOF MS (Maldi Byotyper 3.0 System, Bruker \nDaltonics GmbH) no identific\u00f3 correctamente el microorganis -\nmo, dando como resultado m\u00e1s probable Arthrobacter proto -\nphormiae  (Score 1,432). Se realiz\u00f3 una tinci\u00f3n de Gram de las \ncolonias con la que se concluy\u00f3 que se trataban de bacilos \ngrampositivos no formadores de esporas. Tras varios subculti -\nvos, la espectrometr\u00eda de masas sigui\u00f3 determinando el g\u00e9nero \nArthrobacter  como m\u00e1s probable, aunque especies diferentes \na la recogida previamente ( A. polychromogenes , A. oxydans ). \nAnte la imposibilidad de realizar una identificaci\u00f3n v\u00e1lida, se \nenvi\u00f3 la cepa al Centro Nacional de Microbiolog\u00eda (Instituto \nde Salud Carlos III), que identific\u00f3 el microorganismo median -\nte secuenciaci\u00f3n como Actynomyces marseillensis , una nueva \nespecie de Actinomyces . \nPara el estudio de la sensibilidad antibi\u00f3tica se emplea -\nron Etest (Biom\u00e9rieux\u00ae) en agar sangre Brucella reincubados \nen anaerobiosis a 37\u00baC durante 48 horas. Las concentraciones \nm\u00ednimas inhibitorias (CMI) obtenidas fueron: amoxicilina/\u00e1ci -\ndo clavul\u00e1nico (2 mg/L), moxifloxacino (2 mg/L) y clindamici -\nna (\u2265256mg/L). Tras aplicar los puntos de corte del European \nCommittee on Antimicrobial Susceptibility Testing (EUCAST) \npara microorganismos anaerobios grampositivos, se determin\u00f3 \nque la cepa era sensible a amoxicilina/clavul\u00e1nico y resisten -\nte a clindamicina. No se pudo establecer una sensibilidad para \nmoxifloxacino debido a que no existe punto de corte publicado \npara este antibi\u00f3tico.Sr. Editor: La infecci\u00f3n periamigdalina constituye la com -\nplicaci\u00f3n m\u00e1s frecuente de la amigdalitis. Tradicionalmente el \nmicroorganismo que se asociaba con mayor frecuencia a este \ntipo de infecciones era Streptococcus pyogenes , aunque en la \nactualidad se sabe que suele tratarse de infecciones polimicro -\nbianas, con presencia de microorganismos aerobios y anaero -\nbios [1-3]. Entre ellos se encuentran las bacterias del g\u00e9nero \nActinomyces , constituido por m\u00e1s de 30 especies de bacilos \nfilamentosos grampositivos que forman parte de la flora oro -\nfar\u00edngea, gastrointestinal y genitourinaria [2-4]. Se presenta \nun caso de absceso periamigdalino producido por una nueva \nespecie de este g\u00e9nero, Actinomyces marseillensis  [5].\nVar\u00f3n de 42 a\u00f1os con \u00fanico antecedente personal de inter\u00e9s \nde adenoidectom\u00eda quir\u00fargica. Acudi\u00f3 a los servicios de urgen -\ncias de Otorrinolaringolog\u00eda cuatro veces en un per\u00edodo de 40 \nd\u00edas, aproximadamente una vez cada 10 d\u00edas, por odinofagia y \nfiebre de hasta 39\u00baC, diagnosticado de amigdalitis con flem\u00f3n/\nabsceso periamigdalino izquierdo. En dos ocasiones la punci\u00f3n \nfue positiva y se dren\u00f3 abundante contenido purulento del pilar \nanterior amigdalino izquierdo. Fue tratado con diferentes ciclos \nde antibi\u00f3tico, intravenoso durante el ingreso, y oral al alta a do -\nmicilio, alternando con amoxicilina/\u00e1cido clavul\u00e1nico (875/125 \nmg cada 8 horas, 7 d\u00edas) clindamicina (450 mg cada 6 horas, 10 \nd\u00edas) y moxifloxacino (400 mg cada 24 horas, 7 d\u00edas), adem\u00e1s \nde prednisona como tratamiento antiinflamatorio. En el cuar -\nto ingreso, se recogi\u00f3 una muestra del contenido purulento del \nabsceso periamigdalino izquierdo y se envi\u00f3 al Servicio de Micro -\nbiolog\u00eda. A los 10 d\u00edas se realiz\u00f3 amigdalectom\u00eda y se enviaron \nlas muestras al servicio de Anatom\u00eda Patol\u00f3gica, con diagn\u00f3stico \nde hiperplasia linfoide reactiva y sin sospecha de malignidad. El \npaciente tras la intervenci\u00f3n quir\u00fargica, present\u00f3 una evoluci\u00f3n Absceso periamigdalino producido por Actinomyces \nmarseillensis \n1Servicio de Microbiolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria Princesa, Hospital Universitario La Princesa, Madrid, Espa\u00f1a. \n2Servicio de Otorrinolaringolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria Princesa, Hospital Universitario La Princesa, Madrid, \nEspa\u00f1aSara G\u00f3mez de Frutos1\nMarta Soledad Rodr\u00edguez \nAnzules2\nArturo Manuel Fraile Torres1\nLaura Carde\u00f1oso Domingo1\nDiego Domingo Garc\u00eda1\nCorrespondencia:\nSara G\u00f3mez de Frutos\nServicio de Microbiolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria Princesa, Hospital Universitario \nLa Princesa, Madrid, Espa\u00f1a.\nTfno.: 628670617 \nFax: 915202547 \nE-mail: saragdf0610@gmail.com Carta al Director\nArticle history\nReceived: 22 February 2019; Revision Requested: 13 April 2019; Revision Received: 19 May 2019; Accepted: 22 May 2019Absceso periamigdalino producido por Actinomyces marseillensis S. G\u00f3mez de Frutos, et al.\nRev Esp Quimioter 2019;32(4): 398-399399sist. 2014; 7: 183\u2013197. DOI: 10.2147/IDR.S39601\n5. Bogning Fonkou MD, Bilen M, Cadoret F, Fournier PE, Dubourg G, \nRaoult D. \u2018Enterococcus timonensis\u2019  sp. nov., \u2018Actinomyces mar -\nseillensis\u2019  sp. nov., \u2018Leptotrichia massiliensis\u2019  sp. nov., \u2018Actinomyces \npacaensis\u2019  sp. nov., \u2018Actinomyces oralis\u2019  sp. nov., \u2018Actinomyces \nculturomici\u2019  sp. nov. and \u2018Gemella massiliensis\u2019  sp. nov., new \nbacterial species isolated from the human respiratory microbio -\nme. New Microbes New Infect. 2018; 22: 37\u201343. DOI: 10.1016/j.\nnmni.2017.12.005 \n6. Al Yaghchi C, Cruise A, Kapoor K, Singh A, Harcourt J. Out-patient \nmanagement of patients with a peritonsillar abscess. Clin Otolaryn -\ngol. 2008;33(1):52-5. DOI: 10.1111/j.1749-4486.2007.01575.x\n7. Mel\u00e9ndez Garc\u00eda JM, Ileana Hamdan Zavarce M, Ara\u00fajo da Costa.AS  \nAbsceso periamigdalino: Incidencia y manejo actual. Revista Por -\ntuguesa De Otorrinolaringologia E Cirurgia De Cabe\u00e7a E Pesco\u00e7o, \n2011; 49(3), 147-150. https://www.journalsporl.com/index.php/\nsporl/article/view/173A. marseillensis  fue descrito en diciembre de 2017 en \nFrancia como una nueva especie filogen\u00e9ticamente pr\u00f3xima a \nA. odontolyticus  [5]. La similitud en la secuenciaci\u00f3n de la cepa \naislada y A. odontolyticus  fue <68,65% por lo que se propuso \ncomo una nueva especie denominada A. marseillensis . Tras una \nrevisi\u00f3n de la literatura, parece ser el primer caso recogido de \ninfecci\u00f3n por este microorganismo.\nEl manejo de los abscesos periamigdalinos se fundamen -\nta en el drenaje y administraci\u00f3n de corticoides y tratamiento \nantibi\u00f3tico emp\u00edrico [6, 7]. Aunque no se considera necesario \nhacer estudios bacteriol\u00f3gicos de forma sistem\u00e1tica, s\u00ed parece \ninteresante realizar cultivo para microorganismos aerobios y \nanaerobios en cuadros recurrentes como el que se presenta, \npuesto que puede servir de gu\u00eda para elecci\u00f3n del tratamiento \nantibi\u00f3tico, siendo especialmente \u00fatil en infecciones produci -\ndas por microorganismos que no producen de forma habitual \nestos cuadros y que, por lo tanto, pueden no estar cubiertos \ncon el tratamiento emp\u00edrico. Pese a que la mayor parte de las \ninfecciones periamigdalinas tienen etiolog\u00eda polimicrobiana, el \ncaso presentado se trata de una infecci\u00f3n monomicrobiana, \nen la que se aisl\u00f3 de forma exclusiva A. marseillensis . Este he -\ncho parece indicar que, aunque puede encontrarse formando \nparte de la flora orofar\u00edngea habitual tambi\u00e9n tiene potencial \npat\u00f3geno. Cabe destacar la dificultad para la identificaci\u00f3n de \neste microorganismo mediante las t\u00e9cnicas habitualmente dis -\nponibles en laboratorios de Microbiolog\u00eda Cl\u00ednica como la es -\npectrometr\u00eda de masas, siendo necesaria la colaboraci\u00f3n de un \nlaboratorio de referencia.\nFINANCIACI\u00d3N\nLos autores declaran no haber recibido financiaci\u00f3n para la \nrealizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan conflicto de inte -\nreses.\nBIBLIOGRAF\u00cdA\n1. Costales-Marcos M, L\u00f3pez-\u00c1lvarez F, N\u00fa\u00f1ez-Batalla F, Moreno-\nGalindo C, \u00c1lvarez Marcos C, Llorente-Pend\u00e1s JL. Peritonsillar In -\nfections: Prospective Study of 100 Consecutive Cases. Acta Otorri -\nnolaringol. 2012; 63(3);212-217. DOI: 10.1016/j.otorri.2012.01.001\n2. K\u00f6n\u00f6nen E, Wade WG. Actinomyces  and Related Organisms in \nHuman Infections. Clinl Microbiol Rev. 2015, 28 (2) 419-442. DOI: \n10.1128/CMR.00100-14\n3. Mazur E, Czerwi \u0144ska E, Korona-G\u0142owniak I, Grochowalska A, Kozio\u0142-\nMontewka M. Epidemiology, clinical history and microbiology of \nperitonsillar abscess. Eur J Clin Microbiol Infect Dis. 2014;34(3):549-\n54. DOI: 10.1007/s10096-014-2260-2\n4. Valour F, S\u00e9n\u00e9chal A, Dupieux C, Actinomycosis: etiology, clinical \nfeatures, diagnosis, treatment, and management. Infect Drug Re -Rev Esp Quimioter 2019;32(4): 400-409400\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Consensus document for sepsis code \nimplementation and development in the \nCommunity of Madrid \nABSTRACT\nThe consensus paper for the implementation and develo -\npment of the sepsis code, finished in April 2017 is presented \nhere. It was adopted by the Regional Office of Health as a wor -\nking document for the implementation of the sepsis code in \nthe Community of Madrid, both in the hospital setting (acute, \nmiddle and long-stay hospitals) and in Primary Care and Out-\nof-Hospital Emergency Services. It is now published without \nchanges with respect to the original version, having only added \nthe most significant bibliographical references.\nThe document is divided into four parts: introduction, ini -\ntial detection  and assessment, early therapy and organizational \nrecommendations. In the second to fourth sections, 25 state -\nments or proposals have been included, agreed upon by the \nauthors after several face-to-face meetings and an extensive \n\u201conline\u201d discussion. The annex includes nine tables that are in -\ntended as a practical guide to the activation of the sepsis code.\nBoth the content of the recommendations and their for -\nmal writing have been made taking into account their applica -\nbility in all areas to which they are directed, which may have \nvery different structural and functional characteristics and \nfeatures, so that we have deliberately avoided a greater de -\ngree of concretion: the objective is not that the sepsis code is \norganized and applied identically in all of them, but that the \nhealth resources work in a coordinated manner aligned in the \nsame direction.\nKey-words: sepsis, sepsis code, quick-SOFA (qSOFA), consensus documentRESUMEN\nSe presenta aqu\u00ed el documento de consenso para la implan -\ntaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid, \ncuya redacci\u00f3n se complet\u00f3 en abril de 2017. Este documento ha \nsido adoptado por la Consejer\u00eda de Sanidad madrile\u00f1a como base \nde trabajo para la puesta en marcha del C\u00f3digo Sepsis, tanto en \nel \u00e1mbito hospitalario (hospitales de agudos y de media y larga \nestancia) como en Atenci\u00f3n Primaria y los Servicios de Emer -\ngencia Extrahospitalaria. Se publica ahora sin modificaciones con \nrespecto a la versi\u00f3n original, a\u00f1adiendo \u00fanicamente las referen -\ncias bibliogr\u00e1ficas m\u00e1s significativas. El documento se estructura \nen cuatro partes: introducci\u00f3n, detecci\u00f3n y valoraci\u00f3n iniciales, \ntratamiento inicial y organizaci\u00f3n asistencial. En las partes se -\ngunda a cuarta se proponen 25 recomendaciones, consensuadas \npor los autores despu\u00e9s de varias reuniones presenciales y una \nextensa discusi\u00f3n \u201conline\u201d. Se incluyen nueve tablas que preten -\nden servir de gu\u00eda pr\u00e1ctica para la activaci\u00f3n y aplicaci\u00f3n del \nc\u00f3digo sepsis. Tanto el contenido de las recomendaciones como \nsu redacci\u00f3n formal se han realizado teniendo en cuenta su apli -\ncabilidad en todos los \u00e1mbitos a los que se dirigen, que cuentan \ncon recursos y caracter\u00edsticas estructurales y funcionales muy \ndispares, por lo que deliberadamente se ha huido de un mayor \ngrado de concreci\u00f3n: el objetivo no es que el c\u00f3digo sepsis se \norganice y se aplique de forma id\u00e9ntica en todos ellos, sino que \nlos recursos sanitarios trabajen de forma coordinada alineados \nen la misma direcci\u00f3n.\nPalabras clave: sepsis, c\u00f3digo sepsis, quick-SOFA (qSOFA), documento de \nconsensoDocumento de consenso para la implantaci\u00f3n y \ndesarrollo del C\u00f3digo Sepsis en la Comunidad de \nMadrid\n1Servicio de Medicina Intensiva Hospital Universitario Infanta Leonor, Madrid\n2Servicio de Urgencias Hospital Cl\u00ednico San Carlos, Madrid\n3Servicio de Anestesiolog\u00eda y Reanimaci\u00f3n Hospital Universitario La Princesa, Madrid\n4Servicio de Microbiolog\u00eda Hospital Cl\u00ednico San Carlos, Madrid\n5Servicio de Medicina Interna Hospital Universitario Infanta Leonor, Madrid\n6Servicio de Urgencias Hospital Universitario La Princesa, Madrid\n7Servicio de Medicina Intensiva Hospital Universitario del Henares, Coslada, Madrid\n8M\u00e9dico de Urgencias SUMMA 112, Madrid\n9Servicio de Urgencias Hospital Universitario La Paz, Madrid\n10Servicio de Medicina Intensiva Hospital Universitario La Princesa, Madrid\n11Servicio de Enfermedades Infecciosas Hospital Ram\u00f3n y Cajal, Madrid\n12SAMUR-Protecci\u00f3n Civil, Madrid\n13Servicio de Radiolog\u00eda Hospital Universitario La Paz, Madrid\n14Enfermer\u00eda de Hospitalizaci\u00f3n Hospital Universitario Infanta Leonor, MadridEduardo Palencia Herrej\u00f3n1\nJuan Gonz\u00e1lez del Castillo2\nFernando Ramasco Rueda3\nFrancisco Javier Candel \nGonz\u00e1lez4\nBeatriz S\u00e1nchez Artola5\nAndr\u00e9s von Wernitz Teleki6\nFederico Gordo Vidal7\nPatricia Roces Iglesias8\nGuillermina Bejarano \nRedondo9\nDiego An\u00edbal Rodr\u00edguez \nSerrano10\nFrancisco Javier Cobo \nReinoso11\nErvigio Corral Torres12\nMilagros Mart\u00ed de Gracia13\nAna Ruiz \u00c1lvarez14\ny el Grupo Multidisciplinar \nC\u00f3digo Sepsis Madrid*\nCorrespondencia:\nEduardo Palencia Herrer\u00f3n\nServicio de Medicina Intensiva. Hospital Universitario Infanta Leonor. \nE-mail: epalenciah@salud.madrid.orgDocumento de ConsensoDocumento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al.\nRev Esp Quimioter 2019;32(4): 400-409401de disfunci\u00f3n org\u00e1nica y sospecha cl\u00ednica de infecci\u00f3n  (ta-\nbla 1) [4, 13, 14]. En todo paciente con disfunci\u00f3n de \u00f3rganos \nse debe investigar la existencia de una infecci\u00f3n como causa \nde la misma, y en todo paciente con sospecha o evidencia de \ninfecci\u00f3n se debe investigar la posible existencia de disfunci\u00f3n \nde \u00f3rganos. La activaci\u00f3n del c\u00f3digo sepsis supone el inicio de \nlas medidas de diagn\u00f3stico y tratamiento de forma inmediata, \npendientes de la confirmaci\u00f3n diagn\u00f3stica, tanto en el \u00e1mbito \nextra como intrahospitalario.\n2. Debe quedar reflejada como alerta en la Historia Cl\u00ednica  \nla activaci\u00f3n del C\u00f3digo Sepsis, que se mantendr\u00e1 al menos du -\nrante las primeras 72 horas o hasta que se descarte su existencia.\n3. El est\u00e1ndar para el reconocimiento precoz de sepsis es el \nsistema quick-SOFA  (qSOFA) (tabla 2), y la escala SOFA  (tabla \n3) para el diagn\u00f3stico definitivo de sepsis y la cuantificaci\u00f3n de \nla disfunci\u00f3n de \u00f3rganos [4]. La disfunci\u00f3n de \u00f3rganos puede \nser debida a otras causas, y solo se considerar\u00e1 sepsis cuando \nla disfunci\u00f3n de \u00f3rganos se considera debida a una infecci\u00f3n. \nCada hospital puede emplear adem\u00e1s otros sistemas que consi -\ndere convenientes para la detecci\u00f3n precoz de infecci\u00f3n, como \nel SRIS  (S\u00edndrome de Respuesta Inflamatoria Sist\u00e9mica) (tabla \n4), y para la valoraci\u00f3n de las situaciones de deterioro cl\u00ednico de \ncualquier causa (puntuaci\u00f3n NEWS ) (tabla 5) [15, 16].\n4. En la valoraci\u00f3n cl\u00ednica del paciente con sospecha de in -\nfecci\u00f3n, es recomendable la determinaci\u00f3n de biomarcadores \ncomo la procalcitonina  (PCT) para apoyar la sospecha cl\u00ednica \nde infecci\u00f3n y guiar el inicio y la interrupci\u00f3n de la antibiote -\nrapia [17-19].\n5. En la valoraci\u00f3n del paciente con sospecha de sepsis es \nnecesaria la determinaci\u00f3n de lactato  (en muestra arterial o \nvenosa sin compresor) [20, 21], y en caso de existir signos cl\u00ed -\nnicos de compromiso respiratorio (frecuencia respiratoria alta, \ndisnea, signos de trabajo respiratorio, saturaci\u00f3n arterial de \nox\u00edgeno baja) se debe realizar gasometr\u00eda arterial .INTRODUCCI\u00d3N\n\u2022 El presente es un documento de trabajo, elaborado por un \ngrupo multidisciplinar de profesionales m\u00e9dicos y de enfer -\nmer\u00eda que se constituyen en impulsores del proyecto \u201cC\u00f3digo \nSepsis Madrid\u201d, con propuestas y recomendaciones que debe -\nr\u00e1n ser avaladas por instituciones, organizaciones y sociedades \ncient\u00edficas y profesionales de nuestra Comunidad.\n\u2022 La sepsis es la primera causa de muerte en los hospitales [1]. \nEn nuestro pa\u00eds, como en otros, su incidencia y mortalidad si -\nguen aumentando [2]. Es uno de los motivos m\u00e1s frecuentes de \ningreso en el hospital y en las unidades de cuidados intensivos, \na menudo complica el curso de otros procesos, y es el principal \nmotivo de las llamadas por deterioro cl\u00ednico en los pacientes \nhospitalizados [3]. Su letalidad es del 10%, mayor que la del \nictus, el infarto agudo de miocardio o el trauma grave, y au -\nmenta hasta el 40% cuando se produce shock s\u00e9ptico [4]. En los \n\u00faltimos a\u00f1os, distintas iniciativas nacionales e internacionales \nhan demostrado que la detecci\u00f3n y el tratamiento precoces y \norganizados de la sepsis disminuyen su mortalidad hasta en un \n50% [5, 6]. Se trata por tanto de una entidad cl\u00ednica tiempo-\ndependiente, que es y debe tratarse como una emergencia [7].\n\u2022 Es en este contexto que surge la necesidad de sistematizar \nla asistencia a los pacientes con sepsis. Hace 15 a\u00f1os las prin -\ncipales sociedades cient\u00edficas desarrollaron a nivel mundial la \n\u201cCampa\u00f1a sobrevivir a la sepsis\u201d, con el objetivo de disminuir la \nmortalidad de este s\u00edndrome en al menos un 25%, mediante la \nelaboraci\u00f3n de gu\u00edas de pr\u00e1ctica cl\u00ednica basadas en la evidencia \ny su aplicaci\u00f3n a la pr\u00e1ctica diaria promoviendo en los hospita -\nles y servicios sanitarios los cambios organizativos y la forma -\nci\u00f3n necesarios para asegurar su efectividad [8, 9]. En nuestro \npa\u00eds, esto se ha plasmado recientemente en el desarrollo del \nproyecto \u201cc\u00f3digo sepsis\u201d, avalado por las principales sociedades \ncient\u00edficas y con el apoyo del Gobierno de la Naci\u00f3n y de todas \nlas Comunidades Aut\u00f3nomas [10].\n\u2022 En la Comunidad de Madrid distintos hospitales han empe -\nzado a desarrollar \u201cc\u00f3digo sepsis\u201d [11], pero en la mayor\u00eda de \nlos hospitales y en el \u00e1mbito extrahospitalario este desarrollo o \nbien no se ha iniciado o bien est\u00e1 circunscrito a solo determi -\nnadas \u00e1reas. Por otra parte, faltan la necesaria uniformidad e \nintercomunicaci\u00f3n en las pr\u00e1cticas de c\u00f3digo sepsis en Madrid. \nAunque la realidad en cada hospital es muy diferente, existen \nunos m\u00ednimos que se pueden compartir para unificar los aspec -\ntos clave del tratamiento de la sepsis.\n\u2022 Las recomendaciones plasmadas en este documento son ba -\nsadas en la evidencia y acordes a las propuestas en las gu\u00edas \nde pr\u00e1ctica cl\u00ednica m\u00e1s recientes de la \u201cCampa\u00f1a sobrevivir a \nla sepsis\u201d, que cuentan con el respaldo un\u00e1nime de las socie -\ndades cient\u00edficas nacionales e internacionales implicadas en el \nmanejo de la sepsis y que han demostrado ser eficaces y costo-\nefectivas [9, 12] .\nDETECCI\u00d3N PRECOZ Y VALORACI\u00d3N INICIAL\n1. El C\u00f3digo Sepsis  se activar\u00e1 en los pacientes con signos Tabla 1  Definici\u00f3n de sepsis\nDefinici\u00f3n conceptual:  disfunci\u00f3n org\u00e1nica grave (amenazante para la vida), \ndebida a una respuesta an\u00f3mala del individuo a la infecci\u00f3n\nDefinici\u00f3n operativa:  aumento en dos o m\u00e1s puntos en la escala SOFA (2 o \nm\u00e1s puntos si se asume una puntuaci\u00f3n previa de cero)\nTabla 2  qSOFA (quick SOFA)\nPositivo si dos o m\u00e1s de los siguientes:\n1. Presi\u00f3n arterial sist\u00f3lica < 100 mmHg\n2. Frecuencia respiratoria > 21 rpm\n3. Alteraci\u00f3n del estado mental (puntuaci\u00f3n de Glasgow para el coma < 15)Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al.\nRev Esp Quimioter 2019;32(4): 400-409402de este extremo. Aunque la gasometr\u00eda arterial es necesaria \npara realizar el c\u00e1lculo de la puntuaci\u00f3n SOFA (relaci\u00f3n paO2/\nFiO2), en pacientes sin compromiso respiratorio aparente este \npar\u00e1metro se puede sustituir por la relaci\u00f3n SpO2/FiO2, que solo \nrequiere la pulsioximetr\u00eda y no la gasometr\u00eda arterial [22].\n8. En el paciente con sospecha de sepsis se deben obtener \nhemocultivos  (dos extracciones obtenidas de venopunciones \nindependientes y consecutivas), independientemente de su \ntemperatura, antes de iniciar la antibioterapia emp\u00edrica [23]. Se \nobtendr\u00e1n tambi\u00e9n muestras para cultivo de los focos sos -\npechosos de infecci\u00f3n  lo m\u00e1s precozmente posible, y a ser \nposible antes de iniciar el tratamiento antibi\u00f3tico, sin que esto \nsuponga una demora en el inicio de la antibioterapia.\n9. La identificaci\u00f3n del foco de infecci\u00f3n  causante de la \nsepsis es prioritaria para seleccionar el tratamiento antibi\u00f3tico \nm\u00e1s apropiado, dirigir la toma de muestras y valorar la necesi -\ndad de llevar a cabo una intervenci\u00f3n para el control del foco \n[24\u201326]. Ello requiere habitualmente la realizaci\u00f3n ordenada \nde pruebas diagn\u00f3sticas  radiol\u00f3gicas (radiograf\u00eda simple, \necograf\u00eda, TAC), anal\u00edticas y consulta entre especialistas; para \nfacilitar y acelerar este proceso, la solicitud de dichas pruebas \nestar\u00e1 etiquetada como \u201cC\u00d3DIGO SEPSIS\u201d.\nTRATAMIENTO INICIAL\n10. En los pacientes con sepsis se debe iniciar tratamiento antibi\u00f3 -\ntico para cubrir todos los microorganismos potencialmente causan -\ntes, adaptado al foco de infecci\u00f3n, a las caracter\u00edsticas del paciente y \na la microbiolog\u00eda local [27\u201330]. El tratamiento antibi\u00f3tico se iniciar\u00e1 \nsiempre tras la obtenci\u00f3n de hemocultivos, y en la  primera hora  \ndesde la detecci\u00f3n de la sepsis [12]. La adecuaci\u00f3n del tratamiento \nantibi\u00f3tico se revisar\u00e1 diariamente, en base a la informaci\u00f3n cl\u00ednica \ny microbiol\u00f3gica existente, las pautas de antibioterapia locales y con \nla participaci\u00f3n del infect\u00f3logo y de los profesionales encargados \nen cada hospital de la optimizaci\u00f3n del tratamiento antibi\u00f3tico [30].\n11. En el paciente con sepsis e hipotensi\u00f3n o hipoperfusi\u00f3n 6. En el paciente con sospecha de sepsis (c\u00f3digo sepsis acti -\nvado) la evoluci\u00f3n cl\u00ednica inicial puede ser impredecible, por \nlo que es necesaria inicialmente una vigilancia estrecha y la \nreevaluaci\u00f3n  cl\u00ednica peri\u00f3dica , para valorar la evoluci\u00f3n de la \ndisfunci\u00f3n de \u00f3rganos y la respuesta al tratamiento. Se consi -\nderar\u00e1 el ingreso en una Unidad de Cuidados Intensivos en caso \nde hipotensi\u00f3n o hiperlactacidemia persistentes, necesidad de \nf\u00e1rmacos vasoactivos (noradrenalina), disfunci\u00f3n de \u00f3rganos \ngrave, persistente o progresiva, o deterioro cl\u00ednico.\n7. Dentro de la valoraci\u00f3n cl\u00ednica del paciente con sepsis es \nnecesaria la evaluaci\u00f3n sistem\u00e1tica de la funci\u00f3n de \u00f3rganos \n(cardiovascular, neurol\u00f3gico, respiratorio, renal, hep\u00e1tico y \ncoagulaci\u00f3n), lo que requiere, adem\u00e1s de las constantes vitales \ny la valoraci\u00f3n de diuresis y nivel de conciencia, la realizaci\u00f3n \nde un perfil anal\u00edtico de sepsis , que incluye, como m\u00ednimo: \nhemograma, coagulaci\u00f3n, creatinina, bilirrubina, lactato y pro -\ncalcitonina (o en su defecto prote\u00edna C reactiva) (tabla 6). Se \nrecomienda repetir estas determinaciones anal\u00edticas en las pri -\nmeras 24 horas, dependiendo el momento \u00f3ptimo de su extrac -\nci\u00f3n de la evoluci\u00f3n cl\u00ednica particular de cada caso. Siempre \nque el lactato inicial se encuentre elevado se debe seriar su \ndeterminaci\u00f3n hasta comprobar su normalizaci\u00f3n. Si la hiper -\nlactacidemia se considera un error de laboratorio o de la toma \nde muestras, se debe repetir la determinaci\u00f3n para asegurarse Tabla 4  SRIS (s\u00edndrome de respuesta \ninflamatoria sist\u00e9mica)\nPositivo si dos o m\u00e1s de los siguientes:\n1. Temperatura corporal > 38 o < 36\u00baC\n2. Frecuencia cardiaca > 90 mmHg\n3.  Frecuencia respiratoria > 20 rpm o paCO2 < 32 mmHg o necesidad de ventila -\nci\u00f3n mec\u00e1nica\n4. Recuento de leucocitos > 12.000 o < 4.000 o > 10% de formas inmaduras0 1 2 3 4\nRespiratorio:  paO2/FiO2b\u2265 400 < 400 < 300 < 200a< 100a\nRenal:  creatinina, diuresis < 1,2 1,2-1,9 2,0-3,4 3,5-4,9 o < 500 ml/d\u00eda \u2265 5 o < 200 ml/d\u00eda\nHep\u00e1tico:  bilirrubina < 1,2 1,2-1,9 2,0-5,9 6,0-11,9 \u2265 12\nCardiovascular: PA, f\u00e1rmacos vasoactivos No hipotensi\u00f3n PAM < 70 DA < 5 o DBT DA > 5,1-15 o N/A \u2264 0,1 DA > 15; N/A > 0,1\nHematol\u00f3gico:  plaquetas \u2265 150 < 150 < 100 < 50 < 20\nNeurol\u00f3gico:  Glasgow 15 13-14 10-12 6-9 < 6Tabla 3  Puntuaci\u00f3n de disfunci\u00f3n de \u00f3rganos SOFA (\u201cSepsis Organ Failure Assessment\u201d)\naRespiratorio: las puntuaciones 3 y 4 se aplican solo si el enfermo recibe soporte ventilatorio; creatinina en mg/dl; bilirrubina en mg/dl; PAM = presi\u00f3n arterial \nmedia mm Hg; f\u00e1rmacos vasoactivos administrados durante m\u00e1s de una hora, dosis en \u03bcg/kg/min; DA = dopamina; N/A = noradrenalina o adrenalina; DBT = \ndobutamina (cualquier dosis); Glasgow = puntuaci\u00f3n en la escala de Glasgow para el coma\nbSi no se dispone de gasometr\u00eda arterial pero s\u00ed de pulsioximetr\u00eda, una SpO2/FiO2 de 235 equivale a una paO2/FiO2 de 200, y una SpO2/FiO2 de 315 a una paO2/\nFiO2 de 300 [Rice 2007, Chest].Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al.\nRev Esp Quimioter 2019;32(4): 400-409403microbiol\u00f3gico precoz , por lo que se deben emplear siempre \nque sea posible pruebas microbiol\u00f3gicas r\u00e1pidas como tincio -\nnes, t\u00e9cnicas inmunocromatogr\u00e1ficas, PCR y otras [35, 36]. Es \nfundamental el contacto estrecho mediante la creaci\u00f3n de cir -\ncuitos espec\u00edficos con el laboratorio de Microbiolog\u00eda. El equipo \nmultidisciplinar de sepsis debe contar siempre con la participa -\nci\u00f3n de un microbi\u00f3logo.\nORGANIZACI\u00d3N ASISTENCIAL\n15. El c\u00f3digo sepsis tiene como objetivo fundamental mejorar \nla asistencia a la sepsis, incidiendo especialmente en aquellos \naspectos organizativos necesarios para asegurar la aplicaci\u00f3n \ncompleta y a tiempo de las medidas diagn\u00f3sticas y terap\u00e9uticas \nque han demostrado eficacia. En este sentido, son problemas \ncomunes por solucionar  el retraso en la detecci\u00f3n, evaluaci\u00f3n \ny tratamiento, la falta de formaci\u00f3n de los profesionales, los \nproblemas de comunicaci\u00f3n durante las transferencias (tras -\nlados), o la falta de sistematizaci\u00f3n en los criterios y procedi -\nmientos de trabajo [5, 37\u201348]. \n16. Se constituir\u00e1 un Comit\u00e9 Central del C\u00f3digo Sepsis Ma -\ndrid, formado por representantes de las sociedades cient\u00edficas \nimplicadas. Su labor ser\u00e1 atender el buen funcionamiento del (lactato \u2265 4 mmol/L) se administrar\u00e1 una carga de cristaloi -\ndes de al menos 30 ml/kg en las tres primeras horas [12]; la ad -\nministraci\u00f3n posterior de fluidos se guiar\u00e1 por la reevaluaci\u00f3n \ncontinuada del estado hemodin\u00e1mico. La hiperlactacidemia de \nmenor grado (lactato > 2 y < 4 mmol/L) generalmente indica \nhipoperfusi\u00f3n y se asocia a mal pron\u00f3stico en el paciente con \nsepsis; en estos casos est\u00e1 indicado generalmente el inicio de \nfluidoterapia, que ser\u00e1 individualizada seg\u00fan las cifras de lac -\ntato y su evoluci\u00f3n, as\u00ed como otros signos de hipoperfusi\u00f3n y \ndisfunci\u00f3n de \u00f3rganos [31].\n12. Cuando la hipotensi\u00f3n es profunda y/o no se corrige con \nfluidoterapia se utilizar\u00e1 como vasopresor de primera elecci\u00f3n \nla noradrenalina [32, 33], a una diluci\u00f3n de 200 mg/mL, para \nmantener una presi\u00f3n arterial media de 65 mm Hg (tabla 7) \n[34]. La infusi\u00f3n de noradrenalina a cualquier dosis requiere \nla monitorizaci\u00f3n invasiva de la presi\u00f3n arterial en cuanto las \ncircunstancias cl\u00ednicas y estructurales lo permitan.\n13. Cuando est\u00e9 indicado, se llevar\u00e1 a cabo el control del \nfoco (cirug\u00eda, drenaje, retirada de dispositivos) lo antes posible \n[24\u201326]. El control del foco no debe demorarse hasta completar \nla resucitaci\u00f3n, y ser\u00e1 tanto m\u00e1s urgente cuanto mayor sea el \nin\u00f3culo bacteriano.\n14. En el paciente con sepsis es fundamental el diagn\u00f3stico 3 2 1 0 1 2 3\nFrecuencia respiratoria \u2264 8 9-11 12-20 21-24 \u2265 25\nSaO2 % \u2264 91 92-93 94-95 \u2265 96\nOxigenoterapia S\u00ed No\nTemperatura oC \u2264 35 35,1-36 36,1-38 38,1-39 \u2265 39,1\nPA sist\u00f3lica \u2264 90 91-100 101-110 111-219 \u2265 220\nFrecuencia cardiaca \u2264 40 41-50 51-90 91-110 111-130 \u2265 131\nConcienciaaA V, P, UTabla 5  NEWS (\u201cNew Early Warning Score\u201d)\naConciencia: sistema AVPU: A = alerta; V = respuesta a la voz; P = respuesta al dolor; U = no respuesta\nPuntuaciones entre 0 y 4 indican bajo riesgo; entre 5 y 7 riesgo medio (precisa observaci\u00f3n en \u00e1rea intermedia), y por encima de 7 riesgo \nalto (puede precisar Cuidados Intensivos).\nTabla 6  Determinaciones de laboratorio (\u201cperfil de sepsis\u201d)\n\u2022  Hemograma\n\u2022  Coagulaci\u00f3n\n\u2022  Creatinina (urea, iones)\n\u2022  Bilirrubina total y directa (bioqu\u00edmica hep\u00e1tica completa en caso de shock o sospecha de foco hepato-bilio-pancre\u00e1tico)\n\u2022  Lactato\n\u2022  Gasometr\u00eda arterial en caso de compromiso respiratorio\n\u2022  Procalcitonina (en su defecto, prote\u00edna C reactiva)Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al.\nRev Esp Quimioter 2019;32(4): 400-409404momento el ingreso en la Unidad de Cuidados Intensivos (UCI), \nel preaviso de sepsis se realizar\u00e1 directamente al responsable \nde la UCI.\n18. El servicio de urgencias hospitalario  tendr\u00e1 establecido \nun circuito para la asistencia del paciente con c\u00f3digo sepsis \ndesde su llegada al hospital, bien por preaviso de los SEM bien \ndesde el triaje [39], o desde la aparici\u00f3n de la alerta de sepsis \nen el paciente que ya se encuentra en observaci\u00f3n. En el pa -\nciente que llega tras preaviso, la obtenci\u00f3n de hemocultivos y \nel inicio de la antibioterapia se llevar\u00e1n a cabo a la llegada del \npaciente al hospital, salvo en circunstancias extremas a valorar \npor los SEM.\n19. En todos los \u00e1mbitos donde pueda aparecer la alerta de sepsis \n(SEM, urgencias hospitalarias, plantas de hospitalizaci\u00f3n, UCI/REA) \nse debe asegurar la disponibilidad inmediata  de todo lo nece -\nsario para el manejo inicial de la sepsis: frascos de hemocultivos, \nantibi\u00f3ticos de amplio espectro, fluidoterapia y noradrenalina.\n20. Se consideran criterios de consulta con la Unidad de c\u00f3digo, evaluando sus debilidades y fortalezas, evaluar sus re -\nsultados y promover su mejora continuada tanto a nivel asis -\ntencial como organizativo, en funci\u00f3n de las nuevas evidencias \ncient\u00edficas y el an\u00e1lisis de los indicadores obtenidos en los dis -\ntintos hospitales.\n17. Los servicios de emergencia m\u00e9dica extrahospitalaria  \n(SEM) son responsables de la activaci\u00f3n del c\u00f3digo sepsis  \nen su \u00e1mbito de actuaci\u00f3n, siguiendo las mismas pautas que \nen el hospital; es responsabilidad de los SEM la valoraci\u00f3n y el \ntratamiento iniciales del paciente con sospecha de sepsis, in -\ncluyendo la canulaci\u00f3n venosa, el inicio de la fluidoterapia y, si \nes necesario, del soporte vasoactivo [44, 45, 49\u201351]. En casos \nseleccionados est\u00e1 justificado el inicio de la antibioterapia an -\ntes de la llegada al hospital (sospecha de meningitis bacteriana \ngrave, shock s\u00e9ptico, etc.) [52]. La activaci\u00f3n del c\u00f3digo sepsis \nse acompa\u00f1ar\u00e1 de preaviso de sepsis  al servicio de Urgencias \ndel hospital de destino, especificando si el paciente ha presen -\ntado hipotensi\u00f3n o hiperlactacidemia y requiere por tanto re -\nsucitaci\u00f3n. En caso de que el paciente requiera desde el primer Tabla 8  Definici\u00f3n de shock s\u00e9ptico\nDefinici\u00f3n conceptual:  Se define como la sepsis en que las alteraciones circulatorias, celulares y metab\u00f3licas son lo \nsuficientemente profundas como para incrementar sustancialmente la mortalidad.\nDefinici\u00f3n operativa:  sepsis que precisa de tratamiento vasopresor para mantener una presi\u00f3n arterial media mayor o \nigual a 65 mmHg y lactato mayor de 2 mmol/L tras una adecuada resucitaci\u00f3n con fluidosml/hora mg/min mg/kg/min\n50 kg 60 kg 70 kg 80 kg 90 kg 100 kg\n3 10 0,2 0,17 0,14 0,13 0,11 0,10\n6 20 0,4 0,33 0,29 0,25 0,22 0,20\n9 30 0,6 0,50 0,43 0,38 0,33 0,30\n12 40 0,8 0,67 0,57 0,50 0,44 0,40\n15 50 1 0,83 0,71 0,63 0,56 0,50\n18 60 1 0,86 0,75 0,67 0,60\n21 70 1 0,88 0,78 0,70\n24 80 1 0,89 0,80\n27 90 1 0,90\n30 100 1Tabla 7  Diluci\u00f3n y dosificaci\u00f3n de noradrenalina\nPreparado: bitartrato de noradrenalina. Viales de 1 mg/ml de noradrenalina base (viales de 10 ml con 10 mg y de 50 ml con \n50 mg de noradrenalina base). Diluir siempre en glucosa al 5%, no en suero salino. Contiene bisulfito s\u00f3dico, que puede \nproducir reacciones al\u00e9rgicas y broncoespasmo en sujetos predispuestos. La infusi\u00f3n de noradrenalina a cualquier dosis \nrequiere la monitorizaci\u00f3n invasiva de la presi\u00f3n arterial tan pronto como sea posible.\nDiluci\u00f3n: 20 mg en 100 ml G5% o 50 mg en 250 ml G5% (concentraci\u00f3n: 200 mg/ml)Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al.\nRev Esp Quimioter 2019;32(4): 400-409405detecci\u00f3n precoz de las situaciones de riesgo, incluida la sep -\nsis, sugerimos la puesta en marcha en el hospital de sistemas \nde detecci\u00f3n autom\u00e1tica de deterioro cl\u00ednico , basados en \nla puntuaci\u00f3n NEWS o similares  [48, 55, 56]. En los servicios \no centros donde a\u00fan no existe posibilidad de crear una alerta \nelectr\u00f3nica, se establecer\u00e1n los m\u00e9todos de detecci\u00f3n acordes a \nsus recursos o modos de trabajo, contando con la participaci\u00f3n \nde los profesionales de enfermer\u00eda para su implantaci\u00f3n.\n23. Cada hospital debe implementar un sistema de respuesta  \nr\u00e1pida ante la detecci\u00f3n de una situaci\u00f3n de deterioro cl\u00ednico \nen el paciente hospitalizado, que sea adecuada a la gravedad \nde la situaci\u00f3n, y acorde a sus recursos y modos de trabajo \n[57\u201359]. Los profesionales que formen parte de dicho sistema \nson responsables de asegurar la evaluaci\u00f3n, diagn\u00f3stico y tra -\ntamiento de la sepsis y de cualquier otra causa de deterioro \ncl\u00ednico hasta la estabilizaci\u00f3n del paciente o su ingreso en una \nUnidad de Cuidados Intensivos. El sistema de respuesta r\u00e1pida \nno reemplaza la labor de los profesionales responsables del pa -\nciente, sino que la complementa.\n24. Cada organizaci\u00f3n (SEM, hospitales) debe disponer de un \nprograma de formaci\u00f3n  reglada para m\u00e9dicos y enfermeras Cuidados Intensivos : shock s\u00e9ptico (tabla 8), hipotensi\u00f3n o \nhiperlactacidemia persistentes, disfunci\u00f3n de \u00f3rganos grave, \npersistente o progresiva, deterioro cl\u00ednico. Esta consulta no se \ndebe retrasar por la espera de respuesta al tratamiento.\n21. Cada hospital dispondr\u00e1 de un equipo multidisciplinar \nde sepsis [5, 53, 54], integrado por profesionales de distintos \nestamentos (m\u00e9dicos, farmac\u00e9uticos, enfermeras) y especiali -\ndades (urgencias, medicina interna, medicina intensiva, cirug\u00eda, \nanestesiolog\u00eda y reanimaci\u00f3n, pediatr\u00eda, microbiolog\u00eda, etc.), \nabiertos a la participaci\u00f3n espor\u00e1dica o permanente de otros \nprofesionales. Dicho equipo es el responsable del seguimiento \ndel c\u00f3digo sepsis en el hospital: revisar las activaciones del c\u00f3 -\ndigo, evaluar su eficacia, y mantener un registro de las actua -\nciones realizadas sobre los pacientes con activaci\u00f3n del c\u00f3digo \nsepsis y sus resultados (ver m\u00e1s abajo el ep\u00edgrafe \u201cIndicadores \nde calidad\u201d). El equipo multidisciplinar de sepsis desarrollar\u00e1 su \nlabor de forma conjunta y sin\u00e9rgica con la Comisi\u00f3n de Infec -\nciones, infect\u00f3logos y grupos de optimizaci\u00f3n del tratamiento \nantibi\u00f3tico (PROA) del hospital.\n22. Muchas de las alertas de sepsis se generan en pacientes \nya hospitalizados por infecci\u00f3n o por otros motivos. Para la S N NP\n1. \u00bfTiene el paciente una infecci\u00f3n aguda sospechada o documentada?\n2. \u00bfCumple dos o m\u00e1s criterios qSOFA? (anotar n\u00famero)\n3. \u00bfCumple otros criterios de disfunci\u00f3n org\u00e1nica? (especificar)\nSi son positivas las respuestas a la pregunta 1 y 2 o 3, activar el c\u00f3digo sepsis. Registrarlo en la historia cl\u00ednica y anotar la fecha y hora de inicio de la sepsis y de \nactivaci\u00f3n (la hora de inicio es la de la determinaci\u00f3n de qSOFA positivo o detecci\u00f3n de la disfunci\u00f3n org\u00e1nica).\nToma y registro de constantes vitales (PA, FC, FR, temperatura), nivel de conciencia, medici\u00f3n de diuresis, pulsioximetr\u00eda\nPuntuaci\u00f3n NEWS (anotar):\nCanulaci\u00f3n venosa (x2), obtenci\u00f3n de hemocultivos (x2) y anal\u00edtica de perfil de sepsis, incluyendo determinaci\u00f3n de lactato. C\u00e1lculo de la \npuntuaci\u00f3n SOFA (anotar n\u00famero) y confirmaci\u00f3n del diagn\u00f3stico de sepsis\nToma de cultivos de los focos sospechosos de infecci\u00f3n\nInicio de la antibioterapia emp\u00edrica en la primera hora desde el inicio de la sepsis (acorde a los protocolos locales de antibioterapia). \nRegistrar la fecha y hora de administraci\u00f3n de la primera dosis\nEn caso de hipotensi\u00f3n o hiperlactacidemia > 4 mmol/L, administrar al menos 30 ml/kg de cristaloides en las primeras 3 horas\nInvestigaci\u00f3n del foco completa (pruebas de imagen, anal\u00edtica, toma de muestras para microbiolog\u00eda, interconsultas si procede, etc.)\nControl del foco de infecci\u00f3n, si procede\nIniciar noradrenalina en caso de hipotensi\u00f3n refractaria a la fluidoterapia, para mantener PAM \u2265 65 mm Hg\nSeriaci\u00f3n de los niveles de l\u00e1ctico, en caso de hiperlactacidemia > 2 mmol/L o hipotensi\u00f3n\nConsulta con Medicina Intensiva/Reanimaci\u00f3n\nIngreso en UCI/Reanimaci\u00f3n\nReevaluaci\u00f3n completa en seis horas\nReevaluaci\u00f3n completa en 24 horas\nAnal\u00edtica de control en las primeras 24 horas\nRevisar diariamente la adecuaci\u00f3n del tratamiento antibi\u00f3ticoTabla 9  Check-list de activaci\u00f3n del c\u00f3digo sepsisDocumento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al.\nRev Esp Quimioter 2019;32(4): 400-409406\u2022 Pilar L\u00f3pez Vadillo (M\u00e9dico de Urgencias SUMMA 112, Madrid)\n\u2022 Fernando Mart\u00ednez Sagasti (Servicio de Medicina Intensiva \nHospital Cl\u00ednico San Carlos, Madrid)\n\u2022 Emilio Maseda Garrido (Servicio de Anestesiolog\u00eda y Reani -\nmaci\u00f3n Hospital Universitario La Paz, Madrid)\n\u2022 Milagros Mart\u00ed de Gracia (Servicio de Radiolog\u00eda Hospital \nUniversitario La Paz, Madrid)\n\u2022 Rosario Molina Lobo (Servicio de Medicina Intensiva Hospital \nUniversitario del Henares, Coslada, Madrid)\n\u2022 Ana Mar\u00eda Montero Feijoo (Servicio de Anestesiolog\u00eda y Rea -\nnimaci\u00f3n Hospital Universitario La Paz, Madrid)\n\u2022 Marta Najarro de la Parra (Servicio de Urgencias Hospital Ra -\nm\u00f3n y Cajal, Madrid)\n\u2022 Mar\u00eda Jos\u00e9 N\u00fa\u00f1ez Orantos (Servicio de Medicina Interna Hos -\npital Cl\u00ednico San Carlos, Madrid)\n\u2022 Eduardo Palencia Herrej\u00f3n (Servicio de Medicina Intensiva \nHospital Universitario Infanta Leonor, Madrid)\n\u2022 Antonio P\u00e9rez Alonso (Enfermer\u00eda de Urgencias SUMMA 112, \nMadrid)\n\u2022 Fernando Ramasco Rueda (Servicio de Anestesiolog\u00eda y Rea -\nnimaci\u00f3n Hospital Universitario La Princesa, Madrid)\n\u2022 Patricia Roces Iglesias (M\u00e9dico de Urgencias SUMMA 112, \nMadrid)\n\u2022 Diego An\u00edbal Rodr\u00edguez Serrano (Servicio de Medicina Inten -\nsiva Hospital Universitario La Princesa, Madrid)\n\u2022 In\u00e9s Rubio P\u00e9rez (Servicio de Cirug\u00eda General Hospital Uni -\nversitario La Paz, Madrid)\n\u2022 Ana Ruiz \u00c1lvarez (Enfermer\u00eda de Hospitalizaci\u00f3n Hospital \nUniversitario Infanta Leonor, Madrid)\n\u2022 Mart\u00edn Ruiz Grinspan (Servicio de Urgencias Hospital Univer -\nsitario del Henares, Coslada, Madrid)\n\u2022 Carmen S\u00e1ez B\u00e9jar (Servicio de Medicina Interna Hospital \nUniversitario La Princesa, Madrid)\n\u2022 Beatriz S\u00e1nchez Artola (Servicio de Medicina Interna Hospital \nUniversitario Infanta Leonor, Madrid)\n\u2022 Milagros Sancho Gonz\u00e1lez (Servicio de Medicina Intensiva \nHospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid)\n\u2022 Regino Serrano Heranz (Servicio de Medicina Interna Hospi -\ntal Universitario del Henares, Coslada, Madrid)\n\u2022 Elena Velasco L\u00f3pez (Servicio de Medicina Intensiva Hospital \nCl\u00ednico San Carlos, Madrid)\n\u2022 Angela Trueba Vicente (Servicio de Urgencias Hospital Ra -\nm\u00f3n y Cajal, Madrid)\n\u2022 Andr\u00e9s von Wernitz Teleki (Servicio de Urgencias Hospital \nUniversitario La Princesa, Madrid)\nBIBLIOGRAF\u00cdA\n1.  Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, et al. \nHospital deaths in patients with sepsis from 2 independent co -sobre el diagn\u00f3stico, evaluaci\u00f3n y tratamiento precoces de la \nsepsis; este programa incluir\u00e1 tanto sesiones cl\u00ednicas peri\u00f3dicas \ncomo ayudas cognitivas (carteler\u00eda, d\u00edpticos, etc.) [60, 61]. La \norganizaci\u00f3n del C\u00f3digo Sepsis Madrid elaborar\u00e1 e impartir\u00e1 \nactividades formativas dirigidas a todos los profesionales im -\nplicados en la asistencia a la sepsis.\n25. Se crear\u00e1 un registro de datos electr\u00f3nico  donde reco -\nger la informaci\u00f3n de todos los pacientes de la Comunidad de \nMadrid en los que se haya activado el c\u00f3digo sepsis. Esta infor -\nmaci\u00f3n puede utilizarse para analizar las respuestas y planificar \nlas actividades de mejora donde y cuando sea necesario, y para \nmantener el feed-back  sobre los \u00e9xitos y aspectos a mejorar en \nla aplicaci\u00f3n del c\u00f3digo. Adem\u00e1s, la documentaci\u00f3n adecua -\ndamente estructurada permitir\u00e1 establecer una Red de Inves -\ntigaci\u00f3n dentro de la Comunidad de Madrid para llevar a cabo \nproyectos en esta \u00e1rea de conocimiento.\n*INTEGRANTES DEL GRUPO MULTIDISCIPLINAR \nC\u00d3DIGO SEPSIS MADRID (ORDEN ALFAB\u00c9TICO)\n\u2022 Jos\u00e9 Manuel A\u00f1\u00f3n Elizalde (Servicio de Medicina Intensiva \nHospital Universitario La Paz, Madrid)\n\u2022 M\u00aa Jos\u00e9 Asensio Mart\u00edn (Servicio de Medicina Intensiva Hos -\npital Universitario La Paz, Madrid)\n\u2022 Jos\u00e9 Barber\u00e1n L\u00f3pez (Servicio de Medicina Interna HM Hos -\npitales, Madrid)\n\u2022 Guillermina Bejarano Redondo (Servicio de Urgencias Hospi -\ntal Universitario La Paz, Madrid)\n\u2022 Carlos Bibiano Guill\u00e9n (Servicio de Urgencias Hospital Uni -\nversitario Infanta Leonor, Madrid)\n\u2022 Francisco Javier Candel Gonz\u00e1lez (Servicio de Microbiolog\u00eda \nHospital Cl\u00ednico San Carlos, Madrid)\n\u2022 Isabel Casado Fl\u00f3rez (SAMUR-Protecci\u00f3n Civil, Madrid)\n\u2022 Francisco Javier Cobo Reinoso (Servicio de Enfermedades In -\nfecciosas Hospital Ram\u00f3n y Cajal, Madrid)\n\u2022 Ervigio Corral Torres (SAMUR-Protecci\u00f3n Civil, Madrid)\n\u2022 Carlos Mar\u00eda Elvira Mart\u00ednez (Servicio de Medicina Preventiva \nHospital Cl\u00ednico San Carlos, Madrid)\n\u2022 Juan Gonz\u00e1lez del Castillo (Servicio de Urgencias Hospital \nCl\u00ednico San Carlos, Madrid)\n\u2022 Carlos Gonz\u00e1lez Maldonado (M\u00e9dico de Urgencias SUMMA \n112, Madrid)\n\u2022 Federico Gordo Vidal (Servicio de Medicina Intensiva Hospital \nUniversitario del Henares, Coslada, Madrid)\n\u2022 David Jim\u00e9nez Jim\u00e9nez (Enfermero de UCI, Hospital Universi -\ntario La Princesa, Madrid)\n\u2022 Bel\u00e9n Joyanes Abancens (Servicio de Pediatr\u00eda Hospital Cl\u00edni -\nco San Carlos, Madrid)\n\u2022 Esther Mar\u00eda L\u00f3pez Ramos (Servicio de Medicina Intensiva \nHospital Universitario Pr\u00edncipe de Asturias, Alcal\u00e1 de Henares, \nMadrid)Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al.\nRev Esp Quimioter 2019;32(4): 400-4094072016;315(8):775-787. doi:10.1001/jama.2016.0289\n15.  Churpek MM, Snyder A, Han X, Sokol S, Pettit N, Howell MD, et al. \nQuick Sepsis-related Organ Failure Assessment, Systemic Inflam -\nmatory Response Syndrome, and Early Warning Scores for Detec -\nting Clinical Deterioration in Infected Patients outside the Inten -\nsive Care Unit. Am J Respir Crit Care Med. 2017;195(7):906-911. \ndoi:10.1164/rccm.201604-0854OC\n16.  Singer AJ, Ng J, Thode HC, Spiegel R, Weingart S. Quick SOFA \nScores Predict Mortality in Adult Emergency Department Pa -\ntients With and Without Suspected Infection. Ann Emerg Med. \n2017;69(4):475-479. doi:10.1016/j.annemergmed.2016.10.007\n17.  Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin \nas a diagnostic marker for sepsis: a systematic review and meta-\nanalysis. Lancet Infect Dis. 2013;13(5):426-435. doi:10.1016/\nS1473-3099(12)70323-7\n18.  Kondo Y, Umemura Y, Hayashida K, Hara Y, Aihara M, Yamakawa \nK. Diagnostic value of procalcitonin and presepsin for sepsis in cri -\ntically ill adult patients: a systematic review and meta-analysis. J \nIntensive Care. 2019;7(1):22. doi:10.1186/s40560-019-0374-4\n19.  Li Q, Wang BS, Yang L, Peng C, Ma LB, Chai C. Assessment of adre -\nnomedullin and proadrenomedullin as predictors of mortality in \nseptic patients: A systematic review and meta-analysis. Med Inten -\nsiva. 2018;42(7):416-424. doi:10.1016/j.medin.2017.10.013\n20.  Gu W-J, Zhang Z, Bakker J. Early lactate clearance-guided the -\nrapy in patients with sepsis: a meta-analysis with trial sequen -\ntial analysis of randomized controlled trials. Intensive Care Med. \n2015;41(10):1862-1863. doi:10.1007/s00134-015-3955-2\n21.  Jansen TC, van Bommel J, Bakker J. Blood lactate monitoring \nin critically ill patients: a systematic health technology as -\nsessment. Crit Care Med. 2009;37(10):2827-2839. doi:10.1097/\nCCM.0b013e3181a98899\n22.  Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, \nWare LB. Comparison of the SpO2 /FiO2 Ratio and the PaO2 /\nFiO2 Ratio in Patients With Acute Lung Injury or ARDS. Chest. \n2007;132(2):410-417. doi:10.1378/chest.07-0617\n23.  Coburn B, Morris AM, Tomlinson G, Detsky AS. Does this adult \npatient with suspected bacteremia require blood cultures? JAMA. \n2012;308(5):502-511. doi:10.1001/jama.2012.8262\n24.  Azuhata T, Kinoshita K, Kawano D, Komatsu T, Sakurai A, Chiba \nY, et al. Time from admission to initiation of surgery for source \ncontrol is a critical determinant of survival in patients with gas -\ntrointestinal perforation with associated septic shock. Crit Care. \n2014;18(3):R87. doi:10.1186/cc13854\n25.  Mart\u00ednez ML, Ferrer R, Torrents E, Guillamat-Prats R, Gom\u00e0 G, Su\u00e1 -\nrez D, et al. Impact of Source Control in Patients With Severe Sepsis \nand Septic Shock*: Crit Care Med. 2017;45(1):11-19. doi:10.1097/\nCCM.0000000000002011\n26.  Oliver ZP, Perkins J. Source Identification and Source Control. \nEmerg Med Clin North Am. 2017;35(1):43-58. doi:10.1016/j.\nemc.2016.08.005\n27.  Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. \nDuration of hypotension before initiation of effective antimicro -\nbial therapy is the critical determinant of survival in human sep -horts. JAMA. 2014;312(1):90-92. doi:10.1001/jama.2014.5804\n2.  Bouza C, L\u00f3pez-Cuadrado T, Saz-Parkinson Z, Amate-Blanco JM. \nEpidemiology and recent trends of severe sepsis in Spain: a na -\ntionwide population-based analysis (2006-2011). BMC Infect Dis. \n2014;14(1):3863. doi:10.1186/s12879-014-0717-7\n3.  Cross G, Bilgrami I, Eastwood G, Johnson P, Howden BP, Bello -\nmo R, et al. The epidemiology of sepsis during rapid respon -\nse team reviews in a teaching hospital. Anaesth Intensive Care. \n2015;43(2):193-198. doi:10.1177/0310057X1504300208\n4.  Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane \nD, Bauer M, et al. The Third International Consensus Definitions for \nSepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810. \ndoi:10.1001/jama.2016.0287\n5.  Zubrow MT, Sweeney TA, Fulda GJ, Seckel MA, Ellicott AC, Mahoney \nDD, et al. Improving care of the sepsis patient. Jt Comm J Qual \nPatient Saf. 2008;34(4):187-191.\n6.  Barochia AV, Cui X, Vitberg D, Suffredini AF, O\u2019Grady NP, Banks \nSM, et al. Bundled care for septic shock: an analysis of clini -\ncal trials. Crit Care Med. 2010;38(2):668-678. doi:10.1097/\nCCM.0b013e3181cb0ddf\n7.  Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, \nPhillips GS, et al. Time to Treatment and Mortality during Manda -\nted Emergency Care for Sepsis. N Engl J Med. 2017;376(23):2235-\n2244. doi:10.1056/NEJMoa1703058\n8.  Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, \net al. Surviving Sepsis Campaign guidelines for management of se -\nvere sepsis and septic shock. Intensive Care Med. 2004;30(4):536-\n555. doi:10.1007/s00134-004-2210-z\n9.  Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, \net al. Surviving Sepsis Campaign: International Guidelines for Ma -\nnagement of Sepsis and Septic Shock: 2016. Intensive Care Med. \n2017;43(3):304-377. doi:10.1007/s00134-017-4683-6\n10.  Borges Sa M, Candel Gonz\u00e1lez F, Ferrer Roca R, Zaragoza Crespo \nR. C\u00f3digo sepsis: documento de consenso. 2014. https://www.se -\nguridaddelpaciente.es/en/information/publicaciones/2016/codigo-\nsepsis-documento-de-consenso/.\n11.  Ramasco F, Figuerola A, Mendez R, Rodr\u00edguez Serrano D, von \nWernitz A, Hern\u00e1ndez-Aceituno A, et al. Initial clinical outcomes \nand prognostic variables in the implementation of a Code Sep -\nsis in a high complexity University Hospital. Rev Esp Quimioter. \n2019;32(3):238-245. PMID: 30968675\n12.  Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign \nBundle: 2018 update. Intensive Care Med. 2018;44(6):925-928. \ndoi:10.1007/s00134-018-5085-0\n13.  Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Sche -\nrag A, et al. Assessment of Clinical Criteria for Sepsis: For the \nThird International Consensus Definitions for Sepsis and Septic \nShock (Sepsis-3). JAMA. 2016;315(8):762-774. doi:10.1001/ja -\nma.2016.0288\n14.  Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deuts -\nchman CS, et al. Developing a New Definition and Assessing New \nClinical Criteria for Septic Shock: For the Third International Con -\nsensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al.\nRev Esp Quimioter 2019;32(4): 400-409408tic shock. Crit Care Med. 2006;34(6):1589-1596. doi:10.1097/01.\nCCM.0000217961.75225.E9\n28.  Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, \net al. Effectiveness of Treatments for Severe Sepsis: A Prospecti -\nve, Multicenter, Observational Study. Am J Respir Crit Care Med. \n2009;180(9):861-866. doi:10.1164/rccm.200812-1912OC\n29.  Kollef MH. Inadequate antimicrobial treatment: an important de -\nterminant of outcome for hospitalized patients. Clin Infect Dis. \n2000;31 Suppl 4:S131-138. doi:10.1086/314079\n30.  Burnham JP, Olsen MA, Stwalley D, Kwon JH, Babcock HM, Kollef \nMH. Infectious Diseases Consultation Reduces 30-Day and 1-Year \nAll-Cause Mortality for Multidrug-Resistant Organism Infections. \nOpen Forum Infect Dis. 2018;5(3). doi:10.1093/ofid/ofy026\n31.  Liu V, Morehouse JW, Soule J, Whippy A, Escobar GJ. Fluid Volume, \nLactate Values, and Mortality in Sepsis Patients with Intermedia -\nte Lactate Values. Annals ATS. 2013;10(5):466-473. doi:10.1513/\nAnnalsATS.201304-099OC\n32.  Stratton L, Berlin DA, Arbo JE. Vasopressors and Inotropes in Sep -\nsis. Emerg Med Clin North Am. 2017;35(1):75-91. doi:10.1016/j.\nemc.2016.09.005\n33.  Hern\u00e1ndez G, Teboul J-L, Bakker J. Norepinephrine in septic shock. \nIntensive Care Med. 2019;45(5):687-689. doi:10.1007/s00134-\n018-5499-8\n34.  Asfar P, Meziani F, Hamel J-F, Grelon F, Megarbane B, Anguel N, et \nal. High versus low blood-pressure target in patients with septic \nshock. N Engl J Med. 2014;370(17):1583-1593. doi:10.1056/NEJ -\nMoa1312173\n35.  Burillo A, Bouza E. Use of rapid diagnostic techniques in ICU pa -\ntients with infections. BMC Infect Dis. 2014;14(1):593. doi:10.1186/\ns12879-014-0593-1\n36.  Cercenado E. Utility of rapid microbiological techniques for the \ndiagnosis of severe infections. Rev Esp Quimioter. 2017;30 Suppl \n1:52-55. PMID: 28882017\n37.  Anesi GL, Liu VX, Gabler NB, Delgado MK, Kohn R, Weissman GE, \net al. Associations of Intensive Care Unit Capacity Strain with \nDisposition and Outcomes of Patients with Sepsis Presenting to \nthe Emergency Department. Annals ATS. 2018;15(11):1328-1335. \ndoi:10.1513/AnnalsATS.201804-241OC\n38.  Holder AL, Gupta N, Lulaj E, Furgiuele M, Hidalgo I, Jones MP, et \nal. Predictors of early progression to severe sepsis or shock among \nemergency department patients with nonsevere sepsis. Int J Emerg \nMed. 2016;9(1):10. doi:10.1186/s12245-016-0106-7\n39.  Mitzkewich M. Sepsis Screening in Triage to Decrease Door-to-\nAntibiotic Time. J Emerg Nurs. 2019;45(3):254-256. doi:10.1016/j.\njen.2018.08.002\n40.  Mohr NM, Harland KK, Shane DM, Ahmed A, Fuller BM, Torner \nJC. Inter-hospital transfer is associated with increased morta -\nlity and costs in severe sepsis and septic shock: An instrumental \nvariables approach. J Crit Care. 2016;36:187-194. doi:10.1016/j.\njcrc.2016.07.016\n41.  Peltan ID, Bledsoe JR, Oniki TA, Sorensen J, Jephson AR, Allen TL, \net al. Emergency Department Crowding Is Associated With Dela -\nyed Antibiotics for Sepsis. Ann Emerg Med. 2019;73(4):345-355. doi:10.1016/j.annemergmed.2018.10.007\n42.  Peltan ID, Brown SM, Bledsoe JR, Sorensen J, Samore MH, Allen TL, \net al. ED Door-to-Antibiotic Time and Long-term Mortality in Sep -\nsis. Chest. 2019;155(5):938-946. doi:10.1016/j.chest.2019.02.008\n43.  Peltan ID, Mitchell KH, Rudd KE, Mann BA, Carlbom DJ, \nHough CL, et al. Physician Variation in Time to Antimicrobial \nTreatment for Septic Patients Presenting to the Emergency De -\npartment: Crit Care Med. 2017;45(6):1011-1018. doi:10.1097/\nCCM.0000000000002436\n44.  Peltan ID, Mitchell KH, Rudd KE, Mann BA, Carlbom DJ, Rea TD, \net al. Prehospital Care and Emergency Department Door-to-\nAntibiotic Time in Sepsis. Annals ATS. 2018;15(12):1443-1450. \ndoi:10.1513/AnnalsATS.201803-199OC\n45.  Smyth MA, Brace-McDonnell SJ, Perkins GD. Identification of \nadults with sepsis in the prehospital environment: a systema -\ntic review. BMJ Open. 2016;6(8):e011218. doi:10.1136/bmjo -\npen-2016-011218\n46.  Stevenson JE, Israelsson J, Nilsson GC, Petersson GI, Bath PA. Re -\ncording signs of deterioration in acute patients: The documen -\ntation of vital signs within electronic health records in patients \nwho suffered in-hospital cardiac arrest. Health Informatics J. \n2016;22(1):21-33. doi:10.1177/1460458214530136\n47.  Stevenson JE, Israelsson J, Petersson G, Bath PA. Factors influencing \nthe quality of vital sign data in electronic health records: A qua -\nlitative study. J Clin Nurs. 2018;27(5-6):1276-1286. doi:10.1111/\njocn.14174\n48.  Zaccone V, Tosoni A, Passaro G, Vallone CV, Impagnatiello M, Li Pu -\nma DD, et al. Sepsis in Internal Medicine wards: current knowledge, \nuncertainties and new approaches for management optimization. \nAnn Med. 2017;49(7):582-592. doi:10.1080/07853890.2017.13327\n76\n49.  Jones J, Lawner BJ. Prehospital Sepsis Care. Emerg Med Clin North \nAm. 2017;35(1):175-183. doi:10.1016/j.emc.2016.08.009\n50.  Pedersen PB, Henriksen DP, Mikkelsen S, Lassen AT. Dispatch and \nprehospital transport for acute septic patients: an observatio -\nnal study. Scand J Trauma Resusc Emerg Med. 2017;25(1):51. \ndoi:10.1186/s13049-017-0393-x\n51.  Smyth M, Brace-McDonnell S, Perkins G. Impact of Prehospi -\ntal Care on Outcomes in Sepsis: A Systematic Review. WestJEM. \n2016;17(4):427-437. doi:10.5811/westjem.2016.5.30172\n52.  Alam N, Oskam E, Stassen PM, Exter P van, van de Ven PM, Ha -\nak HR, et al. Prehospital antibiotics in the ambulance for sepsis: \na multicentre, open label, randomised trial. Lancet Respir Med. \n2018;6(1):40-50. doi:10.1016/S2213-2600(17)30469-1\n53.  de Dios B, Borges M, Smith TD, del Castillo A, Socias A, Guti\u00e9rrez L, \net al. Protocolo inform\u00e1tico de manejo integral de la sepsis. Des -\ncripci\u00f3n de un sistema de identificaci\u00f3n precoz. Enferm Infecc Mi -\ncrobiol Clin. 2018;36(2):84-90. doi:10.1016/j.eimc.2016.11.011\n54.  Viale P, Tedeschi S, Scudeller L, Attard L, Badia L, Bartoletti M, et \nal. Infectious Diseases Team for the Early Management of Severe \nSepsis and Septic Shock in the Emergency Department. Clin Infect \nDis. 2017;65(8):1253-1259. doi:10.1093/cid/cix548\n55.  Bhattacharjee P, Edelson DP, Churpek MM. Identifying Patients Documento de consenso para la implantaci\u00f3n y desarrollo del C\u00f3digo Sepsis en la Comunidad de Madrid E. Palencia, et al.\nRev Esp Quimioter 2019;32(4): 400-409409With Sepsis on the Hospital Wards. Chest. 2017;151(4):898-907. \ndoi:10.1016/j.chest.2016.06.020\n56.  Songsangjinda T, Khwannimit B. Comparison of severity score \nmodels based on different sepsis definitions to predict in-hospital \nmortality among sepsis patients in the Intensive Care Unit. Med \nIntensiva. 2019 Jan 30. pii: S0210-5691(18)30337-1. doi:10.1016/j.\nmedin.2018.12.004\n57.  Dummett BA, Adams C, Scruth E, Liu V, Guo M, Escobar GJ. Incor -\nporating an Early Detection System Into Routine Clinical Practice \nin Two Community Hospitals: Incorporating an EWS Into Practice. J \nHosp Med. 2016;11:S25-S31. doi:10.1002/jhm.2661\n58.  Gordo F, Molina R. Evoluci\u00f3n a la detecci\u00f3n precoz de gravedad. \n\u00bfHacia d\u00f3nde vamos? Medicina Intensiva. 2018;42(1):47-49. \ndoi:10.1016/j.medin.2017.06.008\n59.  Granich R, Sutton Z, Kim YS, Anderson M, Wood H, Scharf JE, et \nal. Early detection of critical illness outside the intensive care unit: \nClarifying treatment plans and honoring goals of care using a \nsupportive care team: Critical Illness Outside the ICU. J Hosp Med. \n2016;11:S40-S47. doi:10.1002/jhm.2660\n60.  Ferrer R, Artigas A, Levy MM, Blanco J, Gonz\u00e1lez-D\u00edaz G, Garnacho-\nMontero J, et al. Improvement in process of care and outcome \nafter a multicenter severe sepsis educational program in Spain. \nJAMA. 2008;299(19):2294-2303. doi:10.1001/jama.299.19.2294\n61.  for the ABISS-Edusepsis Study group, Ferrer R, Mart\u00ednez ML, Gom\u00e0 \nG, Su\u00e1rez D, \u00c1lvarez-Rocha L, et al. Improved empirical antibiotic \ntreatment of sepsis after an educational intervention: the ABISS-\nEdusepsis study. Crit Care. 2018;22(1):167. doi:10.1186/s13054-\n018-2091-0", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}